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CHAPTER I 
 
TOTAL SYNTHESIS OF GOMBAMIDE A 
 
Introduction 
 
Marine organisms have demonstrated to be the source of chemically diverse secondary 
metabolites which, due to its structural uniqueness and biological properties, represent interesting 
scaffolds for drug discovery.
1–3
 In this realm, marine sponges have been a prolific source, 
yielding natural products in different structural groups from polyketides to polypeptides, 
including the FDA approved anticancer drug Eribulin (Halaven
®
).
4
 
The genus Clathria provides a good example of chemical diversity in products isolated 
from marine sponges. Initial research of organic fractions from some species proved that the 
extracts inhibited quorum sensing, and had antibacterial activity as well as antiplasmadium 
properties,
5–8
 while subsequent isolation reports showed the discovery of chemically diverse 
compounds with interesting biological activity such as clathsterol 1.1,
9
 mirabilin G 1.2,
10
  
clathriol 1.3,
11
 microacionamide A 1.4  and B 1.5,
12
 clathriadic acid 1.6, norbatzelladine L 1.7,
13
 
clathric acid 1.8,
14
 and crambescindin 800 1.9 (Fig.1.1).
15
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Figure 1.1. Natural products isolated from marine sponges of the Clathria genus with confirmed 
biological activity. 
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Clathria gombawuiensis is a red encrusting marine sponge from the order 
Poecillosclerida, family Microcionidae. This sponge has provided unique sesterterpenes with 
cytotoxic activity such as phorone B 1.10, ansellone B 1.11, gombaspiroketals A-C 1.12-1.14, 
saponin gombaside A 1.15 and the peptide derived Gombamide A 1.16. While 1.12, 1.14 and 
1.15 have also shown antibacterial activity (Fig. 1.2).
16–18
 
 
 
Figure 1.2. Marine sponge Clathria gombawuiensis and examples of isolated natural products 
from this organism.  
 
Gombamide A (1.16, Fig. 1.3) was the first reported metabolite from this marine sponge. 
This cyclopeptide was isolated by Jongheon Shin’s research group at Seoul National University, 
from specimens of C.gombawuiensis collected in the coast of Gaheo-Do, South Korea. 1.16 
displayed cytotoxic activity against A549 (epithelial lung carcinoma) and K562 (chronic 
myelogenous leukemia) cell lines with LC50s of 7.1 μM and 6.9 μM, respectively. Furthermore, 
this natural product displayed inhibitory activity of the Na
+
/K
+
-ATPase pump with an IC50 of 17.8 
μM, only 2-fold less potent with respect to the positive control ouabaine (IC50 = 9.4 µM).
18
  
4 
 
 
Figure 1.3.  Structure of Gombamide A (1.16), a thiohexapeptide with unusual amino acids and a 
rare disulfide-containing, 17-membered macrocycle. 
Remarkably, 1.16 presents various distinctive chemical features in its structure. 
Gombamide A is a rare, 17-membered macrocycle with a disulfide bond forming part of the cycle 
and two uncommon exocyclic substitutions: an L-pyroglutamic amide (pyroGlu) and an (E)-para-
hydroxystyrylamide (pHSA). 
The O-substituted pHSA feature has been observed in macrocyclic peptides, primarily 
forming part of  the 14-member cycle of cyclopeptide alkaloids in the Z configuration, like 
Sanjoinine A 1.17;
19–21
 while the only endocyclic E example has been found in the non-peptidic 
bastadins 1.18 and 1.19.
22
 The uncapped pHSA has only been reported in small, linear natural 
products 1.20-1.25,
23–30
 and 1.16 is the sole reported molecule where this moiety is present in a 
cyclic peptide (Fig. 1.4). Moreover, 1.16 is the first reported sulfur-containing molecule with an 
enamide functionality. 
5 
 
Figure 1.4. Examples of natural products with pHSA in its structure. 
 
The examples of cyclic peptides with disulfide linkages isolated from marine sponges are 
scant.
12,31,32
 Moreover, the 17-member ring thiopeptide cycle has only been reported before in two 
classes of peptide molecules: the eudistomide lipopeptides from the fijian ascidian Eudistoma sp. 
1.26,
33
 and the malformins metabolites 1.27 from the Aspergillus niger; which are stimulants of 
6 
 
plant growth and possess cytotoxic and antibacterial activity (Fig. 1.5).
34,35
  The structure of the 
antitumor antibiotics related to quinomycin, like Triostin A 1.28 and SW-163C 1.29, have an 18-
membered macrocycle which could be considered the homologue of  the ring in 1.16; these 
cyclopeptides act as topoisomerase and DNA polymerase inhibitors.
36
 Considering that 
malformins and quinomycin analogs present a bicyclic arrangement, it would be possible that the 
monocyclic structure of 1.16 would represent a simpler pharmacophore for cytotoxic activity.  
 
 
Figure 1.5. Representative structures of macrocyclic peptides containing 17 (1.26 and 1.27) and 
18-member rings (1.28 and 1.29). 
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The mechanism for the cytotoxic activity of Gombamide A is unknown. In order to carry 
out the required experiments to study the biological effects of this natural product and elucidate 
its mechanism of action, the compound should be available in reasonable quantities. Obtaining 
this substance just by isolation from the marine sponge specimens would be an inefficient 
strategy, as 1.16 is produced in very small amounts from these organisms and can only be isolated 
after labor intensive purification of the material. Hence, a synthetic route to obtain Gombamide A 
appears as a promising way to solve the compound supply problem. A target oriented synthesis of 
this molecule additionally opens the possibility to explore the structure-activity relationships of 
this natural product, and to learn about chemical modifications that can eventually improve its 
anticancer or pharmacokinetic properties. Therefore, due to synthetic intrigue and our interest in 
the biological activity of this rare cyclic thiopeptide, we decided to embark in the total synthesis 
of Gombamide A. 
 
Retrosynthetic analysis for the synthesis of Gombamide A 
 
 The analysis of the retrosynthesis of 1.16 led us to propose the formation of the disulfide 
bond as final step. Having as the final intermediate the enamide acyclic hexapeptide with the 
cysteines protected, it was envisioned that the 17-membered macrocycle could be accessed 
through an oxidative deprotection/disulfide formation cascade (Scheme 1.1).  
The acyclic precursor for this reaction would originate from the amide coupling between 
L-Phe and L-Cys-1 which will bring together Fragments A 1.30 and Fragment B 1.31, facilitating 
a convergent synthetic route. Fragment B 1.31 could be readily prepared by employing suitable 
protected versions of L-phenylalanine, two L-prolines, L-cysteine and L-pyroglutamic acid. 
The synthesis of Fragment A 1.30 is limited by the formation of the pHSA feature and 
this enamide could be accessed by several different approaches. Between these options, we 
selected the dehydration of octopamine derived amide 1.32, the copper catalyzed-amidation of 
8 
 
vinyl halide 1.33 with carboxamide 1.34, intermolecular metathesis of styrene 1.35 with enamide 
1.36 and Grieco elimination of phenylselenide 1.37. 
 
 
Scheme 1.1. Retrosynthetic strategy for the total synthesis of Gombamide A, 1.16. 
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Dehydration route for Gombamide A 
 
The first attempts to accomplish the synthesis of fragment A were performed around the 
dehydration approach. In order to obtain intermediate 1.40 and being able to evaluate different 
dehydration strategies, a HATU-mediated amide coupling was performed using (±)-octopamine 
1.38 and L-cysteine 1.39 (Scheme 1.2). The reaction proceeded smoothly at room temperature in 
multi-gram scale and without the need of using a protection group on the alcohols, to provide 
1.40 in 86% yield. 
 
 
Scheme 1.2. Synthesis of 1.40 en route to intermediate 1.41. 
 
 Here, the benzylthioether was chosen as the protecting group in the cysteine due to its 
great stability, as it allows for the exploration of a diverse array of dehydration conditions. When 
testing different alcohol dehydration methods, we tried to avoid base-promoted methodologies, as 
the cysteine residue has a high tendency for racemization. The first efforts involved the use of the 
specific dehydrating agents, Burgess reagent
37
 and Martin sulfurane;
38
 however, after several 
trials varying the number of equivalents employed and reaction temperature, the formation of the 
desired product 1.41 was not observed. Other dehydration conditions such as trifluoroacetic acid, 
trifluoroacetic anhydride, p-toluensulfonic acid, p-toluensulfonic anhydride, p-toluensulfonyl 
chloride in pyridine or thionyl chloride in pyridine were screened but they led to decomposition 
of starting material or no reaction. 
10 
 
 Then, the dehydration reaction was performed employing BF3·OEt2 in N,N-
dimethylformamide (DMF), conditions reported for the introduction of the olefin in 
makaluvamine E.
39
 Following the literature procedure, it was possible to observe by LC-MS the 
formation of the desired enamide along with the deprotection of the Boc group (1.42) (entry 1, 
Table 1.1) and no remaining starting material; however, the product was recovered only in small 
amounts and it was not possible to obtain a yield for the reaction. As the original procedure 
required 10 equivalents of the Lewis acid along with heating for 24 hours at 100 °C, we thought 
that it would be possible to increase the yield of this reaction using milder conditions. 
  
 
Table 1.1. One pot Boc-deprotection/dehydration of derivative 1.40.
a
 
Entry BF3·OEt2 equiv. Time Temperature (°C) Yield 
1 10.0 24 h 100 Trace 
2 5.0 24 h 100 27% 
3 2.0 24 h 100 19% 
4 2.0 24 h 50 Trace 
5 2.0 24 h rt 0% 
6 5.0 30 min 100
b
 44% 
7 2.0 30 min 100
b
 52% 
8 2.0 40 min 100
b
 47% 
9 2.0 20 min 100
b
 Trace 
 a
Reactions were performed in DMF at a concentration of 0.09 M. 
b
Microwave heating. 
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Decreasing the amount of BF3·OEt2 to five equivalents, led to an increase in yield to 27% 
(entry 2, Table 1.1), but further reduction to two equivalents of Lewis acid did not provide 
additional advantage (entry 3, Table 1.1). Lowering the temperature did not prove to be 
successful increasing the yield of this transformation, only achieving traces of the desired product 
at 50 °C (entry 4, Table 1.1). Thinking that a more efficient heat source could improve the results 
of this reaction, conventional thermal heating was switched for microwave-assisted heating. 
Effectively, microwave promoted internal heating was accompanied by an increase in yield to 
44% when using five equivalents of  BF3·OEt2 and a remarkable shortening of reaction time from 
24 hours to 30 minutes without modifying the reaction temperature (entry 6, Table 1.1). In this 
setting, reduction of the amount of Lewis acid to two equivalents was slightly beneficial 
increasing the yield of the dehydration/deprotection to 52% yield (entry 7, Table 1.1). After this, 
different reaction times were evaluated but had no further improvement in the yield of this 
chemical transformation (entry 8 and 9, Table 1.1). 
After approaching successfully the synthesis of fragment A 1.42, our attention shifted to 
building fragment B. During the first attempts, a convergent approach was carried out by 
coupling a Phe-Pro dipeptide with a Pro-Cys-Pyr tripeptide; although, in this case the amide 
coupling of this pieces led to racemization and formation of diastereomers. Therefore, the 
construction of the pentapeptide 1.43 was performed linearly, starting from the C-terminal to the 
N-terminal, as it has been demonstrated that this approach is less prone to racemization of the 
aminoacids.
40
 Following this strategy, we observed racemization when using 
diisopropylethylamine (DIEA) as a base for the amide couplings. We eventually set in the use of 
2,4,6-collidine (TMP) as a base, which being a pyridine derivative possesses a lower pka than the 
tertiary alkylamines and it has been reported as a suitable base for peptide synthesis, especially in 
the presence of cysteine residues.
41
 
Then, synthesis of fragment B 1.43 started with the amide coupling between benzyl L-
phenylalaninate 1.44  and Boc-L-proline using EDCI/HOBt conditions to obtain dipeptide 1.45 in 
12 
 
quantitative yield (Scheme 1.3).Trifluoroacetic acid (TFA) deprotection of the Boc group, and a 
second EDCI/HOBt-mediated coupling with another Boc-L-proline delivered tripeptide 1.46 in 
89% yield over two steps. Introduction of the cysteine residue was performed after TFA 
deprotection of the Boc group in 1.46, through EDCI/HOBt-mediated coupling with Boc-L-
Cysteine-SBn  to give tetrapeptide 1.47 in 63% yield for the two steps. Repetition of this two 
steps with 1.47 but employing L-pyroglutamic acid and HATU-mediated amide coupling 
conditions afforded the key pentapeptide 1.48 in quantitative yield for the two-step 
deprotection/coupling sequence.   
 
 
Scheme 1.3. Synthesis of pentapeptide 1.43. 
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Initially, the pentapeptide was prepared using methyl L-phenylalaninate. When it came to 
the hydrolysis deprotection step, regular basic hydrolysis led to production of diastereoisomers 
identified as different peaks in the LC-MS chromatogram. This led to a change in the protecting 
group to the benzyl ester in 1.48.  
The benzyl gives the advantage of not requiring basic hydrolysis for its removal and 
being stable during the amide coupling and Boc-deprotection steps. However, benzyl 
deprotection of 1.48 proved to be challenging as standard conditions were not successful in 
removing the protecting group. Hydrogenolysis procedures catalized with palladium/carbon did 
not provide the deprotected product, even when using Brønsted acids (formic acid) as additives. 
Intact starting material was recovered during these reactions, pointing probably to poisoning of 
the palladium by the sulfur in the cysteine residue of 1.48.  
Exploring different procedures, it was found that neither heating in neutral or acidic 
alumina achieved the transformation effectively.
42
 Then, the use of Lewis acid based 
deprotections was assessed. Executing the deprotection with boron trichloride in DCM did not 
provide the desired product when carried at 0 °C,
43
 while it only achieved 20% conversion at 
room temperature (determined by LC-MS) after 16 hours of reaction. Aluminum trichloride was 
subsequently tested as the deprotecting reagent; although, performing the reaction with 3 
equivalents at 0 °C and room temperature did not provide the desired product. Increasing the 
amount of AlCl3 to six equivalents showed clean and full conversion of starting material to the 
desired carboxylic acid 1.43. This reaction was carried out in a mixture of nitromethane:DCM 
(1:1), a solvent system that allows the dissolution of AlCl3.
44
 Further enhancement in the 
efficiency of the reaction was observed by adding three equivalents of anisole, shortening the 
reaction time to close to two hours and allowing the obtention of fragment A 1.43 in almost 
quantitative yields. 
With both fragments in hand, the acyclic precursor of Gombamide A 1.49 was assembly 
during a HATU-mediated amide coupling of 1.42 and 1.43. This reaction proceeded smoothly 
14 
 
and delivered 1.49 in good yield (82%) (Scheme 1.4), setting the stage to assay conditions that 
achieve the deprotection of the thioethers and cyclization to obtain the natural product 1.16. The 
tandem deprotection/cyclization was attempted employing the trichloromethylsilane-
diphenylsulfoxide system in trifluoroacetic acid at 0 °C, conditions that proved useful to remove 
benzyl thioethers and form the disulfide bond in good yields according to the literature;
45–47
 
however, no desired product was obtained after multiple variables were modified, and  the result 
was a complex mixture from which the main substances were the unreacted starting material and 
overoxidation products of the starting material, detected by the appearance of masses with +16 
and +32 m/z during the LC-MS analysis. This transformation was also tried using iodine
48,49
 and 
with a procedure based on magnesium/ammonium formate,
50
 both without success and recovering 
only starting material. Sodium in liquid ammonia at -78 °C was the only methodology in which 
the deprotection of the starting material was observed;
51,52
 though, the intermediate product 
decomposed quickly during the course of the reaction and it was not possible to isolate it from the 
mixture or to obtain the natural product 1.16. 
 
 
Scheme 1.4. Synthesis of the acyclic hexapeptide 1.49 and first attempt to prepare 1.16. 
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Therefore, despite the advantages in stability that provides the benzylthioether protecting 
group, the difficulties found during its removal made us look for a more labile substitute that 
could allow the final cyclization. This effort was performed using L-cysteines protected with 
benzylthioether derivatives, such as p-methylbenzyl, p-methoxybenzyl and the trityl group, as 
well as the acetamidomethyl protecting groups. Starting by the preparation of fragment A, no 
issues were observed with the formation of the amide coupling with octopamine 1.38; however, 
none of these more labile protecting groups were stable enough to survive the BF3·OEt2 
dehydration conditions previously used to obtain 1.42, hindering the evaluation of its applicability 
in the tandem deprotection/cyclization reaction. 
 
Copper-catalized amidation route for Gombamide A 
 
As the dehydration route did not produce satisfactory results to achieve the synthesis of 
Gombamide, we proceeded to study other routes presented in the retrosynthetic analysis (Scheme 
1.1). Independently, Buchwald and Porco have described the synthesis of enamides trough the 
copper-catalized amidation of vynil halides with primary carboxamides.
53,54
 The applicability of 
this procedure in total synthesis has been demonstrated by Porco in the preparation of the 
antitumor macrolide lobatamide C and close analogs of this natural product.
55
 
To assess this alternative, the new synthesis of fragment A started with L-cysteine-S-Acm 
1.50 to form the respective carboxamide 1.51 (Scheme 1.5). For this reaction, two ammonia 
sources were tried, solid ammonium chloride and 28% ammonium hydroxide aqueous solution. 
The reaction was performed using HATU as the amide coupling reagent and DCE as solvent, 
offering the opportunity of accessing 1.51 in good yields (85%). 
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Scheme 1.5. Synthesis of carboxamide 1.51. 
 
 After the synthesis of the carboxamide 1.51, vinyl iodide 1.53 was synthesized en route 
to the evaluation of the amidation procedure. 1.53 was obtained through a Takai olefination 
reaction using 4-hydroxybenzaldehyde 1.52, this procedure allowed the obtention of the E alkene 
selectively but in moderate yields.
56
 
 
 
Scheme 1.6. Synthesis of vynil iodide 1.53 through a Takai olefination reaction. 
  
The amidation procedure was evaluated using carboxamide 1.51 and iodide 1.53. For this 
reaction, two different copper sources were tried: copper iodide and copper oxide; additionally, 
different ligands were screened: N,N-dimethylglycine, ethylendiamine, N,N-diethylamine and 
N,N’-diethylamine. The reactions were carried in refluxing dioxane for 24 hours without sign of 
formation of the desire product, with decomposition of the vinyl iodide and recovering the 
carboxamide starting material. This approach was also attempted using the bromide version of 
1.53 and with the TBDMS phenoxysilane protected iodide, but formation of the enamine was not 
observed, which led us to abandon this strategy. 
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Metathesis route for Gombamide A 
 
 The synthesis of the enamide in the cyclopeptide alkaloid Paliurine E has been achieved 
by a Grubbs metathesis procedure (Scheme 1.7). In this case, when using intermediate 1.54, the 
metathesis occurred intramolecularly between a 4-phenoxy styrene and a simple vinyl amide to 
provide the core of the natural product in moderate yields.
57
 This alternative presents as an 
interesting strategy for the construction of the fragment A, necessary to obtain Gombamide A. 
Being aware that in our case the metathesis reaction would be intermolecular and the limitations 
of this approach, we advanced into the synthesis of the necessary intermediates to evaluate this 
route. 
 
Scheme 1.7. Application of alkene metathesis in the synthesis of Paliurine E.
57
 
 
 The preparation of the vinyl amide was envisioned as a two-step process with the 
formation of an amide between a protected cysteine and allylamine, followed by isomerization of 
the double bond to the vinylamide. Initial trials to perform the HATU-mediated amide coupling 
between allylamine and cysteine 1.57 provided a low yielding transformation. Here, prior 
distillation of the allylamine proved to enhance the yield of this coupling, allowing the obtention 
of 1.58 in good yields (86%) (Scheme 1.8). Then, isomerization of the double bond to obtain 1.59 
was attempted using a ruthenium(II) monohydride catalyst. In this case, no reaction was observed 
18 
 
when using different amounts of RuHCl(CO)(PPh3)3 and different solvents at refluxing 
temperature. Also, the use of titanium isopropoxide as a Lewis acid additive did not improve the 
results. 
 
 
Scheme 1.8. Obtention of intermediate 1.58 and attempts for production of 1.59. 
 
As we were evaluating the results of the isomerization, it was thought that the presence of 
sulfur might be poisoining the ruthenium catalyst by complexing with the metal. This could be 
also the reason why the copper amidation methodology did not yield positive results. In an effort 
to improve upon this observation, it was decided to use a bulkier protecting group in the sulfur 
that diminishes the possibility of interaction with the metal; therefore, the trityl thioether was 
selected. The amide coupling between Boc-L-cysteine-STr 1.60 and the distilled allylamine 
proceeded smoothly and providing 1.61 in excellent yield (93%) (Scheme 1.9). The isomerization 
of the double bond to obtain 1.62 was performed using two different sources of ruthenium(II) 
hydride, RuHCl(CO)(PPh3)3 and RuH2CO(PPh3)3, and refluxing in benzene for two hours. In this 
case, effective transformation from the allylamide to the vinylamide 1.62 in quantitative yields 
was confirmed with both catalysts; with the only difference being that the monohydride provided 
a 1:1 mixture E:Z enamides, while with the dihydride catalyst the ratio was 3:1 E:Z. It was 
confirmed that this mixture of alkenes could be separated by silica gel flash chromatography and 
semipreparative HPLC. 
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Scheme 1.9. Synthesis of intermediate 1.62 through isomerization of 1.61. 
 
The assessment of the metathesis reaction was performed with the vinylamide 1.62 
mixture and 4-hydroxystyrene using 10 mol% Grubbs’ second generation as the catalyst. No 
formation of product was observed after executing the reaction in DCE or toluene at reflux, or 
increasing the catalyst loading to 20 mol%. The use of Hoveyda-Grubbs’ second generation 
provide similar results, as well as the addition of titanium isopropoxide as Lewis acid additive. 
Protecting the phenol group with an acetyl, did not produce any improvement in the reaction, and 
only starting material was isolated from the reaction matrix. 
 
Grieco elimination route for Gombamide A 
 
Efforts then shifted towards the preparation of the required intermediates to pursue the 
Grieco elimination procedure to access the unusual pHSA moiety of 1.16. This methodology has 
been employed in the synthesis of different cyclopeptide alkaloids such as Zizyphine A 1.65 
(Scheme 1.10).
58
 In this case, the transformation was performed in the advance intermediate 1.63 
with the selenide substituent in one carbon of the macrocycle, providing the Z olefin 1.64. We 
believed that a non-cyclic intermediate carrying the adequate substituents would allow us to 
access the E enamide. 
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Scheme 1.10. Application of Grieco elimination in the synthesis of Zizyphine A.
58
 
 
To obtain the selenide, the amide obtained after the coupling of (±)-octopamine 1.38 and 
Boc-L-Cys-Sacm was employed. The HATU-facilitated procedure provided amide 1.67 in 
excellent yields. However, the introduction of the required arylselenide for the Grieco elimination 
proved to be difficult, and regular conditions using diphenyldiselenide and sodium borohydride or 
nitrophenylselenocyanate with tributylphosphine were not fruitful. These procedures are 
supposed to occur through a nucleophilic substitution mechanism, and the highly functionalized 
1.67 might pose a challenge for the nucleophilic attack. Therefore, it was decided to evaluate the 
formation of the selenide prior to the amide coupling. 
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Scheme 1.11. Efforts for the synthesis of intermediate 1.68. 
 
 A new method to form the aryl selenide was pursued based on the formation of a styrene 
and then the addition of phenylselenide to the double bond.
59
 Starting with 4-
hydroxybenzaldehyde, a Henry reaction was performed, using nitromethane and catalytic 
amounts of diethylamine to obtain the nitrostyrene 1.69 in excellent yields. In the next step, 
addition of the selenide was carried out by adding the Henry product 1.69 into a solution of 
preformed phenylselenide. Monitoring of the reaction showed formation of the desired product; 
however, the product 1.70 demonstrated to decompose with time during and after purification. It 
was possible to observe the generation of the starting material and diphenyldiselenide from the 
purified product, indicating that this reaction is probably reversible. 
 
 
Scheme 1.12. Efforts to synthesize intermediate 1.70. 
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As intermediate 1.70 decomposed quickly, we sought to install a different nitrogenated 
group that could give a handle for the synthesis of the proper selenoamine to advance to the 
synthesis of fragment A. An option to do this was the development of a selenoazide intermediate 
for which a synthetic procedure has been described by Tingoli and collaborators starting from an 
olefin.
60–63
 This procedure has been employed for the azido-phenylselenylation of aliphatic and 
aromatic double bonds, as well as with protected glycals. The reaction is believed to occur 
through a radical mechanism and gives an anti-markonikov regiochemistry in unsymmetric 
olefins, positioning the phenylselenide in the most substituted carbon.  
In order to evaluate this methodology, the synthesis of styrene 1.72 was performed in two 
steps (Scheme 1.13). Starting with 4-hydroxybenzaldehyde, 1.71 was obtained in excellent yields 
(95%) after the formation of the olefin through a Wittig reaction with 
methyltriphenylphosphonium bromide. Subsequent TBS protection allowed to access styrene 
1.72 in almost quantitative yield.  
 
 
Scheme 1.13. Synthesis of phenylselenoamine 1.74. 
 
Then, the azidophenylselelenylation procedure was evaluated using olefin 1.72 as starting 
material. The process which requires sodium azide and (diacetoxyiodo)benzene (PIDA), 
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generated an heterogenous matrix and, in our case, it was carried out at room temperature to 
afford α-selenoazide 1.73 in low yields (30-40%). Switching the sodium azide for 
trimethylsililazide rendered the reaction homogenous,
64,65
 giving more robust scalability and 
improving the yield to 74%. 
Phenylselenoamine 1.74 was obtained through the reduction of intermediate 1.73. The 
use of lithium aluminum hydride at room temperature quickly provided amine 1.74 in modest 
yields (42%). Looking for a higher yield in this transformation, Staudinger reduction conditions 
were tested, but this method produced the amine only in 29% yield. The one pot procedure 
(azidophenylselenylation/LAH reduction) provided the desired product 1.74 in 31% over the two 
steps, similarly to the combination of the two reactions performed separately. 
Then, amine 1.74 was coupled via HATU with different protected L-cysteines to obtain 
different fragments A. Three cysteines were chosen: Boc-L-cysteine-SAcm, Boc-L-cysteine-STr 
and Fmoc-L-cysteine-STr; the three residues provided good yields for the amide coupling (70%, 
96% and 98%, respectively). The three compounds were submitted to oxidation by the addition of 
aqueous 30% hydrogen peroxide and stirring at room temperature. The experiment showed that 
the S-Acm protected compound yield no desired product with apparent oxidation of the molecule, 
while with the S-Tr compounds clean transformation of the selenide to the olefin was observed 
(Scheme 1.14).  
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Scheme 1.14. Synthesis of fragment A via Grieco elimination procedure. 
 
The yield for the elimination was 91% for the Boc-protected cysteine adduct, while the 
Fmoc variant gave 80% of the product. In both, formation of the E enamide was observed without 
production of the Z isomer. This is probably explained by the steric bulk of the trityl group which 
destabilized the conformation with the larger substituents on the same side of the molecule, 
disfavoring the cis geometry.  
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Figure 1.6. 
1
H-NMR monitoring of the oxidation of 1.75 to produce enamide 1.76. The reaction 
was performed in d8-THF. 
 
As overoxidation was observed with the S-Acm protecting group, the propensity for 
formation of byproducts was assessed with the trytil protected cysteine. Using the Fmoc congener 
1.75, the oxidation reaction was carried out in deuterated THF (d8-THF) and monitored by 
1
H-
NMR (Figure 1.6). NMR monitoring indicated that the reaction was completed in less than 30 
minutes. Additionally, monitoring for up to 90 minutes showed no further changes in the 
spectrum after conversion of the starting material to the desired olefin, demonstrating no over 
oxidation or formation of byproducts. 
t = 0 min 
t = 10 min 
t = 30 min 
t = 90 min 
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With the enamides in hand, the amino protecting groups were remover and fragment A 
was generated. The removal of the Boc group was challenging, as TFA deprotection conditions 
led to decomposition of the starting material. Therefore, we focused our attention on the Fmoc 
protected 1.76. For this deprotection, we tried to avoid the common piperidine (pka = 11.2) 
conditions, as racemization has been an issue in the past, and instead employed morpholine, a 
weaker base (pka = 8.4). The use of this base in acetonitrile at room temperature allowed clean 
deprotection of 1.76 to obtain amine 1.77 in 72% yield (Scheme 1.14). 
After achieving the synthesis of fragment A, the construction of a new fragment B was 
initiated. This time, instead of the S-benzyl group, the more labile S-Tr and S-Acm were 
employed to construct fragment B in parallel. The synthesis of fragment B started by Boc-
deprotection of the previously prepared Phe-Pro-Pro 1.46, followed by the amide coupling with 
the corresponding cysteine. The amide coupling with Fmoc-L-cysteine-STr was performed 
successfully with EDCI/HOBt, proceeding in 82% isolated yield over two steps. Then, the Fmoc 
group was removed with the morpholine conditions previously employed for 1.76, and a HATU-
mediated amide coupling with L-pyroglutamic acid gave the desired pentapeptide in 58% yield. 
Deprotections of the ester was needed for accessing fragment B; however, the conditions 
previously employed to execute this transformation did not provide positive results with this 
substrate, as AlCl3 caused decomposition of the starting material and early deprotection of the 
trityl thioether.  
The synthesis of fragment B using Boc-L-cysteine-Sacm started by the EDCI/HOBt 
mediated amide coupling  with the deprotected amine from 1.46 to obtain 1.78 in good yield 
(83% over two steps). Then, it was followed by the deprotection of the Boc group with TFA and a 
second amide coupling with the L-pyroglutamic acid, to afford the ester 1.79 in 87% isolated 
yield for the two-step sequence. In this case, the deprotection of the benzylic ester was carried out 
using the AlCl3/anisole system, providing fragment B 1.80 in excellent yield. Next, formation of 
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the protected acyclic precursor of Gombamide A was performed by the coupling of fragment A 
1.77 and fragment B 1.80, providing 1.81 in 51% yield 
 
 
Scheme1.15. Synthesis of acyclic precursor 1.81. 
 
With 1.81 in hand, the stage was set to attempt the formation of the 17-membered 
macrocycle. For this transformation, we selected to employ an iodine-mediated oxidative 
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cyclization protocol.
48,49
 The iodine will promote tandem removal of the S-Acm and S-Tr 
protecting groups and formation of the disulfide bond (Scheme 1.16). Following the literature 
procedure describe by Boger and collaborators (entry 1, Table 1.2), the reaction was run with 10 
equivalents of iodine and fairly diluted (0.0008M). These conditions proved to deprotect quickly 
both S-Acm and S-Tr groups, but also caused over oxidation of the intermediate species which 
did not allow the isolation of the desired product. By decreasing the amount of iodine to five 
equivalents (entry 2, Table 1.2), the tandem deprotection/cyclization reaction occurred without 
observable over oxidation byproducts, while maintaining short reaction times. This procedure 
permitted the synthesis of 1.82 in moderate isolated yield. Further decrease in the amount of 
iodine (entry 3, Table 1.2) caused a decrease in yield and longer times to achieve full 
consumption of the starting material. The reaction was also run at higher concentration (entries 4 
and 5, Table 1.2), and despite fast formation of 1.82 was observed, no improvement in yield was 
achieved with respect to the diluted conditions. 
 
 
Scheme 1.16. Completion of the synthesis of Gombamide A. 
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Table 1.2. Tandem deprotection/cyclization of 1.81.
a
 
Entry I2 equiv. Concentration (M) Time
b
 Yield 
1 10.0 0.0008 5 min 0%
c
 
2 5.0 0.0008 30 min 51% 
3 2.0 0.0008 22 h 28% 
4 5.0 0.008 15 min 34% 
5 2.0 0.008 2 h 43% 
a
Reactions were performed in a mixture of DCM:MeOH (12:1) at room temperature. 
b
Time to 
achieve consumption of starting material. 
c
Deprotection along with overoxidation was observed. 
 
The final step to obtain 1.16 was the deprotection of TBS-phenoxysilane 1.82. The 
assessment of several conditions to achieve the formation of 1.16 showed that using 
tetrabutylammonium fluoride or HCl in methanol caused mainly product degradation; while HF-
pyridine or KF in methanol proved to effectively produced 1.16. Ultimately, KF in methanol was 
selected, as this method had the advantage of faster reaction times (6 hours to completion, 
compared to 24 hours for HF-pyridine), and it provided for the first time, Gombamide A 1.16 in 
58% yield (Scheme 1.16). The produced synthetic material displayed identical spectroscopic data 
with respect to the reported isolated Gombamide A. 
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Summary and future directions 
 
In summary, the first total synthesis of Gombamide A 1.16 has been completed, 
employing a convergent synthetic route that required a total of 18 steps, with an overall yield of 
2.5% from p-hydroxybenzaldehyde 1.52 (10 linear step sequence), and 9.1% from benzyl L-
phenylalaninate 1.44 (11 linear step sequence).  
The presented synthesis shows how the introduction of sulfur in a natural product 
molecule is harmful for the majorities of methodologies currently developed for the production of 
enamides. At the same time, this synthesis exemplified the non-trivial task of protecting group 
selection in the presence of distinct functionalities in Gombamide A 1.16. 
The developed synthetic route highlights the azidophenylselenylation and Grieco 
elimination procedures as useful methods in the synthesis of E enamides in the presence of sulfur, 
and a tandem deprotection/cyclization procedure to achieve the formation of the 17-membered 
macrocycle in 1.16. 
The synthetic natural product will allow exploring further the biological effect of these 
molecules. The obtained material is in the process of being submitted to the CANVASS panel 
assay, a program run by the National Center for Advancing Translational Sciences (NCATS) of 
the National Institute of Health (NIH). In these assays, the compound will be tested for its 
anticancer, antibacterial and antiinflammatory activity.  
Finally, this synthetic route provides a way to start questioning the SAR of Gombamide 
A. The use of the synthetic procedure for formation of the enamide and cyclization of the natural 
product, in combination with fast solid-phase peptide synthesis, would allow the production of 
analogs libraries where the impact of mutilple chemical modifications on the activity of 
Gombamide A could be evaluated.   
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EXPERIMENTAL METHODS 
 
General 
All reagents and solvents were commercial grade and purified prior to use when 
necessary. Thin layer chromatography (TLC) was performed on glassbacked silica gel. 
Visualization was accomplished with UV light and/or the use of iodine or ninhydrin solution 
followed by charring on a hot-plate. Flash chromatography on silica gel was performed using 
Silica Gel 60 (230-400 mesh) from Sorbent Technologies. 
1
H and 
13
C NMR spectra were 
recorded on Bruker DRX-400 (400 MHz) instrument. Chemical shifts are reported in ppm 
relative to residual solvent peaks as an internal standard at the following chemical shifts (
1
H and 
13
C respectively): 7.26 and 77.0 ppm for CDCl3; 2.50 and 39.52 ppm for DMSO-d6, 3.31 and 49.2 
ppm for CD3OD. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, dd = doublet of doublets, br = broad, m = multiplet), coupling 
constant (Hz), integration. Optical rotations were measured on a JASCO P-2000 digital 
polarimeter. Concentration in g/100 ml and solvent are given in parentheses and the reported 
value is an average of n=3 independent measurements. Low resolution mass spectra were 
obtained on an Agilent 6130 mass spectrometer with ESI source.  MS parameters were as 
follows:  fragmentor:  100, capillary voltage:  3000 V, nebulizer pressure:  40 psig, drying gas 
flow:  11 L/min, drying gas temperature:  350° C.  Samples were introduced via an Agilent 1200 
HPLC comprised of a degasser, G1312A binary pump, G1367B HP-ALS, G1316A TCC, 
G1315D DAD, and a Varian 380 ELSD.  UV absorption was generally observed at 215 nm and 
254 nm with a 4 nm bandwidth.  Column:  Thermo Accucore C18, 2.1 x 30 mm, 2.6 um. Gradient 
conditions, Method A:  7% to 95% CH3CN in H2O (0.1% TFA) over 1.6 min, hold at 95% 
CH3CN for 0.35 min, 1.5 mL/min, 45° C. Gradient conditions, Method B: 40% to 95% CH3CN in 
H2O (0.1% TFA) over 1.1 min, hold at 95% CH3CN for 0.25 min, 1.5 mL/min, 45° C.  A 
Micromass Qtof API-US mass spectrometer was used to acquire high-resolution mass 
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spectrometry (HRMS) data. The value Δ is the error in the measurement (in ppm) given by the 
equation Δ = [(ME –MT)/ MT] × 106, where ME is the experimental mass and MT is the 
theoretical mass. The HRMS results were obtained with ES as the ion source and leucine 
enkephalin as the reference.  
 
 
Benzyl  N-(tert-butoxycarbonyl)-L-prolyl-L-phenylalaninate (1.45). In a flask, Boc-L-
proline (1.844 g, 8.568 mmol) and hydroxybenzotriazole (1.737 g, 12.85 mmol) were weighted 
and suspended in 75 mL of DCE. Then, while in an ice bath, EDCI hydrochloride was added 
(1.969 g, 10.28 mmol) followed by 2,4,6-collidine (3.4 mL, 25.71 mmol), and finally benzyl L-
phenylalaninate hydrochloride (2.500 g, 8.568 mmol). The mixture was warmed to room 
temperature and stirred for two hours. The reaction was worked up by washing the mixture with 
HCl 1.0 M twice, then the aqueous phase was extracted thrice with DCM. The organic phases 
were combined, washed with brine, dried with magnesium sulfate and filtered. The volatiles were 
eliminated in vacuo and the crude was purified by silica gel flash chromatography (0-20% 
EtOAc/Hex).  A clear oil was obtained (3.890 g, quant.). LC-MS retention time (Method A): 
1.201 min, m/z 352.9 (M-Boc), 396.9 (M-O-t-Bu), 452.9 (M+H). 
1
H NMR (600.1 MHz, CDCl3) 
δ (ppm): 7.34 (m, 5H), 7.20 (m, 3H), 7.02 (m, 2H), 6.50 (br s, 1H, NH), 5.14 (m, 2H), 4.79-4.98 
(m, 1H), 4.13-4.56 (m, 1H), 3.22-3.48 (m, 2H), 3.16 (dd, JABX = 13.9 Hz, 5.9 Hz, 1H), 3.02 (dd, 
JABX = 13.9 Hz, 6.6 Hz, 1H), 1.50-2.34 (m, 4H), 1.40 (m-rotamers, 9H). 
13
C NMR (150.0 MHz, 
CDCl3) δ (ppm) rotamers were observed and denoted with *: 172.2*, 171.8*, 171.1, 155.7*, 
154.6*, 136.0*, 135.7*, 135.2, 129.3*, 129.2*, 128.6, 128.5, 127.1*, 126.9*, 80.8*, 80.3*, 67.2, 
61.0*, 59.9*, 53.4*, 52.7*, 46.9, 38.0, 30.6, 28.3*, 28.2*, 24.5*, 23.4*. 
1
H-NMR corresponds to: 
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Arch. Pharm. Pharm. Med. Chem. 334, 167–172 (2001). [α]D
25
: -66.5 (c 1.0, CHCl3); HRMS 
(TOF,ES+) C26H32N2O5 [M] calculated 452.2311, found 452.2309, Δ = -0.42 ppm. 
 
 
Benzyl  N-(tert-butoxycarbonyl)-L-prolyl-L-prolyl-L-phenylalaninate (1.46). In a 
flask, 1.45 (3.842 g, 8.490 mmol) was dissolved in 72 mL of DCM, to this mixture 8 mL of TFA 
were added drop wise while in an ice bath and the reaction was allowed to warm until room 
temperature. After two hours of stirring, full deprotection of starting material was confirmed by 
LC-MS. The reaction was worked-up by evaporating the solvent and TFA in vacuo. The 
generated amine was used without further purification for the next reaction. Then, in a new flask, 
the Boc-L-proline (2.741 g, 12.734 mmol) and hydroxybenzotriazole (2.581 g, 19.100 mmol) 
were weighted and suspended in 50 mL of DCE. Then, while in an ice bath, EDCI hydrochloride 
was added (2.927 g, 15.284 mmol) followed by 2,4,6-collidine (3.37 mL, 25.491 mmol), and 
finally a solution of the deprotected amine obtained from 1.45 in 20 mL of DCE. The mixture 
was warmed to room temperature and stirred for 1.5 hours. The reaction was worked up by 
washing the mixture with HCl 1.0 M twice, then the aqueous phase was extracted thrice with 
DCM. The organic phases were combined, washed with brine, dried with magnesium sulfate and 
filtered. The volatiles were eliminated in vacuo and the crude was purified by silica gel flash 
chromatography (0-50% EtOAc/Hex).  A clear solid was obtained (4.140 g, 89%). LC-MS 
retention time (Method A): 1.150 min, m/z 450.1 (-Boc), 550.2 (M+H), 572.1 (M+Na). 
1
H NMR 
(600.1 MHz, CDCl3) δ (ppm): 8.58 (d, J = 8.3 Hz, 1H, NH), 7.28-7.38 (m, 5H), 7.24-7.28 (m, 
2H), 7.17-7.23 (m, 2H), 7.03-7.08 (m, 1H), 5.06-5.18 (m, 2H), 4.81 (m, 0.5H), 4.72 (m, 0.5H), 
4.63 (m, 0.5H), 4.43 (dd, J = 7.8 Hz, J = 3.2 Hz, 0.25H), 4.31 (dd, J = 8.2 Hz, J = 4.7 Hz, 0.25H), 
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4.17 (m, 1H), 3.69 (q, J = 8.6 Hz, 0.25H), 3.56-3.62 (m, 0.25H), 3.48-3.56 (m, 1H), 3.35-3.48 (m, 
2H), 3.29-3.34 (m, 0.5H), 3.23-3.28 (m, 0.5H), 3.13-3.20 (m, 1H), 3.01-3.09 (m, 0.5H), 2.22-2.42 
(m, 1H), 1.52-2.07 (m, 6.5H), 1.32-1.52 (m, 9H), 0.86-0.99 (m, 0.5H).
13
C NMR (150.0 MHz, 
CDCl3) δ (ppm): 173.1, 172.7, 171.7, 171.3, 171.21, 171.16, 171.0, 170.9, 154.7, 154.5, 153.6, 
137.7, 136.1, 136.0, 135.6, 135.2, 129.21, 129.18, 129.1, 128.53, 128.49, 128.4, 128.4, 128.2, 
128.0, 128.8, 126.6, 79.9, 79.6, 79.5, 67.14, 67.09, 66.96, 60.8, 59.84, 59.78, 58.0, 57.52, 57.47, 
54.3, 53.45, 53.39, 47.00, 46.98, 46.97, 46.85, 46.62, 46.58, 37.63, 37.57, 36.0, 31.3, 30.2, 29.4, 
28.9, 28.53, 28.50, 28.39, 27.1, 27.0 25.2, 25.1, 24.4, 24.2, 23.7, 21.5; [α]D
25
: -84.4 (c 1.0, 
CHCl3); HRMS (TOF,ES+) C31H39N3O6 [M] calculated 549.2839, found 549.2838, Δ = -0.23 
ppm. 
 
 
4-Vinylphenol (1.71). In a flask, methyltriphenylphosphonium bromide (25.01 g, 
70.01mmol) was suspended in 80 mL of THF. Then, potassium tert-butoxide (15.71 g, 140.0 
mmol) was added and the reaction was stirred at room temperature for 10 minutes. After this 
time, a solution of 4-hydroxybenzaldehyde (8.550 g, 70.01mmol) dissolved in THF (40 ml) was 
added dropwise. The reaction was stirred for 16 hours at room temperature, consumption of 
starting material and formation of product was confirmed by LC-MS. The reaction was worked 
up by addition of HCl 1.0 M and successive extractions with DCM. The organic phase was 
reextracted with a solution of K2CO3 20%, diluted in water to obtain a pH of 10. Then, the 
aqueous phase was neutralized and acidified to pH=5, and extracted with CHCl3:IPA (3:1). These 
last organic phases were combined, dried with MgSO4 and filtered. The volatiles were eliminated 
in vacuo and the crude was purified by silica gel flash chromatography (0-20% EtOAc/Hex). A 
white solid was obtained (8.00 g, 95%). LC-MS retention time (Method A): 0.778 min. 
1
H NMR 
(600.1 MHz, CDCl3) δ (ppm): 7.31 (d, J = 8.5 Hz, 2H), 6.80 (d, J = 8.6 Hz, 2H), 6.66 (dd, J = 
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17.6, 10.9 Hz, 1H), 5.61 (dd, J = 17.6, 0.84 Hz, 1H), 5.13 (dd, J = 10.9, 0.84 Hz, 1H), 4.88 (s, 
1H, OH).
13
C NMR (150.0 MHz, CDCl3) δ (ppm): 155.1, 136.1, 130.6, 127.6, 115.3, 111.6. 
HRMS (TOF,ES+) C8H8O [M] calculated 120.0575, found 120.0571, Δ = -3.25 ppm. 
  
 
tert-Butyldimethyl(4-vinylphenoxy)silane (1.72). In a flask, 1.71 (1145 mg, 9.530 
mmol) was weighted and suspended in a mixture of DCM (36 mL) and DMF (4mL). Then, 
triethylamine (2.66 mL, 19.06 mmol) was added, followed by tert-butyldimethylchlorosilane 
(2873 mg, 19.06 mmol) . The reaction was stirred at room temperature for 3 hours, after this time 
LC-MS showed full consumption of the starting material and formation of product. The reaction 
was worked up by addition of water and successive extractions with DCM. The organic phases 
were combined, dried with MgSO4, filtered. The volatiles were eliminated in vacuo and the crude 
was purified by silica gel flash chromatography (0-10% EtOAc/Hex). A clear colorless oil was 
obtained (2202 mg, 99%). LC-MS retention time (Method A): 1.477 min. 
1
H NMR (400.1 MHz, 
CDCl3) δ (ppm): 7.35 (d, J = 8.5 Hz, 2H), 6.88 (d, , J = 8.6 Hz, 2H), 6.72 (dd, J = 17.6, 10.9 Hz, 
1H), 5.67 (dd, J = 17.6, 0.9 Hz, 1H), 5.19 (dd, J = 10.9, 0.9 Hz, 1H), 1.08 (s, 9H), 0.28 (s, 6H). 
13
C NMR (100.0 MHz, CDCl3) δ (ppm): 155.5, 136.3, 131.0, 127.3, 111.6, 25.7, 18.2, -4.4; 
HRMS (TOF,ES+) C14H22Osi [M] calculated 234.1440, found 234.1430, Δ = -4.38 ppm. 
 
 
(4-(2-azido-1-(phenylselanyl)ethyl)phenoxy)(tert-butyl)dimethylsilane (1.73). In a 
flask, 1.72 (1000 mg, 4.266 mmol) was dissolved in  21 mL DCM. The mixture was cooled to -30 
°C, then, the diphenyl diselenide (1332 mg, 4.266 mmol) was added. To this solution, 
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iodobenzene diacetate (1374 mg, 4.266mmol) and azidotrimethylsilane (1.12 mL, 8.53mmol) 
were added sequentially. After two hours, LC-MS showed full consumption of starting material 
along with formation of the desired product. The solvent was evaporated and the crude product 
was purified by silica gel flash chromatography (0-3% EtOAc/Hex). A yellow oil was obtained 
(1368 mg, 74%). LC-MS retention time (Method B): 1.159 min, m/z 276.2 (M-PhSe), 391.0 (M-
N3). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.44-7.50 (m, 2H), 7.35-7.22 (m, 3H), 7.11 (d, J = 
8.5 Hz, 2H), 6.78 (d, J = 8.5 Hz, 2H), 4.40 (dd, J = 9.6, 5.7 Hz, 1H), 3.84 (dd, J = 12.6, 9.6 Hz, 
1H), 3.66 (d, J = 12.6, 5.7 Hz, 1H),   1.00 (s, 9H),  0.21 (s, 6H). 
13
C NMR (100.0 MHz, CDCl3) δ 
(ppm): 155.3, 135.6, 131.3, 129.1, 128.9, 128.4, 128.3, 120.3, 55.5, 45.9, 25.6, 18.2, -4.5. HRMS 
(TOF,ES+) C57H58N2O4SseSi [M] calculated 433.1081, found 433.1089, Δ = -1.83 ppm. 
 
 
2-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-(phenylselanyl)ethan-1-amine (1.74). In 
a flask, 1.73 (2500 mg, 5.781 mmol) was weighted and suspended in THF (29 mL). Then,  a 
solution of lithium aluminum hydride 1.0 M in THF (5.8 mL, 5.781 mmol) was added, partial 
consumption of the azide product was observed after 30 minutes of reaction. Another 1.0 
equivalent of LiAlH4 was added and after 10 minutes of stirring, full consumption of the starting 
material was observed. The reaction was quenched using Glauber’s salt, stirred for 30 minutes 
and filtered. The solvent was evaporated and the crude product was purified by silica gel flash 
chromatography (0-5% MeOH in DCM). A yellow oil was obtained (979 mg, 42%).  LC-MS 
retention time (Method A): 1.150 min, m/z 391.0 (M-NH2). 
1
H NMR (400.1 MHz, CDCl3) δ 
(ppm): 7.23-7.29 (m, 2H), 7.00-7.13 (m, 3H), 6.89 (d, J = 8.5 Hz, 2H), 6.59 (d, J = 8.5 Hz, 2H), 
4.05 (dd, J = 8.3, 6.3 Hz, 1H), 3.04 (dd, J = 13.4, 8.4 Hz, 1H), 2.97 (dd, J = 13.4, 6.3 Hz, 1H), 
0.82 (s, 9H),  0.03 (s, 6H). 
13
C NMR (100.0 MHz, CDCl3) δ (ppm): 154.8, 135.5, 132.6, 129.0, 
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128.8, 128.7 127.8, 120.1, 51.1, 46.8, 25.6, 18.1, -4.5. HRMS (TOF,ES+) C57H58N2O4SseSi [M] 
calculated 407.1183, found 407.1184, Δ = -0.21 ppm. 
 
 
(9H-fluoren-9-yl)methyl ((2R)-1-((2-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-
(phenylselanyl)ethyl)amino)-1-oxo-3-(tritylthio)propan-2-yl)carbamate (1.75). In a flask,  
Fmoc-L-cysteine-S-trityl (1506 mg, 2.571 mmol) and HATU (1066 mg, 2.804 mmol), were 
weighted and suspended in 13 mL of DCE. Then, 2,4,6-trimethylpyridine (0.93 mL, 7.011 
mmol) was added and the mixture was stirred for 2 minutes. After this time, a solution of 1.74 
(950 mg, 2.337 mmol) in 10 mL of DCE was added. The reaction was stirred for 1 h at room 
temperature. The reaction was quenched by addition of water and extracted with DCM thrice. The 
organic phases were combined, dried with MgSO4 and filtered. The solvent was evaporated and 
the crude product was purified by silica gel flash chromatography (0-25% EtOAc in Hex). A 
white solid was obtained (2240 mg, 98%).  LC-MS retention time (Method B): 1.450 min, m/z 
996.6 (M+Na). 
1
H NMR (600.1 MHz, CDCl3) δ (ppm): 7.63 (t, J = 7.4 Hz, 2H), 7.39-7.46 (m, 
2H), 7.23-7.29 (m, 10H), 7.03-7.18 (m, 14H), 6.82 (d, J = 8.4 Hz, 2H), 6.48-6.54 (m, 2H), 5.73-
5.85 (m, 1H), 4.69-4.79 (m, 1H), 4.13-4.26 (m, 3H), 4.00-4.07 (m, 1H), 3.59-3.69 (m, 1H), 3.42-
3.54 (m, 1.5H), 3.29-3.36 (m, 0.5H), 2.38-2.54 (m, 2H), 0.83-0.88 (m, 9H), 0.03-0.07 (m, 6H). 
13
C NMR (150.0 MHz, CDCl3) δ (ppm): 169.82, 169.79, 155.8, 155.7, 155.1, 155.0, 144.3, 
143.73, 143.67, 141.3, 135.5, 135.3, 131.8, 129.6, 129.04, 129.00, 128.9, 128.1, 127.8, 127.1, 
126.92, 126.91, 125.04, 120.22, 120.18, 120.0, 67.38, 67.33, 66.92, 66.86, 53.97, 53.88, 47.1, 
45.9, 44.1, 43.9, 33.8, 25.7, 18.2, -4.4. 
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(9H-fluoren-9-yl)methyl (R,E)-(1-((4-((tert-butyldimethylsilyl)oxy)styryl)amino)-1-
oxo-3-(tritylthio)propan-2-yl)carbamate (1.76). In a flask, 1.75 (1000 mg, 1.027 mmol)  was 
added and suspended in THF (20 mL). Then, an aqueous solution of hydrogen peroxide 30% (127 
µL, 1.23 mmol) was added. The reaction was stirred for 1 hour at room temperature. LC-MS 
shows consumption of the starting material and formation of the desired product. The solvent was 
evaporated and the crude product was purified by silica gel flash chromatography (0-20% EtOAc 
in Hex). A colorless solid was obtained, (673 mg, 80%). LC-MS retention time (Method B): 
1.285 min, m/z 838.9 (M+Na). 
1
H NMR (600.1 MHz, CDCl3) δ (ppm): 7.75 (m, 2H) 7.52-7.64 
(m, 2H),  7.34-7.43 (m, 8H), 7.24-7.29 (m, 8H), 7.15-7.22 (m, 5H), 7.13 (d, J = 8.4 Hz, 2H), 6.74 
(d, J = 8.4 Hz, 2H), 6.00 (d, J = 14.6 Hz, 1H), 4.93-5.0 (m, 1H), 4.38-4.46 (m, 2H), 4.18 (t, J = 
6.6 Hz, 1H), 3.78-3.84 (m, 1H), 2.69-2.74 (m, 1H), 2.62-2.68 (m, 1H), 0.97 (s, 9H), 0.18 (s, 6H). 
13
C NMR (150.0 MHz, CDCl3) δ (ppm): 167.3, 156.3, 154.8, 144.3, 143.6, 141.3, 129.6, 128.9, 
128.2, 127.8, 127.1, 127.0, 126.8, 125.0, 120.35, 120.30, 120.1, 114.2, 67.5, 67.1, 54.1, 47.1, 
33.5, 25.7, 18.2, -4.4. [α]D
25
: -8.8 (c 1.0, CHCl3); HRMS (TOF,ES+) C51H52N2O4Ssi [M] 
calculated 816.3417, found 816.3390, Δ = -3.29 ppm. 
 
 
(R,E)-2-amino-N-(4-((tert-butyldimethylsilyl)oxy)styryl)-3-(tritylthio)propanamide 
(1.77). In a vial, 1.76 (2043 mg, 2.5 mmol) was added and dissolved in 60 mL of acetonitrile. 
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Then, morpholine (647 µL, 7.5 mmol) was added while stirring. The reaction was stirred at room 
temperature for 24 hours, formation of product and full conversion was confirmed by LC-MS.  
The reaction was quenched by addition of water and extracted with DCM. The organic phases 
were combined and washed with aqueous LiCl 5%, dried with sodium sulfate and filtered. The 
solvent was evaporated and the crude product was purified by silica gel flash chromatography (0-
5% MeOH in DCM). A pale yellow oil was obtained, (1067 mg, 72%). LC-MS retention time 
(Method B): 0.932 min, m/z 243.0 (Tr), 633.0 (M+K), 1189.1 (2M+H). 
1
H NMR (600.1 MHz, 
CDCl3) δ (ppm): 8.97 (d, J = 8.4 Hz, 1H), 7.45-7.50 (m, 6H), 7.28-7.35 (m, 6H), 7.21-7.27 (4H), 
7.18 (d, J = 8.6 Hz, 2H), 6.77 (d, J = 8.6 Hz, 2H), 6.08 7 (d, J = 14.6 Hz, 1H), 3.11-3.16 (m, 1H), 
2.77-2.82 (m, 1H), 2.60-2.67 (m, 1H), 1.00 (s, 9H), 0.21 (s, 6H). 
13
C NMR (150.0 MHz, CDCl3) δ 
(ppm): 170.2, 154.6, 144.5, 129.5, 129.2, 128.0, 126.8, 126.6, 120.5, 120.2, 113.3, 67.1, 53.7, 
37.0, 25.6, 18.1, -4.5. [α]D
25
: -17.1 (c 1.0, CHCl3); HRMS (TOF,ES+) C36H42N2O2Ssi [M] 
calculated 594.2736, found 594.2729, Δ = -1.22 ppm. 
 
 
Benzyl S-(acetamidomethyl)-N-(tert-butoxycarbonyl)-L-cysteinyl-L-prolyl-L-prolyl-
L-phenylalaninate (1.78).  In a flask, 1.46 (670 mg, 1.219 mmol) was dissolved in 18 mL of 
DCM; to this mixture, 2 mL of TFA were added drop wise while in an ice bath and the reaction 
was allowed to warm until room temperature. After two hours of stirring, full deprotection of 
starting material was confirmed by LC-MS. The reaction was worked-up by evaporating the 
solvent and TFA in vacuo. The generated amine was used without further purification for the next 
reaction. Then, in a new flask, the Boc-L-cysteine-SAcm (535 mg, 1.828 mmol) and 
hydroxybenzotriazole (371 mg, 2.743 mmol) were weighted and suspended in 10 mL of DCE. 
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Then, while in an ice bath, EDCI hydrochloride was added (420 mg, 2.194 mmol) followed by 
2,4,6-collidine (483 µL, 3.657 mmol), and finally a solution of the deprotected amine obtained 
from 16 in 10 mL of DCE. The mixture was warmed to room temperature and stirred for 2 hours. 
The mixture was worked up by washing with HCl 1.0 M twice, then the aqueous phase was 
extracted thrice with DCM. The organic phases were combined, washed with brine, dried with 
magnesium sulfate and filtered. The volatiles were eliminated in vacuo and the crude was purified 
by silica gel flash chromatography (0-70% EtOAc/Hex).  A white solid was obtained (730 mg, 
83%). LC-MS retention time (Method A): 1.197 min, m/z 724.3 (M+H). 
1
H NMR (600.1 MHz, 
CDCl3) δ (ppm): 8.40 (d, J = 8.3 Hz, 0.5H, NH), 7.61 (m, 0.5H, NH), 7.49 (m, 0.5H, NH), 7.31-
7.38 (m, 3H), 7.27-7.30 (m, 2H), 7.22-7.25 (m, 1H), 7.16-7.21 (m, 3H), 6.97-7.02 (m, 1H), 6.82 
(d, J = 7.1 Hz, 0.5H, NH), 5.48-5.65 (m, 1H, NH), 5.02-5.19 (m, 2H), 4.79-4.84 (m, 0.5H), 4.70-
4.76 (m, 0.5H), 4.56-4.64 (m, 1H), 4.48-4.51 (m, 0.5H), 4.23-4.47 (m, 2.5H), 4.12-4.17 (m, 1H), 
3.64-3.76 (m, 2H), 3.51-3.58 (m, 0.5H), 3.44-3.49 (m, 0.5H), 3.33-3.41 (m, 1H), 3.19-3.25 (m, 
0.5H), 3.10-3.18 (m, 1H), 3.03-3.09 (m, 0.5H), 2.82-2.98 (m, 2H), 2.61-2.66 (m, 0.5H), 2.21-2.41 
(m, 1H), 1.79-2.12 (m, 7H), 1.62-1.76 (m, 2H), 1.40-1.50 (m, 9H), 1.014-1.14 (m, 0.5H). 
13
C 
NMR (150.0 MHz, CDCl3) δ (ppm): 173.4, 171.9, 171.2, 171.1, 170.72, 170.67, 170.63, 170.58, 
170.1, 169.9, 155.42, 155.37, 154.7, 137.3, 135.7, 137.5, 135.0, 129.3, 129.1, 128.63, 128.61, 
128.54, 128.45, 128.41, 128.34, 128.1, 127.1, 126.8, 123.6, 80.4, 80.1, 67.3, 67.1, 61.1, 60.1, 
59.1, 58.2, 54.1, 53.2, 51.5, 51.1, 47.7, 47.5, 47.2, 46.9, 42.2, 41.6, 41.4, 37.5, 36.4, 35.3, 32.9, 
32.7, 31.4, 28.44, 28.41, 28.35, 28.33, 28.2, 27.6, 24.99, 24.96, 24.94, 23.2, 23.0, 21.6, 21.5, 
21.0.[α]D
25
: -38.9 (c 1.0, CHCl3); HRMS (TOF,ES+) C37H49N5O8S [M] calculated 723.3302, 
found 723.3295, Δ = -0.94 ppm. 
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Benzyl S-(acetamidomethyl)-N-((S)-5-oxopyrrolidine-2-carbonyl)-L-cysteinyl-L-
prolyl-L-prolyl-L-phenylalaninate (1.79). In a flask, 1.78 (485 mg, 0.670 mmol) was dissolved 
in 7.6 mL of DCM; to this mixture, 0.4 mL of TFA were added drop wise while in an ice bath and 
the reaction was allowed to warm until room temperature. After two hours of stirring, full 
deprotection of starting material was confirmed by LC-MS. The reaction was worked-up by 
evaporating the solvent and TFA in vacuo. The generated amine was used without further 
purification for the next reaction. Then, in a new flask, the L-pyroglutamic (95 mg, 0.737 mmol) 
and 1-hydroxyl-7-azabenzotriazole (137 mg, 1.005 mmol) were weighted and suspended in 7 mL 
of DCE. Then, while in an ice bath, HATU was added (306 mg, 0.804 mmol) followed by 2,4,6-
collidine (266 µL, 2.010 mmol), and finally a solution of the deprotected amine obtained from 28 
in 7 mL of DCE. The reaction was warmed to room temperature and stirred for 2 hours. The 
mixture was worked up by washing with HCl 1.0 M twice, then the aqueous phase was extracted 
thrice with DCM. The organic phases were combined, washed with brine, dried with magnesium 
sulfate and filtered. The volatiles were eliminated in vacuo and the crude was purified by reverse 
phase C18 flash chromatography (0-50% ACN/water 0.1% TFA).  A white solid was obtained 
(428 mg, 87%). LC-MS retention time (Method A): 0.891 min, m/z 735.0 (M+H). 
1
H NMR 
(600.1 MHz, CDCl3) δ (ppm): 8.37 (d, J = 9.0 Hz, 0.5H, NH), 7.60 (d, J = 7.7 Hz, 0.5H, NH), 
7.45-7.50 (m, 0.5H, NH), 7.32-7.38 (m, 3H), 7.26-7.32 (m, 3H), 7.22-7.25 (m, 1H), 7.16-7.21 (m, 
3H), 7.03-7.06 (m, 0.5H, NH), 6.97-7.03 (m, 1H), 6.92 (d, J = 7.0 Hz, 0.5H, NH), 6.77 (s, 1H, 
NH), 5.01-5.21 (m, 1.5H), 4.83-4.96 (m, 2H), 4.76-4.82 (m, 0.5H), 4.59-4.66 (m, 0.5H), 4.51-
4.56 (m, 0.5H), 4.37 (d, J = 6.1 Hz, 1H), 4.27-4.33 (m, 0.5H), 4.21-4.21 (m, 1H), 4.11-4.18 (m, 
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1H), 3.99-4.05 (m, 0.5H), 3.62-3.78 (m, 1.5H), 3.49-3.55 (m, 0.5H), 3.42-3.48 (m, 1H), 3.32-3.39 
(m, 0.5H), 3.23-3.29 (m, 0.5H), 2.79-3.16 (m, 4H), 2.52-2.59 (m, 0.5H), 2.40-2.50 (m, 1.5H), 
2.15-2.37 (m, 3H), 1.90-2.13 (m, 7H), 1.71-1.79 (m, 0.5H), 1.60-1.70 (m, 1.5H), 1.39-1.48 (m, 
0.5H), 0.97-1.07 (m, 0.5H). 
13
C NMR (150.0 MHz, CDCl3) δ (ppm): 179.1, 178.8, 172.4, 172.0, 
171.4, 171.2, 171.0, 170.92, 170.86, 170.23, 170.18, 137.1, 135.8, 135.3, 135.0, 129.3, 129.1, 
128.7, 128.61, 128.57, 128.45, 128.41, 128.36, 127.0, 126.7, 67.3, 67.1, 61.2, 60.1, 59.2, 58.3, 
57.12, 57.06, 53.3, 53.1, 50.7, 50.2, 47.7, 47.6, 47.2, 46.9, 41.4, 41.1, 37.5, 36.3, 32.0, 31.6, 31.5, 
29.35, 29.26, 28.4, 28.1, 27.9, 26.0, 25.6, 25.0, 24.9, 24.8, 23.1, 23.0, 21.5. [α]D
25
: -73.9 (c 1.0, 
CHCl3); HRMS (TOF,ES+) C37H46N6O8S [M] calculated 734.3098, found 734.3092, Δ = -0.86 
ppm. 
 
 
S-(acetamidomethyl)-N-((S)-5-oxopyrrolidine-2-carbonyl)-L-cysteinyl-L-prolyl-L-
prolyl-L-phenylalanine (1.80). In a flask, 1.79 (2.360 g, 3.211 mmol) was dissolved in 30 mL of 
DCM. Then, a solution of aluminum chloride (2.569 g, 19.26 mmol) in nitromethane was added 
dropwise while in an ice bath. The reaction was warmed to room temperature and stirred for 1 
hour. After this time, formation of product and consumption of starting material was confirmed 
by LC-MS. The reaction was quenched by addition of water and it was worked up by successive 
extractions with CHCl3:IPA (3:1). The organic phases were combined, washed with brine, dried 
with magnesium sulfate and filtered. The volatiles were eliminated in vacuo and the crude was 
purified by reverse phase C18 flash chromatography (0-60% ACN/water 0.1% TFA).  A white 
solid was obtained (1.950 g, 94%). LC-MS retention time (Method A): 0.748 min, m/z 645.0 
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(M+H). 
1
H NMR (600.1 MHz, CDCl3) δ (ppm): 8.16 (d, J = 8.9 Hz, 1H), 7.71 (s, 1H), 7.68 (t, J = 
5.8 Hz, 1H), 7.27 (t, J = 7.3 Hz, 2H), 7.18-7.23 (m, 3H), 6.98 (d, J = 8.6 Hz, 1H), 4.89-5.00 (m, 
2H), 4.64 (dd, JABX = 13.5 Hz, J = 6.8 Hz, 1H), 4.21-4.32 (m, 3H), 4.11 (dd, JABX = 13.6 Hz, J = 
5.6 Hz, 1H), 3.76-3.87 (m, 1H), 3.65-3.73 (m, 1H), 3.46 (dd, JABX = 14.1 Hz, J = 4.6 Hz, 1H), 
3.38-3.43 (m, 1H), 3.21-3.27 (m, 1H), 2.93-3.00 (m, 2H), 2.74 (dd, JABX = 14.3 Hz, J = 5.3 Hz, 
1H), 2.56-2.64 (m, 2H), 2.42-2.50 (m, 2H), 2.12-2.26 (m, 3H), 2.06 (s, 3H), 1.85-2.01 (m, 3H), 
1.57-1.64 (m, 1H), 0.80-0.90 (m, 1H). 
13
C NMR (150.0 MHz, CDCl3) δ (ppm): 181.0, 175.1, 
171.6, 171.4, 170.6, 170.4, 168.6, 136.9, 129.0, 128.6, 127.0, 61.4, 59.6, 57.6, 53.0, 51.7, 47.9, 
46.9, 42.9, 38.0, 33.1, 31.7, 29.5, 28.8, 25.6, 25.2, 22.8, 21.4. [α]D
25
: -86.7 (c 1.0, CHCl3); HRMS 
(TOF,ES+) C30H40N6O8S [M] calculated 644.2628, found 644.2630, Δ = +0.26 ppm. 
 
 
(S)-N-((S)-1-((I-3-((acetamidomethyl)thio)-1-(((E)-4-((tert-
butyldimethylsilyl)oxy)styryl)amino)-1-oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-
1-(N-((S)-5-oxopyrrolidine-2-carbonyl)-S-trityl-L-cysteinyl-L-prolyl)pyrrolidine-2-
carboxamide (1.81). In a flask, 1.80 (1149 mg, 1.781 mmol) and HATU (813 mg, 2.138 
mmol), were weighted and suspended in 30 mL of DCE. Then, 2,4,6-trimethylpyridine (0.353 
mL, 2.673 mmol) was added and the mixture was stirred for 2 minutes. Then, while in an ice 
bath, a solution of 1.77 (1060 mg, 1.781 mmol) in 15 mL of DCE was added dropwise. The 
reaction was warmed to room temperature and stirred for 1 hour; formation of product and 
consumption of starting material was confirmed by LC-MS. The reaction was quenched by 
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addition of water. Then, it was worked up by successive extractions with CHCl3:IPA (3:1). The 
organic phases were combined, dried with MgSO4 and filtered. The solvent was evaporated and 
the crude product was purified by reverse phase C18 flash chromatography (0 to 60% ACN in 
water-TFA 0.1%). A white solid was obtained (1129 mg, 51%). LC-MS retention time (Method 
A): 1.368 min, m/z 243.0 (Tr+), 979.2 (M-Tr) 1243.2 (M+Na). 
1
H NMR (600.1 MHz, CDCl3) δ 
(ppm): 8.66 (d, J = 10.3 Hz, 1H), 8.24-8.37 (m , 1H), 7.37-7.42 (m, 3H), 7.31-7.36 (m, 6H), 7.27-
7.31 (m, 5H), 7.07-7.25 (m, 13H), 6.70-6.77 (m, 2H), 6.10-6.23 (m, 1H), 4.94-5.02 (m, 0.6H), 
4.74-4.82 (m, 0.4H), 4.61-4.67 (m, 0.6H), 4.56-4.61 (m, 0.6H), 4.49-4.53 (m, 0.4H), 4.43-4.48 
(m, 0.4H), 4.24-4.36 (m, 0.8H), 4.17-4.24 (m, 1.6H), 4.06-4.17 (m, 2H), 3.92-3.98 (m, 0.6H), 
3.72-3.79 (m, 1H), 3.55-3.64 (m, 1H), 3.14-3.41 (m,3H), 2.92-3.11 (m, 2H), 2.79-2.87 (m, 1H), 
2.63-2.69 (m, 1H),  2.27-2.59 (m, 3H), 2.15-2.26 (m, 2H), 1.55-2.07 (m, 11H), 0.94-0.99 (m, 9H), 
0.16-0.19 (m, 6H). 
13
C NMR (150.0 MHz, CDCl3) δ (ppm): 178.8, 172.7, 172.5, 172.4, 172.2, 
171.1, 170.9, 170.7, 170.6, 170.2, 169.2, 169.1, 167.5, 167.3, 154.9, 154.6, 144.4, 144.1, 136.9, 
135.7, 129.8, 129.6, 129.5, 129.36, 129.32, 129.1, 129.02, 129.97, 128.6, 128.2, 128.1, 127.08, 
127.03, 126.9, 126.7, 120.4, 120.3, 114.5, 114.3, 67.6, 67.5, 61.4, 61.2, 59.3, 58.3, 57.2, 57.0, 
54.9, 54.5, 53.6, 53.1, 51.2, 50.7, 47.9, 47.5, 46.9, 42.1, 41.8, 36.3, 33.8, 33.1, 32.9, 32.1, 31.5, 
29.6, 29.4, 28.7, 28.4, 28.2, 26.0, 25.7, 25.4, 25.3, 25.0, 23.1, 23.0, 21.5, 18.3, -4.4. [α]D
25
: -31.7 
(c 1.0, CHCl3). 
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(6R,11R,14S,16aS,21aS)-14-benzyl-N-((E)-4-((tert-butyldimethylsilyl)oxy)styryl)-
5,13,16,21-tetraoxo-6-((S)-5-oxopyrrolidine-2-carboxamido)hexadecahydro-1H,5H,10H-
dipyrrolo[2,1-j:2’,1’-m][1,2]dithia[5,8,11,14]tetraazacycloheptadecine-11-carboxamide 
(1.82). In a flask, iodine (104 mg, 0.410mmol) was dissolved in 80 mL of a mixture of 
DCM:MeOH (9:1). A solution of 1.81 (100 mg, 0.082 mmol) in 16 mL of DCM was added 
dropwise and while stirring. The reaction was stirred for 30 minutes, formation of product and 
consumption of starting material was confirmed by LC-MS. The reaction was quenched with 5% 
sodium thiosulfate solution, then water was added to the mixture and extractions with DCM were 
performed.  The organic phases were combined, dried with MgSO4 and filtered. The solvent was 
evaporated and the crude product was purified by reverse phase C18 column flash 
chromatography (0 to 70% ACN in water-TFA 0.1%). A white solid was obtained (37.9 mg, 
51%). LC-MS retention time (Method A): 1.243 min, m/z 906.2 (M+H). 
1
H NMR (600.1 MHz, 
CDCl3) δ (ppm): 9.64 (br s, 1H), 9.16 (br d, J =7.1 Hz), 7.88-8.16 (m, 2H), 7.27-7.34 (m, 3H), 
7.18-7.25 (m, 5H), 7.06 (t, J = 7.1 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.38 (t, J = 7.1 Hz, 1H), 
4.90-4.99 (m, 1H), 4.62-4.85 (m, 3H), 4.32-4.39 (m, 1H), 4.19-4.30 (m, 1H), 3.69-3.82 (m, 1H), 
3.50-3.61 (m, 1H), 3.30-3.39 (m, 1H), 3.19-3.29 (m, 2H), 3.10-3.19 (m, 2H), 2.97-3.07 (m, 1H), 
2.87-2.96 (m, 1H), 2.61-2.75 (m, 2H), 2.18-2.35 (m, 4H), 1.75-1.98 (m, 5H), 1.32-1.44 (m, 1H), 
0.97 (s, 9H), 0.25-0.35 (m, 1H), 0.19 (s, 6H). 
13
C NMR (150.0 MHz, CDCl3) δ (ppm): 180.5, 
172.7, 171.6, 171.4, 169.9, 169.1, 166.7, 154.7, 136.9, 129.4, 129.3, 128.8, 126.9, 120.9, 120.6, 
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120.2, 115.1, 61.0, 59.8, 56.6, 54.0, 51.3, 49.4, 47.0, 46.8, 42.4, 38.6, 33.7, 32.3, 30.9, 29.6, 25.9, 
25.7, 22.3, 20.0, 18.2, -4.4. [α]D
25
: 29.6 (c 1.0, CHCl3); HRMS (TOF,ES+) C44H59N7O8S2Si [M] 
calculated 905.3636, found 905.3634, Δ = -0.24 ppm. 
 
 
Gombamide A, (6R,11R,14S,16aS,21aS)-14-benzyl-N-((E)-4-hydroxystyryl)-
5,13,16,21-tetraoxo-6-((S)-5-oxopyrrolidine-2-carboxamido)hexadecahydro-1H,5H,10H-
dipyrrolo[2,1-j:2’,1’-m][1,2]dithia[5,8,11,14]tetraazacycloheptadecine-11-carboxamide 
(1.16). In a flask, 1.82 (29.0 mg, 0.032 mmol)  was weighted and dissolved in methanol (1.60 
mL). Then, potassium fluoride (1.9 mg, 0.032 mmol) was added to the mixture and the reaction 
was stirred for 6 hours at room temperature. Consumption of starting material and formation of 
product was confirmed by LC-MS. The solvent was evaporated and the crude product was 
purified by reverse phase C18 column flash chromatography (0 to 40% ACN in water-TFA 
0.1%). A white solid was obtained (14.6 mg, 58%). LC-MS retention time (Method A): 0.951 
min, m/z 792.1 (M+H). For 
1
H NMR (600.1 MHz, CDCl3) δ (ppm) and 
13
C NMR (150.0 MHz, 
CDCl3) δ (ppm) see Table S1. [α]D
25
: 79.8 (c 1.0, CHCl3); HRMS (TOF,ES+) C44H59N7O8S2Si 
[M] calculated 791.2771, found 791.2767, Δ = -0.54 ppm. 
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Table 1.3. NMR data comparison between isolated
a
 and synthetic
b
 Gombamide A (1.16). 
 
Position 
Isolated Synthetic 
δC δH (J in Hz) δC δH (J in Hz) 
Cys 1 1 167.4, C - 167.5, C - 
 2 51.5, CH 4.62, ddd (12.0, 8.7, 3.2) 51.6, CH 4.62, m (3.2, 8.7) 
 3 41.8, CH2 3.15, dd (14.1, 3.2) 41.8, CH2 3.14, dd (14.6, 3.4) 
   2.91, dd (14.1, 12.0)  2.90, dd (13.9, 12.2) 
 2-NH  7.67, d (8.7)  7.67, d (8.6) 
Phe 4 171.0, C - 171.1, C - 
 5 53.2, CH 4.88, ddd (12.7, 8.8, 4.3) 53.2, CH 4.88, dd (8.8, 4.3) 
 6 33.8, CH2 3.07, dd (14.2, 12.7) 33.9, CH2 3.07, dd (13.7, 13.2) 
   2.96, dd (14.2, 4.3)  2.96, dd (14.0, 3.7) 
 7 138.1, C - 138.1, C - 
 8/12 129.5, CH 7.39, br d (7.4) 129.6, CH 7.38, br d (7.4) 
 9/11 128.0, CH 7.22, dd (7.7, 7.4) 128.1, CH 7.22, t (7.4) 
 10 126.0, CH 7.16, t (7.7) 126.0, CH 7.15 ,dd (8.0, 6.6) 
 5-NH  9.14, d (8.8)  9.14, d (8.6) 
Pro 3 13 171.4, C - 171.5, C - 
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 14 60.3, CH 4.35, br d (8.0) 60.4, CH 4.34, br d (7.9) 
 15 31.1, CH2 1.83, m 31.1, CH2 1.83, m 
   1.70, m  1.69, m 
 16 19.7, CH2 1.31, m 19.7, CH2 1.30, m 
   0.23, m  0.22, m 
 17 45.8, CH2 3.22, ddd (11.0, 8.6, 3.2) 45.8, CH2 3.22, m, (11.0, 8.5) 
   3.02, br dd (11.0, 9.0)  3.02, dd (11.5, 10.2) 
Pro 4 18 169.4, C - 169.5, C - 
 19 59.3, CH 4.86, dd (8.9, 3.3) 59.3, CH 4.86, dd (8.9, 3.1) 
 20 30.3, CH2 2.23, m 30.4, CH2 2.22, m 
   1.87, m  1.86, m 
 21 21.8, CH2 1.77, m 21.8, CH2 1.76, m 
   1.71, m  1.71, m 
 22 46.4, CH2 3.50, ddd (11.7, 8.2, 4.1) 46.5, CH2 
3.49, ddd (11.4, 8.3, 
4.1) 
   3.35, m  3.35, m 
Cys 5 23 168.0, C - 168.1, C - 
 24 48.5, CH,  
4.59, ddd (11.6, 10.0, 
5.5) 
48.5, CH 4.58, m (5.5, 10.1) 
 25 37.6, CH2 3.19, dd (12.0, 5.5) 37.6, CH2 3.18, m 
   2.62, dd (12.0, 11.6)  2.62, t (11.8) 
 24-NH  8.64, d (10.0)  8.63, d (9.7) 
pyroGlu 26 172.0 C - 172.0, C - 
 27 54.9, CH 4.12, br dd (9.1, 1.5) 54.9, CH 4.11, br d (9.2) 
 28 25.5, CH2 2.24, m 25.6, CH2 2.23, m 
   2.09, m  2.08, m 
 29 28.8, CH2 2.36, m 28.9, CH2 2.36, m 
   2.06, ddd (12.5, 9.7, 2.7)  2.05, m 
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 30 177.9, C - 178.0, C - 
 27-NH  7.93, br s  7.93, s 
pHSA 31 120.4, CH 7.15, dd (14.8, 10.0) 120.4, CH 7.13, d (15.0) 
 32 113.6, CH 6.26, d (14.8) 113.7, CH 6.25, d (14.6) 
 33 126.9, C - 127.0, C - 
 34/38 115.6, CH 6.71, d (8.7) 115.6, CH 6.70, d (8.5) 
 35/37 126.5, CH 7.18, d (8.7) 126.6, CH 7.17, d (8.6) 
 36 156.4, C - 156.3. C - 
 31-NH  10.21, d (10.0)  10.21, d (9.8) 
 36-OH  9.40, s  9.39, s 
a
600 MHz for 
1
H-NMR and 150 for 
13
C-NMR, from Woo, J-K..; Jeon, J.; Kim, C-K.; Sim, C.J.;  Oh, D-C.; 
Oh, K-B.; Shin, J. J. Nat. Prod. 2013, 76, 1380-1383.
b
600 MHz for 
1
H-NMR and 150 for 
13
C-NMR. 
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CHAPTER II 
 
TOTAL SYNTHESIS OF ACTINOPHENANTHROLINE A 
 
Introduction 
 
 As mentioned in Chapter I, the marine ecosystems are widely recognized for being the 
source of chemically diverse and biologically active natural products. Until recently, marine 
plants and invertebrates were the principle species studied from this habitats, leaving the 
microorganism of the sea vastly unexplored. This was due in part to the difficulty to collect the 
samples from deep-sea sediments, perform the purification and classification of the organism, and 
culture these species in vitro; however, due to technological advances in sequencing and 
molecular biology multiple marine microbial have been isolated and characterized.
66
  
 The actinomycetes class of bacteria has been an abundant source of antibiotics. After 
being discovered in the earth soil, the exploration of the marine actynomicetes has led to the 
discovery of a novel species in the class. Within these new species, new genres have also been 
found like the salt water-dependent Salinospora. Additionally, new species of known genres have 
been discovered, for example within the Streptomyces.
67
 
 Efforts to characterize the biology and chemistry of these new species of Streptomyces 
have led to the discovery of numerous interesting and uncommon natural products, by different 
research groups. The molecules isolated from these Streptomyces species are structurally diverse 
and exemplify most different classes of metabolites, as illustrated by the natural products in Fig. 
2.1. An example, is the polyketide metabolite nahuoic acid A 2.1, that has been isolated from 
Streptomyces spp (isolate RJA2928) from marine sediments of Papua New Guinea and it has 
shown inhibition of SETD8, a protein methyl transferase involve in epigenetic regulation and 
overexpressed in various types of cancer.
68
 From the terpenoids class, the meroterpenoid 
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actinoranone 2.2 was isolated from a non-described species of Streptomyces, strain CNQ-027, 
and it proved to have cytotoxic activity in the HCT-116 cell line.
69
 In this same strain, peptidic 
metabolites have also been found, such as actinoramide A 2.3.
70
 While from the alkaloids group, 
the cytotoxic marineosin A 2.4 has also been isolated from the marine Streptomyces spp. (CNQ-
617).
71
  
 
Figure 2.1. Representative examples of natural products isolated from marine actinomycetes. 
 
In 2015, Fenical and collaborators reported the isolation of a non described actinomycete 
bacterium from the marine sediments of the coast of La Jolla, San Diego. The bacterial strain, 
which required seawater for growth and culture, was described as a likely member of the genus 
Streptomyces based on available sequence data and was coded as CNQ-149. Large scale 
fermentation and LC-MS analysis of crude extracts identified several compounds with a UV 
pharmacophore at low wavelength and with molecular weight between 300 and 400 amu. This 
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effort led to the identification of four new alkaloids: actinobenzoquinoline 2.5 and 
actinophenanthrolines A-C 2.6-2.8 (Figure 2.2).
72
  
 
 
Figure 2.2. Structures of actinobenzoquinoline (2.5) and actinophenanthrolines A-C (2.6-2.8), 
unprecedented marine sediment alkaloids.  
 
Actinophenanthroline A 2.6 is the first 1,7-phenanthroline alkaloid isolated from a 
natural source, and one of the rare examples of phenanthroline natural products. Compound 2.6 
did not show general cytotoxicity in HCT-116 cell line, as well as alkaloids 2.7-2.8. However, 
synthetic 1,7-phenanthrolines have demonstrated biological activity. 
There have been reports of the anticancer and mutagenic activities of 1,7-phenanthrolines 
analogs,
73–81
 and other biological effects have also been described. 1,7-phenanthroline promotes 
epithelial chloride secretion by opening of the Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR) chloride channel.
82
 It has also been observed that administration of naked 1,7-
phenanthroline in mice causes induction of drug metabolizing enzymes. This heterocycle 
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increased the activity of glutathione S-transferase and NADPH-quinone reductase in mice, while 
not affecting P450 metabolism.
83,84
 The compound also proved to increase the transcription of 
quinone reductase, glucoronyltransferases (UGT1A6, UGT2B1), along with mRNA levels of the 
transporter Mrp3 in rat liver and kidney.
85
 Besides, the phenanthroline derived bufrolin acts as an 
agonist of GPR35 receptor and has antiallergic and mast cell stabilizing properties.
86
 1,7-
phenanthroline analogs have shown weak antimicrobial activity against Mycobacterium 
tuberculosis and Plasmodium falciparum.
87,88
 Moreover, this type of compounds have also shown 
anti-HIV-1 integrase activity.
89,90
 
The precedent of diverse biological activity of secondary metabolites from strains related 
to CNQ-149, along with the presence of various bioactive synthetic 1,7-phenanthrolines, argues 
for further exploration of the effects of actinophenanthrolines. The isolation of 2.6-2.8 in 
milligram quantities required large fermentation volumes (70 L) and lengthy purification, and we 
believed that the obtention of this natural products could be achieve more efficiently through a 
synthetic procedure. Therefore, because of its potential biological activity and their 
unprecedented structure, it was decided to start the synthesis of actinophenanthrolines. As 
Actinophenanthroline A 2.6 presents the simpler core from this set of compounds and might 
provide a route that can be used later for the building of 2.7 and 2.8, we decide to embark in its 
total synthesis first. 
 
Retrosynthetic analysis for the synthesis of Actinophenanthroline A 
 
 For the retrosynthesis of compound 2.6, we envisioned a short and linear route where the 
(S)-2-hydroxypropanamide would be installed in the last step through the coupling between 
aminohydroxyphenanthroline 2.9 and L-lactic acid (Scheme 2.1). The intermediate 2.9 would be 
derived from the directed nitrosylation of 2.10 followed by the reduction to the amino. 
Meanwhile, the phenanthroline core and installation of carbon 14 would be performed following 
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a Brønsted acid-catalyzed Dobner-Miller procedure, with 2.11 as starting material. The first steps 
would involve the regioselective nitrosylation of 8-hydroxyquinaldine 2.12 and further reduction 
to obtain 5-amino-8-hydroxyquinaldine 2.12. This route would provide quick access to the natural 
product 2.5 from inexpensive commercial material (8-hydroquinaldine 2.12, $0.23 per gram) and 
it potentially would not require the use of protection/deprotection steps.  
 
Scheme 2.1.  Retrosynthetic analysis for obtention of 2.6. 
 
Synthesis of Actinophenanthroline A 
 
The synthesis of actinophenanthroline A 2.6 started with the regioselective para-directed 
nitrosylation reaction of 2.12 using sodium nitrite and concentrated HCl in water (Scheme 2.2). 
This procedure provided a regioisomeric mixture of 5-nitroso 2.13 and the undesired 7-nitroso 
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compound, in a ratio of 10:1. The preference for the para-substituted regioisomer has been 
described in the literature,
91–94 
 and it can be explained by considering the stabilization of the 
sigma complex after the introduction of the nitroso group in the ring.  In the case of an 
unsubstituted quinoline, the most reactive positions are 5 and 8, while electrophilic substitution is 
less favored in 6 and 7. The introduction of the hydroxyl group in position 8, besides blocking 
this position for nitrosylation favors even more electrophilic substitution in position 5 due to 
electron donation by resonance and the possibility of more resonance forms that stabilize the 
sigma complex. 
 
Scheme 2.2. Synthesis of 1,7-phenanthroline 2.10. 
 
It was attempted to separate the mixture of regioisomers rate through silica gel flash 
chromatography; however, formation of a complex matrix and decomposition of the nitrosylation 
products was observed during the purification, which led to little recovery of pure 2.13. 
Eventually, it was found that the regioisomers could be separated by trituration with cold water, 
as the 7-nitroso isomer presumably has a larger dipole moment. This operation allowed obtaining 
2.13 in 89% isolated yield. 
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Reduction of 2.13 to the amine 2.11 was attempted through hydrogenation with 
palladium on carbon as the catalyst and ethanol as solvent. Monitoring of the reaction 
demonstrated the formation of product; although, decomposition was observed after filtration of 
the reaction matrix through a celite pad during the workup that led to no isolation of the desired 
product.  Then, it was found that the reaction could also be performed effectively with tin(II) 
chloride in concentrated HCl with dioxanes.  However, the purification of compound 2.11 proved 
to be difficult as it showed very high solubility in water during extractive workup. Attempts to 
increase the pH of the aqueous phase also led to the decomposition of the product and once 
enough crude material could be recovered the electron rich 2.11 compound decomposed during 
silica gel chromatography.  
At this point, it was thought that the possible decomposition process was caused by the 
oxidation of 2.11 to the corresponding reactive iminoquinone, and that protecting the phenol 
group might be beneficial to impede this transformation. Before adding more steps to our 
sequence, the modification of the purification operations was explored. In order to circumvent 
column chromatography and maintaining an acidic media to avoid degradation of the product, it 
was decided to perform the reaction in conditions that favored the precipitation of the product in 
the reaction media. The concentration of starting material was increased gradually and it was 
found that an organic solvent was not necessary for the transformation to occur. The reaction was 
carried out in concentrated hydrochloric acid at a concentration of 2.2 M of 2.13, which favored 
the precipitation of product 2.11 from the media; this permitted the purification of 2.11 as the 
hydrochloride salt in excellent isolated yields (98%). Moreover, this synthetic protocol 
demonstrated to be robust as it afforded comparable yields and purities when performed on either 
a 20 mg or 10 g scale. 
After the obtention of 2.11, we studied the use of a Doebner-Miller pyridine ring 
annulation reaction to construct the 1,7-phenanthtoline core. The procedure was performed in 
conjunction with trans-crotonaldehyde to provide the tricycle and introduce the C14 methyl 
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group. Using classic Brønsted acid-catalized conditions,
95,96 
employing HCl in an aqueous media 
and heating to reflux temperature, did not prove effective to achieve the transformation as mainly 
polymerization of the crotonaldehyde was observed.  
To decrease the aldehyde decomposition, the reaction was carried out in a biphasic 
solvent system of toluene:aqueous acid. Although this modification improved the reaction 
productivity, the yield of 2.10 was still very low (17%). In an effort to increase the yield, a 
solution of crotonaldehyde in toluene was added slowly via syringe pump over one hour to a 
stirred a solution of 2.11 in 6.0 M HCl at 110 
o
C, followed by reflux. This procedure 
demonstrated to give excellent isolated yields of 2.10. The reaction time was a critical parameter 
during this step, as thermal decomposition of the 1,7-phenanthroline 2.10 was detected after one 
hour of the addition of the crotonaldehyde solution. The optimized protocol delivered 
intermediate 2.10 in 90% isolated yield robustly in scales of up to 10 grams. 
The second nitrosylation procedure to provide intermediate 2.15 was performed 
following the procedure for the synthesis of 2.13. 2.10 was nitrosylated with NaNO2 in aqueous 
HCl, and the low solubility in water of the product was profited to obtain the hydrochloride salt of 
2.15 in 67% yield (Scheme 2.3). The selectivity of the reaction for the C5 position of the 1,7-
phenanthroline is given by the low reactivity of the pyridine rings toward electrophilic 
substitution and the hydroxyl electron donating that direct the substitution to the ortho position. 
 
 
Scheme 2.3. Synthesis of aminohydroxyphenanthroline 2.9. 
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For the transformation of nitroso 2.15 to the aniline 2.9, the tin(II) chloride reduction 
procedure proved to be useful. Although, 2.9 demonstrated to be difficult to purify, as its good 
solubility in water and aqueous HCl did not allow the implementation of purification techniques 
based on the precipitation of the product. On top of this, extractive and column chromatograpy 
led to decomposition of the product.  
At this point, it was decided to reevaluate the catalytic hydrogenation procedure for the 
obtention of 2.9. As decomposition of 2.11 was observed when using ethanol, we explored the 
use of alternative aprotic polar solvents and found that the reaction could be carried out 
effectively in DMF at room temperature.  Under these conditions, full consumption of the starting 
material to the desired product was observed within one hour, but the purification proved 
inconvenient as operations for the removal of the DMF complicated the isolation of product 2.9. 
Exploration of more solvents for this reaction let to find  that 1,4-dioxane was also effective to 
perform this hydrogenation, event though the process was substantially more inefficient than 
using DMF, as the reaction occurred more slowly showing only around 20% of conversion after 
one hour. This behavior is probably caused by the little solubility of 2.15 in dioxane. This 
observation prompted us to assess a cosolvent strategy, where it was found that  the use of a 9:1 
dioxane:DMF mixture as solvent improved the solubility of 2.15 and enabled efficient and 
effective standard hydrogenation conditions. This led to straightforward purification of 2.9 in 
98% isolated yield. 
With 2.9 in hand , we proceed to try the amide coupling between this aromatic amine and 
(S)-2-hydroxypropanoic acid, the last step to achieve the total synthesis of 2.6. Initial conditions 
that involved the use of HATU and three equivalents of  Hüning’s base in either DCE or DMF, 
caused the formation of a complex mixture from which formation of  2.6 and the diacylated 
amide ester by-product were identified.   
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Considering the results from the amide coupling, it was decided to test the effect of  
protecting the phenol group, as this would avoid the diacylation observed with aminohydroxy 2.9. 
For this experiment, we selected TBS and acetyl protecting groups and tried to introducing them 
in intermediate 2.15, just before the formation of the aromatic amine. In this case, TBS protection 
under regular conditions proved difficult and this approach was discarded. Acetylation of the 
phenol in 2.15 proved also difficult, and formation of product was only achieved after heating at 
70 °C in neat acetic anhydride for 18 hours. However, purification through silica gel caused the 
deprotection of 2.17 and only 2.15 was isolated.  
 
 
Scheme 2.4. Efforts for the protection of the phenol in 2.15. 
 
 At this stage, it was determined that the oxygen in 2.15 was poorly nucleophilic and not 
amenable for protection and it was decided to revisit the amide coupling methodology. As most 
intermediates in this route showed instability under basic conditions, the amount of Hüning base 
was decreased to just one equivalent, but the change did not translate to an improvement in the 
reaction. The procedure then was run without exogenous, organic amine base, and employed 
instead the lithium salt of  L-lactic acid 2.16.  This approach was highly dependent on both 
solvent and temperature.  The amide coupling in DCE led to no consumption of starting material, 
while mild heating at 60 °C caused only decomposition. Clean but slow formation of 2.5 was 
observed when the reaction was carried out in DMF at room temperature. In this case, heating the 
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reaction to 60 °C caused rapid formation of the desired product delivering Actinophenanthroline 
in moderate isolated yield (47%) (Scheme 2.5). 
 
 
Scheme 2.5. Synthesis of  Actinophenanthroline A 2.6. 
 
 After synthetic actinophenanthroline A 2.6 was fully characterized, it was found that it 
displayed identical physical and spectroscopic properties with respect to the isolated compound.  
To unequivocally establish the structure of synthetic 2.6 and its stereochemistry, crystals of the 
compound were obtained and the X-Ray structure was determined in collaboration with Dr. Joel 
M. Harp from Vanderbilt’s Center for Structural Biology. The crystal structure was identical to 
the reported by Fenical and collaborators,
72
 and  the (S)-configuration of C12 in our synthetic 
material was confirmed (Fig. 2.3).  
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Figure 2.3.  X-ray crystal structure of synthetic actinophenanthroline A (2.6). 
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Summary and future directions 
 
In this chapter, the first total synthesis of Actinophenanthroline A 2.6 was decribed. 
Overall, this approach presents a protecting group free six-step process that proceeds in 24.2% 
overall yield from inexpensive and commercial available starting material 8-hydroxyquinaldine 
2.12. This procedure features two regioselective nitrosylation/reduction sequences and a Brønsted 
acid catalyzed Doebner-Miller reaction, and the use of no chromatographyc purifications until the 
last step.   
The availability of this synthetic natural product will allow exploring further its 
biological properties. As with Gombamide A, this material is in the process of being submitted to 
the CANVASS panel assay. In this assays, the compound will be tested for its anticancer, 
antibacterial and antiinflammatory activity.  
If the compound demonstrates to have interesting biological activity, our synthetic 
strategy provides a feasible route for the generation of analogs providing three points of diversity 
just by using different quinolines, α,β-unsaturated aldehydes and different carboxylic acids. 
Hopefully, our synthetic route to access 2.5 will also facilitate the synthesis of the other 
actinophenanthrolines 2.7-2.8.  
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EXPERIMENTAL METHODS 
 
General  
All reagents and solvents were commercial grade and purified prior to use when 
necessary. Thin layer chromatography (TLC) was performed on glass-backed silica gel. 
Visualization was accomplished with UV light and/or the use of iodine or ninhydrin solution 
followed by charring on a hot-plate. Chromatography on silica gel was performed using Silica 
Gel 60 (230-400 mesh) from Sorbent Technologies. 
1
H and 
13
C NMR spectra were recorded on 
Bruker DRX-400 (400 MHz) instrument. Chemical shifts are reported in ppm relative to residual 
solvent peaks as an internal standard at the following chemical shifts (
1
H and 
13
C respectively): 
7.26 and 77.0 ppm for CDCl3; 2.50 and 39.52 ppm for DMSO-d6, 3.31 and 49.2 ppm for CD3OD. 
Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, dd = doublet of doublets, br = broad, m = multiplet), coupling constant (Hz), integration. 
Optical rotations were measured on a JASCO P-2000 digital polarimeter. Concentration in g/100 
ml and solvent are given in parentheses and the reported value is an average of n=3 independent 
measurements. Low resolution mass spectra (LCMS) were obtained on an Agilent 1200 LCMS 
with electrospray ionization. A Micromass Qtof API-US mass spectrometer was used to acquire 
high-resolution mass spectrometry (HRMS) data. The value Δ is the error in the measurement (in 
ppm) given by the equation Δ = [(ME –MT)/ MT] × 106, where ME is the experimental mass and 
MT is the theoretical mass. The HRMS results were obtained with ES as the ion source and 
leucine enkephalin as the reference. 
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2-methyl-5-nitrosoquinolin-8-ol hydrochloride (2.13). In a flask, 8-hydroxyquinaldine 
(10.00 g, 62.82 mmol) was dissolved in 60 mL of water. The mixture was cool down to 0 °C in 
an ice bath, and 15 mL of concentrated HCl were added. Then, slowly and with stirring, sodium 
nitrite (4.33 g, 62.82 mmol) was added. The mixture was let warmed to room temperature and 
stirred for 4 hours. A yellow solid was formed in the reaction and the mixture was filtered 
through a medium glass fritted funnel and triturated with cold water. 2-methyl-5-nitroso-quinolin-
8-ol hydrochloride was obtained as a yellow solid (12.55 g, 55.90 mmol, 89% yield). 
1
H NMR 
(400.1 MHz, DMSO-d6) δ (ppm): 8.73 (d, J= 8.3 Hz, 1H), 8.46 (br), 8.06 (d, J= 10.4 Hz, 1H), 
7.85 (d, J= 8.4 Hz, 1H), 6.81 (d, J= 10.4 Hz, 1H), 2.73 (s, 3H); 
13
C NMR (100.6 MHz, DMSO-
d6) δ (ppm): 181.43, 159.68, 144.51, 140.94, 135.16, 131.38, 129.15, 129.07, 126.38, 22.86; 
HRMS (TOF,ES+) C10H8N2O2 [M] calculated 188.0586, found 188.0583, Δ = -1.48 ppm. 
 
 
5-amino-2-methylquinolin-8-ol dihydrochloride (2.11). In a flask, 2.13 (8.26 g, 43.89 
mmol) was added and suspended in 10 mL of concentrated HCl. Then, a solution of tin chloride 
(16.6 g, 87.79 mmol) in 10 mL of concentrated HCl was added while in an ice bath. The reaction 
was warmed to room temperature and stirred for 30 minutes, after full conversion was confirmed 
by LC-MS. The suspension was cooled to 0 °C again for 30 minutes to favor precipitation of the 
product, and the mixture was filtered through a medium glass fritted funnel and triturated with 
cold concentrated HCl. 5-amino-2-methyl-quinolin-8-ol dihydrochloride was obtained as a pale 
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cream solid (10.65 g, 43.08 mmol, 98% yield). 
1H NMR (400.1 MHz, CD3OD) δ (ppm): 9.05 (d, 
J= 8.9 Hz, 1H), 8.17 (d, J= 8.9 Hz, 1H), 7.85 (d, J= 8.4 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 3.16 (s, 
3H); 
13
C NMR (100.6 MHz, CD3OD) δ (ppm): 158.96, 148.17, 139.66, 129.26, 125.28, 124.39, 
122.43, 118.99, 115.12, 19.53; HRMS (TOF,ES+) C10H10N2O2 [M] calculated 174.0793, found 
174.0792, Δ = -0.39 ppm. 
 
 
2,8-dimethyl-1,7-phenanthrolin-6-ol (2.10). In a flask, 2.11 (10.35 g, 41.87 mmol) was 
dissolved in HCl 6 M (480 mL). The mixture was refluxed at 110 °C while a solution of trans-
crotonaldehyde (4.16mL, 50.24 mmol) in 60 mL of toluene was slowly added with a syringe 
pump over 60 minutes. After refluxing for an additional hour, the reaction was stopped and cool 
down to 0 °C to favor precipitation of product. The reaction produced a crystalline brown solid, 
which was filtrated under vacuum through a medium glass fritted funnel and washed with DCM 
and cold water. 2,8-dimethyl-1,7-phenanthrolin-6-ol dihydrochloride was obtained as brown 
crystals (11.26 g, 37.89 mmol, 90 % yield). 
1
H NMR (400.1 MHz, DMSO-d6) δ (ppm): 9.89 (d, 
J= 8.6 Hz, 1H), 8.40 (d, J= 8.3 Hz, 1H), 8.13 (d, J= 8.6 Hz, 1H), 7.71 (s, 1H), 7.68 (d, J= 8.3 Hz, 
1H), 3.02 (s, 3H), 2.79 (s, 3H); 
13
C NMR (100.6 MHz, DMSO-d6) δ (ppm): 158.4, 157.2, 145.9, 
140.7, 137.2, 136.7, 134.3, 125.9, 125.5, 125.2, 111.8, 24.6, 21.2; HRMS (TOF,ES+) C14H12N2O 
[M] calculated 224.0950, found 224.0949, Δ = -0.07 ppm. 
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2,8-dimethyl-5-nitroso-1,7-phenanthrolin-6-ol (2.15). In a flask, 2.10 (9.49 g, 31.93 
mmol) was dissolved in 20 mL of water and cool down to 0 °C with an ice bath. The mixture was 
cool down to 0 °C in an ice bath, and 6.7 mL of concentrated HCl were added. Then, slowly and 
with stirring, sodium nitrite (2.42 g, 35.13 mmol) was added. The reaction was allowed to warm 
to room temperature and stirred for 1 hour. The mixture was a suspension and the flask was cold 
in an ice bath to favor precipitation of product. The solid was filtered in vacuo through a medium 
glass fritted funnel, and washed with cold water. 2,8-dimethyl-5-nitroso-1,7-phenanthrolin-6-ol 
dihydrochloride was obtained as a yellow solid (6.94 g, 21.28 mmol, 67% yield). 
1
H NMR (400.1 
MHz, DMSO-d6) δ (ppm): 9.05 (d, J= 8.4 Hz, 1H), 9.00 (d, J= 8.2 Hz, 1H), 7.87 (d, J= 8.2 Hz, 
1H), 7.41 (d, J= 8.4 Hz, 1H), 2.73 (s, 3H), 2.57 (s, 3H); 
13
C NMR (100.6 MHz, DMSO-d6) δ 
(ppm): 178.3, 159.8, 159.7, 143.8, 143.4, 143.2, 137.8, 136.5, 132.1, 129.7, 124.0, 119.4, 24.3, 
22.6; HRMS (TOF,ES+) C14H11N3O2 [M] calculated 253.0851, found 253.0853, Δ = 0.57 ppm. 
 
 
5-amino-2,8-dimethyl-1,7-phenanthrolin-6-ol (2.9). In a flask, 2.15 (1000 mg, 3.95 
mmol) was added and suspended in 40 mL of a 1,4-Dioxane:DMF (9:1) mixture. Then, palladium 
(10%) on activated carbon (197 mg, 0.19 mmol) was added. The mixture was stirred at room 
temperature under 1 atm of H2 for one hour. The reaction was worked up by filtration over a short 
Celite pad and washed DCM. Volatiles were evaporated in vacuo, and the remaining DMF was 
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eliminated through distillation under reduced pressure. 5-amino-2,8-dimethyl-1,7-phenanthrolin-
6-ol was obtained as a bright red solid (926 mg, 3.87 mmol, 98% yield). ). 
1
H NMR (400.1 MHz, 
DMSO-d6) δ (ppm): 10.11 (br, 1H), 9.46 (d, J= 7.2 Hz, 1H), 8.70 (d, J= 7.8 Hz, 1H), 7.66 (d, J= 
7.8 Hz, 1H), 7.48 (d, J= 7.1 Hz, 1H), 7.24 (br, 2H), 2.89 (s, 3H), 2.74 (s, 3H); 
13
C NMR (100.6 
MHz, DMSO-d6) δ (ppm): 158.4, 155.9, 139.8, 139.5, 138.0, 135.0, 131.5, 124.5, 123.8, 119.5, 
117.7, 117.6, 25.1, 20.5; HRMS (TOF,ES+) C14H13N3O [M] calculated 239.1059, found 
239.1059, Δ = 0.29 ppm. 
 
 
(S)-2-hydroxy-N-(6-hydroxy-2,8-dimethyl-1,7-phenanthrolin-5-yl)propanamide 
(Actinophenanthroline A, 2.6). In a vial, 2.9 (40.0 mg, 0.170 mmol), HATU (63.6 mg, 0.170 
mmol)  and  lithium (S)-2-hydroxypropanoate (16.1 mg, 0.170 mmol) were weighted and 
suspended in 2 mL of DMF.  The mixture was stirred for 10 minutes at 60 
o
C. The reaction was 
worked up by addition of water and successive extractions with CHCl3:IPA (3:1). The organic 
phases were recovered and combined, washed with LiCl 5%, dried with MgSO4, filtered and 
concentrated in vacuo. The crude was dissolved in DMSO and purify by Gilson HPLC prep, C18 
column, gradient 0.1% TFA in water:ACN, from 0 to 45% ACN. (S)-2-hydroxy-N-(6-hydroxy-
2,8-dimethyl-1,7-phenanthrolin-5-yl)propanamide was obtained as a pale yellow solid (24.6 mg, 
0.0790 mmol, 47% yield). 1H and 13C-NMR (400 MHz, DMSO-d6), see Table S1. [α]D
25
: -19.0 
(c 0.5, MeOH); HRMS (TOF,ES+) C17H13N3O3 [M] calculated 311.1270, found 311.1270, Δ = 
0.11 ppm. 
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Table 2.1. NMR data comparison between isolated
a
 and synthetic
b
 Actinophenanthroline A (2.6). 
Isolated Synthetic 
δC δH (J in Hz) δC δH (J in Hz) 
174.6 9.50, br 174.6 9.56, br 
158.8 ND 158.9 9.41, s 
154.5 9.30, d (8.5) 154.8 9.30, d (8.3) 
145.8 7.99, d (8.5) 145.2 8.00, d (8.3) 
141.2 7.66, d (8.5) 140.8 7.67, d (8.3) 
138.9 7.49, d (8.5) 139.1 7.50, d (8.4) 
132.7 5.90, br 132.7 5.82, s 
131.3 4.32. q (6.8) 131.4 4.33 (6.5) 
123.2 2.79, s 123.2 2.79, s 
123.1 2.71, s 123.1 2.71, s 
122.8 1.44. q (6.8) 122.9 1.45 (6.7) 
122.5  122.5  
114.2  114.3  
67.7  67.7  
24.6  24.60  
24.6  24.57  
21.3  21.3  
a
500 MHz for 1H-NMR and 75 for 13C-NMR, from Nam, S-J.; Kauffman, C.A.; Jensen, 
P.R.; Moore, C.E.; Rheingold, A.L.; Fenical, W. Org. Lett. 2015, 17, 3240-3243. 
b
400 
MHz for 
1
H-NMR and 100 for 
13
C-NMR. 
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Crystallographic Data of 2.6 
 
Crystal Data  
C17H17N3O3 
M
 
= 311.34  
Monoclinic, P 21 21 21 
Hall symbol: P 2ac 2ab 
a   4.732   
b   11.317   
c    27.570    
V    1476.4  3  
Z=4  
F(000) = 656 
Dx = 1.401 Mg M
-3 
Cu K radiation,  = 1.54178 Å 
Cell parameters from 10878 reflections 
 = 3.2-66.59o 
 = 0.805 mm-1 
T = 293 K 
Needle 
0.19x.04x.01 mm 
Data Collection  
Bruker X8 Proteum 135 diffractometer  
Radiation source: Bruker Microstar rotating-
anode  
Monochromator: confocal, multilayer 
17619 measured reflections 
3641 independent reflections 
3544 reflections with I > 2σ(I) 
Rint = 0.086 
max = 133.17
o
 , min = 6.41
o
  
h = -5  5 
k = -12  13 
l = -31  21
Refinement  
Refinement on F
2 
 
Least-squares matrix: full  
R[F
2 > 2σ(F2)] = 0.0494  
wR(F
2
) = 0.1201 
S = 0.981 
2412 reflections  
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213 parameters  
0 restraint  
Primary atom site location: structure-
invariant direct methods  
Secondary atom site location: difference 
Fourier map Hydrogen site location: inferred 
from neighboring sites  
H atoms treated by a mixture of independent 
and constrained refinement 
w   1/[σ2(F0
2
)+(0.050P)
2 
+ 0.6517P] where 
P = (F
2 
+ 2F
2
3 )/ 
 (∆/σ)max
 
= 0.001  
∆ρmax
 
  0.15 e  −3  
∆ρmin
 
  −0.27 e  −3  
Absolute structure: Flack x determined 
using 528 quotients [(I+)-(I-)]/[(I+)+(I-)]  
(Parsons, Flack and Wagner, Acta Cryst. 
B69 (2013) 249-259). 
Flack parameter: -0.1 (4)  
 
Special Details 
Geometry.  
All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full 
covariance matrix. The cell esds are taken into account individually in the estimation of esds in 
distances, angles and torsion angles; correlations between esds in cell parameters are only used 
when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is 
used for estimating esds involving l.s. planes.  
Refinement. 
Refinement of F
2
 
against ALL reflections. The weighted R-factor wR and goodness of fit S are 
based on F
2
, conventional R-factors R are based on F, with F set to zero for negative F
2
.The 
threshold expression of F
2
 
> 2sigma(F
2
) is used only for calculating R-factors(gt) etc. and is not 
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relevant to the choice of reflections for refinement. R-factors based on F
2 
are statistically about 
twice as large as those based on F, and R- factors based on ALL data will be even larger.  
Computing: 
Data reduction and scaling were done using PROTEUM2 (Bruker,2010). Structure solution was 
done by direct methods using SIR2014 (Burla, et al., 2015). The structure was refined using 
SHELXL (Sheldrick, 2014) and visualized with COOT (Emsley, et al., 2010). The structure was 
examined and figures produced using PLATON (Spek, 2009). 
Table 2.2. Atomic coordinates (Å X 10
5
) and equivalent isotropic displacement parameters (Å
2
 X 
10
4
).  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  E.s.ds are in 
parentheses. 
 
 
x y z U(eq)  S.o.f.#  
O(3) 73630(60) 93000(30) 9049(12) 289(8) 1 
O(2) 11260(60) 107580(30) 13172(11) 276(8) 1 
O(1) 12240(70) 123680(30) 4056(11) 263(8) 1 
N(1) -6410(70) 145530(30) 4229(13) 210(9) 1 
N(3) 54500(80) 154920(30) 17757(13) 212(9) 1 
N(2) 52780(80) 115270(30) 10597(13) 201(9) 1 
C(6) 13160(90) 142860(40) 7646(15) 180(10) 1 
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C(9) 54610(90) 135130(40) 14290(15) 181(10) 1 
C(5) 23520(100) 150760(40) 11122(15) 177(9) 1 
C(8) 43160(90) 127260(40) 10656(16) 188(10) 1 
C(10) 44740(90) 146900(40) 14510(16) 191(10) 1 
C(4) 12050(90) 162220(40) 10977(16) 205(10) 1 
C(2) -16790(90) 156530(40) 4173(16) 212(10) 1 
C(7) 23320(100) 130930(40) 7490(15) 185(10) 1 
C(11) 75360(100) 131760(40) 17623(16) 210(10) 1 
C(3) -7740(90) 165070(40) 7589(16) 211(11) 1 
C(13) 74580(100) 151490(40) 20811(16) 220(10) 1 
C(16) 48790(90) 93770(40) 11789(15) 207(10) 1 
C(15) 36090(90) 106120(40) 11848(15) 193(10) 1 
C(12) 85370(100) 139890(40) 20869(16) 224(10) 1 
C(1) -37980(100) 159340(40) 357(16) 273(11) 1 
C(17) 52030(110) 89400(40) 16948(17) 317(12) 1 
C(14) 86250(110) 160770(40) 24175(17) 298(12) 1 
# - site occupancy, if different from 1  
* - U(iso) (Å
2
 ◊ 104) 
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Table 2.3. Anisotropic displacement parameters (Å
2
 x 10
4
) for the expression: exp –π2 (h2 a*2U11 
+ ...  + 2hka*b*U12).  E.s.ds are in parentheses.  
 
U11  U22  U33  U23  U13  U12 
O(3) 195(15) 286(18) 390(20) -5(16) 39(17) 8(16) 
O(2) 180(17) 277(17) 370(19) 4(15) 43(15) 3(15) 
O(1) 272(19) 247(17) 271(18) -68(15) -103(15) 28(15) 
N(1) 150(19) 250(20) 230(20) 6(17) 15(17) 35(17) 
N(3) 214(19) 240(20) 180(20) 7(17) 0(17) -31(18) 
N(2) 146(18) 166(19) 290(20) -28(16) 31(17) 18(16) 
C(6) 140(20) 220(20) 180(20) 26(19) -2(19) 60(20) 
C(9) 180(20) 170(20) 190(20) -11(19) 10(20) -49(18) 
C(5) 150(20) 180(20) 200(20) 12(19) 0(20) 6(18) 
C(8) 120(20) 190(20) 260(20) 2(19) -18(19) 25(18) 
C(10) 150(20) 200(20) 220(20) 10(20) -20(20) -17(19) 
C(4) 210(20) 200(20) 210(20) -20(20) 50(20) 0(20) 
C(2) 180(20) 220(20) 250(20) 50(20) 40(20) 20(20) 
C(7) 160(20) 190(20) 210(30) -10(19) 0(20) -12(19) 
C(11) 180(20) 220(20) 230(30) 20(20) -10(20) 30(20) 
C(3) 150(20) 210(20) 270(30) 20(20) 30(20) 40(20) 
C(13) 190(20) 270(30) 200(20) -30(20) 20(20) -30(20) 
C(16) 140(20) 260(20) 210(20) 0(20) 20(20) -10(20) 
C(15) 160(20) 230(20) 190(20) 0(20) -20(20) -10(20) 
C(12) 200(20) 270(20) 200(20) 0(20) -30(20) -10(20) 
C(1) 260(20) 340(30) 230(30) 50(20) 0(20) 30(20) 
C(17) 340(30) 300(30) 310(30) 20(20) 10(20) 30(20) 
C(14) 320(30) 300(30) 280(30) 0(20) -100(20) -50(20) 
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Table 2.4. Geometric parameters. Bond lengths are in  ngstroms, angles in degrees.  E.s.d’s are 
in parentheses. 
O(3)–C(16) 1.400(5) C(4)–H(4) 0.95 
O(3)–H(3) 0.84 C(2)–C(3) 1.416(6) 
O(2)–C(15) 1.241(5) C(2)–C(1) 1.488(6) 
O(1)–C(7) 1.358(5) C(11)–C(12) 1.369(6) 
O(1)–H(1) 0.84 C(11)–H(11) 0.95 
N(1)–C(2) 1.338(5) C(3)–H(3) 0.95 
N(1)–C(6) 1.355(5) C(13)–C(12) 1.409(6) 
N(3)–C(13) 1.328(6) C(13)–C(14) 1.506(6) 
N(3)–C(10) 1.356(5) C(16)–C(17) 1.514(6) 
N(2)–C(15) 1.347(5) C(16)–C(15) 1.521(6) 
N(2)–C(8) 1.432(5) C(16)–H(16) 1 
N(2)–H(2) 0.88 C(12)–H(12) 0.95 
C(6)–C(5) 1.400(6) C(1)–H(1A) 0.98 
C(6)–C(7) 1.434(6) C(1)–H(1B) 0.98 
C(9)–C(11) 1.398(6) C(1)–H(1C) 0.98 
C(9)–C(10) 1.413(6) C(17)–H(17A) 0.98 
C(9)–C(8) 1.445(6) C(17)–H(17B) 0.98 
C(5)–C(4) 1.407(6) C(17)–H(17C) 0.98 
C(5)–C(10) 1.439(6) C(14)–H(14A) 0.98 
C(8)–C(7) 1.347(6) C(14)–H(14B) 0.98 
C(4)–C(3) 1.362(6) C(14)–H(14C) 0.98 
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C(16)–O(3)–H(3) 109.5 C(4)–C(3)–H(3) 119.9 
C(7)–O(1)–H(1) 109.5 C(2)–C(3)–H(3) 119.9 
C(2)–N(1)–C(6) 117.8(4) N(3)–C(13)–C(12) 122.7(4) 
C(13)–N(3)–C(10) 117.8(4) N(3)–C(13)–C(14) 116.7(4) 
C(15)–N(2)–C(8) 122.6(4) C(12)–C(13)–C(14) 120.6(4) 
C(15)–N(2)–H(2) 118.7 O(3)–C(16)–C(17) 113.7(4) 
C(8)–N(2)–H(2) 118.7 O(3)–C(16)–C(15) 113.2(4) 
N(1)–C(6)–C(5) 124.9(4) C(17)–C(16)–C(15) 109.3(4) 
N(1)–C(6)–C(7) 114.7(4) O(3)–C(16)–H(16) 106.7 
C(5)–C(6)–C(7) 120.3(4) C(17)–C(16)–H(16) 106.7 
C(11)–C(9)–C(10) 117.4(4) C(15)–C(16)–H(16) 106.7 
C(11)–C(9)–C(8) 123.5(4) O(2)–C(15)–N(2) 121.9(4) 
C(10)–C(9)–C(8) 119.1(4) O(2)–C(15)–C(16) 119.9(4) 
C(6)–C(5)–C(4) 115.8(4) N(2)–C(15)–C(16) 118.2(4) 
C(6)–C(5)–C(10) 119.7(4) C(11)–C(12)–C(13) 119.6(4) 
C(4)–C(5)–C(10) 124.6(4) C(11)–C(12)–H(12) 120.2 
C(7)–C(8)–N(2) 120.4(4) C(13)–C(12)–H(12) 120.2 
C(7)–C(8)–C(9) 121.4(4) C(2)–C(1)–H(1A) 109.5 
N(2)–C(8)–C(9) 118.2(4) C(2)–C(1)–H(1B) 109.5 
N(3)–C(10)–C(9) 123.2(4) H(1A)–C(1)–H(1B) 109.5 
N(3)–C(10)–C(5) 117.5(4) C(2)–C(1)–H(1C) 109.5 
C(9)–C(10)–C(5) 119.3(4) H(1A)–C(1)–H(1C) 109.5 
C(3)–C(4)–C(5) 120.2(4) H(1B)–C(1)–H(1C) 109.5 
C(3)–C(4)–H(4) 119.9 C(16)–C(17)–H(17A) 109.5 
C(5)–C(4)–H(4) 119.9 C(16)–C(17)–H(17B) 109.5 
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N(1)–C(2)–C(3) 121.1(4) H(17A)–C(17)–H(17B) 109.5 
N(1)–C(2)–C(1) 117.0(4) C(16)–C(17)–H(17C) 109.5 
C(3)–C(2)–C(1) 121.9(4) H(17A)–C(17)–H(17C) 109.5 
C(8)–C(7)–O(1) 122.3(4) H(17B)–C(17)–H(17C) 109.5 
C(8)–C(7)–C(6) 120.3(4) C(13)–C(14)–H(14A) 109.5 
O(1)–C(7)–C(6) 117.4(4) C(13)–C(14)–H(14B) 109.5 
C(12)–C(11)–C(9) 119.3(4) H(14A)–C(14)–H(14B) 109.5 
C(12)–C(11)–H(11) 120.3 C(13)–C(14)–H(14C) 109.5 
C(9)–C(11)–H(11) 120.3 H(14A)–C(14)–H(14C) 109.5 
C(4)–C(3)–C(2) 120.2(4) H(14B)–C(14)–H(14C) 109.5 
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CHAPTER III 
 
METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 ACTIVATION AND 
OPTIMIZATION EFFORTS AROUND THE RO 07-11401 SCAFFOLD 
 
Metabotropic glutamate receptor subtype 1 
 
Glutamate in the nervous system 
Glutamate ((S)-2-aminopentanedioic acid) is a non-essential amino acid that plays an 
important role as an excitatory neurotransmitter in the nervous system. Its excitatory action was 
recognized in the brain and spinal cord of mammals back to the 1950s,
97,98
 and it accounts for 
approximately 70% of synaptic transmission in the central nervous system (CNS).
99
 Glutamate 
has been involved in several cognitive functions, such as learning and memory, and dysregulation 
in its release, uptake, metabolism and signaling are associated with neuropsychiatric disorders.
100
 
Glutamate is stored in vesicles in presynaptic terminals and its release occurs via a 
calcium mediated process that requires the activation of N- and P/Q-type voltage-dependent 
calcium channels.
101
 Also, the cystine-glutamate antiporter, mainly expressed in glial cells, acts as 
a non-vesicular source of glutamate as it exchanges intracellular glutamate for extracellular 
cystine.
99,100
 
Brain intracellular concentration of glutamate is approximately 10 mM, and can be up to 
500000 times higher in comparison to the basal concentration in the synaptic cleft, which is 
approximately 20 nM. However, following an action potential the concentration in the synaptic 
space can exceed 1 mM.
102,103
 Therefore, the concentration of glutamate in the synapse needs to 
be tightly regulated.  
There are different transporters in charge of maintaining homeostasis of glutamate levels. 
After release of glutamate in the synapse, the high-affinity excitatory amino acid transporters 
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(EAATs) are in charge of its reuptake and are located on glutamatergic terminals and glial cells. 
EAATs are sodium dependent and have five isoforms (EAAT1-5) in humans. The storage of 
glutamate in these vesicles is carried on by the vesicular glutamate transporters (VGLUTs), for 
which three different isoforms have been reported (VGLUT1-3).
99,104
 These transporters are 
selective for glutamate and driven by a proton gradient.
101
 
Once released into the synaptic cleft, glutamate exerts its actions through ionic and 
metabotropic receptors. The ionotropic glutamate receptors (iGluRs) mediate fast postsynaptic 
potentials and are divided in three types, named by the ligand that prompted its discovery: amino-
3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), N-methyl-D-aspartate (NMDA), and kainite 
receptors. AMPA receptors are tetramers formed by GluR (Glu1-4) subunits. These receptors 
have lower affinity for glutamate than the NMDA receptors but faster kinetics, and they mediate 
the fast initial component of the excitatory postsynaptic potentials (EPSP). NMDA receptors are 
tetramers composed by NR1, NR2 (NR2A-D) and NR3 subunits and their activation requires 
removal of magnesium, facilitated by partial membrane depolarization as well as binding of 
glutamate and glycine.
99,101,105
 
The metabotropic glutamate receptors (mGlus) are G protein-coupled receptors that 
mediate slower neurotransmission, allowing modulation of synaptic activity and intracellular 
metabolic processes via second messenger signaling cascades.
106,107
 There are eight different 
mGlus that have been classified in three groups based on their signaling transduction pathway, 
sequence homology and pharmacological selectivity. Group I is composed by mGlu1 and mGlu5, 
group II consist of mGlu2 and mGlu3, while Group III entails mGlu4, mGlu6, mGlu7 and mGlu8. 
Group I receptors are mainly localized postsynaptically and are usually coupled too Gq/11, while 
groups II and III are generally present in presynaptic glutamate terminals and glial cells and 
coupled to Gi/o, serving as feedback and decreasing glutamate release in the synapse (Fig. 3.1).
99
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Figure 3.1. The glutamatergic synapse. mGlu are depicted as monomers for simplicity, but they 
are functional dimmers in the neurone.
108
  
 
Structural features of the metabotropic glutamate receptor subtype 1 
The mGlu1 receptor is part of the class C family of GPCRs. The receptor has an 
intracellular C-terminus, a transmembrane-spanning domain (TMD) and a distinctive large 
extracellular N-terminal domain (Fig. 3.2).
109
 This extracellular domain is known as the Venus 
Flytrap Domain (VFD) which has two lobes disposed in a clam shell-like structure. The 
glutamate binding site is located in the center of this domain. Dimerization of VFD from two 
different mGlu1 is required for activation of the receptor.
110,111
 The closure of the VFD lobes is 
directly related to the binding of glutamate and it causes significant conformational changes that 
translate to the rest of the protein. These conformational changes are propagated from the VFD to 
the TMD, through a cysteine rich-domain (CRD). The CRD contains nine cysteine residues, eight 
forming disulfide bonds within the domain while the remaining ninth cysteine (Cys518) is 
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involved in a disulfide bond with Cys234 in one of the lobes of the VFD. These interactions occur 
after agonist binding in the receptor’s VFD and disruptive mutations cause a cease in intracellular 
signaling events that has no effect in expression, dimerization or recognition of orthosteric 
ligands. 
107,108
 Recently, the X-ray crystallography determination of the structure of the TMD in 
complex with the negative allosteric modulator FITM was accomplished.
112
 The TMD is 
composed by seven α-helices connected by intra- and extracellular flexible loops. Interactions 
between TM6 and TM7 hold the receptor in an inactive state and a change in the conformation of 
these motifs is essential for activation of the receptor after agonist binding. The TMD is the place 
where most allosteric modulators (positive and negative) bind to the receptor.
107
 Finally, the 
intracellular C-terminus is a region where multiple protein-protein interactions occur. This area is 
subject to phosphorylation and it modulates G-protein coupling and the expression in the cell 
surface as well as the interaction with scaffolding proteins (Homer, tubulin).
113,114
 The alternative 
splicing variants of the mGlu1 receptor are differentiated mainly, by changes in the C-terminal 
region.
115,116
 
                  
Figure 3.2. Diagram and 3-D model based on X-Ray crystal structures of the mGlu1 receptor. 
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Signaling of the metabotropic glutamate receptor subtype 1 
The mGlu1 receptor is predominantly coupled to Gαq/11 causing the activation of 
phospholipase Cβ (PLCβ), leading to the hydrolysis of phosphatidylinositol bisphosphate (PIP2). 
The reaction produces 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), important second 
messengers that together can activate protein kinase C (PKC) and trigger the calcium release from 
the endoplasmic reticuli.
108
 Potential for alternative or additional coupling to other G proteins 
(e.g. Gi/o) has also been reported.
117
 This phenomena varies substantially depending on the 
neuronal population or cell line background, and while in the beginning it was believed to be 
caused by overexpression of the receptor in in vitro systems, later studies have shown that it can 
be of physiological relevance.
109
  Additionally, the mGlu1 receptor has shown to promote 
arachidonate formation through several paths, including: activation of phospholipase A2, 
stimulation of conductance of L-type voltage operated calcium channel (VOCC) (independently 
of PLC activation), phospholipase D (PLD) activation in a PKC-dependent way, recruitment of 
beta-arrestin,
118
 activation of c-Jun N-terminal kinase (JNK) and mitogen-activated protein 
kinase/extracellular receptor kinase (MAPK/ERK) cascades, and the mammalian target of 
rapamycin pathway (mTOR).
119,120
 The fact that these different signal transduction pathways may 
converge synergistically and antagonizing each other, to modulate the biological effects of the 
receptor, provides fine tuning to the observed overall cellular response and also increases the 
complexity of the analysis of the consequences of receptor activation. 
 
Normal distribution of the mGlu1 receptor in the brain 
 The mGlu1 receptor is expressed in different regions of the brain. Studies with rats 
through immunocytochemical and radioligand autoradiography approaches have shown that it is 
specially enriched in the olfactory bulb, stratum oriens/alveus areas of CA1 and polymorph layer 
of dentate gyrus in hippocampus, globus pallidus in the basal ganglia, thalamus, substantia nigra 
pars reticulata, superior colliculus and cerebellum. Lower levels were observed in the neocortex, 
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striatum, amygdala, hypothalamus, medulla, and principal cells of cerebral cortex and 
hippocampus.
121,122
 The distribution in human brain of mGlu1 mRNA is similar to the rat, where 
the highest levels are observed in the cerebellum followed by the cerebral cortex, thalamus, 
subthalamic nucleus and amygdala, and lower levels are detected in the hippocampus, substantia 
nigra, caudate nucleus and putamen.
123
 
Dendrites, spines and neuronal cell bodies contain mGlu1. Ultrastructure studies in rat 
hippocampus and cerebellum showed higher density in postsynaptic membranes, with some 
densities in perisynaptic and extrasynaptic membranes.
124
 On dendritic spines, the receptor is 
highly compartmentalized in plasma membrane domains, showing the highest density in the 
perisynaptic annulus (50%, 60 nm of the edge of the synapse), followed by a decrease 
extrasynaptically (60-900 nM).
125
 Also, there is substantial cytoplasmic immunostaining 
associated with organelles, especially the endoplasmic reticulum.
126
 
In situ hybridization of messenger RNA (mRNA) has detected intense mGlu1 labeling in 
Purkinje cells of the cerebellum, mitral and tufted cells of the olfactory bulb, hippocampus, lateral 
septum, thalamus, globus pallidus, substantia nigra, dorsal cochlear nucleus; while moderate 
labeled neurons were detected in the dentate gyrus, striatum, islands of Calleja, superficial layers 
of the retrosplenial, cingulated and entorhinal cortices, mammillary nuclei, red nucleus, and 
superior colliculus.
127
  
 There is redistribution and reorganization of mGlu1 with age. Expression of the mGlu1 
receptor gradually increases in early post-natal days, in accordance with maturation of neuronal 
elements. Studies in rat pups showed that mGlu1 mRNA increases during the first few weeks and 
does not decrease up to the 5
th
 postnatal week. On day 3, little mRNA is observed and is confined 
in the pyramidal cell layer of CA1-3 in the hippocampus, granular cell layers of the dentate gyrus, 
Purkinje cells and in the olfactory bulb region.
128
 Additionally, mGlu1 is present in thalamus since 
the first day after the rat’s birth, but it can only be activated by corticothalamic stimulation after 
the second postnatal week. During the first postnatal week, mGlu1 is mainly found in proximal 
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dendrites and somata and not usually associated with synaptic contacts. On the second postnatal 
week, the receptor is found in distal dendrites but remains mainly confined to somata and 
proximal dendrites, more synapses are observed but they are still immature with presynaptic 
terminal of irregular shape and containing few vesicles. By week four, the terminals contained 
more vesicles, and they are preferentially associated with corticothalamic synapses. In postnatal 
week seven, the synapses are prominent with mGlu1 immunoreactivity concentrated in 
postsynaptic densities of asymmetric synapses or in perisynaptic areas. At 21 weeks after birth, 
the receptor is localized only in small distal dendrites and specifically concentrated at 
postsynaptic densities of corticothalamic type synapses.
129,130
 
During rat adulthood, mGlu1 mRNA and protein expression increases in the thalamic 
nuclei, caudate-putamen and hippocampal CA1 and CA3; a slight increase is observed in cerebral 
cortex and striatum, while a slight decrease occurs in Purkinje cells and cerebellum.
131
 
 
Role of the mGlu1 receptor in brain function and psychiatric conditions 
 
Role of the mGlu1 receptor in memory and learning 
The hippocampus plays a key role in relational, contextual, spatial or declarative learning 
and memory. The hippocampus is one of the main brain regions related to cognitive processes, 
and is especially involved with distinct types of learning. In the hippocampus, mGlu1 is mainly 
expressed in the dentate gyrus and CA3, and is weaker in the CA1 region, being located in the 
perisynaptic area and in dendrites and dendritic spines.
132–134
  
Memory and learning are dependent on synaptic plasticity, defined as the change of 
intensity in synapse output with time. These changes can occur in tens of milliseconds (short-
term) to a few minutes (long-term). Hippocampal long-term potentiation (LTP) has been 
associated as a mechanism involved in learning and memory. NMDA activation and calcium 
influx are necessary but not sufficient for LTP in the CA1 region. The effect of mGlu1 in these 
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processes has been studied in the hippocampus and it has been observed that direct excitatory 
effect of CA1 pyramidal cells is mediated through group I mGlu receptors.
135
 DHPG, a non-
selective mGlu1/mGlu5 agonist evoked a transient increase in intracellular calcium levels with 
relatively long lasting inward current in CA1 pyramidal neurons, which were enhanced by 
depolarization.
136
 
Although expressed at lower levels than mGlu5, mGlu1 receptors are also involved in 
certain functions within the CA1 regions of hippocampus.
137
 Experiments showed that mGlu1 was 
not required to maintain the normal gross anatomy of the hippocampus, as well as to generate 
short-term potentiation and LTD on CA1 pyramidal cells; however, absence of the GRM1 gene in 
mice diminishes considerably the magnitude of LTP and causes moderate impairment in the 
acquisition of memory in a context-dependent fear conditioning task (context specific associative 
learning). 
138,139
 LTP in Schaffer collateral-CA1 synapses requires inhibition of SK channels by 
mGlu1, which removes a negative feedback loop that constitutively regulates NMDAR. Rather 
than being controlled simply by the magnitude of the postsynaptic calcium rise, LTP induction 
requires activation of distinct sources of calcium and mGlu1 dependent facilitation.
140
 
Additionally, mGlu1 antagonists impaired both induction and late phases of LTP and LTD in the 
CA1 region of the hippocampus of adult male rats when applied before high-frequency 
tetanization or low frequency stimulation, but no effect if applied after. These effects were 
reduced with a protein synthesis inhibitor.
141
 
The hippocampal CA1 inhibitory interneurons control the excitability of pyramidal cells 
and hippocampal plasticity. LTP of excitatory postsynaptic currents (EPSC) in stratum 
oriens/alveus (O/A) interneurons is induced after pairing theta burst stimulation with postsynaptic 
depolarization. This LTP is significantly reduced in mGlu1 knock-out mice, is blocked by mGlu1/5 
antagonists and is independent of NMDAR activation.
142,143
 mGlu1 activation elicits dendritic 
calcium signals in CA1 hippocampus and in O/A interneurons, resulting from calcium influx via 
transient receptor potential (TRP) channels and calcium release from intracellular stores, and 
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ERK1/2 activation; these biochemical features play an important role to control LTP at 
interneuron synapses.
144
 
DHPG enhances NMDA, AMPA and kainate responses in CA1 pyramidal neurons; 
although, a brief perfusion of DHPG can induce a robust LTD in this area, along with an 
enhancement in the paired-pulse facilitation ratio. DHPG facilitates postsynaptic responses but 
also suppress synaptic transmission, and the observed net effect is a reduction of the response. 
DHPG also reduces calcium-dependent responses in CA3 pyramidal neurons (presynaptic to 
CA1).
145,146
 Blockade of both mGlu1 and mGlu5 is required to block induction of LTD by DHPG, 
and the inhibition of mGlu1, but not mGlu5, reduces expression of LTD and the associated 
decrease in AMPA expression in cell surface; this is observed as well with the deletion of the 
GRM1 gene.
147
 This form of synaptic plasticity has been observed in both young and adult rats in 
the CA1 region, and is facilitated by corticosterone during periods of acute stress.
148,149
 
In the dentate gyrus of the wild-type mice, stimulation of the medial perforant path 
produced paired-pulse depression of inter-pulse intervals (IPIs) up to 30 ms. The mGlu1 knock-
out mice, showed significantly longer IPI depression, up to 50 ms. Paired-pulse depression results 
from the activation of inhibitory interneurons and it is facilitated by GABAb agonists. Mice 
lacking mGlu1 have reduced LTP in dentate gyrus compared to wild-type, and these effects have 
been confirmed with the mGlu1 antagonist LY367385 ex vivo and in vivo. This effect is mediated 
via an inhibitory feedback loop onto the granule cells.
137,150,151
  
Also in the dentate gyrus, LTD induced by low frequency stimulation of the medial 
perforant path was prevented by mGlu1 antagonism, while DHPG induced LTD was blocked by 
both antagonism of mGlu1 and mGlu5, and was impaired by NMDA antagonism.
152
 Acute and 
long-term effects of DHPG are restricted to a subset of GABA afferents that are sensitive to 
depolarization-induced suppression of inhibition (DSI), an effect that depends on activation of 
CB1. Here, antagonist work suggested the effect is mGlu1 dependent.
153
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Coactivation of NMDA and group I mGlu is required for learning. The coapplication of 
an mGlu1 antagonist and an NMDA antagonist blocked acquisition of passive avoidance (PA) 
during the acquisition phase. These antagonists were not effective in acquisition during the Fear-
Potentiated Startle (FPS) Paradigm. The mGlu1 knock-out mice exhibited reduced LTP and 
impaired context-specific learning, but it shows no change in cue-dependent fear conditioning. 
Contextual learning depends both in hippocampus and amygdala, while cue-dependent is a 
hippocampus-independent process.
154,155
 It has also been observed that an mGlu1 antagonist did 
not affect the behavior in the passive avoidance test when administered post-training.
156,157
 
Moreover, infusion of DHPG in the amygdala (BLA) prior to fear conditioning, enhances 
freezing memory.
158
  
In classical eye blink conditioning, a test of associative learning where hippocampal 
circuits are involved in trace conditioning acquisition and consolidation, it was confirmed the role 
of mGlu1 as the acquisition to evoke eyelid responses was impaired in the mGlu1
+/-
 mice and 
abolished in the mGlu1
-/-
 animal, when using conditioned or unconditioned stimulus. This 
acquisition correlates with potentiation of synaptic transmission in the hippocampal circuit, 
reflected by an increase in the slope of fEPSP at the CA3-CA1 synapse.
159
 In a single-trial passive 
discrimination avoidance task in young chicks, blockade of mGlu1 and IP3 receptors impaired 
retention 90 minutes post-training; disturbing memory consolidation and reconsolidation, but not 
memory recall. In this model, intracellular calcium release and protein synthesis was required for 
the formation of long-term memory.
160,161
 
The mGlu1 deficient mice have also impaired ability to learn spatial tasks. In the eight-
arm radial maze, LY367385 (a selective mGlu1 antagonits) induced deficits in reference but not 
working-memory, while leaving rearing, grooming and locomotor activity unaffected.
151
 In a 
mouse water maze study, the mGlu1 antagonist BAY 36-720 increased the escape latency and 
impaired the water escape task acquisition during the first 4 days.
162
 In rats that showed increase 
learned capacity, the effect of group I mGlu agonist DHPG was dependent on the time of 
87 
 
administration of the treatment; pre-training injection caused impaired acquisition in a water 
maze task or amnesia of spatial alternation, whereas post-training injection of the same drug 
enhanced retention of memory.
163
 
In a spatial three-choice reward-finding test, bilateral prelimbic injections of an mGlu1 
antagonist before training sessions blocked the acquisition of correct performance behavior, while 
after full training it impaired correct performance without causing a complete block in the 
learning of the task; the antagonist also prevented normal adaptation of spontaneous exploration 
in the open-field test.
164
 
However, studies using an appetitive/positively reinforced tasks protocol (delayed non-
matching to position, DNMTP; differential reinforcement of low rates of responding 18 s, DRL 
18-s) showed that mGlu1 blockade improved working memory and reduced impulsive choices at 
the doses that have no effect on time perception but appear to facilitate impulsive action. These 
results highlights the intricacies of the role of mGlu1 in memory and learning.
165,166
 
 Additionally, a genetic study of an Azeri population looking to identify candidate genes 
for autosomal recessive intellectual disorder (ARID), identified a rare missense variant in the 
GRM1 gene. The mutation was located in the Venus fly-trap domain in a residue conserved 
(Leu454Phe) in the throughout the animal kingdom and it was predicted to be damaging for the 
function of the receptor. In the affected individuals, the mutation was homozygous and they 
presented moderate to severe intellectual disability, delayed developmental milestones and 
derangement of speech, ataxia, frequent convulsions, aggressive behavior, and increased number 
of cerebellar cisterns and cerebellar atrophy were observed during brain MRI.
167
  
 
Role of the mGlu1 receptor in the motor activity 
 Through different genetic studies, it has been observed that mGlu1 has a prominent role in 
maintaining normal motor behavior. The mGlu1 knock-out mice can be identified by having 
ataxia as soon as 2 weeks after birth and complete loss of righting reflex as adults.
168
 Besides, 
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although these animals can still sit, upon initiation of movement, they exhibit tremors of 
significant amplitude that persists for the duration of the movement. These changes altered 
significantly the performance of the animal in the open field-test and rota-rod experiments.
169
 
Also, these animals showed severe spatial learning deficits in the hidden-platform task in the 
Morris test.
168
 The introduction of the GRM1 gene back in the animals demonstrated to rescue 
this motor phenotype.
170
 
 Conditional mGlu1 knockout mice can reach adulthood with a normal phenotype, but 
selective blockade of mGlu1 expression in Purkinje cells causes impaired motor coordination, 
suggesting that mGlu1 is not only essential during development but also for maintaining 
cerebellar function during adulthood.
171
 
It is estimated that these characteristics have their origin in the deficient development and 
function of the cerebellum, but changes in the anatomy of this brain structure anatomy are not 
evident.
137,172
 Pharmacological studies with antagonists (LY367385 and CPCCOEt) showed that 
both group I mGlu are required for differentiation and survival of cerebellar Purkinje cells.
173
  In 
knock-out mice, excitatory transmission in the parallel fiber-Purkinje cells and climbing fiber-
Purkinje cells appears functional, but this does not extend to synaptic plasticity.
172
 So, while 
short-term plasticity presents no change, activation of mGlu1 is necessary to induce long-term 
depression in the parallel fiber-Purkinje cells synapse, an important structure for motor 
learning.
131
 These synaptic deficits are also reversed by reintroduction of the GRM1 gene.
170
 This 
type of long-term depression has demonstrated to be important for producing conditioned eye 
blink reflex and relies in the functional integrity of the cerebellar motor circuitry.
172,174
 
These deficits have also been observed in other animal models, such as the crv4 mice, 
that carries an autosomal recessive mutation, cervelet-4, in the context of the BALB/c strain. The 
homozygous mutant mice display reduced body size, along with ataxic gait and intention 
tremor.
175
 This effects are also describe in different mammal species and have been characterized 
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in Coton de Tulear dogs that present Bandera’s neonatal ataxia (BNAt), a disease caused by a 
retrotransposon inserted into exon 8 of GRM1.
176
 
Spinocerebellar ataxia type 1 mice have lower mGlu1 mRNA and protein levels in the 
cerebellum. These mice also show high expression of mGlu5 in cerebellar Purkinje cells, which 
normally present low density of these receptors. Pharmacological studies showed that Ro 07-
11401, a mGlu1 positive allosteric modulator,  improved the motor performance of these animals, 
while further impairment was observed after dosing JNJ16259685, an mGlu1 antagonist. The 
improvement with Ro 07-11401 was prolonged and was associated to neuroadaptive changes in 
the cerebellum, such as reduction in mGlu5 expression and changes in the length of spines in 
distal dendrites of Purkinje cells.
177,178
 
In humans, the reduction of mGlu1 in cerebellum with age can be associated with age-
dependent decrease in motor learning and coordination.
131
 Also, patients with Hodgkin’s 
lymphoma have presented paraneoplastic ataxia due to the production of mGlu1 antibodies.
131,179
 
Although more uncommon, this finding has been extended to individuals with subacute cerebellar 
ataxia but with no tumor precedent.
180
 
Mutations in the GRM1 have transduced into a form of autosomal-recessive congenital 
cerebellar ataxia in Roma patients. These subjects also presented global developmental delay, 
stance and gait ataxia, dysarthria, dysdiadochokinesia, dysmetria and tremors, intellectual deficit, 
and mild pyramidal signs; and a subset of them showed progressive cerebellar atrophy through 
brain imaging analysis.
181
 
Finally, in cerebellum samples of mice with  autoimmune-induced encephalomyelitis and 
multiple sclerosis patients, progressive loss of mGlu1 was found in Purkinje cells, along with 
increase mGlu5. Treatment of these animals with Ro 07-11401demonstrated to improve motor 
coordination.
174,182
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Role of the mGlu1 receptor in anxiety 
The findings that point to a function of mGlu1 in anxiety are less straightforward. 
Although the mGlu1 knock-out mice appear more agitated and prone to stress, there are 
conflicting studies that show that mGlu1 antagonist can be anxiolytic.
137
 The mGlu1 antagonist 
AIDA had anxiolytic activity in the conflict drinking test and the elevated plus maze in rats 
without affecting motor coordination.
183
 The negative allosteric modulator JNJ16259685 
increased the number of licks but no anxiolytic effects were observed in the elevated plus 
maze.
184
 EMQMCM results for anxiolytic activity are mixed as it could inhibit fear-potentiated 
startle, but it had no effects on the Geller-Seifter conflict test, and mixed effects in elevated plus 
maze test.
185,186
 
 A study showed that in DBA/2 mice, which display a high anxiety phenotype, amygdala 
neurons express asynchronous activity with diverse excitability, and weak transmission in 
GABAergic synapses compared to low anxiety FVB/N mice. mGlu1/5 activation with DHPG 
improved anxiety-like behaviors in the DBA/2 mice, synchronized the activity of amygdala 
neurons and strengthened the GABAergic synapses.
187
 These results demonstrate how the 
outcome of mGlu1 activation can vary depending on the initial condition of the individual. 
Also, in experiments where social isolation stress is produced to induce anxious-
depressive like behavior, a decrease expression of mGlu1 in the prefrontal cortex was observed; 
however, this study did not elucidate if this finding could be a driver of the observed behavior or 
a compensatory mechanism.
188
 
 
Role of the mGlu1 receptor in the hyperexcitability and seizures 
Group I mGlu receptors have been involved in neuron hyperexcitability and the induction 
of seizures. The application of DHPG  in the CA3 region of the hippocampus transforms normal 
neuronal activity into prolonged epileptiform discharges (interictal discharges and longer 
synchronous seizure-like), an effect that persists after removal of the agonist.
189
 Group I agonists 
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induce seizure discharges in vivo and cause prolonged ictal-like activity in brain slices in a 
mechanism believed to be related to PLCβ and ERK1/2 activation.190 So, it has been stated that 
mGlu1 contributes to long-lasting plastic changes associated with seizure activity.
191
 
The use of an mGlu1 antagonist suppressed the induction of ictal activity but showed 
almost no effect on maintenance of epileptiform activity, inhibition of PLC and TRPC displayed 
a similar effect.
192,193
 DPHG induced an increase in burst frequency up to 300% in the 
hippocampal CA1 region, along with a decrease in amplitude and duration. LY367385, AIDA 
and MPEP prevented these changes.
194,195
  LY367385 decreased the duration of these discharges, 
and the effect is additive when an mGlu5 antagonist is employed.
196
  
In vivo, group I mGlu agonists have shown convulsant activity, while antagonists impede 
DHPG generalized motor seizures.
197
 It has been found that activation of mGlu5, but not mGlu1, 
induced epileptogenesis, while synaptic activation of both maintains group I mGlu-induced 
epileptogenesis. 
198
  
Studies with antagonists LY367385 and AIDA showed that mGlu1 inactivation 
transiently suppressed sound-induced clonic seizures in the DBA/2 mice, an epilepsy prone 
strain; and also reduced spontaneous spike and wave discharges in lethargic mice (lh/lh).
199
 
Additionally, animal models have shown that kindled seizures can increase mGlu1 mRNA and 
protein expression in different regions of the brain (e.g. dentate gyrus, CA3, supraoptic 
nucleus).
191,200
 Kainate-induction of status epilepticus caused also an increase in mGlu1 
expression in inhibitory interneurons of the CA1 stratum oriens/alveus. This increase may be a 
compensatory mechanism that contributes to the resistance and tolerance of the immature 
hippocampus from damage. Excessive stimulation of excitatory synapses enhances the inhibitory 
drive of the immature brain by increasing GABA release.
201
 However, different studies have 
reported that status epilepticus did not alter expression of mGlu1 in hippocampal neurons, while 
causing mGlu5 downregulation in the hippocampus and losing its induced long-term 
depression.
202,203
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 Contrasting results have been observed in absence seizures. A spontaneously epileptic rat 
strain that develops tonic convulsions and absence-like seizures at 8-weeks, showed increase 
glutamate and low mGlu1 mRNA in hippocampus, with lower expression of mGlu1 in CA3 and 
dentate gyrus.
204
 The  WAG/Rij rats develop spontaneous absence seizures and it was found in 
these animals that mGlu1 response and expression were decreased in the thalamus. This finding 
was especially important in the reticular thalamic nucleus. Administration of Ro 07-11401 
reduced the spontaneous spike and spike-wave discharges (incidence and duration), while dosing 
the JNJ16259685 increased these discharges.
205,206
 This effect was also observed with mGlu5 
PAM VU0360172. When administered chronically, animals develop tolerance for Ro 07-11401 
after the third day of treatment, while this was not observed with VU0360172. The application of 
Ro 07-11401 increased the expression of mGlu1 and mGlu5 in the thalamus and cortex. 
Interestingly, in non-epileptic rats repeated injections of Ro 0711401 down-regulated the 
expression of mGlu1 and mGlu5 receptors.
207
 
 
Role of the mGlu1 receptor in addiction 
 The role of mGlu1 in addiction is still not clear. Several single nucleotide polymorphisms 
in GRM1 found in populations of the Detroit Neighborhood Health Study and Grady Trauma 
Project were linked to an increment in alcohol consumption.
208
 Chronic ethanol consumption 
caused a  decrease in expression of mGlu1 mRNA in the CA3 region of the hippocampus and 
cerebellum; and upregulation of Homer2 and mGlu1 in the nucleus accumbens.
209,210
 Meanwhile, 
history of binge alcohol drinking led to higher expression of mGlu1, GluN2B, Homer2 and PLCβ 
in the central nucleus of the amygdala, but not in the adjacent basolateral amygdala.
211
  
In ethanol consumption studies, mixed results have been observed with mGlu1 
antagonists. EMQMCM attenuated ethanol-induced conditioned place preference and ethanol 
withdrawal audiogenic seizures in rats, the antagonist also potentiated the inhibitory effect of 
MK-801 on the expression of ethanol induced sensitization.
212
 Administration of CPCCOEt in a 
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chronic intermittent ethanol consumption model has shown that ethanol activates mGlu1 to 
promote withdrawal-associated cytotoxicity in vitro and physical dependence in vivo.
213
 
CPCCOEt also resulted in reduced instrumental responding for ethanol, free-choice ethanol 
drinking and ethanol-induced locomotor sedation in mice in one study; however, these actions are 
not robust, as different reports have shown how the treatment with this compound resulted in no 
effect.
210,214
 In the case of JNJ16259685, intra-CeA infusions moderately reduced binge intake, 
without influencing sucrose drinking, and the effect was enhanced with the use of mGlu5 and 
PLC inhibitors.
211
 This compound also reduced ethanol self-administration, dose dependently, in 
alcohol preferring inbred rats; although, it was concluded that the effect was due to motor 
impairment, even with the lowest effective dose.
215–217
 
 The effect of mGlu1 in the action of stimulants has also been studied and conflicting 
results have emerged. Activation of group I mGlus is necessary for acquisition and expression of 
amphetamine induced conditioned place preference, and it has been observed that it is inhibited 
by MPEP but not to by mGlu1 NAM JNJ16259685.
218
 Additionally, EMQMCM attenuated 
expression of behavioral sensitization cocaine in rats.
210,214
 Antagonism of mGlu1 receptors in the 
dorsal hippocampus has been reported to attenuate the reinstatement of cocaine-seeking behavior 
evoked by cocaine-associated contextual cues.
219
 Moreover, intra-accumbens administration of 
DHPG promoted cocaine seeking in rats,  while the mGlu1 antagonist YM298198 attenuated 
drug-induced reinstatement of cocaine seeking.
220
 
Group I mGlu is believed to be involved in drug-related learning. Cocaine-experienced 
animals exhibited a time-dependent intensification of cue-induced cocaine seeking and impaired 
extinction, an effect that was associated with reduction in mGlu1/5 within ventromedial PFC. 
Dosing of mGlu1 antagonists in cocaine-experienced rats did not affect drug-seeking behavior, 
while application of DHPG before the test after 30-day withdrawal facilitated extinction learning. 
Deficits in mGlu1 in PFC mediate resistance to extinction and stimulation of mGlu1 could 
facilitate learned suppression of drug-seeking behavior, helping drug abstinenence.
221
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It has also been observed that application of DHPG in the medial prefrontal cortex 
increased glutamate levels in cocaine-sensitized rats, indicating that group I mGlu activation may 
contribute to the increased excitability in neurons in sensitized animals.
222
 However, the Homer2 
knock-out mice, which has reduced mGlu1 function, also exhibited increased sensitivity to the 
psychomotor activation and conditioned rewarding effects of cocaine, and an enhanced capacity 
to increase glutamate in the striatum. Deletion of mGlu1 also blunted ethanol reward and place 
conditioning, causing reduced reward and aversion of ethanol, with higher sensitivity to motor-
impairing/sedative effects.
223
 
Acute and chronic cocaine use decreases expression of mGlu1 in dendrites of nucleus 
accumbens, with no change in mGlu5.
224
 Repeated cocaine injections for 3 weeks, decreased the 
capacity of DHPG to induce glutamate release in the nucleus accumbens and reduced the increase 
in locomotor activity, a change associated to reduction in Homer1b/c.
225
 
High conductance calcium-permeable AMPAR are normally low in the nucleus 
accumbens synapses, but levels increase with cocaine administration and it has been found that 
they mediate cue-induced cocaine craving. Stimulation of mGlu1 inhibits synaptic transmission 
by these receptors in several brain regions (e.g. VTA, cerebellum, and amygdala). Specifically in 
the nucleus accumbens, mGlu1 activation eliminates the contribution of these receptors in 
synaptic transmission, and facilitates transmission with calcium-impermeable AMPAR, reducing 
cue-induced cocaine craving, an effect that could be beneficial for cue-induced relapse in 
abstinent cocaine addicts.
226–228
 
Cocaine also produces a switch of NMDAR subunit composition at excitatory synapses 
on dopaminergic neurons of the VTA, provoking the insertion of GluN3A subunits which reduces 
NMDAR function and are necessary for cocaine-evoked plasticity of AMPAR in these synapses. 
mGlu1 potentiates NMDA transmission and restores subunit composition via a protein synthesis-
dependent mechanism.
229
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 Besides reversing the effects in adults, it has been observed that mGlu1 activation can 
attenuate developmental deficits caused by in utero exposure to cocaine. Prenatal cocaine 
exposure uncouples mGlu1 from its anchoring protein Homer and signal transducer Gq/11, reducing 
phosphoinositide hydrolysis in the hippocampus and brain cortex.
230
 It also causes delayed 
postsynaptic maturation of glutamatergic transmission in the VTA, and this effect is blunted by 
mGlu1 positive modulation.
231
 
 
Role of the mGlu1 receptor in schizophrenia  
The hypofunction of the NMDA receptor has been highlighted as an etiological factor for 
schizophrenia. The NMDA receptor function can be modulated by group I mGlus and it has been 
proposed that these receptors could also contribute to the disease.  
In postmortem studies of schizophrenic patients, an increase in protein expression of 
mGlu1a in the prefrontal cortex has been observed, but not in the striatum or the thalamus.
232,233
 
Higher postmortem mGlu1a mRNA levels have also been found in the prefrontal cortex. These 
changes were not attributed to the use of antipsychotic medications, and the patient samples 
presented no difference when they were stratified by sex, tendency for suicide or history of 
substance abuse.
234
 However, the involvement of the receptor is hard to elucidate as these events 
could be the cause or a compensatory reaction to neurotransmitter dysregulation in schizophrenia.  
The mGlu1 knockout mice displayed deficits in prepulse inhibition (PPI) and the 
sensorimotor gating.
235
 But the application of mGlu1 antagonists EMQMCM and BAY 36-7620 
in normal animals did not disturb PPI.
236,237
 While mGlu1 deletion in mice caused amphetamine to 
induce a higher motor response compared to wild type, studies using the amphetamine-induced 
hyperlocomotion have shown that mGlu1 antagonists AIDA and MCPG did not affect the 
amphetamine related behavior.
238,239
 
Additionally, mGlu1 function has been reported to be affected by the action of other 
molecules related to schizophrenia, like dysbindin-1 encoded by schizophrenia risk gene dtnbp1. 
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This protein is reduced in the brain of schizophrenics and a loss of function mutation in dtnbp1 
caused cognitive and social behavior impairment, accompanied by great reduction in DHPG-
induced phosphorylation of ERK1/2, with no effect in group I mGlu expression. The mutation 
also affected plasticity related to group I mGlu receptor, reducing DHPG-induced LTD at CA1 
excitatory synapses. Application of an mGlu5 PAM rescued this phenotype, and the authors of the 
study indicated that the role of mGlu1 should be explored.
240
 
Multigenic clustered coding variants analysis of glutamatergic “hub genes” in the 
genome of schizophrenic and bipolar patients identified two exons encoding for the cysteine rich 
domain and the first TMD helix of GRM1, as a risk locus with five highly enriched mutations. 
Even though these mutations were not studied in in vitro or in vivo, in silico exploration identified 
them as polymorphisms that would probably affect protein folding, trafficking or activation of the 
receptor.
241
  
More recently, deleterious mutations of GRM1 were found in an Australian population of 
schizophrenics. These mutations were hereditary and they also were predicted to be deleterious. 
Four of these mutations were found in family members, and their diseases were not limited to 
schizophrenia (depression, anxiety, drug and alcohol dependence, and epilepsy). The in vitro 
analysis showed that these genetic changes decreased mGlu1 induced inositol phosphate 
production and one of them reduced membrane expression. 
242,243
 The finding of appropriate 
activators of the mGlu1 receptor could provide therapeutic benefit for patients carrying these 
mutations. 
 
Ligands for the metabotropic glutamate receptor subtype 1 
 
Orthosteric Agonists  
mGlu1 endogenous ligand, glutamate 3.1, can potentiate both mGlu1 and mGlu5 with 
comparable EC50s.
244
 The orthosteric mGlu1 agonists available are characterized for being amino 
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acid derivatives that bind in the same N-terminal site as glutamate (Table 3.1). Products of 
oxidation of cysteine, such as S-sulfo-L-cysteine 3.2, have demonstrated to activate the receptor 
weakly.
245
 Ibotenic acid 3.3 is a natural product identified in the Amanita muscaria mushroom, 
this molecule can activate the group I and II of the metabotropic receptors, along with NMDA 
and has shown weak agonism in the AMPA and kainate receptors.
244
 The first synthetic agonists 
discovered were ring-constrained amino acids, such as ACPD 3.4 and L-CCG-I 3.5, which 
despite of activating the receptor lack selectivity with respect to the other forms of mGlus.
244,246
 
Quisqualate 3.6, an oxadiazolidine analog, is one of the most potent mGlu1 agonists and is 
selective for group I mGlus; although, it also activates AMPA and kainite receptor. The most 
selective agonists for group I orthosteric agonist are based on the structure of (S)-3-
hydroxyphenylglycine 3.7. In this group, (S)-DHPG 3.8 stands out as the most potent and 
employed chemical tool in the study of the effects of activation of mGlu1 and mGlu5.
244
 
 
Table 3.1. Representative orthosteric agonists for the mGlu1 receptor. 
Structure Cpd # Name EC50 Ref 
 
3.1 Glutamate 1.0 µM
b
 
244
 
 
3.2 S-Sulfo-L-cysteine >1000 µM
a
 
245
 
 
3.3 Ibotenic acid 2.3 µM
b
 
244
 
 
3.4 1S,3R-ACPD 
36.1 µM
a 
8 µM
b
 
246
 
 
3.5 L-CCG-I 2 µM
b
 
244
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3.6 Quisqualic acid 0.045 µM
b
 
244
 
 
3.7 (S)-HPG 52 µM
b
 
244
 
 
3.8 (S)-DHPG 
10 µM
a 
3.25 µM
b
 
246
 
a
Based on PI hydrolysis. 
b
Calcium mobilization assay. 
 
Orthosteric Antagonists 
Similarly to the agonists, orthosteric antagonists are also amino acid based molecules that 
exert their function competing for the extracellular glutamate binding site and stabilizing a 
resting/inactive conformation of the receptor (Table 3.2). DCG-IV 3.9 and AIDA 3.10 are ring-
constrained amino acids, of which the former has cross activity between group I and II, while the 
latter selectively inhibits mGlu1 but with low potency (Ki = 124 µM).
244,247
 Similarly, the 
phosphonic acid L-AP3 3.11 inhibits phosphatidylinositol hydrolysis caused by group I mGlu but 
only at high concentrations.
248
 In a campaign to find an mGlu1 antagonist, structure-activity 
relationship studies were carried on using the agonist ibotenic acid 3.3 as a starting point. (S)-
HexylHIBO 3.12 was obtained from this efforts, where homologation and n-hexyl substitution 
caused the switch in its pharmacological profile and also rendered the molecule preferential for 
group I mGlu receptors.
249
 Studying similar structures to (S)-DHPG 3.8, it was found that 
carboxyphenylglycines 3.13-3.19 can act as group I mGlu antagonists. The aromatic carboxylic 
acid function together with the introduction of an alkyl group in the α-carbon are important 
features to develop antagonist activity.
250,251
 From this scaffold, the most potent and selective 
molecules are LY367385 3.18 and 3-MATIDA 3.19, which share an ortho-methyl substitution 
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with respect to the amino acid; in 3.19, the phenyl ring has been replaced for the thiophene 
bioisostere.
252,253
 
 
Table 3.2. Representative orthosteric antagonists for the mGlu1 receptor. 
Structure Cpd # Name Ki/IC50 Ref. 
 
3.9 DCG-IV IC50: 389 µM 
247
 
 
3.10 AIDA Ki: 124 µM
a
 
244
 
 
3.11 L-AP3 IC50: 2.1 mM
b
 
248
 
 
3.12 (S)-HexylHIBO Kb: 140 µM
c
 
249
 
 
3.13 (S)-4CPG 
Ki:18 µM
a 
IC50: 40 µM
c
 
244,250,251
 
 
3.14 (S)-3C4HPG IC50: 400 µM
c
 
250,251
 
 
3.15 (S)-4C3HPG 
Ki:11 µM
a 
IC50: 30 µM
c
 
244,250
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3.16 (S)-MCPG IC50: 70 µM
c
 
250,251
 
 
3.17 E4CPG Kb: 367 µM
c
 
254
 
 
3.18 LY 367385 IC50: 8.8 µM
c
 
253
 
 
3.19 3-MATIDA IC50: 6.3 µM
c
 
252
 
a
Calcium mobilization assay. 
b
Evoke inward currents in voltage clamped.
 c
Inhibition of 
phosphatidylinositol hydrolysis. 
 
Allosteric ligands 
 The allosteric modulators differentiate from the orthosteric ligands functionally and 
structurally. From a topographic stand point, the allosteric modulators bind to a site distinct from 
the orthosteric site; hence, ideally, they are not competitive with the endogenous agonist. The 
difference in binding site comes accompanied by a difference in chemical structure and properties 
with respect to the endogenous ligand. For example, in the class C of the GPCR family, the 
allosteric sites are usually found in the transmembrane domain and its allosteric modulators are in 
overall more lipophilic than the orthosteric ligands. In the case of central nervous system 
application, the design of allosteric modulators favors bioavailability, brain penetration and 
exposure to target. 
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Allosteric modulators act by causing or stabilizing conformational changes in the 
receptor which in turn will affect the sensitivity and the efficacy of the orthosteric ligand. A pure 
allosteric modulator would not cause an observable effect on its own, but only when the agonist is 
present. Then, allosteric modulation possess the advantage of a more fine tuning with better 
spatial and temporal control, which is especially important in the nervous system, where the 
signaling events are highly compartmentalized and synchronized. This feature will anticipate 
better efficacy and lower adverse event potential. In the case of positive allosteric modulators, 
these will additionally cause less desensitization and down-regulation of the receptor than an 
orthosteric agonist by not being permanently activating the receptor. 
Besides, allosteric modulation has the intrinsic strategy of targeting a less evolutionary 
conserved site. When developing agonists compounds, the orthosteric binding site usually shares 
a higher homology in a family of receptors, as it has evolved to accommodate the same 
endogenous ligand; however, the allosteric sites are more divergent in its sequence, facilitating 
the discovery of isoform-selective allosteric modulators. 
 
Negative allosteric modulators 
 The role of mGlu1 in pain perception led to extensive studies for the production of non-
competitive antagonists for the receptor. Several institutions have worked in the development of 
mGlu1 negative allosteric modulators around different scaffolds (Table 3.3). The first molecule 
discovered in this group was (-)-CPCCOEt 3.20. This oxime interacts with amino acids distant 
from the orthosteric site in the extracellular surface of TM7 (T815 and A818).
255,256
 3.20 
demonstrated to be a selective and potent enough chemical probe to explore the target in vitro; 
however, it lacked good characteristics for in vivo use. Its analog, PHCCC 3.21, inhibits the 
receptor with higher potency, but it is also active in mGlu4.  
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BAY36-7620 3.22 was the first potent and selective mGlu1 NAM with IC50 below 160 
nM, and behaving as an inverse agonist.
257
 After that, several NAMs with high potencies have 
been obtained, and some of these compounds have been used in their tritiated form as 
radioligands, including EM-TBPC 3.23, YM-298198 3.38, R214127 3.25, to study the 
distribution of mGlu1 in the rat brain and quantify the affinity of other glutamate non-competitive 
ligands.
258
 EM-TBPC 3.23, despite being highly potent, shows significant cross-species 
difference, as this NAM is active in the rat form of the receptor but it has low affinity for the 
human one.
258
 NPS2390 3.24 is a quinoxaline analog with preferential mGlu1 NAM activity and 
residual mGlu5 inhibition.
259
 Additional compounds in this series have improved selectivity for 
mGlu1, such as NPS2407, a 2-quinoxaline carboxamide, and NPS3018, a quinoxaline ester.  
R214127 3.25 is a non-competitive and selective mGlu1 negative allosteric modulator 
with high affinity for the receptor. 3.20, 3.22, 3.23, 3.24 and 3.38 can displace [
3
H]-R214127 ex 
vivo and in vivo slices, arguing for a common allosteric binding site for these different 
compounds. This radioligand facilitated the discovery of JNJ16259685 3.26, a potent mGlu1 
NAM with good receptor occupancy and long lasting coverage after systemic administration.
260
 
Abbott has also developed different series of mGlu1 NAMs, of which the most optimized 
is A841720 3.27. This compound has good pharmacodynamic properties and brain penetration, 
and it proved to have analgesic activity in models of neuropathic pain; although, it showed 
disruption of cognitive function.
261
 Even when other series were explored to increase solubility, 
such as 3.28, the SAR in the core was flat and 3.27 remained the more potent compound.
262
 This 
scaffold was also explored by Schering-Plough with similar results.
263
   
Pfizer also disclosed two different scaffolds for non-competitive antagonists of mGlu1, 
the first being 3.29 which showed to be potent, selective and stable in human liver microsomes.
264
 
The second scaffold 3.30 contains an indanamine and morpholine substituent, features that 
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balance potency along with CNS penetration (50% in CSF). This molecule also possesses a 
relatively short half-live, but with good oral bioavailability, and its analgesic effects are 
comparable with morphine when concentration on target is ten-times its Ki.
265
 A compound 3.31 
with this pyrido[3,4-d]pyrimidine core has also been reported by Lilly as a selective mGlu1 NAM 
with anticonvulsant, antinociceptive and anxiolytic effects.
237,266
 
 FTIDC 3.35 and FITM 3.34 are compounds developed by Merck-Banyu. FITDC 3.35 
features in its structure a pyridine ring to decrease the log D with respect to previous molecules, a 
2-fluoro substitution to decrease the basicity of the molecule, and a methyl group  in the triazole 
that demonstrated to be important for potency and selectivity.
267,268
 These characteristics allowed 
the study and confirmation of the analgesic profile of the compound; however, the compound has 
a short half-life do to oxidative dealkylation of the urea. FITM 3.34 was developed to improve 
P450 metabolism and water solubility.
269
 The introduction of an N-isopropylpyrimidin-4-amine 
demonstrated to be useful to achieve these goals. FITM 3.34 demonstrated to be active as 
antipsychotic and to enable positive emission tomography (PET) studies through is 
11
C-methyl 
and 
18
F radiolabeled analogs.
270
 
GlaxoSmithKline has reported different potent compounds, like 3.32, obtained through a 
tied-back ring strategy on a pyrrole high-throughput screening hit.
271
 Astellas has also disclosed 
various mGlu1 NAMs (3.36, 3.37, 3.38) with high potency and selectivity that were efficacious 
inhibiting nociception and as neuroprotective agents in stroke;
272–274
 as well as the Banyu´s 
Tsukuba Research Institute with CFMMC 3.39. Merz also attempted to develop mGlu1 NAMs 
through a virtual screening effort, using a template based on JNJ16259685, NPS2390, EM-TBPC, 
and even though antagonists with good potency were obtained (e.g. 3.33) the compounds 
generated were very lipophlic.
275
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Finally, at Vanderbilt University our research group discovered potent and selective 
mGlu1 NAM VU0469650 3.40.
276
 This chemical probe is brain penetrant, has good free fraction 
in plasma (7%), but it suffers from high clearance. 
 
Table 3.3. Representative negative allosteric modulators for the mGlu1 receptor. 
Structure Cpd # Name Ki/IC50 Ref. 
 
3.20 CPCCOEt IC50: 6.5 µM
a
 
255,256
 
 
3.21 PHCCC IC50: 3.0 µM
a
 
277
 
 
3.22 BAY 36-7620 IC50: 160 nM 
257
 
 
3.23 EM-TBPC 
IC50: 15 nM 
Kd: 6.6 nM 
258
 
 
3.24 NPS2390 Ki: 1.36 nM 
259
 
 
3.25 R214127 Kd: 0.9 nM 
259
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3.26 JNJ16259685 IC50: 3.2 nM 
260
 
 
3.27 A841720 
IC50: 11 nM 
Ki: 10 nM 
 
261
 
 
3.28 --- Ki: 127 nM 
262
 
 
3.29 --- Ki: 9 nM 
264
 
 
3.30 --- Ki: 6 nM 
265
 
 
3.31 LY456236 Ki: 143 nM 
266
 
 
3.32 --- IC50: 19 nM 
271
 
 
3.33 --- Ki: 24 nM 
275
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3.34 FTIDC IC50: 6 nM 
267,268
 
 
3.35 FITM Ki: 55 nM 
269
 
 
3.36 YM202074 
IC50: 8.6 nM 
Ki: 4.8 nM 
272
 
 
3.37 YM230888 
IC50: 13 nM 
Ki: 13 nM 
273
 
 
3.38 YM298198 
IC50: 16 nM 
Kd: 32 nM 
274
 
 
3.39 CFMMC IC50: 50 nM 
278
 
 
3.40 VU0469650 IC50: 99 nM 
276
 
a
Calcium mobilization assay. 
b
Evoke inward currents in voltage clamped.
 c
Inhibition of 
phosphatidylinositol hydrolysis. 
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Positive allosteric modulators 
In the mGlu1 allosteric modulator realm, the negative allosteric modulators have been 
explored vastly in comparison with the positive allosteric modulator. The scaffolds available are 
mainly a contribution from Hoffman-La Roche (Table 3.4). Ro 67-7476 3.41 and Ro 01-6128 
3.42 were obtained directly as hits from a high-throughput screening campaign, and while they 
were active at the rat form of the receptor, they do not potentiate the response in the human 
receptor; similar to what happened with VU-71 3.44. Both compounds, increased the binding of 
radiolabeled mGlu1 agonist [
3
H]-quisqualate.
279
 It is remarkable that none of these compounds can 
displace [
3
H]-R214127, indicating a different binding site with respect to the one observed for 
many negative allosteric modulators.
280
 The only compound that has cross species activity is Ro 
07-11401 3.43 and its development will be described in the next section. 
 
Table 3.4. Representative positive allosteric modulators for the mGlu1 receptor. 
Structure Cpd # Name EC50 Ref 
 
3.41 Ro 67-7476 174 nM 
279
 
 
3.42 Ro 01-6128 200 nM 
279
 
 
3.43 Ro 07-11401 56 nM 
281
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3.44 VU-71 
2.4 µM
 
 
280
 
 
 
Study of the structure-activity relationship around Ro 07-11401 
 
Development of Ro 07-11401 
 After finding Ro 67-7476 3.41 and Ro 01-6128 3.42 during a high throughput screening 
effort, the compounds were studied in kinetic fluorescence-based calcium mobilization assays and 
in electrophysiology models, where they demonstrated to potentiate the rat mGlu1 receptor and 
selectivity with respect to other members of the mGlu family. These compounds bind in the 
transmembrane domain and different activity in the rat and human form of the receptor arises 
from a single amino acid change in position 757 in TM5 (leucine in human, valine in rat).
279
 
  In order to improve activity in the human receptor, SAR studies were carried on using Ro 
01-6128 3.42 as parent compound, employing different alkyl substituents in the oxygen of the 
carbamate and a cyclization strategy to produce xanthene and thioxanthene analogs. Here, the n-
alkyl 9H-xanthene-carbonyl carbamates were slightly more active than their diphenylacetyl 
congeners, while analogs with a 9H-thioxanthene core were considerably less active. In the 9H-
xanthene scaffold, replacement of the carbamate with a thiocarbamate or an urea led to decrease 
the potency. A linear chain is preferred as the substituent in the carbamate, with bulkier 
substituents (i-Pr, t-Bu) being not well tolerated. The optimized length for the alkyl chain is four 
carbons in both series. Compound Ro 67-4853 3.45 was obtained from this task, a highly potent 
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mGlu1 PAM with cross species activity, but less selectivity than its predecessor and a small 
potentiating effect in mGlu5 at 10 µM (Fig. 3.3).
282
 
 
 
Figure 3.3. Discovery of compound Ro 67-4853 3.45. 
 
However the improvements, Ro 67-4853 3.45 demonstrated to be a highly labile 
compound, as the carbamate moiety is quickly hydrolyzed by esterases in blood plasma to 
generate inactive amides. A replacement of the carbamate for bioisosteric five-membered 
heteroaromatic rings, such as oxadiazoles and tetrazoles was performed. In this series, small alkyl 
and cycloalkyl substituents in the newly introduced rings were beneficial for mGlu1 PAM activity 
(Fig. 3.4). Overall, 3.46 and 3.47 provided the best balance in potency, in vitro rat liver 
microsomal metabolism and solubility; but, when employed in vivo, IV administration showed 
that compounds metabolized quickly with half-lives of less than 30 minutes, they possess good 
bioavailability after per oral administration, but their brain penetration was poor (Kp: 0.16), even 
after IV infusion administration. Studies demonstrated that low access to CNS was not caused by 
the P-glycoprotein efflux transporter.
283  
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Figure 3.4. Bioisosteric replacement of the carbamate in the Ro 67-4853 3.45 series. 
 
In an effort to improve the pharmacokinetic profiles of newly generated mGlu1 PAMs, 
SAR studies were performed employing an oxazole molecule. The 4-methyloxazole analog was 
found to have similar activity to the previously tried five-member rings. Biotransformation of this 
compound, as well as the 3-methyloxazole, revealed that oxidation occurred in the methyl and on 
positions C2 and C7 in the xanthene. Different fluorinated compounds around this scaffold were 
prepared to increase their metabolic stability. It was found that fluorine substitution in the 
xanthene decrease the mGlu1 activity, affecting mostly the efficacy of the compounds. Also, 
replacing the methyl substituent for trifluoromethyl resulted in active compounds with decreased 
clearance with respect to the parent compound (Fig. 3.5). Ro 07-11401 3.43 was obtained, a 
potent mGlu1 PAM with a half-life of 54 minutes and Kp of 0.8.
281
 However, when Ro 07-11401 
3.43 was tested in our laboratories its properties differed considerably, especially its 
pharmacokinetics properties. Our measurements determined and in vitro rat intrinsic clearance of 
661 mL/min/kg (63.3 mL/min/kg adjusted for hepatic blood flow), brain-plasma partition 
coefficient of 0.28 in mouse and rat, and inhibition of P450 1A2 (IC50 = 13 µM) and 2C9 (IC50 = 
0.62 µM). Our studies also showed low fraction unbound in human (0.3%) and rat plasma (1.4%), 
and in rat brain homogenate (1.4%). 
111 
 
 
 
Figure 3.5. Discovery of compound Ro 07-11401 3.43. 
 
Modifications to the Ro 07-11401 scaffold 
The lack of good pharmacokinetic properties for Ro 07-11401 1.43 motivated us to 
explore its SAR and develop an optimized chemical probe that could be used in target validation 
studies to determine the role that mGlu1 activation can have in schizophrenia and other 
neuropsychiatric conditions. 
The compound is an amide, and a vast chemical space can be explored by using different 
amines and carboxylic acids. In the amine side, the published SAR showed that only few rings 
were tried when replacing the carbamate from the previous series; therefore, we could survey 
different aromatic and saturated rings, as well as different substituents in those rings. As the 
xanthene had remained unchanged since the obtention of the high-throughput screening hit, 
chemical modifications on this ring system have not been explored; the xanthene moiety can be 
modified by eliminating rings, opening the tricyclic core, or introducing heteroatoms. Also, we 
could try to modify the linker that brings together both rings, such as the alkylation or performing 
the reverse amide (Fig. 3.6).  
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Figure 3.6. Possible chemical modifications to study the SAR around Ro 07-11401. 
 
 The first SAR iteration was directed towards probing the amine region.  The synthesis of 
these molecules was carried out by performing the amide coupling between xanthene-9-
carboxylic acid 3.48 and the respective amines, using 1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) as amide coupling reagent 
and N,N-diisopropylethylamine as base, to generate analogs 3.49-3.160 (Scheme 3.1). 
 
 
Scheme 3.1. Synthesis of diverse amines library, analogs 3.49-3.162. 
 
 Acyclic saturated amines 3.49-3.67 were tried first and their propensity to enhance the 
mGlu1 response towards glutamate was assayed at a single point concentration of 10 µM. From 
this set, no amine potentiated an EC20 of glutamate (Fig. 3.7). A second subset of amides, 
synthesized using cyclic amines 3.68-3.113 derived from azetidine, pyrrolidine, piperidine, 
piperazine and morpholine, gave similar results with complete loss of activity at a 10 µM 
concentration in calcium mobilization assays (Fig. 3.8).  
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Figure 3.7. Saturated acyclic amines that yield inactive compounds for mGlu1 PAM activity, 
analogs 3.49-3.67. 
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Figure 3.8. Saturated cyclic amines that yield inactive compounds for mGlu1 PAM activity, 
analogs 3.68-3.113. 
 
 A third subset consisting of aromatic amines 3.114-3.162 was employed. The single point 
screening at 10 µM of these compounds was performed using the human form of mGlu1 and 
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revealed the presence of active compounds in this set (Fig. 3.9 and Table 3.5). The naked and 
ortho, meta or para-substituted anilines (3.114-3.123) showed no PAM activity, as well as the 
pyridines (3.124-3.126), with the exception of the ortho-aminopyridine 3.124 which potentiated 
weakly the glutamate response to 48% of GluMax. Five-membered aromatic rings were also tried, 
from this set the pyrazole (3.129-3.139), imidazole (3.140-3.142), isoxazole (3.128), 1,2,3-
triazole (3.143), 1,2,4-triazole (3.144-3.146) and thiophenes (3.147-3.149) variants tested did not 
achieve potentiation of the EC20. Meanwhile, the 2-aminooxazole analog 3.127 caused an 
enhancement in glutamate response close to 79% of GluMax, and several thiazole containing 
compounds were found to be active. In this family, it was observed that the 2-aminothiazole 
(3.151) achieved a higher level of %GluMax, than the 5-aminothiazole (3.152) (88% vs 54%, 
respectively). Also, it was found that small groups were tolerated in the 4-position of the 2-
aminothiazole, such as the cyano (3.157) and the iso-propyl (3.153), but bigger groups like tert-
butyl (3.154) and phenyl (3.158) yield inactive compounds. Doubly substituted aminothiazole 
appeared to maintain part of the mGlu1 activity, like the 4,5-dimethyl version 3.155 and the 2-
aminobenzothiazole 3.160, but when large groups were employed a complete loss of activity was 
observed, like in 3.156. It was interesting that in the case of 3.156 a complete inhibition of the 
EC20 was observed, a feature that could be associated with mGlu1 NAM activity. Also, the 5-
amino-1,2,4-thiadiazole 3.162 demonstrated to be active with a %GluMax of 103%. 
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Figure 3.9. Comparison of the single point screening result for PAM activity in human mGlu1 at 
10 µM for the aromatic amine library, analogs 3.114-3.162. Calcium mobilization was used to 
obtain %GluMax values for each compound in the presence of a submaximal concentration of 
glutamate (EC20) in cell lines expressing human mGlu1. Data represent the mean ± S.E.M. of at 
least three replicate experiments with similar results. 
 
Table 3.5. Structures of the aromatic amine library analogs 3.114-3.162 and associated PAM 
activity from the single point screening at 10 µM in human mGlu1. Calcium mobilization 
responses for each compound are reported as a percentage of the maximum glutamate response. 
VU number denotes the compound identifier assigned by Vanderbilt University. Data represent 
the mean ± S.E.M. of at least three replicate experiments with similar results. 
Structure Cpd # VU # hmGlu1 %GluMax 
 
3.114 VU6005359 22.5±3.9 
 
3.115 VU0056706 4.6±3.2 
 
3.116 VU0001272 13.0±2.9 
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Compound 
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3.117 VU0357322 16.4±3.3 
 
3.118 VU0001277 10.0±1.8 
 
3.119 VU0001321 8.9±2.7 
 
3.120 VU6005360 8.9±3.8 
 
3.121 VU0357879 16.0±2.2 
 
3.122 VU6005361 9.6±2.8 
 
3.123 VU0001320 12.8±3.4 
 
3.124 VU0033100 47.7±1.9 
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3.125 VU0032962 16.1±2.8 
 
3.126 VU0189388 13.5±1.6 
 
3.127 VU6000807 78.9±15.5 
 
3.128 VU6000802 29.2±6.3 
 
3.129 VU6000776 30.8±10.0 
 
3.130 VU6000800 25.9±5.9 
 
3.131 VU6000783 17.0±5.2 
 
3.132 VU6000782 8.8±2.3 
119 
 
 
3.133 VU6000781 20.1±0.1 
 
3.134 VU6000792 9.4±1.9 
 
3.135 VU6000793 4.1±1.0 
 
3.136 VU6000777 15.6±4.3 
 
3.137 VU6000784 9.9±2.2 
 
3.138 VU6000791 17.2±6.6 
 
3.139 VU6000785 17.3±7.9 
 
3.140 VU6000797 8.0±2.3 
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3.141 VU6000786 20.1±3.5 
 
3.142 VU6000803 10.2±5.3 
 
3.143 VU6000806 13.9±4.6 
 
3.144 VU6000795 25.7±3.1 
 
3.145 VU6000796 6.4±1.0 
 
3.146 VU6000778 20.5±10.5 
 
3.147 VU6000805 10.8±5.7 
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3.148 VU6000804 5.5±3.7 
 
3.149 VU6000789 9.2±5.1 
 
3.150 VU6000787 88.0±5.4 
 
3.151 VU6000774 54.2±5.2 
 
3.152 VU6000790 60.0±4.9 
 
3.153 VU6000788 28.5±8.3 
 
3.154 VU6000801 68.0±15.7 
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3.155 VU6000794 1.1±0.3 
 
3.156 VU6000799 98.0±23.0 
 
3.157 VU6005362 20.0±2.4 
 
3.158 VU0068341 13.9±2.6 
 
3.159 VU0029218 58.2±3.9 
 
3.160 VU6000775 11.1±2.6 
 
3.161 VU6000779 24.7±1.4 
123 
 
 
3.162 VU6000798 102.7±15.3 
 
3.43 RO 07-11401 90.7±7.2 
 
 The compounds that potentiate the glutamate response were assayed to obtain a 
concentration-response curve (CRC) and to determine their EC50 in human and rat mGlu1 (Table 
3.6). Here, the 2-aminopyridine 3.124 demonstrated to have relatively good potency but with low 
efficacy. In this screening mode, the 2-aminothiazole 3.150 differentiated well from the 2-
aminooxazole 3.127 and the 5-aminothiazole 3.151, showing an EC50 close to 1 µM and the latter 
two being only weak activators with potencies above 10 µM. The double substitution of the 
thiazole was confirmed to be detrimental for mGlu1 activity even with small substituents (3.154) 
or in the case of fused aminobenzothiazole (3.159). The introduction of the additional nitrogen in 
the aminothiadiazole (3.162) produced a decrease of almost 2-fold in potency with respect to the 
aminothiazole. From this series, the most active compounds proved to be the 4-substituted 2-
aminothiazole analogs 3.152 and 3.156, with both compounds possessing an mGlu1 EC50 below 1 
µM. In our screening, Ro 07-11401 3.43 proved to be far less potent than the reported values; 
however, the compound is still close to 3-fold more potent than our most potent hits. 
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Table 3.6. Potencies in human and rat mGlu1 for the active compounds obtained from the 
aromatic amine libraries single point screen. Calcium mobilization responses for each compound 
are reported as a percentage of the maximum glutamate response. VU number denotes the 
compound identifier assigned by Vanderbilt University. Data represent the mean ± S.E.M. of at 
least three independent experiments with similar results. ND, not determined. 
Structure Cpd # VU # 
hmGlu1 rmGlu1 
EC50 
(µM) 
%Glu 
Max 
EC50 
(µM) 
%Glu 
Max 
 
3.124 VU0033100 1.68 59 ND ND 
 
3.127 VU6000807 >10.0 79 ND ND 
 
3.150 VU6000787 1.41 75.0 3.67 82 
 
3.151 VU6000774 >10.0 54 ND ND 
 
3.152 VU6000790 0.901 90 2.39 111 
 
3.154 VU6000801 >10.0 68 --- --- 
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3.156 VU6000799 0.711 110 1.84 124 
 
3.159 VU0029218 4.77 97 --- --- 
 
3.162 VU6000798 2.69 101 3.62 82 
 
3.43 RO 07-11401 0.246 96 0.277 109 
 
 Compounds 3.152 and 3.156 demonstrated to be active across species as they can 
potentiate the glutamate response of the rat form of the receptor; however, their EC50s showed a 
close to 2-fold decrease with respect to human mGlu1 potency. It is worth mentioning that these 
PAMs showed an important increase in efficacy when screened in the rat receptor and this causes 
an apparent shift to the right in the concentration-response curve and its inflexion point, 
increasing the EC50.  
 To explore the SAR around the xanthene moiety, we attempted to prepare new amides 
keeping constant the 2-amino-4-trifluoromethyloxazole moiety from Ro 07-11401 3.43. After the 
use of different amide coupling conditions, using carboxylic acid and coupling reagents or using 
acyclic chlorides, we were able to obtain only one product, the fluorenecarboxylic acid analog 
using PyClU as amide coupling reagent and heating in the microwave for 20 minutes at 120 °C 
(Scheme 3.2A). This molecule demonstrated to be a weak activator with potency over 10 µM and 
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efficacy of 56% of GluMax. This reaction did not allow us to obtain more analogues, probably due 
to the poor nucleophilicity of the 2-amino-4-trifluoromethyl 3.163.  
 
 
Scheme 3.2. Synthesis of xanthene replacements library, analogs 3.165-3.180. 
 
In the report from the discovery of Ro 07-11401 3.43, the authors claimed that the 4-
methylaminooxazole variant had similar mGlu1 PAM activity;
281
 thinking this could be beneficial 
for our chemistry, we proceeded to prepare the library of xanthene replacements using this amine 
piece (Scheme 3.2B). The 2-amino-4-methyloxazole 3.164 allowed us to obtain products for this 
reaction (3.165-3.180); although, yields were generally low. In this library, we assayed different 
strategies to replace the xanthene, such as elimination of rings (3.165 and 3.166), different fused 
rings (3.167-3.177) and ring opening (3.178-3.180). The compounds obtained from this library 
were screened in calcium mobilization assay in single point concentration mode at 10 µM and we 
found that none of the replacement strategies was successful to produce an active mGlu1 PAM 
(Fig. 3.10). 
A 
B 
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Figure 3.10. Xanthene replacements that yield inactive compounds for mGlu1 PAM activity, 
analogs 3.165-3.180. 
 
After finding a very steep SAR in the xanthene moiety of the scaffold, it was decided to 
move forward with the characterization of VU6000790 3.152 and VU6000799 3.156. The 
biological activity of these two compounds was analyzed in a fold-shift paradigm, using a fixed 
single concentration of the mGlu1 PAMs and a full concentration-response curve of glutamate. 
This method allowed us understanding how the compounds affected the sensitivity and efficacy 
of the receptor towards glutamate. From this study, it was observed that the PAMs potentiate the 
glutamate response, increasing the potency of glutamate for the receptor and also the maximal 
response obtained (Fig. 3.11). The increase in fold-shift is correlated to the potency of the 
compounds, being Ro 07-11401 the one that induced the largest leftward shift of the CRC (6.6-
fold decrease in EC50), while for VU6000790 3.152 and VU6000799 3.156 the fold-shift was 4.5 
and 5.7, respectively. In contrast, the efficacy of the receptor was enhanced more with 
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compounds 3.152 and 3.156 than with Ro 07-11401, increasing the efficacy of the receptor signal 
to almost 115% GluMax (Table 3.7).  
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Figure 3.11. Glutamate concentration-response curve fold-shift experiments for compound 
VU6000790 3.152, VU6000799 3.156 and Ro 07-11401 3.43. TR-Ex 293 cells expressing human 
mGlu1 were employed in calcium mobilization studies to obtain glutamate CRC in the presence 
of vehicle or 10 µM concentration of compound. Data represent the mean ± S.E.M. of at least 
three independent experiments with similar results.  
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Table 3.7. Effect of the VU6000790 3.152, VU6000799 3.156 and Ro 07-11401 3.43 at 10 µM in 
the potency and efficacy of glutamate in the human mGlu1 receptor in a fold-shift experiment. 
Data represent the mean ± S.E.M. of at least three independent experiments with similar results.  
 
Glutamate VU6000790 VU6000799 Ro 07-11401 
Top 95.2 115 116 109 
EC50 
(nM) 
983 219 172 141 
Fold-shift --- 4.48 5.72 6.59 
 
The introduction of the thiazole in these molecules might be beneficial to their 
pharmacokinetic properties, as it is observed that the thiazole is more soluble in water and can 
increase free fraction unbound and decreased clearance with respect to the oxazole version (Table 
3.8). Compounds VU6000790 3.152 and VU6000799 3.156 displayed an improvement in the 
human microsomal stability with respect to Ro 07-11401 3.43; however, this did not translate to a 
slower predicted rat hepatic clearance, which was our main driver for the development of a 
chemical probe for target validation studies. With respect to P450 inhibition, 3.152 and 3.156 
caused inhibition of CYP2C9, but in less extent compared with Ro 07-11401 3.43, and 3.156 
showed strong inhibition also in CYP1A2.  
VU6000799 3.156, showed a slight increase in free fraction in rat and human plasma, as 
well as in rat brain homogenate, while a considerable decrease was observed for VU6000790 
3.152. This is related to the polarity of the molecule, and it can be associated to a higher logP due 
to the presence of the isopropyl group in VU6000790 3.152 (clogP = 4.53; TPSA: 51.2), with 
respect to VU6000799 3.156 (clogP = 3.25; TPSA = 75.0).  
Finally, the property that was affected dramatically with 3.152 and 3.156 was the 
brain:plasma concentration coefficient (Kp). After intravenous administration of the PAMs, the 
CNS penetration was evaluated and it was found that 3.152 and 3.156 diffused freely into the 
brain with Kp close to the unity. The unbound concentrated partition coefficient was also 
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calculated. The Kp,uu values confirmed the superiority of 3.15 and 3.16 with respect to the Roche 
analog, in terms of exposure of the probes to the target in the brain. The unbound coefficient is 
also a differentiating factor between 3.15 and 3.16, as Kp,uu is almost 8-fold higher in the case of 
the latter. This represents a significant improvement for this scaffold and it could pave the way to 
better analogs in this class. 
 
Table 3.8. In vitro pharmacokinetic characterization and brain penetrance evaluation of 
VU6000790 3.152, VU6000799 3.156 and Ro 07-11401 3.43. 
Parameter VU6000790 VU6000799 Ro 07-11401 
clogP 
4.53  
(TPSA: 51.2) 
3.25  
(TPSA: 75.0) 
3.75  
(TPSA: 64.4) 
Hum Clint (mL/min/kg) 59.0 18.6 262 
Hum Clhep (mL/min/kg)  15.5 9.85 19.4 
Rat Clint (mL/min/kg) 753 560 661 
Rat Clhep (mL/min/kg)  64.0 62.2 63.3 
Hum Fu plasma  0.001 0.027 0.014 
Rat Fu plasma  0.002 0.005 0.003 
Rat Fu brain  0.001 0.017 0.001 
P450 IC50 (µM) 
1A2       2C9 
2D6      3A4  
 
19.3     2.0 
26.5  >30 
 
2.9      2.9 
10.3   >30 
 
13      0.6 
>30   >30 
Kp (0.25 mg/kg IV , 
0.25 h)  
1.01 1.19 0.29 
Kp,uu 0.51 4.05 0.10 
 
Computational efforts to optimize Ro 07-11401 
In order to find an improved replacement to the xanthene group in Ro 07-11401 and to 
develop an mGlu1 PAM with good potency and pharmacokinetic characteristics, we started a 
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virtual screening campaign in collaboration with Alexander Geanes, a member from the Jens 
Meiler laboratory.  
Some amino acid residues that interact with the PAMs produced by Roche have been 
identified and an X-ray crystal structure of the transmembrane domain of human mGlu1 has been 
obtained. These data provided preliminary information that could aid an attempt at a structure-
based design strategy, though it does not provide information of the binding pose of the ligand in 
the receptor, or the actual conformation of the protein when the ligand is bound. Furthermore, the 
published mGlu1 structure was crystallized in the presence of a negative allosteric modulator, and 
it probably reflects an inactive conformation of the receptor which would be different from the 
one that would be produced upon binding of a PAM. Therefore, we decided to carry on a ligand-
base design effort. 
We envisioned a ligand-centric approach with different filters that could provide 
reasonable structures that allow getting a handle of compounds with mGlu1 PAM activity and 
without the xanthene ring system (Fig. 3.12). In this approach we planned to start with a large 
library of compounds, submit them to a first screening round based on neural network models 
trained to identify mGlu1 PAMs versus inactive compounds generated using available mGlu1 
PAM activity data, submit the top hits from this model into a second round of screening using a 
SurflexSim model, and finally evaluate the synthetic feasibility to obtain the top hit compounds. 
After every screening round, we performed visual inspection of the hits to avoid duplicates and to 
also remove structures with undesired features that we were not able to filter out with automated 
curation of the data sets. 
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Figure 3.12. Flow diagram of the ligand-based approach to improve the properties of Ro 07-
11401. 
 
 We prepared our screening library by performing an in silico amide coupling between 2-
amino-4-trifluoromethyloxazole and the carboxylic acids available in eMolecules (approx. 
83000). This would allow for the exploration of chemical diversity on the xanthene side, while 
the oxazole would facilitate finding mGlu1 PAM active compounds. The library was then curated 
with a pan-assay interference compound (PAINS) and rapid elimination of swill (REOS) filters to 
remove structures with undesired reactive features, to afford a set of 44109 compounds. 
The neural network models were built with mGlu1 PAM activity data taken from Roche 
papers (all compounds sharing a similar scaffold with Ro 07-11401) and the analogs from our 
libraries. Overall the data set presents 55 actives (EC50<10 µM) and 220 inactives (EC50>10 µM) 
compounds. For this model, the two-dimensional chemical structure is converted into a set of 
numerical descriptors that act as a fingerprint for each molecule. The neural network models are 
trained to recognize features of fingerprints that indicate a compound is mGlu1 PAM active 
versus one that is inactive. Model performance was evaluated using a cross-validation procedure 
where the model predicts biological activities on a portion of the data that was not used for 
training. This approach provided a way of approximating how well the model will recognize the 
active from inactive compounds on new data. Our model demonstrated the ability to differentiate 
active mGlu1 PAMs over inactive ones at a rate substantially higher than random chance, as the 
calculated area under the receiver-operator characteristic (ROC) curve was 0.92 (perfect 
model=1.0, random chance=0.5) (Fig. 3.13). 
 
 
Curation of data set 
Neural network 
descriptor 
model 
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model 
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Figure 3.13. Machine-learning neural network model performance.  Area under the curve: 0.92 
(perfect model=1.0, random chance=0.5), average enrichment (up to 0.10 FPR): 2.26 (random 
chance=1.0). 
 
Our in silico compound library was analyzed using the machine-learning neural network 
model, and the fit of the compounds was scored. The results for the screening were clustered by 
structure similarity and representative examples of each class were selected. From this, the top 
100 hits were visually inspected and we chose the 85 hits to advance to the next filter step with a 
three dimensional model. The Surflex-Sim model
284
 was produced employing the most active 
mGlu1 PAMs in the literature, compound Ro 07-11401 3.43 and Ro 67-4853 3.45. Using this 
template, the hits from the previous model were screened. The molecules were scored based on 
the similarity of the query molecules to the template molecules. Using these results, we chose 15 
compounds from this set based on their score and synthetic feasibility. We proceeded to 
synthesize these compounds, but again the 2-amino-4-trifluoromethyloxazole presented problems 
for the amide coupling. Instead, we decided to use the 4-methyl version 3.164 as we did 
previously, and were able to obtain the desired amide products 3.181-3.195 (Fig. 3.14). These 
compounds were analyzed in a calcium mobilization assay at a concentration of 10 µM, but none 
of them potentiated an EC20 of glutamate in the mGlu1 receptor. 
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Figure 3.14. Synthesized virtual screening hits, analogs 3.181-3.195. 
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Summary and future directions 
  
We have tried to optimize Ro 07-11401, a potent and selective mGlu1 PAM with a poor 
pharmacokinetic profile for a chemical probe to be used in target validation studies in 
neurosciences. We explored the amine region and the acid region of this amide and generated 
several libraries. The SAR around this scaffold proved to be steep, and it was shown that only 
thiazole analogs maintain some activity, being the most relevant VU6000790 3.152 and 
VU6000799 3.156 (Fig. 3.15). These compounds have submicromolar potency, and even when 
they showed a decrease in potency with respect to Ro 07-11401, they increased approximately 5-
fold the sensitivity of mGlu1 towards glutamate, along with raising considerably its maximal 
response.  
 
Figure 3.15. Summary of the results of the structure-activity relationship study around Ro 07-
11401 3.43. 
 
The study of the pharmacokinetic properties of these compounds showed that despite still 
having a high clearance, they can diffuse freely into the CNS with a brain to plasma partition 
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coefficient close to one. This is the most relevant feature denoted from our SAR studies, as the 
use of the thiazole might prove useful if it can be introduced in a molecule with improved 
potency. 
Our computational efforts to provide a better compound, in terms of stability, were 
hindered by the production of only inactive analogs. At this point, it is clear that the model needs 
further improvement. The introduction of the new generated data to retrain the model and a 
successful synthesis methodology that allows obtaining the trifluoromethyl analogs of the 
compounds tested, are potential actions that could improve our results. 
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EXPERIMENTAL METHODS 
 
General chemical synthesis and characterization  
All reactions were carried out employing standard chemical techniques under inert 
atmosphere. All reagents and solvents were commercial grade and purified prior to use when 
necessary. Solvents used for extraction, washing, and chromatography were HPLC grade. 
Analytical thin layer chromatography was performed on 250 μm silica gel glass backed plates 
from Sorbent Technologies. Visualization was accomplished with UV light and/or the use of 
iodine or ninhydrin solution followed by heating. Analytical HPLC was performed on an Agilent 
1200 LCMS with UV detection at 215 and 254 nm along with ELSD detection and electrospray 
ionization, with all final compounds showing >95% purity and a parent mass ion consistent with 
the desired structure. Low resolution mass spectra were obtained on an Agilent 6130 mass 
spectrometer with electrospray ionization source.  MS parameters were as follows:  fragmentor:  
100, capillary voltage:  3000 V, nebulizer pressure:  40 psig, drying gas flow:  11 L/min, drying 
gas temperature:  350 °C.  Samples were introduced via an Agilent 1200 HPLC comprised of a 
degasser, G1312A binary pump, G1367B HP-ALS, G1316A TCC, G1315D DAD, and a Varian 
380 ELSD.  UV absorption was generally observed at 215 nm and 254 nm with a 4 nm 
bandwidth.  Column:  Thermo Accucore C18, 2.1 x 30 mm, 2.6 µm. Gradient conditions:  7% to 
95% CH3CN in H2O (0.1% TFA) over 1.6 min, hold at 95% CH3CN for 0.35 min, 1.5 mL/min, 
45 °C. Flash column chromatography was performed on a Teledyne ISCO Combiflash Rf system. 
Preparative purification of library compounds was performed on a Gilson 215 preparative LC 
system. Column: Thermo Accucore C18, 2.1 x 30 mm, 2.6 µm.  Gradients condition: variable, 
CH3CN in H2O (0.1% TFA) over 4 minutes, hold at 95% CH3CN for 0.35 min, 50 mL/min. 
Purity for all final compounds was >95%, and each showed a parent mass ion consistent with the 
desired structure in low resolution LC-MS. 
1
H and 
13
C NMR spectra were recorded on Bruker 
DRX-400 (400 MHz) instrument. Chemical shifts are reported in ppm relative to residual solvent 
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peaks as an internal standard at the following chemical shifts (
1
H and 
13
C respectively): 7.26 and 
77.0 ppm for CDCl3; 2.50 and 39.52 ppm for DMSO-d6, 3.31 and 49.2 ppm for CD3OD. Data are 
reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q 
= quartet, dd = doublet of doublets, br = broad, m = multiplet), coupling constant (Hz).  
 
General procedure for the synthesis of amine library analogs 3.49-3.162 
In a vial, 9H-xanthene-9-carboxylic acid (3.48, 25 mg, 0.111 mmol) was added and 
dissolved in 1 mL of a mixture of dichloroethane (DCE) and N,N-diisopropylethylamine (DIEA) 
(9:1). 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide 
hexafluorophosphate (HATU) (46 mg, 0.122 mmol, 1.1 equivalents) was added to the vial and the 
reaction was stirred for five minutes. Then, the amine (0.122 mmol, 1.1 equivalents) was added. 
The reaction was stirred for 2 hours at room temperature; completion and formation of the desired 
product were confirmed by LC-MS monitoring. The reaction was worked up by addition of water 
and extractions with DCM (thrice). The organic phases were combined, filter through a phase 
separator and the volatiles were evaporated. The crude was dissolved in DMSO and purified by 
HPLC prep (C18 column, ACN in Water-TFA 0.1% gradient). 
 
 
Ro 07-11401, N-methyl-N-(4-(trifluoromethyl)oxazol-2-yl)-9H-xanthene-9-
carboxamide (3.43). Cream solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 7.89 (1H, s), 7.74 
(1H, m), 7.35-7.47 (4H, m), 7.22 (2H, dd, J= 8.2 Hz, J= 1.0 Hz), 7.18 (2H. td, J= 7.5 Hz, J= 1.1 
Hz), 5.20 (1H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 153.6, 150.8, 134.8, 130.2, 129.3, 
124.2, 117.6, 116.5, 47.5. 
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VU6000790, N-(4-isopropylthiazol-2-yl)-N-methyl-9H-xanthene-9-carboxamide 
(3.152). Pale yellow solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 7.44 (2H, d, J= 7.7 Hz), 7.37 
(2H, dd, J= 7.0 Hz, J= 1.4 Hz), 7.21 (2H, dd, J= 8.1 Hz, J= 0.8 Hz), 7.14 (2H. td, J= 7.5 Hz, J= 
1.1 Hz), 6.51 (1H, s), 5.23 (1H, s), 2.91 (1H, heptet, J= 6.8 Hz), 1.23 (6H, d, J= 6.8 Hz). 
13
CNMR 
(100.6 MHz, CDCl3) δ (ppm): 169.6, 157.8, 151.1, 129.7, 129.3, 127.0, 123.9, 117.4, 117.2, 
105.9, 46.7, 30.2, 21.9. 
 
 
VU6000799, N-(4-cyanothiazol-2-yl)-N-methyl-9H-xanthene-9-carboxamide (3.156). 
Pale yellow solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 7.62 (1H, s), 7.37-7.44 (4H, m), 7.24 
(2H, d, J= 7.9 Hz), 7.18 (2H. td, J= 7.5 Hz, J= 1.1 Hz), 5.23 (1H, s). 
13
CNMR (100.6 MHz, 
CDCl3) δ (ppm): 169.8, 158.1, 151.0, 130.2, 129.3, 125.5, 124.2, 121.8, 117.6, 116.5, 113.9, 46.6. 
 
General procedure for the synthesis of carboxylic acid library analogs 3.165-3.180 and hit 
compounds from virtual screening 3.181-3.195. 
In a vial, the carboxylic acid (0.1 mmol) was added and dissolved in 1 mL of a mixture of 
N,N-dimethylformamide (DMF) and DIEA (9:1). HATU (54.8 mg, 0.144 mmol, 1.2 equivalents) 
was added to the vial and the reaction was stirred for five minutes. Then, 2-amino-4-
methyloxazole 3.164 (11.8 mg, 0.122 mmol, 1.2 equivalents) was added. The vial was closed and 
the reaction was stirred for 2 hours at 85 °C; completion and formation of the desired product 
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were confirmed by LC-MS monitoring. The reaction was worked up by the addition of water and 
extractions with DCM (thrice). The organic phases were combined, filter through a phase 
separator and the volatiles were evaporated. The crude was dissolved in DMSO and purified by 
HPLC prep (C18 column, ACN in Water-TFA 0.1% gradient).  
 
Molecular pharmacology 
Tetracycline-tested fetal bovine serum (FBS) was purchased from Atlanta Biologicals 
(Lawrenceville, GA), and all other tissue culture reagents and Fluo-4-acetoxymethylester (Fluo-4-
AM) were purchased from Life Technologies (Carlsbad, CA). Tetracycline hydrochloride 
(Sigma), L-glutamic acid (Tocris, Minneapolis, MN). 
 
Cell Culture. Tetracycline-inducible rat and human mGlu1 WT T-REx
TM
-293 cells
112
  
were cultured at 37 ºC in Dulbecco’s Modified Eagle Medium (DMEM) growth medium 
containing 10% Tet-tested FBS, 2 mM L-glutamine, 20 mM HEPES, 0.1 mM non-essential 
amino acids, 1 mM sodium pyruvate, antibiotic/antimycotic, 100 μg/mL hygromycin and 5  
μg/mL blasticidin in the presence of 5% CO2.  
 
Poly-D-lysine plate coating. A stock solution of poly-D-lysine hydrobromide (Sigma 
P7886) at a concentration of 1 mg/mL was prepared using sterile deionized water, and filtering 
through a 0.22 µm in the cell culture hood. The solution was aliquoted and stored at -20 °C, and 
on the day of use the solution was thawed and diluted with sterile water to 100 µg/mL. 96-well 
black wall, clear bottom plate, sterile (Costar 3603) were coated using 50 µL of the poly-D-lysine 
work solution. The plate was placed in the cell incubator for 3 hours at 37 °C. After this time, the 
poly-D-lysine solution excess was removed, and the plates were gently washed twice with 100 
µl/well of sterile water. The plates were stored at 2-8 °C.   
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Calcium Mobilization Assay. To determine the potency of the mGlu1 PAMs in calcium 
assays, Ca flux was measured as previously described.
112
 Briefly, the day before the assay, human 
or rat mGlu1 T-REx
TM
-293 cells were plated in black-walled, clear-bottomed, poly-D-lysine 
coated 96-well plates at 80,000 cells/100 μL assay medium (DMEM supplemented with 10% 
dialyzed FBS, 20 mM HEPES, and 1 mM sodium pyruvate) containing 50 ng/mL (human mGlu1) 
or 10 ng/mL (rat mGlu1) of tetracycline to induce mGlu1 expression. The next day, media was 
removed and the cells were incubated with 50 μL of 1.15 μM Fluo-4 AM dye solution prepared in 
assay buffer (Hank’s balanced salt solution, 20 mM HEPES, and 2.5 mM probenecid) for 45 min 
at 37 °C, the dye was removed and replaced with 45 μL of assay buffer. Then, calcium flux was 
measured using Flexstation II (Molecular Devices, Sunnyvale, CA). The compounds or DMSO 
vehicle were added to cells and incubated for 2.5 min and an EC20 concentration of glutamate was 
added and incubated for 1 min. An ECmax concentration of glutamate was also added to cells that 
were incubated with DMSO vehicle to accurately calculate the EC20 calcium response. Data were 
normalized by subtracting the basal florescent peak before EC20 agonist addition from the 
maximal peak elicited by EC20 agonist and PAMs. For the single point concentration screening, a 
single concentration of 10 µM of compound in assay buffer was employed. For EC50 
determinations compounds were serially diluted at half log concentrations in DMSO and further 
diluted in assay buffer. Using GraphPad Prism 5.0, the concentration response curves were 
generated and the potencies of the mGlu1 PAMs were determined using a four-parameter non-
linear regression model. In the case of fold-shift assays, a 10 µM solution of the compound in 
assay buffer was used, and instead of a fix concentration of glutamate, a serial dilution of 
glutamate was performed to generate concentration-response curves that were analyzed with 
GraphPad Prism 5.0 to obtain the EC50 values for glutamate. 
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Pharmacokinetic characterization 
The in vitro DMPK assays, including those assessing hepatic microsomal intrinsic 
clearance (Clint), cytochrome P450 inhibition, plasma protein binding (PPB) and brain 
homogenate binding (BHB) were performed as described previously.
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Intrinsic clearance: Human or rat hepatic liver microsomes (0.5 mg/mL) and 1 μM test 
compound were incubated in 100 mM potassium phosphate pH 7.4 buffer with 3 mM MgCl2 at 
37 °C with constant shaking. After a 5 min preincubation, the reaction was initiated by addition 
of NADPH (1 mM). The incubations, performed in 96-well plates, were continued at 37 °C under 
ambient oxygenation and aliquots (80 μL) were removed at selected time intervals (0, 3, 7, 15, 
25, and 45 min). Aliquots were taken and subsequently placed into a 96-well plate containing 
cold acetonitrile with internal standard (50 ng/mL carbamazepine), to promote protein 
precipitation. Plates were then centrifuged at 3000 rcf (4 °C) for 10 min, and the supernatant was 
transferred to a separate 96-well plate and diluted 1:1 with water for LC/MS/MS analysis. The in 
vitro half-life (t1/2, min, Eq. 1), intrinsic clearance (Clint, mL/min/kg, Eq. 2) and subsequent 
predicted hepatic clearance (Clhep, mL/min/kg, Eq. 3) were determined employing the following 
equations: 
 
          
      
 
     [3.1] 
Equation 3.1. Determination of half-life. k represents the slope from linear regression analysis 
(% test compound remaining) in function of incubation time. 
 
        
     
    
 
             
            
 
              
       
 
          
             
  [3.2] 
Equation 3.2. Determination of intrinsic clearance. 
a
scale-up factor: 20 (human) or 45 (rat). 
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    [3.3] 
Equation 3.3. Determination of predicted hepatic clearance. Qh represents hepatic blood flow: 21 
mL/min/kg (human) and 70 mL/min/kg (rat). 
  
Plasma protein binding and homogenate brain binding. Protein binding was 
determined in rat or human plasma via equilibrium dialysis employing single-use rapid 
equilibrium dialysis (RED) plates with inserts (ThermoFisher Scientific, Rochester, NY). Briefly, 
plasma (220 μL) was added to the 96 well plate containing test compound and mixed thoroughly 
to a final compound concentration of 5 µM. Subsequently, 200 μL of the plasma-test compound 
mixture was transferred to the cis chamber (red) of the RED plate, with an accompanying 350 μL 
of phosphate buffer (25 mM, pH 7.4) in the trans chamber. The RED plate was sealed and 
incubated 4 h at 37 °C with shaking. At completion, 50 μL aliquots from each chamber were 
diluted 1:1 (50 μL) with either plasma (cis) or buffer (trans) and transferred to a new 96 well 
plate, at which time ice-cold acetonitrile containing 50 ng/mL carbamazepine as internal standard 
(2 volumes) was added to extract the matrices. The plate was centrifuged (3000 rcf, 10 min) and 
supernatants transferred to a new 96 well plate. The sealed plate was stored at −20 °C until 
LC/MS/MS analysis. Each compound was assayed in triplicate within the same 96-well plate. 
Fraction unbound in plasma was determined using the following equation:  
 
        
         
        
     [3.4] 
Equation 3.4. Determination of fraction unbound in plasma.  
 
Rat brain homogenate binding was determined through a similar methodology using RED 
plates, using brain homogenate instead of plasma. In this experiment, the compound was tested at 
a final concentration of 1 µM. The brain preparation was obtained from naïve rat brains 
homogenized in Dulbecco’s Phosphate Buffered Saline (DPBS) (1:3 brain:DPBS, w/w) using a 
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Mini-Bead Beater
TM
 machine. Fraction unbound was determined using equation 3.4, but 
replacing the concentration in plasma for concentration in homogenate. 
 
LC/MS/MS Bioanalysis of Samples from Plasma Protein Binding and Intrinsic 
Clearance Assays. Samples were analyzed on a Thermo Electron TSQ Quantum Ultra triple 
quad mass spectrometer (San Jose, CA) via electrospray ionization (ESI) with two Thermo 
Electron Accella pumps (San Jose, CA), and a Leap Technologies CTC PAL autosampler 
(Carrboro, NC). Analyses were separated by gradient elution on a dual column system with two 
Thermo Hypersil Gold (2.1 x 30 mm, 1.9 μm) columns (San Jose, CA) thermostated at 40°C. 
HPLC mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid 
in acetonitrile. The gradient started at 10% B after a 0.2 min hold and was linearly increased to 
95% B over 0.8 min; hold at 95% B for 0.2 min; returned to 10% B in 0.1 min. The total run time 
was 1.3 min and the HPLC flow rate was 0.8 mL/min. While pump 1 ran the gradient method, 
pump 2 equilibrated the alternate column isocratically at 10% B. Compound optimization, data 
collection and processing was performed using Thermo Electron's QuickQuan software (v2.3) 
and Xcalibur (v2.0.7 SP1). 
 
Inhibition of P450 enzymes. A cocktail of substrates for cytochrome P450 enzymes 
(1A2: Phenacetin, 10 μM; 2C9: Diclofenac, 5 μM; 2D6: Dextromethorphan, 5 μM; 3A4: 
Midazolam, 2 μM) were mixed for cocktail analysis. The positive control for pan-P450 inhibition 
(miconazole) was included alongside each test compound in analysis. A reaction mixture of 100 
mM potassium phosphate buffer, pH 7.4, 0.1 mg/mL human liver microsomes (HLM) and 
substrate mix is prepared and aliquoted into a 96-deepwell block. Test compound and positive 
control (in duplicate) were then added such that the final concentration of test compound ranged 
from 0.1 – 30 μM. The plate was vortexed briefly and then pre-incubated at 37 °C while shaking 
for 15 minutes. The reaction was initiated with the addition of NADPH (1 mM final 
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concentration). The incubation continued for 8 min and the reaction was quenched by adding cold 
acetonitrile containing internal standard (50 nM carbamazepine) (2 volumes). The plate was 
centrifuged for 10 minutes (4000 rcf, 4°C) and the resulting supernatant diluted 1:1 with water for 
LC/MS/MS analysis. A 12 point standard curve of substrate metabolites over the range of 0.98 
nM to 2000 nM was employed.   
Samples were analyzed via electrospray ionization (ESI) on an AB Sciex API-4000 
(Foster City, CA) triple-quadrupole instrument that was coupled with Shimadzu LC-10AD pumps 
(Columbia, MD) and a Leap Technologies CTC PAL auto-sampler (Carrboro, NC). Analytes 
were separated by gradient elution using a Fortis C18 3.0 x 50 mm, 3 μm column (Fortis 
Technologies Ltd, Cheshire, UK) thermostated at 40 °C. HPLC mobile phase A was 0.1% formic 
acid in water (pH unadjusted), mobile phase B was 0.1% formic acid in acetonitrile (pH 
unadjusted). The gradient started at 10% B after a 0.2 min hold and was linearly increased to 90% 
B over 1.2 min; held at 90% B for 0.1 min and returned to 10% B in 0.1 min followed by a re-
equilibration (0.9 min). The total run time was 2.5 min and the HPLC flow rate was 0.5 mL/min. 
The source temperature was set at 500°C and mass spectral analyses were performed using 
multiple reaction monitoring (MRM), with transitions specific for each compound utilizing a 
Turbo-Ionspray® source in positive ionization mode (5.0 kV spray voltage). 
The IC50 values for each compound were obtained for the individual P450 enzymes by 
quantitating the inhibition of metabolite formation for each probe substrate. A 0 μM compound 
condition (or control) was set to 100% enzymatic activity and the effect of increasing test 
compound concentrations on enzymatic activity could then be calculated from the % of control 
activity. Curves were fitted using XLfit 5.2.2 (four-parameter logistic model, equation 201) to 
determine the concentration that produces half-maximal inhibition (IC50). 
 
Animal care and use All animal study procedures were approved by the Institutional 
Animal Care and Use Committee and were conducted in accordance with the National Institutes 
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of Health regulations of animal care covered in Principles of Laboratory Animal Care (National 
Institutes of Health). All animals were group housed under a 12-hour light/dark cycle with food 
and water available ad libitum.  
 
In vivo plasma and brain drug concentration measurements in rodents. Compounds 
were formulated as 10% tween 80 micro suspensions in sterile water at the concentration of 1 
mg/ml and administered intraperitoneally to male Sprague-Dawley rats weighing 225 to 250 g 
(Harlan, Inc., Indianapolis, IN) at the dose of 0.25 mg/kg. The rat blood and brain were collected 
at 0.25 hr. Animals were euthanized and decapitated, and the brains were removed, thoroughly 
washed in cold phosphate buffered saline and immediately frozen on dry ice. Trunk blood was 
collected in EDTA Vacutainer tubes, and plasma was separated by centrifugation and stored at -
80 °C until analysis. Plasma was separated by centrifugation (4000 rcf, 4°C) and stored at -80 °C 
until analysis. On the day of analysis, frozen whole-rat brains were weighed and diluted with 1:3 
(w/w) parts of 70:30 isopropanol:water. The mixture was then subjected to mechanical 
homogenation employing a Mini-Beadbeater™ and 1.0 mm Zirconia/Silica Beads (BioSpec 
Products) followed by centrifugation. The sample extraction of plasma (20 μL) or brain 
homogenate (20 μL) was performed by a method based on protein precipitation using three 
volumes of ice-cold acetonitrile containing an internal standard (50 ng/mL carbamazepine). The 
samples were centrifuged (3000 rcf, 5 min) and supernatants transferred and diluted 1:1 
(supernatant:water) into a new 96 well plate, which was then sealed in preparation for 
LC/MS/MS analysis.  
In vivo samples were analyzed via electrospray ionization (ESI) on an AB Sciex API-
5500 QTrap (Foster City, CA) instrument that was coupled with Shimadzu LC-20AD pumps 
(Columbia, MD) and a Leap Technologies CTC PAL auto-sampler (Carrboro, NC). Analytes 
were separated by gradient elution using a Fortis C18 3.0 x 50 mm, 3 μm column (Fortis 
Technologies Ltd, Cheshire, UK) thermostated at 40 °C. HPLC mobile phase A was 0.1% formic 
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acid in water (pH unadjusted), mobile phase B was 0.1% formic acid in acetonitrile (pH 
unadjusted). The gradient started at 30% B after a 0.2 min hold and was linearly increased to 90% 
B over 0.8 min; held at 90% B for 0.5 min and returned to 30% B in 0.1 min followed by a re-
equilibration (0.9 min). The total run time was 2.5 min and the HPLC flow rate was 0.5 mL/min. 
The source temperature was set at 500°C and mass spectral analyses were performed using 
multiple reaction monitoring (MRM), with transitions specific for each compound utilizing a 
Turbo-Ionspray® source in positive ionization mode (5.0 kV spray voltage). The calibration 
curves were constructed in blank plasma. All data were analyzed using AB Sciex Analyst 
software v1.5.1.  
 
Computational methods 
QSAR models. Artificial neural network (ANN) models were built to classify mGlu1 
PAMs over inactives using data available from in-house medicinal chemistry projects and from 
literature (gathered via the ChEMBL database).
286
  Preprocessing the mGlu1 PAM dataset 
involved associating the pEC50 value with each structure, ensuring that only unique structures 
were present, and generating a single 3-dimensional conformation for each compound using 
CORINA version 3.60.
287
  These structures were then encoded into a feature vector using the 
BioChemical Library which resulted in 1315 floating point values and encoded information such 
as the 2- and 3-dimensional distribution of charge, steric bulk, and polarizability.
288
 The 
architecture of the ANNs consisted of a single hidden of 32 nodes, and a single-valued output 
layer, and used sigmoid transition functions.  These models were trained using a binary-valued 
dataset in which the compounds were labeled as either mGlu1 PAMs (pEC50 > 5) or inactive 
(pEC50 < 5).  A five-fold cross-validation procedure using both monitoring and validation dataset 
and dropout were used to prevent overtraining.  The cross-validation procedure also provided an 
unbiased way to evaluate model performance in the absence of additional data.  This procedure 
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resulted in a total of 20 ANN models whose scores were averaged to provide a consensus score 
for each input for virtual screening. 
Compound generation. An in-silico reaction-based approach was used to select possible 
replacements for the xanthene moiety.  The eMolecules database was filtered for compounds 
containing single carboxylic acid or acyl chloride groups, and were converted to the 
corresponding trifluoromethyl oxazole-containing mGlu1 PAM analogs through an in-silico 
amide coupling reaction using the BioChemical Library (BCL).  This resulted in a total of 4250 
candidate compounds which were then subjected to virtual screening. 
Initial compound selection. The in-silico candidate compounds were prioritized using 
the ANN QSAR models described previously and the top compounds were visually inspected.  
The top compounds initially contained a substantial number of artifacts such as multiple fluorine 
atoms or other highly charged groups which were likely picked out as a result of an insufficient 
number of training examples to circumvent this problem.  A comparison of histogram of scores 
between the generated compounds and the known mGlu1 PAMs (Fig. 1.16) revealed that these 
compounds had artificially high scores relative to the training data.  Therefore, only the 
compounds that had scores between 1.09 (lowest active score) and 4.42 (highest active score) 
were used.  The top 10 percent of highest scoring compounds that fit these criteria were selected 
for further analysis. 
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Figure 3.16. Initial compound selection from the virtual screening by the artificial neural 
network. Left, examples of compounds containing artifacts picked up by the ANN models. Right, 
a comparison of QSAR scores for known mGluR1 PAMs (red) and in-silico designed compounds 
(green). 
 
Clustering. Clustering was performed using an in-house clustering algorithm to select a 
diverse set of compounds within the set of prioritized compounds. First, a random portion of the 
prioritized molecule data set is sampled.  Murcko scaffolds are generated for each selected 
compound, and the maximum common substructure between each pair of Murcko scaffolds is 
calculated.
289
  Ring and chain fragments from each scaffold are also added to supplement the 
fragment list.  Fingerprint vectors of each compound of interest were computed by searching for 
the presence of each fragment in the query structure.  A distance metric between pairs of 
compounds was calculated as the Tanimoto coefficient between fingerprint vectors and 
hierarchical agglomerative clustering was applied to the molecule data set using this distance 
metric.
290
  Application of this clustering approach to the top 10 percent of the highest-scoring in-
silico generated compounds resulted in 658 clusters at a Tanimoto similarity cutoff of 0.3.  The 
top two compounds (or a single compound if the cluster was a singleton) were selected from each 
cluster, and the top 100 highest-scoring compounds from this set were visually inspected.  Of 
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these compounds, 15 contained undesirable structures and were discarded.  The remaining 85 
compounds were used in further processing steps. 
SurflexSim model. The Surflex-Sim program
284
 was used to generate binding hypotheses 
and perform shape-based virtual screening for prioritizing mGlu1 PAM compounds in a ligand-
based manner.  Two compounds were chosen to model the xanthene-containing compounds, 
namely Ro 67-4853 3.45 and Ro 07-11401 3.43.  Both compounds contained a xanthene ring, but 
differed at the terminal end and contained a propylcarbamate or a 4-trifluoro-2-oxazole, 
respectively.  These compounds were aligned with the Surflex-Sim mutual alignment algorithm 
using default parameters with the exception of allowing ring flexibility.  The highest-scoring 
hypothesis (Fig. 1.17) was used to align desired compounds picked using machine learning 
QSAR models and further reduce the 85 selected compounds from the machine learning models 
to 15 through a combination of score consideration and visual inspection.  The corresponding 
carboxylic acids from these compounds were then identified and purchased to enable synthesis 
and experimental testing of the resulting compounds. 
 
Figure 3.17. The highest-scoring Surflex-Sim binding hypothesis using Ro 07-11401 3.43 and 
Ro 67-4853 3.45. 
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CHAPTER IV 
 
DISCOVERY OF POSITIVE ALLOSTERIC MODULATORS FOR THE METABOTROPIC 
GLUTAMATE RECEPTOR SUBTYPE 1 AROUND A NEW CHEMOTYPE  
 
Identification of a starting point for a campaign to develop an mGlu1 positive allosteric 
modulator 
 
Medicinal chemistry around CDPBB and VU-71 structure 
 The first steps for developing an mGlu1 PAM, around a different scaffold from Ro 07-
11401 3.43, within the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) led to the 
discovery of  VU-71.
280
 This new class of  mGlu1 PAMs was discovered when doing analogs 
around the mGlu5 PAM CDPPB 4.1 to explore the structural requisites for activation of this 
receptor.
291
 Through this exercise, it was found that different benzamide replacements could 
generated compound with dual mGlu1/mGlu5 activity in the rat form of these receptors, such as 
4.2-4.6 (Fig. 4.1).  
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Figure 4.1. CDPPB analogs that potentiate the rat mGlu1 receptor. 
 
These analogs were further analyzed and showed leftward fold-shift in a glutamate 
response curve from 2 to 3, EC50s between 0.5 and 3.9 µM (Fig 4.2) and no displacement of [
3
H]-
R214127 in radioligand binding studies.
280
 From this subset, the most selective compound was 
VU-71 4.4, which differentiates from CPDBB only by a 4-nitro substituent in the benzamide 
region. 4.4 demonstrated to be only active in the rat form of the receptor and to lose activity when 
the mutation V757L was introduced. The importance of this mutation relies in that this is the only 
change observed between that rat (V757) and human (L757) mGlu1 transmembrane domain. 
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A  B  
Figure 4.2. VU-71 4.4 activity in the rat mGlu1 receptor. A) Concentration-response curve and 
rat mGlu1 EC50 for CDPBB analogs 4.2-4.6. B) Fold-shift analysis of 4.4 in rat mGlu1 V757L.
280
 
 
At the VCNDD, a medicinal chemistry campaign was started with 4.4 to improve its 
suboptimal potency and cross-species difference in activity. Analogs with different benzamides, 
altering the position of the phenyl ring in the core and various N-substituents in the pyrazole were 
synthesized and screened but these chemical modifications did not yield any active compound. 
Furthermore, when they resynthesized VU-48, the most potent compound in the family, it showed 
a potency of 2.35 µM, more than 5-fold less its reported value.
280
 These results led to stop the 
exploration of further SAR around this scaffold.  
 
Dual mGlu1/mGlu4 PAMs as a starting point for the development of selective mGlu1 PAMs 
Interested in their possible antiparkinsonian effects, a program for the discovery and 
development of mGlu4 positive allosteric modulators initiated at the VCNDD. In this effort, 
thousands of compounds have been synthesized around several chemotypes and when a 
compound demonstrates good potency for the mGlu4 receptor they are tested in other members of 
the mGlu family. During these selectivity screenings, some picolinamide derivatives showed 
cross-activity on the human mGlu1 receptor (Fig. 4.3). Based on its potency, we chose to explore 
VU0405622 4.8 further and we were pleased to observe that it also activated the rat mGlu1 
receptor with a similar potency. 4.8 represents a novel scaffold for mGlu1 PAM activity. 
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Figure 4.3. Dual mGlu1/mGlu4 PAMs derived from mGlu4 PAM drug discovery program at the 
VCNDD. 
 
Exploration of the structure-activity relationship around VU0405622 
 
Medicinal chemistry strategy for the exploration of VU0405622 4.8 
Being a cross-species active potentiator of mGlu1, we decided to use the scaffold of 4.8 
as the starting point for our medicinal chemistry campaign to develop novel positive allosteric 
modulators for this receptor. The scaffold is synthetically accessible, facilitating the production of 
libraries of analogs with changes in different parts of the molecule. The structure can be divided 
in three main regions: the western phthalimide, the central phenyl ring and the eastern 
picolinamide. Analogs with different substituents or replacements of these groups can be 
synthesized to evaluate the impact of these modifications in the potency and selectivity for mGlu1 
(Fig. 4.4). 
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Figure 4.4. Possible chemical modifications to explore the SAR around VU0405622 4.8 scaffold. 
  
So, a multidimensional, iterative, parallel synthesis approach to develop analogs of 4.8 
was initiated. This methodology consisted of the synthesis of focused chemical libraries based 
around a specific region of the molecule while the rest of the pharmacophore is held constant. 
Following this, the new compounds will be screened for biological activity in cell-based calcium 
mobilization assays. The bioactivity of the compounds guided subsequent design, so beneficial 
structural characteristics for mGlu1 PAM activity could be discovered and held constant in 
additional rounds of chemical modification. In this way, the molecule would be improved 
iteratively as we expanded and developed valuable SAR knowledge. In our initial efforts, the 
primary goal was to make the compounds more selective for mGlu1, but our overall goal was to 
obtain a compound that satisfied the pharmacodynamic and pharmacokinetic properties needed 
for in vivo target validation studies; and these characteristics described our optimization workflow 
(Fig. 4.5).   
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Figure 4.5. Optimization work flow for the development of adequate mGlu1 PAMs for in vivo 
target validation studies. Clhep: predicted hepatic clearance from studies with liver microsomes. Q: 
hepatic blood flow. Fu: fraction unbound in plasma. Kp: brain to plasma partition coefficient. 
 
Modification on the eastern picolinamide of VU0405622 4.8 
 We initiated our SAR study by exploring different amides in the picolinamide side. A 3-
step synthetic route using simple starting materials was developed to access analogs with 
diversity in this side of the molecule. Our synthesis started condensing phthalic anhydride 4.9  
and 2-chloro-4-nitroaniline 4.10 in refluxing acetic acid to provide phthalimide 4.11 in 88% yield.  
The nitroaromatic intermediate 4.11 was reduced to the aniline 4.12 using tin(II) chloride (72% 
yield). The library step was an amide coupling performed under standard HATU conditions, 
where different carboxylic acids were employed along with intermediate 4.12. For this library, 
pyridine carboxylic acid derivatives as well as some alkyl acid examples were used. 
 
 
Scheme 4.1. Synthesis of picolinamide analogs 4.13-4.65. 
hmGlu1 activation 
at 10 µM 
EC50 in 
hmGlu1 
EC50 in 
hmGlu4 
EC50 in 
rmGlu1 
in vitro PK in vivo PK 
>70% activation EC50  <1 µM 
EC50  >10 
µM 
EC50 <1 µM 
Clhep <50%Q 
Fu >3% 
t1/2 >2 h 
Kp ~1 
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 The library was screened in both human and rat mGlu1 receptors at a single concentration 
of 10 µM. From this set, several compounds showed an enhancement of the submaximal EC20 
concentration of glutamate (Figure 4.6 and Table 4.1); however, this potentiating effect was lower 
with respect to VU0405622 4.8. The few aliphatic analogs (4.40, 4.41, 4.45 and 4.48) assayed did 
not show any activity and most of the active compounds are picolinamide or pyrazine analogs. It 
was observed that derivatives of nicotinic acid (4.23, 4.29, 4.30, 4.35, 4.37-4.39, 4.44, and 4.50) 
and isonicotinic acid (4.24, 4.49) were inactive, indicating the importance of the position of the 
nitrogen in the eastern ring; also, oxidation of the nitrogen of the picolinamide (4.64) render the 
compound inactive. Moreover, the use of 2-quinoline and 2-quinoxalinecarboxylic acid generated 
inactive compounds (4.32, 4.62), indicating limitations for steric bulk in this position. In the 
picolinamide analogs, 3- and 4-substitutions generally maintained mGlu1 PAM activity, while 
substituents in the 5 and 6 position were detrimental. Positions 3 and 4 in the picolinamide 
tolerated small substituents, but when the group was bigger the activity decreased considerably, 
such as the 4-cyano 4.19, 4-methoxy 4.54 and the 4-phenyl 4.26.  
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Figure 4.6. Comparison of the single point screen result for PAM activity in rat (top) and human 
(bottom) mGlu1 at 10 µM for the amide library, analogs 4.13-4.65. Calcium mobilization was 
used to obtain %GluMax values for each compound in the presence of a submaximal concentration 
of glutamate (EC20) in cell lines expressing human mGlu1. Data represent the mean ± S.E.M. of at 
least three experiments with similar results. 
 
Table 4.1. Structures of the amide library analogs 4.13-4.65 and associated PAM activity from 
the single point screening at 10 µM in human mGlu1. Calcium mobilization responses for each 
compound are reported as a percentage of the maximum glutamate response. VU number denotes 
the compound identifier assigned by Vanderbilt University. Data represent the mean ± S.E.M. of 
at least three replicate experiments with similar results. 
Structure Cpd # VU # hmGlu1 %GluMax 
 
4.13 VU0474468 34.3±1.4 
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Compound 
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4.14 VU0474405 51.0±1.0 
 
4.15 VU0474457 39.7±3.0 
 
4.16 VU0474389 69.1±2.3 
 
4.17 VU0474407 37.0±1.8 
 
4.18 VU0474394 60.0±0.2 
 
4.19 VU0474467 31.0±0.6 
 
4.20 VU0474436 30.5±0.7 
 
4.21 VU0474397 35.8±2.8 
160 
 
 
4.22 VU0474482 66.4±4.8 
 
4.23 VU0474408 30.6±3.0 
 
4.24 VU0474386 29.4±2.1 
 
4.25 VU0474458 38.8±1.0 
 
4.26 VU0474474 31.9±3.4 
 
4.27 VU0474438 34.9±1.7 
 
4.28 VU0474640 74.5±2.1 
161 
 
 
4.29 VU0474670 18.1±3.1 
 
4.30 VU0474627 24.8±1.9 
 
4.31 VU0474575 15.1±3.5 
 
4.32 VU0474661 21.4±1.3 
 
4.33 VU0474581 20.4±0.2 
 
4.34 VU0474609 17.7±3.2 
 
4.35 VU0474658 12.9±4.4 
 
4.36 VU0474605 14.8±1.0 
162 
 
 
4.37 VU0474612 23.9±3.3 
 
4.38 VU0474580 23.1±4.4 
 
4.39 VU0474566 36.6±2.5 
 
4.40 VU0475761 32.5±1.6 
 
4.41 VU0475788 33.7±1.3 
 
4.42 VU0475781 41.5±0.9 
 
4.43 VU0475711 36.6±1.4 
 
4.44 VU0475715 45.7±1.8 
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4.45 VU0475753 43.7±1.6 
 
4.46 VU0475729 32.4±2.4 
 
4.47 VU0475755 80.4±1.6 
 
4.48 VU0475725 41.0±3.2 
 
4.49 VU0475724 38.0±2.2 
 
4.50 VU0475759 32.2±2.6 
 
4.51 VU0477930 87.4±4.2 
 
4.52 VU0477878 56.9±3.3 
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4.53 VU0477908 21.4±3.8 
 
4.54 VU0477909 41.2±3.1 
 
4.55 VU0477940 93.8±5.3 
 
4.56 VU0478023 36.9±3.0 
 
4.57 VU0477976 23.3±4.1 
 
4.58 VU0477840 75.6±3.9 
 
4.59 VU0477886 67.9±3.3 
 
4.60 VU0478034 26.4±4.3 
165 
 
 
4.61 VU0477841 25.5±5.8 
 
4.62 VU0477972 19.3±4.9 
 
4.63 VU0477931 45.6±5.7 
 
4.64 VU0477973 17.8±4.4 
 
4.65 VU0478024 47.2±3.3 
 
4.8 VU0405622 101.4±4.7 
  
 To assess the differences between the active compounds obtained from our first library, 
we proceed to determine the EC50 of the analogs that display over 50% mGlu1 potentiation during 
the single point screening (Table 4.2). Besides, compounds were screened in hmGlu4 to evaluate 
their selectivity. Pyridazine 4.47 showed submicromolar potency in hmGlu1 and an EC50 close to 
1 µM in rmGlu1 keeping good efficacy in both cases; however, it presents low efficacy and very 
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high potency in hmGlu4 (EC50 = 70 nM). The introduction of a 6-chloro substitution 4.22, 
maintain similar potency in mGlu1 and provide a significant improvement in selectivity. 
 
Table 4.2. Potencies in human and rat forms of mGlu1 and human mGlu4 for the active 
compounds obtained from the amide library single point screening. Calcium mobilization 
responses for each compound are reported as a percentage of the maximum glutamate response. 
VU number denotes the compound identifier assigned by Vanderbilt University. Data represent 
the mean ± S.E.M. of at least three independent experiments with similar results. ---, no 
potentiation. ND, not determined. 
Cpd # VU # 
hmGlu1 ratmGlu1 hmGlu4 
EC50 
(µM) 
%Glu
Max 
EC50 
(µM) 
%Glu
Max 
EC50 
(µM) 
%Glu
Max 
4.8 VU0405622 0.13 108 0.14 101 0.042 130 
4.14 VU0474405 1.02 92 0.378 64 >10 --- 
4.16 VU0474389 0.64 105 1.09 85 >10 --- 
4.18 VU0474394 4.08 90 5.49 91 ND ND 
4.22 VU0474482 1.246 100 0.748 53 >10 --- 
4.28 VU0474640 1.29 102 0.57 77 >10 --- 
4.47 VU0475755 0.73 105 1.09 85 0.070 52 
4.51 VU0477930 0.87 95 1.41 109 >10 --- 
4.52 VU0477878 2.20 85 >10 80 >10 --- 
4.55 VU0477940 0.43 103 0.032 105 0.13 115 
4.58 VU0477840 0.96 90 0.49 95 >10 60 
4.59 VU0477886 1.87 83 ND ND 0.095 89 
        
 The 3-substituted picolinamides present an interesting SAR. Although fluoro (4.31) and 
bromo (4.56) were not tolerated, other small groups (4.28, 4.51, 4.55, and 4.59) allowed retaining 
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cross-species mGlu1 activity. The 3-methyl (4.51) and the 3-chloro (4.28) substitution gained 
significant selectivity, showing no potentiation of mGlu4 even at 30 µM. Hydrogen bond donating 
groups in the 3-position (4.55, 4.59) had a singular effect. The 3-amino substituted 4.59 showed a 
human mGlu1 EC50 close to 2 µM, but was potent for mGlu4; while the 3-hydroxy analog 4.55 
was potent in both mGlu1 (especially the rat form) and mGlu4. These findings caught the attention 
of the mGlu4 PAM drug discovery program and they selected the 3-aminopicolinamide 4.59 for 
further studies and optimization. 4.59 demonstrated to be brain penetrant (Kp = 1.3), possessing 
low clearance (Clp = 4.0 mL/min/kg, t1/2 = 3.7 h) and robust efficacy in haloperidol-induced 
catalepsy, a preclinical model for Parkinson.  
 As mentioned, the 4-position tolerates little steric bulk, this was reiterated with the 4-
trifluoromethyl analog 4.52 which maintains moderate potency in human mGlu1 but is very weak 
enhancing glutamate responses in the rat receptor. The 4-methyl 4.14, 4-chloro 4.16 and 4-bromo 
4.58 were active in both human and rat mGlu1, with potencies between 400 nM and 1.1 µM. 4.14 
and 4.16 were inactive in mGlu4, while 4.58 was a weak activator. As in the 3-picolinamide, the 
4-fluoro analog 4.63 was inactive in both mGlu1 and mGlu4. 
 
Exploration of the SAR in the phthalimide in the context of 4.51, 4.28 and 4.22 
These first iteration represented a great advancement in terms of differentiation between 
mGlu1 and mGlu4 activity; however, all selective compounds showed significantly lower potency 
for mGlu1 activation with respect to its parent, VU0405622. We decided to take analogs 4.51, 
4.28 and 4.22, and develop focused matrix libraries around them, varying the phthalimide region. 
The synthesis of these compounds was based on our prior route from scheme 4.1, but inverting 
the order of steps so the diversity step could be performed last (Scheme 4.2). In this case, we 
started with the amide coupling between the nitroaniline 4.66 and carboxylic acids 4.67-4.69 to 
obtain amides 4.70-4.72. The regular conditions used in Scheme 4.1 that were useful to obtain 
final library compounds did not result in good yields when using nitroaniline 4.66. After trying 
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several amide coupling reagents, yields did not improve, but it was found that carrying the 
reaction in the microwave gave robust amounts of product in good yields (75-78%). Then, the 
nitroaromatic intermediates 4.70-4.72 were reduced with tin(II) chloride under acidic conditions 
(72-93% yield). Finally, anilines 4.73-4.75 were condensed with different phthalic anhydrides by 
heating the reaction in NMP in the microwave, to yield compounds 4.76a-4.78g in moderate 
yields (55-78%). 
 
 
Scheme 4.2. Synthesis of the matrix library with variations on the picolinamide and phthalimide 
region, analogs 4.76a-4.78g. 
 
Analogs with methyl, chloro and fluoro substituents in the phthalimide, as well as the 
introduction of a nitrogen atom in the position 4 of the phthalimide ring were obtained.  The 
potencies of these analogs were evaluated in human mGlu1 and mGlu4 in calcium mobilization 
assays (Table 4.3). The introduction of a nitrogen in the ring and 4-substitutions generated less 
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potent compounds (4.76d-4.76g, 4.77d-4.77g and 4.78d, 478e,4.78g), with the exception of 4.78f 
(VU6002183) that had an hmGlu1 EC50 of 360 nM. Despite the improvement in potency, 4.78f 
lacked of adequate selectivity as is only 3-fold more potent in hmGlu1 with respect to hmGlu4.  
The 3-substituted phthalimide analogs demonstrated to be more potent than their naked 
phthalimide versions. All 3-subsituted compounds 4.78a-4.78c from the 6-chloropyridazine 
library, were potent for mGlu1 but they still exhibited considerable mGlu4 PAM activity, except 
for 4.78b, that is a weak activator. In the case of the series derived from 3-methylpicolinamide 
4.51 and 3-chloropicolinamide 4.28, the most potent members are the 3-methylphthalimide 
analogs (4.76a and 4.77a), but again with little selectivity over mGlu4 activation. The 3-chloro 
analogs 4.76b and 4.77b displayed good potency for mGlu1 (EC50 = 250 nM and 360 nM, 
respectively) with weak activation of mGlu4 (EC50>10µM), allowing for 40-fold and 28-fold 
differences in potencies between the receptors. Finally, the 3-fluoroanalogs 4.76c and 4.77c 
showed a divergent behavior with respect to mGlu1 activity; while 4.77c was less active than its 
unsubstituted phthalimide parent 4.28, 4.76c represents an improvements in potency of 2-fold 
with respect to the original compound 4.51, but recover some mGlu4 potentiation. 
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Table 4.3. Potencies in human mGlu1 and mGlu4 of compounds derived from the matrix library 
4.76a-4.78g. Calcium mobilization responses for each compound are reported as a percentage of 
the maximum glutamate response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean ± S.E.M. of at least three independent 
experiments with similar results. ---, no potentiation. ND, not determined. 
Structure Cpd # VU # 
hmGlu1 hmGlu4 
EC50 
(µM) 
%Glu
Max 
EC50 
(µM) 
%Gl
uMax 
 
4.76a VU0483657 0.19 99 2.20 186 
 
4.76b VU0483737 0.25 90 >10 170 
 
4.76c VU0483635 0.40 87 0.37 45 
 
4.76d VU0486392 9.27 88 ND ND 
 
4.76e VU0483681 2.00 92 ND ND 
 
4.76f VU0483604 >10 87 ND ND 
 
4.76g VU0483621 >10 86 ND ND 
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4.77a VU0483710 0.23 104 0.47 89 
 
4.77b VU0483605 0.36 102 >10 51 
 
4.77c VU0483709 1.15 119 ND ND 
 
4.77d VU0486324 3.14 107 ND ND 
 
4.77e VU0483712 1.83 85 ND ND 
 
4.77f VU0483537 3.89 101 ND ND 
 
4.77g VU0483653 >10 88 ND ND 
 
4.78a VU6002199 0.18 93 1.35 94 
 
4.78b VU6002180 0.15 93 >10 80 
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4.78c VU6002200 0.14 99 0.70 41 
 
4.78d VU6002181 >10 82 ND ND 
 
4.78e VU6002182 >10 91 ND ND 
 
4.78f VU6002183 0.36 93 1.04 31 
 
4.78g VU6002184 >10 96 ND ND 
 
Due to their good potency and selectivity, it was decided to evaluate 4.76b (VU0483737) 
and 4.77b (VU0483605) further and determine their activity in the rat mGlu1 receptor (Fig. 4.7). 
In this assay, the compounds displayed robust efficacy and EC50s  comparable to the human 
mGlu1 potencies (VU0483737 EC50: 327.0 nM, 116.7% GluMax; VU0483605 EC50: 290 nM, 
111.6% GluMax). 
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Figure 4.7. Potency of analogs 4.76b (VU0483737, up) and 4.77b (VU0483605, down) in the rat 
and human mGlu1 receptor. Calcium mobilization assays were used to obtain CRCs in the 
presence of a fixed submaximal concentration of glutamate (EC20). Data represent the mean ± 
S.E.M. of at least three independent experiments with similar results. 
 
Besides mGlu4, the selectivity of VU0483605 4.77b was evaluated against the other 
members of mGlu family using a calcium mobilization assay in the case of mGlu5 and thallium 
flux/GIRK assays for the other mGlus that couple to Gi/o. 4.77b was assayed in fold-shift format 
and no potentiation of the mGlu receptors was observed, granting good selectivity against all 
members in the family (Fig. 4.8).  
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Figure 4.8. Selectivity of VU0483605 4.77b against the mGlus determined in fold-shift mode. Ca 
mobilization assays with hmGlu1 and rmGlu5 were used to obtain CRCs in the presence of 10 µM 
of 4.77b. The analysis of mGlu2,3,4,6,7,8 selectivity was performed with thallium flux assays. Data 
represent the mean ± S.E.M. of at least three independent experiments with similar results. 
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Additional SAR around scaffold VU0405622 and its picolinamide derivatives 
 Besides modification to the phthalimide and picolinamide region, a few changes in the 
central phenyl ring were explored. Here, we explore analogs with the naked central phenyl ring 
and also walking the chlorine substituent to the position adjacent to the picolinamide region. For 
this, compounds were synthesized in a similar fashion to our first amide library but changing the 
nitroaniline core (Scheme 4.3). Derivatives with the naked phenyl ring 4.84-4.87 were readily 
synthesized in overall good yields for the 3-step sequence, while compounds with the chloro 
substituent close to the picolinamide were harder to obtain. After trying several methodologies for 
the amide coupling unsuccessfully, we decide to invert the sequence of steps similarly to Scheme 
4.2; however, this approach did not allow us to obtain the compounds with naked phthalimide. In 
order to be able to test this substitution pattern in the central ring, we decided to switch to the 
more electrophilic 3-fluorophthalic anhydride during our condensation reaction and we were able 
to obtain 4.88 and 4.89 in low yields. 
 
 
Scheme 4.3. Synthesis of phenyl ring modified analogs 4.84-4.87. 
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 When the evaluation of these compounds was performed, it was found that both 
modifications, the removal and shifting of the chlorine in the central ring were detrimental for 
mGlu1 activity (Fig. 4.9 and Table 4.4). Only 4.86 (VU0484059) still enhanced the response of 
glutamate in mGlu1, therefore this compound was evaluated further to determine its potency. 4.86 
hmGlu1 EC50 was 905 nM, which represented a 2-fold loss in potency with respect to the parent 
compound 4.55 and a reason to halt the exploration of its properties. 
 
 
Figure 4.9. Comparison of the single point screen result for PAM activity in human mGlu1 at 3 
µM for the phenyl ring modified analogs 4.84-4.89. Calcium mobilization was used to obtain 
%GluMax values for each compound in the presence of a submaximal concentration of glutamate 
(EC20) in cell lines expressing human mGlu1. Data represent the mean ± S.E.M. of at least three 
replicate experiments with similar results. 
 
  
0 
20 
40 
60 
80 
100 
VU0483986 VU0484033 VU0484059 VU0484096 VU0486536 VU0486619 
%
G
lu
ta
m
a
te
 M
a
x
im
u
m
  
C
a
lc
iu
m
 R
e
sp
o
n
se
 
Compound 
177 
 
Table 4.4. Structures of phenyl ring modified analogs 4.84-4.89and associated PAM activity 
from the single point screening at 3 µM in rat mGlu1. Calcium mobilization responses for each 
compound are reported as a percentage of the maximum glutamate response. VU number denotes 
the compound identifier assigned by Vanderbilt University. Data represent the mean ± S.E.M. of 
at least three replicate experiments with similar results. 
Structure Cpd # VU # hmGlu1 %GluMax 
 
4.84 VU0483986 27.3 
 
4.85 VU0484033 24.9 
 
4.86 VU0484059 92.4 
 
4.87 VU0484096 35.2 
 
4.88 VU0486536 23.2 
 
4.89 VU0486619 27.2 
 
 Modifications in the linker between the picolinamide and the central phenyl ring were 
also assessed. Here, a reverse amide strategy was attempt first. The analogs to evaluate this 
change were synthesized in a 3-step process (Scheme 4.4). Starting from p-nitrobenzoic acid 
4.90, the amide coupling with anilines 4.91 and 4.92 was performed to obtain derivatives 4.93 
and 4.94 in 75% and 78% yield respectively. These intermediates were reduced with tin(II) 
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chloride to obtain anilines 4.95 and 4.96 in 55% to quantitative yields. For the library step, 
condensation of the anilines with phthalic anhydrides was performed to obtain analogs 4.97-
4.104. 
 
 
Scheme 4.4. Synthesis of reverse amide analogs 4.97-4.104. 
  
The synthesized compounds 4.97-4.104 were evaluated in the human mGlu1 receptor in a 
single point concentrations study; however, none of them showed potentiation of the glutamate 
response at a concentration of 10 µM (Fig. 4.10). This indicates that the disposition of the amide 
is critical for mGlu1 activity. 
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Figure 4.10. Comparison of the single point screen result for PAM activity in human mGlu1 at 10 
µM for the phenyl ring modified analogs 4.97-4.104. Calcium mobilization was used to obtain 
%GluMax values for each compound in the presence of a submaximal concentration of glutamate 
(EC20) in cell lines expressing human mGlu1. Data represent the mean ± S.E.M. of at least three 
replicate experiments with similar results. 
 
The removal of the carbonyl group in the picolinamide was also studied by swapping the 
amide for the alkylamine. These compounds were synthesized employing intermediate 4.12 and 
subjected to reductive amination conditions with different aldehydes (Scheme 4.5). In this set, we 
assayed some of the pyridine substitutions that engender mGlu1 PAM activity, as well as a couple 
of aliphatic substituents and multiple benzyl derivatives with different substitution patterns (Fig. 
4.11).  
 
 
Scheme 4.5. Synthesis of analogs 4.105-4.140 to assess the effect of the removal of the carbonyl 
group in the picolinamide side of VU0405622. 
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Figure 4.11. Analogs to assess the effect of the removal of the carbonyl group in the 
picolinamide side of VU0405622. 
 
Compounds 4.105-4.140 were tested in our single point calcium mobilization assay for 
mGlu1 potentiation and overall, the change in the linker from the carbonyl to the methylene had 
detrimental effects in hmGlu1 potency. The only compound from this subset that displayed 
discernible activity was 4.106 (VU6000839), with an EC50 of 1.00 µM, which is a close value to 
the activity of the parent amide. 
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Evaluation of the new mGlu1 PAMs in the wild type and mutated receptors 
 
There is evidence of a higher density of non-synonymous single nucleotide 
polymorphisms in the GRM1 gene in the schizophrenic and bipolar population.
241
 Part of these 
mutations have reported to cause a decrease in phosphoinositide hydrolysis,
242
 and showed how 
powerful a change in a single amino acid can be for receptor’s function. These mutations are not 
confined to a single region of the protein; they are widespread from the Venus fly-trap domain to 
the intracellular C-terminus (Fig. 4.12). 
 
Figure 4.12. Distribution of mutations in the hmGlu1 gene that are enriched in schizophrenic and 
bipolar patients. 
 
We decided to confirm in our laboratory the effects of these mutations in the output of the 
receptor. The mutant receptors were tested by Ayoub and collaborators in an end point assay after 
incubation with 10 µM of glutamate after for 45 minutes.
242
 We believed that this set up is not the 
most adequate for this system, as the events that generate the phosphatidylinositol hydrolysis 
occur rapidly in the cell and other biochemical processes might affect the outcome of experiment 
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after long incubation times, such as receptor desensitization. We selected to study the activation 
of the receptor using a calcium mobilization kinetic protocol, a procedure that monitors 
continuously the intracellular calcium concentration, allowing for better tracking of receptor’s 
activity. 
Nine of the reported mutations were introduced into human mGlu1 constructs and 
expressed in TR-Ex
TM
 293. The effect of glutamate and the group I selective agonist DHPG was 
evaluated in these constructs in our kinetic calcium mobilization assay (Fig. 4.13). The mutations 
affected considerably the effect of glutamate on the receptors (Fig. 4.13A, C, and E). The main 
change was observed in the maximum achievable signal, a reflection of the efficacy of the 
receptor towards glutamate activation; while the EC50 for glutamate is relatively similar across the 
wild type and mutant constructs. Most of the mutants showed and efficacy between 48 and 64% 
of the maximum response obtained with the wild type receptor, with the exception of K563N 
(90%) and P1015A (86%) that were less affected (Table 4.5). The responses exerted by DHPG in 
these receptors were higher than the ones observed by glutamate, but overall they show the same 
tendency (Fig. 4.13B, D, and F). The different mutations did not affect much the EC50 but they 
decrease the amplitude of the signal (Table 4.5). However, using DHPG as agonist demonstrated 
to have a considerably different effect in K563N with respect to glutamate, as the response was 
even higher that in the wild-type mGlu1 in this mutant construct. 
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Figure 4.13. Effect of mutations in the mGlu1 response of glutamate (A, C, E) and DHPG (B, D, 
F), with respect to wild type in fold shift experiments. Calcium mobilization assays were used to 
obtain CRCs in the different mGlu1 constructs. Data represent the mean ± S.E.M. of at least three 
independent experiments with similar results. 
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Table 4.5. Maximal efficacy of agonists glutamate and DHPG in wild type and mutant mGlu1 
receptors obtained in kinetic calcium mobilization assays. Data represent the mean ± S.E.M. of at 
least three independent experiments with similar results. 
Receptor 
%Maximal 
glutamate response 
%Maximal  
DHPG response 
Wild type 96.4 97.0 
T548 53.3 57.0 
K563N 90.8 110.3 
L575V 62.0 55.0 
F122L 54.5 71.9 
Y632H 64.4 71.5 
A683E 48.4 59.5 
P729T 57.0 64.4 
P1014S 60.2 59.9 
P1015A 86.4 86.4 
 
After confirming the decrease in function of the mutant mGlu1 constructs, we proceeded 
to evaluate the effect of various mGlu1 PAMs in these receptors. For these experiments we select 
two of our PAMs, VU0483737 4.76b, VU0483605 4.77b, and Ro 07-11401 3.43. The selection 
of 4.76b and 4.77b responds to their good potency, efficacy in mGlu1 and selectivity against 
human mGlu4.  In preparation for these experiments, we started by characterizing the effect of the 
compounds in the wild-type receptor using a fold-shift assay. Using glutamate as agonist, Ro 07-
11401 and VU0483605 4.77b displayed similar increase in potency for glutamate and efficacy; 
while with VU0483737 4.76b, despite having similar potency to VU0483605 4.77b, the 
enhancement was weaker and the fold-shift smaller (Fig. 4.14A).  
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Figure 4.14. Effect of PAMs on the concentration-response curve of glutamate (A) and DHPG 
(B) in hmGlu1. Calcium mobilization fold-shift assays with hmGlu1 were used to obtain 
glutamate CRCs in the absence and presence of 10 µM concentration of VU0483737 4.76b, 
VU0483605 4.77b and Ro 07-11401 3.43. Data represent the mean ± S.E.M. of at least three 
independent experiments with similar results. 
 
 
Table 4.6. Effect of PAMs on the parameters of concentration-response curve of glutamate and 
DHPG in hmGlu1. Calcium mobilization fold-shift assays with hmGlu1 were used to obtain 
glutamate CRCs in the absence and presence of 10 µM concentration of VU0483737 4.76b, 
VU0483605 4.77b and Ro 07-11401 3.43. Data represent the mean ± S.E.M. of at least three 
independent experiments with similar results. 
Cpd 
Glutamate DHPG 
EC50 
(µM) 
Fold-Shift 
Efficacy 
(%) 
EC50 
(µM) 
Fold-Shift 
Efficacy 
(%) 
Glutamate 0.871 1.00 97.9 --- --- --- 
DHPG --- --- --- 2.65 1.00 98.3 
Ro 07-11401 3.43 0.118 7.38 102.8 0.159 16.7 108.6 
VU0483605 4.77b 0.139 6.27 104.4 0.402 6.59 110.4 
VU0483737 4.76b 0.294 2.96 94.80 0.783 3.38 97.1 
 
When the experiments were run with DHPG as agonist, a larger differentiation between 
the PAMs was observed (Fig 4.14B). This time Ro 07-11041 3.43 and VU0483605 4.77b did not 
show equivalent responses, being Ro 07-11401 the one that displayed the largest leftward shift in 
the concentration response curve, and increasing the potency of glutamate around 2 times more 
A B 
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than VU0483605 4.77b. Although, these compounds had similar effect increasing of efficacy of 
the receptor, achieving an increment of close to 10% the original value. Meanwhile, VU0483737 
4.76b achieve the smallest fold-shift with no increment in the efficacy with respect to control. 
After this, we evaluated the effect of the mGlu1 PAMs in the nine mutant constructs that 
we analyzed previously. A concentration of 10 µM of every compound demonstrates to potentiate 
the activity of glutamate in all mutants, although this increase was smaller than in the wild type 
receptor (Fig. 4.15). Ro 07-11401 induced the largest increase in potency with variable fold-shift 
depending on the mutant (3.6-7.4). The mutants that display the largest enhancement were 
T548M, K563, P729 and P1014S, increasing the potency for glutamate close to 6-fold and more 
than 7-fold in the case of P729. In terms of efficacy, Ro 07-11401 did not show major 
improvement with respect to vehicle, in most instances it actually decrease the maximum 
glutamate activity (Table 4.7).  
From our compounds, VU0483605 4.77b is the one that induced the largest change in 
potency (2.3-4.4), potentiating more the responses of mutations in the transmembrane domain 
(Y632H, A683E, P729T). VU0483605 4.77b is also the compound that provoked the largest 
increase in efficacy of the glutamate response, while VU0483737 4.76b showed decreased 
efficacy with respect to vehicle. VU0483605 4.77b increments in efficacy are between 10 to 25% 
of the original response of the mutants, except for Y632H and P729T were it increased only a 
5%. Moreover, in the case of the P1015S, it showed full recovery from the decrease in efficacy 
caused by the mutation (Fig. 4.15). 
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Figure 4.15. Effect of the application of mGlu1 PAMs on the concentration response curve of 
glutamate in hmGlu1 mutant constructs. Calcium mobilization fold-shift assays with different 
mGlu1 constructs were used to obtain glutamate CRCs in the absence and presence of 10 µM 
concentration of VU0483737 4.76b, VU0483605 4.77b and Ro 07-11401 3.43. Data represent the 
mean ± S.E.M. of at least three independent experiments with similar results different mGlu1 
constructs. 
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Table 4.7. Effect of PAMs on the parameters of concentration-response curve of glutamate in 
hmGlu1 mutant constructs. Calcium mobilization fold-shift assays with different mGlu1 constructs 
were used to obtain glutamate CRCs in the absence and presence of 10 µM concentration of 
VU0483737 4.76b, VU0483605 4.77b and Ro 07-11401 3.43. Data represent the mean ± S.E.M. 
of at least three independent experiments with similar results. 
Cpd 
 Mutant 
 F122L 
T548
M 
K563N L575V Y632H A683E P729T 
P1014
S 
P1015
A 
Vehicle 
EC50 
(nM) 
264 533 404 378 661 532 539 591 538 
Efficacy 
(%) 
55.7 54.7 91.1 63.1 65.0 49.8 58.4 61.6 87.3 
Ro 07-
11401 
EC50 
(nM) 
72.8 92.0 67.5 80.6 120 104 92.0 80.2 99 
Fold-
shift 
3.63 5.79 5.98 4.68 5.50 5.11 5.85 7.37 5.44 
Efficacy 
(%) 
49.7 52.0 75.5 55.5 64.9 48.2 57.1 56.8 86.0 
VU048
3605 
EC50 
(nM) 
99.9 130 119 110 152 127 129 151 167 
Fold-
shift 
2.64 4.10 3.39 3.44 4.35 4.19 4.18 3.91 3.23 
Efficacy 
(%) 
55.6 57.1 94.8 65.6 67.8 55.9 60.4 64.1 94.5 
VU048
3737 
EC50 
(nM) 
139 210 178 176 271 194 199 222 220 
Fold-
shift 
1.90 2.54 2.27 2.12 2.44 2.74 2.71 2.66 2.44 
Efficacy 
(%) 
50.4 51.6 84.5 59.7 63.2 50.9 53.4 57.2 85.0 
 
We repeated this experiments using DHPG as agonist to activate the mGlu1 mutants and 
with a 10 µM concentration of the PAMs. The results showed that the compounds potentiated the 
DHPG response in all the mutated receptors (Fig. 4.16). In contrast to glutamate, the potentiating 
effect match better what was observed in the wild-type with DHPG for the three PAMs. Ro 07-
11401 was the compound that achieved the largest fold-shift, and in most cases this is even larger 
that the shift observed in wild type (16.7), like in T548M (29.3) and P1014S (22.0) (Table 4.8). 
However, the compound effect in efficacy was minimal, maintaining or slightly decreasing the 
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maximum response obtained in the mutants with vehicle alone. The only exception for this was 
mutant Y632H where an increase in efficacy of around 8% was observed, an interesting effect as 
this receptor was also the one that present the smallest shift in the EC50 of DHPG. 
Between our compounds, VU0483605 4.77b perform better than VU0483737 4.76b, 
similarly to what was observed with glutamate. VU0483605 4.77b showed fold-shift between 4.6 
and 8.0 in the mutant constructs, being higher than in wild-type for K563N (7.5) and L575V 
(8.0). Also, only this PAM increased the efficacy of the DHPG response with respect to vehicle 
uniformly across the different mutant receptors; this increase ranges between 4 and 15%, and is 
larger for Y632H (12%) and A683E (15%). 
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Figure 4.16. Effect of the application of mGlu1 PAMs on the concentration response curve of 
DHPG in hmGlu1 mutant constructs. Calcium mobilization fold-shift assays with different mGlu1 
constructs were used to obtain glutamate CRCs in the absence and presence of 10 µM 
concentration of VU0483737 4.76b, VU0483605 4.77b and Ro 07-11401 3.43. Data represent the 
mean ± S.E.M. of at least three independent experiments with similar results different mGlu1 
constructs 
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Table 4.8. Effect of PAMs on the parameters of concentration-response curve of DHPG in 
hmGlu1 mutant constructs. Calcium mobilization fold-shift assays with different mGlu1 constructs 
were used to obtain glutamate CRCs in the absence and presence of 10 µM concentration of 
VU0483737 4.76b, VU0483605 4.77b and Ro 07-11401 3.43. Data represent the mean ± S.E.M. 
of at least three independent experiments with similar results. 
Cpd 
 Mutant 
 F122L 
T548
M 
K563
N 
L575V 
Y632
H 
A683E P729T 
P1014
S 
P1015
A 
Vehicle 
EC50 
(nM) 
834 1725 990 1099 1606 1139 1210 1150 1158 
Efficacy 
(%) 
73.9 58.8 112.2 57.0 72.3 61.6 66.3 62.2 88.7 
Ro 07-
11401 
EC50 
(nM) 
48.2 105 48.5 52.3 141 77.7 72.5 52.3 59.3 
Fold-
shift 
17.3 29.3 20.4 21.0 11.3 14.7 16.7 22.0 19.5 
Efficacy 
(%) 
70.3 60.0 98.1 53.9 78.4 64.11 68.6 60.3 91.8 
VU048
3605 
EC50 
(nM) 
133 296 123 147 282 245 201 184 187 
Fold-
shift 
6.3 5.8 8.0 7.5 5.7 4.6 6.0 6.3 6.2 
Efficacy 
(%) 
73.3 60.9 122 60.4 80.8 70.7 71.2 67.6 95.2 
VU048
3737 
EC50 
(nM) 
316 600 282 314 686 407 543 449 425 
Fold-
shift 
2.6 2.9 3.5 3.5 2.3 2.8 2.2 2.6 2.7 
Efficacy 
(%) 
68.2 56.2 109.7 55.4 73.6 63.4 64.3 61.2 84.7 
 
 
Pharmacokinetic characterization of the new mGlu1 PAMs 
 
In vitro pharmacokinetic properties and brain penetrance of novel mGlu1 PAMs 
 To execute target validation studies in animals and elucidate the role of mGlu1 in 
neuropsychiatric disorders, it is necessary to have adequate chemical probes. For these 
experiments, these chemical tools should have good pharmacodynamic properties so the receptor 
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can be activated selectively but also they should have good pharmacokinetic properties, so it can 
be guaranteed that the compound reach its target in enough concentration and at an adequate time 
to have the desired effect. We chose to analyze the pharmacokinetic properties of a few 
compounds from our libraries that showed good potency, including the PAMs tested in the 
hmGlu1 mutants, VU0483605 4.77b and VU0483737 4.76b. The compounds were subjected first 
to in vitro pharmacokinetic experiments, including determination of intrinsic clearance in liver 
microsomes, cytochrome P450 inhibition and plasma protein binding. 
 The intrinsic clearance measurements were performed incubating the compounds with 
preparations of rat and liver microsomes. In these experiments the analyzed compounds presented 
half-life of roughly one hour. After calculations to obtain the intrinsic and predicted hepatic 
clearance, it was observed that the compounds had moderate hepatic clearance in both species. In 
the human liver microsomes, compounds behave similarly, with predicted hepatic clearance 
ranging from 31 to 52% of the hepatic blood flow; while in rat VU0483605 4.77b stand out with 
predicted clearance of 35% of the hepatic blood flow, while the other compounds showed values 
close to 60% (Table 4.9).  
 
Table 4.9. Intrinsic clearance and predicted hepatic clearance for the new mGlu1 PAMs. Intrinsic 
clearance was determined using rat and human liver microsomes. 
Cpd # VU # 
Human Rat 
Clint 
mL/min/kg 
Clhep 
mL/min/kg 
Clint  
mL/min/kg 
Clhep 
mL/min/kg 
4.76a VU0483657 9.66 6.62 77.0 36.7 
4.76b VU0483737 16.1 9.10 95.9 40.5 
4.76c VU0483635 22.5 10.9 108 42.5 
4.77b VU0483605 17.2 9.46 39.9 25.4 
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Using a cocktail strategy, the inhibition of different isoforms of P450 enzymes by the 
PAMs was tested. All of them showed a clean CYP profile with no inhibition of 1A2, 2C9, 2D6 
and 3A4 at a concentration of 30 µM. 
For the probes to interact properly with the receptor they need to be free in solution. We 
proceed to quantify the fraction unbound in human and rat plasma. Unfortunately, it was not 
possible to determine this parameter in the plasma protein binding studies, as the compounds 
quickly degraded during the incubation with the plasma preparations.  
Brain penetrance in rats was assessed for VU0483605 4.77b and VU0483737 4.76b. The 
PAMs were administered intraperitoneally and after 1.25 hours, the concentrations in brain and 
plasma were measured. The brain to plasma partition coefficient of VU0483737 4.76b was 0.64, 
which is not optimal but is more than three times higher the Kp of Ro 07-11401. In the case of 
VU0483605 4.77b, the coefficient was 0.85, a more desirable value indicating greater brain 
penetrance. However, it was observed with both compounds that the actual concentrations 
achieved in plasma and in the brain were low. Even at 56.6 mg/kg (IP), poor exposure is observed 
and concentration in plasma for these compounds was lower that their EC50 in mGlu1 (1.25 h, 51 
nM and 152 nM for VU0483737 4.76b and VU0483605 4.77b, respectively). Also, plasma 
instability of the compounds did not allow the calculation of a Kp,uu value. 
 
Plasma biotransformation analysis of a compound around VU0405622 4.8 scaffold 
 As the compounds have moderate hepatic clearance and demonstrated to partition 
between brain and plasma with relative ease, the cause of the low concentrations of compounds 
achieved in vivo seems to be due to the plasma instability. Therefore, it was decided to study the 
biotransformation in plasma of compounds around this scaffold, in order to identify the 
metabolites generated and the decomposition process that was taking place. This would favor the 
confirmation of the specific region in the molecule that is labile to metabolism and the use of this 
information could guide the design of more stable compounds. 
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At the time, due to availability of the compounds, we selected VU0405623 4.141 to 
perform this biotransformation study. This is an mGlu1/mGlu4 dual PAM closely related to 
VU0405622 4.8 and VU0483605. The compound was incubated with rat and human plasma and 
monitored for two hours (Fig. 4.17).  
 
 
 
Figure 4.17. Biotransformation analysis of VU0405623 1.141 in rat (B and C) and human (D and 
E) plasma. Analysis of samples incubated for 30 minutes and 2 hours was made by LC-MS. 
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In rat plasma, the compound is completely metabolized in less than 30 minutes, while in 
human plasma it took around 1 hour to consume PAM 4.141. As the plasma preparation could 
have a supraphysiological amount of proteins and enzymes, the analysis was also performed in 
whole rat blood, to evaluate if the compound could be more stable in the presence of erythrocytes. 
In rat whole blood, the test article showed slower degradation, but it still degrades rapidly at a 
rate comparable to the observed in human plasma. From these experiments, it was observed that 
the 4.141 was mainly transformed into two more polar metabolites that have 18 more atomic 
mass units. After analyzing the fragmentation patterns with LC/MS
n
, the transformation was 
narrowed down to opening of the phthalimide to generate the regioisomeric phthalamic acids 
(Fig. 4.18). 
 
 
Figure 4.18. Identification of metabolites for plasma degradation of VU0405623 4.141. Analysis 
of samples incubated for 2 hours was made by LC-MS
n
. 
 
Designing of mGlu1 PAMs with better plasma stabilty 
Due to plasma instability of the phthalimide moiety, we started to contemplate 
alternatives to this group. One approach assessed was the replacement of one of the carbonyls in 
the phthalimide for a methylene, engendering an isoindolinone. The use of the lactam poses the 
advantage that its carbonyl will be less electrophilic than the carbonyls in the imide. In the case of 
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the imide, the possibility of more resonance forms will cause the distribution of the electrons 
from the nitrogen into a larger system, while in the amide from the lactam ring this will be 
confined into a smaller region. This will make the carbon in the carbonyl less electropositive and 
less susceptible to nucleophilic attack. Hence, it would be expected that the rate of hydrolysis in 
plasma for the phthalimide diminish. 
In order to test our hypothesis, isoindolinone analogs of VU0483737 4.76b 
anVU0483605 4.77b were envisioned. As these parent compounds have a substituent in the 
phenyl ring of the phthalimide the carbonyls are not equivalent and it was needed to synthesize 
both isoindolinone regioisomers, the 4-chloro and 7-chloro substituted analogs, as they may 
possess different biological activity. Several methods to access the isoindolinone compounds 
were tried. Isobenzofuranone opening with the aniline using different Lewis and Brønsted acids 
did not yield the intermediate acyclic precursor needed for the formation of the lactam. As well, 
copper and palladium amidation procedures using the preformed isoindolinone and the 
corresponding aryl bromide or the aryl iodide did not provide satisfactory results. Finally, we 
tried the synthesis of these compounds through tandem nucleophilic substitution-cyclization 
employing ortho-bromomethylbenzoate esters (Scheme 4.6). Our synthetic route started with the 
formation of the methyl ester 4.143 and 4.148 with the chloro-substituted ortho-methylbenzoic 
acids 4.142 and 4.147 through a classical Fisher esterification procedure. Then, a Wohl-Ziegler 
radical bromination allowed the obtention of 4.144 and 4.149 in good yields. The final step to 
afford analogs 4.145-4.146 and 4.150-4.151 was the nucleophilic substitution with anilines 4.73 
and 4.74 followed by the formation of the lactam; a reaction carried in the microwave with 
potassium carbonate as base that produced the desired isoindolinones in moderate yields. 
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Scheme 4.6. Synthesis of isoindolinone analogs 4.145-4.146 and 4.150-4.151. 
 
Screening of the compounds showed that the position of the chlorine was relevant for 
mGlu1 activity, as the 4-chloroisoindolinone analogs 4.145-4.146 maintain activity while its 7-
chloro regioisomers 4.150-4.151 were only weak potentiators (Table 4.10). It was also learned 
from this experiment that the carbonyls in the phthalimide are important for mGlu1 activity, as the 
EC50s of the active regioisomers 4.145-4.146 are 3 to 5 times larger with respect to their parent 
compounds.  
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Table 4.10. Potencies in human mGlu1 and mGlu4 of isoindolinone analogs 4.145-4.146 and 
4.150-4.151. Calcium mobilization responses for each compound are reported as a percentage of 
the maximum glutamate response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean ± S.E.M. of at least three independent 
experiments with similar results. ---, no potentiation. ND, not determined. 
Structure Cpd # VU # 
hmGlu1 
EC50 (µM) %GluMax 
 
4.145 VU0487229 1.36 89 
 
4.146 VU0487312 1.82 97 
 
4.150 VU0487011 >10.0 117 
 
4.151 VU0487028 >10.0 75 
 
Despite the decrease in activity, these new analogs showed half-lives of over four hours 
in rat and human plasma, demonstrating that the removal of one of the carbonyls was beneficial 
for plasma stability. This allowed us to hypothesize that if we find a phthalimide parent 
compound of adequate potency, we could introduce this chemical modification and afford for the 
loss in potency, gaining remarkable plasma stability. 
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Summary and future directions 
 
After trying to optimize with little success the properties of Ro 07-11401, we focused our 
efforts in the VU0405622 4.8 scaffold. This starting point displayed the advantage of 
submicromolar potency for mGlu1 but with the caveat of no selectivity, being an mGlu1/mGlu4 
dual PAM.  
We started the exploration of the SAR of this scaffold by making modifications on the 
picolinamide side of the molecule (Fig. 4.19). It was found that small substituents in the 3 and 4 
position of the pyridine allowed differentiation between mGlu1 and mGlu4, maintaining the effect 
on mGlu1 and loosing activity for mGlu4; however, this was accompanied by loss in potency. A 
second iteration of chemical modifications this time in the phthalimide region led us to find that 
substituents in the 3 position of the phthalimide can enhance the potency for the mGlu1 receptor 
and allowed us to obtain VU0483605 4.77b and VU0483737 4.76b. Further SAR exploration 
showed that the presence and orientation of the amide in the picolinamide side was essential for 
mGlu1 activity, and also that the chlorine in the phenyl ring was beneficial for mGlu1 potentiation. 
 
 
Figure 4.19. Exploration of SAR in the VU0405622 4.8 scaffold. 
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 VU0483605 4.77b and VU0483737 4.76b showed good potency and activity across 
human and rat mGlu1. Both compounds are selective against mGlu4, and VU0483605 4.77b 
demonstrated to be selective against all other mGlu receptors. These PAMs decreased the EC50 of 
glutamate and DHPG in wild type and schizophrenia related mutants. In the majority of mutant 
constructs, VU0483605 4.77b increased the efficacy of the glutamate response, an effect that was 
not observed as robustly with VU0483737 4.76b and Ro 07-11401 3.43. The relevance of this 
enhancement of EC50 and efficacy of glutamate caused by the PAMs is a question that would 
require additional in vivo testing in mutant mice strains. 
 In preparation for in vivo tests, we started the pharmacokinetic characterization of these 
mGlu1 PAMs. These analogs demonstrated to have moderate intrinsic clearance in rat and human 
liver microsomes and no inhibition of main P450 drug-metabolizing enzymes, but their fraction 
unbound in in plasma could not be obtained due to plasma instability. Analysis of the 
biotransformation of a close analog in plasma and whole blood identified the phthalimide as the 
site of metabolism.  
In an effort to generate more stable compounds, we develop isoindolinone analogs 4.145-
4.146 that demonstrated good plasma stability but with decrease mGlu1 activity. Because of the 
remarkable improvement in plasma stability, it was thought that if the removal of one of the 
carbonyls is applied to a more potent parent compound, the loss in potency might be afforded and 
it will generate a compound with acceptable pharmacokinetic properties. Our next steps were 
focused in finding a more potent compound for mGlu1 activity and these are detailed in the next 
chapter of this document. 
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EXPERIMENTAL METHODS 
 
General chemical synthesis and characterization  
All reactions were carried out employing standard chemical techniques under inert 
atmosphere. All reagents and solvents were commercial grade and purified prior to use when 
necessary. Solvents used for extraction, washing, and chromatography were HPLC grade. 
Analytical thin layer chromatography was performed on 250 μm silica gel glass backed plates 
from Sorbent Technologies. Visualization was accomplished with UV light and/or the use of 
iodine or ninhydrin solution followed by heating. Analytical HPLC was performed on an Agilent 
1200 LCMS with UV detection at 215 and 254 nm along with ELSD detection and electrospray 
ionization, with all final compounds showing >95% purity and a parent mass ion consistent with 
the desired structure. Low resolution mass spectra were obtained on an Agilent 6130 mass 
spectrometer with electrospray ionization source.  MS parameters were as follows:  fragmentor:  
100, capillary voltage:  3000 V, nebulizer pressure:  40 psig, drying gas flow:  11 L/min, drying 
gas temperature:  350° C.  Samples were introduced via an Agilent 1200 HPLC comprised of a 
degasser, G1312A binary pump, G1367B HP-ALS, G1316A TCC, G1315D DAD, and a Varian 
380 ELSD.  UV absorption was generally observed at 215 nm and 254 nm with a 4 nm 
bandwidth.  Column:  Thermo Accucore C18, 2.1 x 30 mm, 2.6 µm. Gradient conditions:  7% to 
95% CH3CN in H2O (0.1% TFA) over 1.6 min, hold at 95% CH3CN for 0.35 min, 1.5 mL/min, 
45 °C. Flash column chromatography was performed on a Teledyne ISCO Combiflash Rf system. 
Preparative purification of library compounds was performed on a Gilson 215 preparative LC 
system. Column: Thermo Accucore C18, 2.1 x 30 mm, 2.6 µm.  Gradients condition: variable, 
CH3CN in H2O (0.1% TFA) over 4 minutes, hold at 95% CH3CN for 0.35 min, 50 mL/min. 
Purity for all final compounds was >95%, and each showed a parent mass ion consistent with the 
desired structure in low resolution LC-MS. 
1
H and 
13
C NMR spectra were recorded on Bruker 
DRX-400 (400 MHz) instrument. Chemical shifts are reported in ppm relative to residual solvent 
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peaks as an internal standard at the following chemical shifts (
1
H and 
13
C respectively): 7.26 and 
77.0 ppm for CDCl3; 2.50 and 39.52 ppm for DMSO-d6, 3.31 and 49.2 ppm for CD3OD. Data are 
reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q 
= quartet, dd = doublet of doublets, br = broad, m = multiplet), coupling constant (Hz).  
 
 
 
2-(2-chloro-4-nitrophenyl)isoindoline-1,3-dione (4.11). In a flask, 200 mg (1.622 
mmol, 1.2 equiv.) of 2-chloro-4-nitroaniline and 280 mg (1.350 mmol, 1.0 equiv.) of phthalic 
anhydride were added and dissolved in 5 mL of acetic acid. The mixture was refluxed for 24 
hours. After cooling the solution a precipitate is formed. The solid was filtered and carefully 
triturated with cold methanol to obtain a light yellow powder (359 mg, 88%). 
1
H-NMR (400.1 
MHz, CDCl3) δ (ppm): 8.45 (1H, d, J=2.4 Hz), 8.28 (1H, dd, J=8.7 Hz, J=2.5 Hz), 8.00 (2H, m), 
7.86 (2H, m), 7.58 (1H, d, J=8.6 Hz).
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 165.6, 148.2, 135.6, 
134.9, 134.6, 131.6, 131.4, 125.7, 124.2, 122.6. 
 
2-(4-amino-2-chlorophenyl)isoindoline-1,3-dione (4.12). In a vial, 300 mg (0.993 
mmol, 1.0 equiv.) of 4.11 were suspended in dioxane. The suspension was cold in an ice bath and 
purged with argon. A previously prepared solution of tin(II) chloride (847 mg, 4.469 mmol, 4.5 
equiv.) in concentrated hydrochloric acid (5M concentration of SnCl2) was added dropwise to the 
suspension. After 2 hours of stirring at room temperature, the reaction was neutralized carefully 
with aqueous potassium carbonate 20%, filtered and extracted with diethyl ether. The organic 
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phase was dried with magnesium sulphate, filtered and the volatiles eliminated in vacuo to yield a 
yellow powder (196 mg, 72%). 
1
H-NMR (400.1 MHz, DMSO-d6) δ (ppm): 7.97 (2H, m), 7.90 
(2H, m), 7.14 (1H, d, J=8.5 Hz), 6.76 (1H, d, J=2.4 Hz), 6.60 (1H, dd, J=8.6 Hz, J=2.4 Hz), 5.74 
(2H, s, -NH2).
13
CNMR (100.6 MHz, DMSO-d6) δ (ppm): 167.5, 151.5, 135.3, 132.7, 131.78, 
131.76, 123.9, 116.5, 113.6, 113.0. 
 
General synthesis of N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)amides (4.13-
4.65). In a vial, 0.088 mmol (1.2 equiv.) of the carboxylic acid were added and dissolved in 0.5 
mL mixture of DCM:DIEA (9:1), then 41 mg (0.110 mmol, 1.5 equiv.) of HATU were added. 
The mixture was stirred for 10 minutes, and 20 mg (0.073 mmol, 1.0 equiv.) of 4.12 dissolved in 
0.5 mL of DCM:DIEA (9:1) were added, followed by 3 drops of DMF. The reaction was stirred 
for 24 hours at room temperature. After this time, the reaction was quenched with the addition of 
water, and was worked up by extraction with DCM. The organic phases was filtered through a 
phase separator, volatiles were evaporated, the crude was dissolved in DMSO and purified by 
preparative HPLC.  
 
N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-chloropicolinamide (4.28). White 
powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.19 (1H, s), 8.55 (1H, dd, J=4.5 Hz, J=1.0 
Hz), 8.19 (1H, d, J=2.3 Hz), 7.98 (2H, m), 7.92 (1H, dd, J=8.1 Hz, J=1.0 Hz), 7.82 (2H, m), 7.76 
(1H, dd, J=8.6 Hz, J=2.3 Hz), 7.48 (1H, dd, J=8.2 Hz, J=4.5 Hz), 7.35 (1H, d, J=8.6 Hz). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 166.7, 160.7, 145.8, 144.5, 141.1, 139.5, 134.4, 133.8, 
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132.9, 131.8, 130.8, 127.2, 125.0, 123.9, 120.8, 118.4. HRMS (TOF, ES+) C20H12Cl2N3O3 
[M+H]+ calc. mass 412.0256, found 412.0253.  
 
N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide (4.51). White 
powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.47 (1H, s), 8.47 (1H, d, J=3.7 Hz), 8.18 (1H, 
d, J=2.3 Hz), 7.97 (2H, m), 7.81 (2H, m), 7.74 (1H, dd, J=8.6 Hz, J=2.3 Hz), 7.67 (1H, d, J=7.3 
Hz), 7.40 (1H, dd, J=7.8 Hz, J=4.6 Hz), 7.33 (1H, d, J=8.6 Hz), 2.83 (3H, s). 
13
CNMR (100.6 
MHz, CDCl3) δ (ppm): 166.8, 163.6, 146.0, 145.4, 141.4, 140.0, 136.5, 134.4, 133.7, 131.9, 
130.7, 126.4, 124.6, 123.9, 120.7, 118.3, 20.7. HRMS (TOF, ES+) C21H15ClN3O3 [M+H]+ calc. 
mass 392.0802, found 392.0799.  
 
N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-hydroxypicolinamide (4.55). 
Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.09 (1H, s), 8.16 (1H, d, J=3.1 Hz), 
8.10 (1H, d, J=2.2 Hz ), 7.97 (2H, m), 7.81 (2H, m), 7.74 (1H, dd, J=8.6 Hz, J=2.3 Hz), 7.44 (1H, 
dd, J=8.5 Hz, J=4.2 Hz), 7.37 (2H, m). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 166.7, 158.3, 
139.6, 138.7, 138.1, 134.5, 133.9, 131.8, 131.0, 130.7, 129.4, 126.7, 124.0, 121.3, 119.1, 118.8. 
HRMS (TOF, ES+) C20H13ClN3O4 [M+H]+ calc. mass 394.0595, found 394.0598.  
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3-amino-N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)picolinamide (4.59). Cream 
powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.33 (1H, s), 8.16 (1H, d, J = 2.3 Hz), 8.01 
(2H, m), 7.95 (1H, dd, J = 4.2 Hz, J = 1.1 Hz), 7.83 (2H, m), 7.74 (1H, dd, J = 8.6 Hz, J = 2.3 
Hz), 7.35 (1H, d, J = 8.6 Hz), 7.25 (1H, dd, J = 8.4 Hz, J = 4.3 Hz), 7.09 (1H, dd, J = 8.4 Hz, J = 
1.2 Hz). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 166.8, 165.6, 146.3, 139.9, 136.6, 134.4, 133.6, 
131.9, 130.7, 128.6, 27.9, 125.4, 124.4, 120.6, 118.3. HRMS(TOF, ES+) C20H14ClN4O3 
[M+H]+ calcd mass 393.0754, found 394.0753. 
 
General synthesis of N-(2-chloro-4-nitrophenyl)picolinamides (4.70-4.72). In a 
microwave vial, 2.20 mmol (1.0 equiv.) of the 3-substituted picolinic acid were added and 
dissolved in 5 mL of DCE:DIEA (9:1), then 1254 mg (3.30 mmol, 1.5 equiv.) of HATU were 
added. The mixture was stirred for five minutes, and 2.64 mmol (1.2 equiv.) of 3-chloro-4-
nitroaniline dissolved in 5 mL of DCE:DIEA (9:1) were added, followed by 3 drops of DMF. The 
reaction was heated in the microwave at 120 °C for 30 minutes. The reaction was cooled to room 
temperature and water was added, causing the precipitation of the product. The crude was 
filtrated in vacuo and carefully triturated with cold methanol. 
 
N-(2-chloro-4-nitrophenyl)-3-methylpicolinamide (4.70). White powder. 500 mg 
(78%). 
1
H-NMR (400.1 MHz, DMSO-d6) δ (ppm): 11.21 (1H, s, -NH), 8.58 (1H, br), 8.34 (1H, 
s), 8.14 (1H, d, J=8.8 Hz), 8.04 (1H, d, J=9.3 Hz), 7.84 (1H, d, J=7.3 Hz), 7.57 (1H, m), 2.65 
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(3H, s). 
13
C-NMR (100.6 MHz, DMSO-d6) δ (ppm): 165.7, 148.3, 146.4, 144.2, 142.2,  141.1, 
134.9, 127.7, 127.0, 126.8, 121.7, 119.0, 19.8. 
 
N-(2-chloro-4-nitrophenyl)-3-chloropicolinamide (4.71). Pale yellow powder. 517 mg 
(75%). 
1
H-NMR (400.1 MHz, DMSO-d6) δ (ppm): 11.36 (1H, s, -NH), 8.69 (1H, dd, J=4.6 Hz, 
J=1.3 Hz), 8.23 (1H, d, J=2.1 Hz), 8.17 (2H, m), 7.92 (1H, dd, J=9.0 Hz, J=2.1Hz), 7.68 (1H, 
1H, dd, J=8.2 Hz, J=4.6 Hz). 
13
C-NMR (100.6 MHz, DMSO-d6) δ (ppm): 164.1, 149.7, 147.8, 
143.7, 142.5, 139.6, 129.4, 128.0, 127.6, 127.1, 121.5, 118.9. 
 
N-(4-amino-2-chlorophenyl)-3-methylpicolinamide (4.73). Compound was obtained 
similarly to 4.12. 500 mg (1.714 mmol) of 4.70 were employed to yield 329 mg (74%) of a pale 
yellow powder. 
1
H-NMR (400.1 MHz, DMSO-d6) δ (ppm): 10.31 (1H, s, -NH), 8.51 (1H, d, J= 
4.0 Hz), 7.87 (1H, d, J=2.1 Hz), 7.79 (1H, d, J=7.6 Hz), 7.49 (1H, dd, J=7.7 Hz, J=4.7 Hz), 7.42 
(1H, dd, J=8.7 Hz, J=2.2 Hz), 6.78 (1H, d, J=8.7 Hz), 5.19 (2H, s, -NH2), 2.56 (3H, s). 
13
C-NMR 
(100.6 MHz, DMSO-d6) δ (ppm): 164.5, 150.0, 146.2, 141.5, 140.7, 133.7, 129.1, 125.9, 121.2, 
120.6, 116.9, 115.6, 19.6. 
 
N-(4-amino-2-chlorophenyl)-3-chloropicolinamide (4.74). Compound was obtained 
similarly to 4.12. 500 mg (1.714 mmol) of 4.71 were employed to yield 428 mg (92%) of a pale 
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yellow powder. 
1
H-NMR (400.1 MHz, DMSO-d6) δ (ppm): 10.42 (1H, s, -NH), 8.61 (1H, dd, J= 
4.6 Hz, J=1.2 Hz), 8.09 (1H, dd, J= 8.2 Hz, J= 1.2 Hz), 7.74 (1H, d, J=2.1 Hz), 7.59 (1H, dd, 
J=8.2 Hz, J=4.7 Hz), 7.33 (1H, dd, J=8.7 Hz, J=2.2 Hz), 6.79 (1H, d, J=8.7 Hz), 5.24 (2H, s, -
NH2). 
13
C-NMR (100.6 MHz, DMSO-d6) δ (ppm): 162.9, 151.6, 147.6, 141.8, 139.0, 128.8, 
126.7, 121.0, 120.4, 116.9, 115.7. 
 
General synthesis of substituted N-(3-chloro-4-(1,3-dioxoisoindolin-2-
yl)phenyl)picolinamides (4.76a-g, 4.77a-g, 4.78a-g). In a microwave vial, 0.0709 mmol (1.0 
equiv.) of the aniline (4.73, 4.74 or 4.75) and 0.106 mmol (1.5 equiv.) of the substituted phthalic 
anhydride were added and dissolved in 1 mL of NMP. The vial was sealed and the mixture was 
heated at 200 °C for 20 minutes. After this time, the reaction was quenched with the addition of 
water, and was worked up by extraction with DCM (2 mL, thrice). The organic phase was filtered 
through a phase separator, volatiles were evaporated; the crude was dissolved in DMSO and 
purified by preparative HPLC.  
 
N-(3-chloro-4-(4-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide 
(4.76a). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.63 (1H, s), 8.40 (1H, d, J=4.3 
Hz), 8.16 (1H, d, J=2.3 Hz), 7.80 (1H, d, J=7.3), 7.76 (1H, dd, J=8.6 Hz, J=2.3 Hz), 7.73 (1H, d 
J=7.7 Hz), 7.66 (1H, t, J=7.5 Hz), 7.55 (1H, d, J =7.8 Hz), 7.45 (1H, dd, J=7.8 Hz, J=4.7 Hz), 
7.33 (1H, d, J=8.6 Hz), 2.83 (3H, s), 2.75 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 167.5, 
166.8, 163.1, 145.9, 144.7, 141.9, 139.9, 138.6, 136.7, 136.6, 133.9, 133.7, 132.3, 130.8, 128.6, 
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126.4, 124.9, 121.5, 120.8, 118.4, 20.6, 17.7. HRMS (TOF, ES+) C22H17ClN3O3 [M+H]+ calc. 
mass 406.0958, found 406.0956.  
 
N-(3-chloro-4-(4-chloro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide 
(4.76b). Cream powder. 
1
H-NMR (500 MHz, CDCl3) δ (ppm): 10.49 (1H, s), 8.47 (1H, d, J=4.3 
Hz, J=1.1 Hz), 8.18 (1H, J=2.3 Hz), 7.90 (1H, m), 7.74 (3H, m), 7.67 (1H, d, J=7.8 Hz), 7.40 
(1H, dd, J=7.8 Hz, J=4.6 Hz), 7.32 (1H, d, J=8.6 Hz), 2.83 (3H, s). 
13
CNMR (100.6 MHz, 
CDCl3) δ (ppm): 165.3, 164.3, 162.8, 145.7, 144.2, 142.3, 140.0, 136.7, 136.1, 135.3, 133.9, 
133.6, 132.0, 130.7, 127.6, 126.5, 124.4, 122.3, 120.9, 118.6, 20.4. HRMS (TOF, ES+) 
C21H14Cl2N3O3 [M+H]+ calc. mass 426.0412, found 426.0414. 
 
N-(3-chloro-4-(4-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide 
(4.76c). Brown powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.48 (1H, s), 8.46 (1H, dd, 
J=4.5 Hz, J=1.0 Hz), 8.18 (1H, d, J=2.3 Hz), 7.81 (2H, m), 7.74 (1H, dd, J=8.6 Hz, J=2.4 Hz), 
7.67 (1H, d, J=7.8 Hz, J=0.8 Hz), 7.47 (1H, m), 7.40 (1H, dd, J=7.8 Hz, J=4.6 Hz), 7.33 (1H, d, 
J=8.6 Hz), 2.83 (3H, s). 
13
CNMR (125.7 MHz, CDCl3) δ (ppm): 165.6, 163.7, 163.4, 157.9 (
1
JCF, 
d, J=266 Hz), 146.0, 145.4, 141.44, 141.39, 140.2, 137.0 (
3
JCF=7.5 Hz), 136.6, 134.0, 133.7, 
130.7, 126.4, 124.2, 122.8 (
2
JCF=19.7 Hz), 120.7, 120.1 (
4
JCF=3.2 Hz), 118.4, 20.8. HRMS (TOF, 
ES+) C21H14ClFN3O3 [M+H]+ calc. mass 410.0708, found 410.0706. 
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N-(3-chloro-4-(5-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide 
(4.76d). Cream powder.  
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.51 (1H, s), 8.45 (1H, d, 
J=3.9 Hz), 8.17 (1H, d, J=2.3 Hz), 7.85 (1H, d, J=7.6 Hz), 7.78 (1H, s), 7.74 (1H, dd, J=8.6 Hz, 
J=2.3 Hz), 7.68 (1H, d, J=7.7 Hz), 7.59 (1H, d, J=7.6 Hz),  7.41 (1H, dd, J=7.8 Hz, J=4.6 Hz), 
7.33 (1H, d, J=8.6 Hz), 2.83 (3H, s), 2.57 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 167.0, 
166.9, 163.2, 145.9, 145.8, 144.8, 141.8, 139.9, 136.6, 134.9, 133.7, 132.2, 130.8, 129.3, 126.4, 
124.8, 124.4, 123.8, 120.8, 118.4, 22.0, 20.6. HRMS (TOF, ES+) C22H17ClN3O3 [M+H]+ calc. 
mass 406.0958, found 406.0956.  
 
 
N-(3-chloro-4-(5-chloro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide 
(4.76e). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.54 (1H, s), 8.45 (1H, d, J=4.0 
Hz), 8.18 (1H, d, J=2.3 Hz), 7.94 (1H, d, J=1.6 Hz), 7.90 (1H, d, J=8.0 Hz), 7.76 (2H, m),7.69 
(1H, d, J=7.6 Hz), 7.42 (1H, dd, J=7.8 Hz, J=4.6 Hz), 7.32 (1H, d, J=8.6 Hz), 2.83 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 165.8, 165.5, 163.0, 145.8, 144.6, 142.0, 141.2, 140.1, 
136.7, 134.5, 133.6, 133.5, 130.7, 129.9, 126.5, 125.1, 124.4, 124.3, 120.8, 118.5, 20.5. HRMS 
(TOF, ES+) C21H14Cl2N3O3 [M+H]+ calc. mass 426.0412, found 426.0416. 
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N-(3-chloro-4-(5-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide 
(4.76f). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.53 (1H, s), 8.46 (1H, d, J=4.2 
Hz), 8.18 (1H, d, J=2.3 Hz), 7.98 (1H, dd, J=8.2 Hz, J= 4.5 Hz), 7.76 (1H, dd, J=8.6 Hz, J=2.3 
Hz), 7.70 (1H, d, J=7.7 Hz), 7.64 (1H, dd, J=7.0 Hz, J=2.2 Hz),  7.48 (1H, dt, J=8.5 Hz, J=8.5 
Hz, J= 2.3 Hz), 7.42 (1H, dd, J=7.8 Hz, J=4.6 Hz), 7.32 (1H, d, J=8.6 Hz), 2.82 (3H, s).
13
CNMR 
(100.6 MHz, CDCl3) δ (ppm): 166.6 (
1
JCF= 258 Hz), 165.7, 165.4, 163.2, 145.8, 144.8, 141.9, 
140.1, 136.6, 134.7 (
3
JCF=9.5 Hz), 133.6, 130.7, 127.6 (
4
JCF=3.2 Hz), 126.5, 126.3 (
3
JCF=9.5 Hz), 
124.4, 121.5 (
2
JCF=19.6 Hz), 120.8, 118.5, 111.6 (
2
JCF=24.6 Hz), 20.6. HRMS (TOF, ES+) 
C21H14ClFN3O3 [M+H]+ calc. mass 410.0708, found 410.0707. 
 
N-(3-chloro-4-(1,3-dioxo-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl)-3-
methylpicolinamide (4.76g). Pale orange solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.57 
(1H, s), 9.29 (1H, s), 9.17 (1H, d, J= 4.8 Hz), 8.47 (1H, d, J= 4.2 Hz), 8.21 (1H, d, J= 2.3 Hz), 
7.89 (1H, d, J= 4.8 Hz), 7.78 (1H, dd, J= 8.6 Hz, J= 2.3 Hz), 7.71 (1H, d, J= 7.7 Hz), 7.44 (1H, 
dd, J= 7.8 Hz, J= 4.6 Hz), 7.34 (1H, d, J= 8.6 Hz), 2.83 (3H, s).
13
CNMR (100.6 MHz, CDCl3) δ 
(ppm): 165.5, 165.2, 163.4, 155.8, 145.3, 145.1, 141.7, 140.4, 139.2, 136.7, 133.5, 130.6, 126.5, 
125.7, 123.8, 120.8, 118.5, 117.3, 20.7. HRMS (TOF, ES+) C20H14ClN4O3 [M+H]+ calc. mass 
393.0754, found 393.0755. 
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N-(3-chloro-4-(4-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-chloropicolinamide 
(4.77a). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.17 (1H, s), 8.55 (1H, dd, 
J=4.5 Hz, J=1.4 Hz), 8.18 (1H, d, J=2.3 Hz), 7.92 (1H, dd, J=8.1 Hz, J=1.4 Hz), 7.80 (2H, d, 
J=7.3 Hz), 7.75 (1H, dd, J=8.6 Hz, J=2.4 Hz), 7.66 (1H, t, J=7.5 Hz), 7.55 (1H, d, J=7.7 Hz), 
7.47 (1H, dd, J=8.2 Hz, J=4.5 Hz), 7.34 (1H, d, J=8.6 Hz), 2.76 (3H, m). 
13
CNMR (100.6 MHz, 
CDCl3) δ (ppm): 167.5, 166.8, 160.7, 145.8, 144.6, 141.1, 139.4, 138.7, 136.7, 133.9, 133.8, 
132.9, 132.3, 130.9, 128.6, 127.1, 125.2, 121.5, 120.8, 118.3, 17.7. HRMS (TOF, ES+) 
C21H14Cl2N3O3 [M+H]+ calc. mass 426.0412, found 426.0411. 
 
N-(3-chloro-4-(4-chloro-1,3-dioxoisoindolin-2-yl)phenyl)-3-chloropicolinamide 
(4.77b). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.18 (1H, s), 8.55 (1H, dd, 
J=4.5 Hz, J=1.4 Hz), 8.19 (1H, d, J=2.3 Hz), 7.91 (2H, m), 7.75 (3H, m), 7.48 (1H, dd, J=8.2 Hz, 
J=4.5 Hz), 7.33 (1H, d, J=8.6 Hz). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 165.2, 164.2, 160.7, 
145.8, 144.5, 141.1, 139.7, 136.1, 135.3, 133.9, 133.7, 132.9, 132.0, 130.8, 127.6, 127.2, 124.7, 
122.4, 120.8, 118.4. HRMS (TOF, ES+) C20H11Cl3N3O3 [M+H]+ calc. mass 445.9866, found 
445.9869. 
 
212 
 
 
N-(3-chloro-4-(4-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-chloropicolinamide 
(4.77c). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.18 (1H, s), 8.55 (1H, dd, 
J=4.5 Hz, J=1.3 Hz), 8.19 (1H, d, J=2.3 Hz), 7.91 (1H, dd, J=8.18 Hz, J=1.4 Hz), 7.81 (2H, m), 
7.75 (1H, dd, J=8.6 Hz, J=2.4 Hz), 7.47 (2H, m), 7.34 (1H, d, J=8.6 Hz). 
13
CNMR (100.6 MHz, 
CDCl3) δ (ppm): 165.5, 163.3, 160.7, 157.9 (d, 
1
JCF=267 Hz), 145.8, 144.5, 141.1, 139.7, 136.96 
(d, 
3
JCF=7.6 Hz), 133.9, 133.8, 132.9, 130.8, 127.2, 127.0, 124.6, 122.8 (
2
JCF=19.7 Hz), 121.7, 
120.8, 120.1, 118.4. HRMS (TOF, ES+) C20H11Cl2FN3O3 [M+H]+ calc. mass 430.0162, found 
430.0163. 
 
N-(3-chloro-4-(5-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-chloropicolinamide 
(4.77d). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.16 (1H, s), 8.55 (1H, dd, 
J=4.5 Hz, J=1.3 Hz), 8.17 (1H, d, J=2.3 Hz), 7.91 (1H, dd, J=8.2 Hz, J=1.3 Hz), 7.85 (1H, d, 
J=7.6 Hz), 7.78 (1H, s), 7.74 (1H, dd, J=8.6 Hz, J=2.4 Hz), 7.60 (1H, d, J=7.7 Hz), 7.47 (1H, dd, 
J=8.2 Hz, J=4.5 Hz), 7.34 (1H, d, J=8.6 Hz), 2.56 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ 
(ppm): 166.9, 166.8, 160.7, 145.8, 145.8, 144.6, 141.1, 139.5, 135.0, 133.8, 132.9, 132.2, 130.9, 
129.2, 127.1, 125.2, 124.4, 123.8, 120.8, 118.3, 22.0. HRMS (TOF, ES+) C21H14Cl2N3O3 
[M+H]+ calc. mass 426.0412, found 426.0413. 
 
213 
 
 
N-(3-chloro-4-(5-chloro-1,3-dioxoisoindolin-2-yl)phenyl)-3-chloropicolinamide 
(4.77e). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.19 (1H, s), 8.55 (1H, dd, 
J=4.5 Hz, J=1.3 Hz), 8.19 (1H, d, J=2.3 Hz), 7.95 (1H, d, J=1.5 Hz), 7.92 (2H, m), 7.77 (2H, m), 
7.48 (1H, dd, J=8.2 Hz, J=4.5 Hz), 7.34 (1H, d, J=8.6 Hz). 
13
CNMR (100.6 MHz, DMSO-d6) δ 
(ppm): 170.8, 170.4, 168.7, 155.3, 152.5, 145.8, 145.1, 144.2, 140.0, 138.5, 137.5, 136.8, 135.1, 
133.9, 132.1, 130.7, 129.7, 129.1, 125.3, 124.3. HRMS (TOF, ES+) C20H11Cl3N3O3 [M+H]+ calc. 
mass 445.9866, found 445.9869. 
 
N-(3-chloro-4-(5-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-chloropicolinamide 
(4.77f). Brown powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.19 (1H, s), 8.55 (1H, dd, 
J=4.5 Hz, J=1.2 Hz), 8.19 (1H, J=2.3 Hz), 7.98 (1H, J=8.2 Hz, J=4.5 Hz), 7.92 (1H, dd, J=8.2 
Hz, J=1.3 Hz), 7.77 (1H, dd, J=8.6 Hz, J=2.4 Hz), 7.65 (1H, dd, J=7.0 Hz, J=2.2 Hz), 7.48 (2H, 
m), 7.34 (1H, d, J=8.6 Hz). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 166.7 (
1
JCF=258 Hz), 165.7, 
165.4, 160.8, 145.9, 144.6, 141.2, 139.8, 134.7 (
3
JCF=10.0 Hz), 133.8, 133.0, 130.8, 127.7 
(
4
JCF=3.2 Hz), 127.3, 126.4 (
3
JCF=9.3 Hz), 124.8, 121.6 (
2
JCF=23.3 Hz), 120.9, 118.5, 111.7 
(
2
JCF=24.5 Hz). HRMS (TOF, ES+) C20H11Cl2FN3O3 [M+H]+ calc. mass 430.0162, found 
430.0163. 
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N-(3-chloro-4-(1,3-dioxo-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl)-3-
methylpicolinamide (4.77g). Orange solid.
 1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.20 (1H, 
s), 9.30 (1H, s), 9.17 (1H, d, J= 4.8 Hz), 8.56 (1H, dd, J=4.5 Hz, J= 1.3 Hz), 8.22 (1H, d, J= 2.3 
Hz), 7.93 (1H, dd, J= 8.2 Hz, J= 1.3 Hz), 7.89 (1H, d, J= 4.8 Hz), 7.78 (1H, dd, J= 8.6 Hz, J= 2.4 
Hz), 7.49 (1H, dd, J= 8.2 Hz, J= 4.5 Hz), 7.35 (1H, d, J= 8.6 Hz). 
13
CNMR (100.6 MHz, CDCl3) 
δ (ppm): 165.5, 165.1, 160.8, 155.8, 145.9, 145.3, 144.5, 141.2, 139.9, 139.2, 133.6, 133.0, 130.6, 
127.2, 125.7, 124.2, 120.9, 118.5, 117.3. HRMS (TOF, ES+) C19H11Cl2N4O3 [M+H]+ calc. mass 
413.0208, found 430.0207. 
 
 
2-(4-nitrophenyl)isoindoline-1,3-dione (4.80). Procedure from the synthesis and 
purification of 4.11 was followed using 4-nitroaniline (336 mg, 2.43 mmol, 1.2 equiv.). A cream 
solid was obtained (507 mg, 93%). 
1
H-NMR (400.1 MHz, DMSO-d6) δ (ppm): 8.42 (2H, d, J=8.9 
Hz), 8.03 (2H, m), 7.95 (2H, m), 7.81 (2H, d, J=8.9 Hz).
13
CNMR (100.6 MHz, DMSO-d6) δ 
(ppm): 166.8, 146.5, 138.2, 135.4, 131.9, 128.1, 124.6, 124.1. 
 
2-(4-aminophenyl)isoindoline-1,3-dione (4.82). Procedure from the synthesis and 
purification of 4.12 was followed using 4-nitroaniline (268 mg, 1.00 mmol). An orange solid was 
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obtained (203 mg, 85%).
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 7.95 (2H, m), 7.79 (2H, m), 7.19 
(2H, d, J=8.6 Hz), 6.79 (2H, d, J=8.6 Hz).
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 167.7, 146.4, 
134.1, 131.8, 127.8, 123.5, 115.2, 112.7. 
 
  
N-(4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylpicolinamide (4.87). This compound 
was synthesized using the general procedure to obtain library 4.13-4.65, but using 4.82 as starting 
material. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.41 (1H, s), 8.49 (1H, d, J =3.9 Hz), 7.98 
(2H, m), 7.94 (2H, d, J=8.8 Hz), 7.81 (2H, m), 7.68 (1H, d, J=7.8 Hz), 7.48 (2H, d, J = 8.8 Hz), 
7.41 (1H, dd, J=7.8 Hz, J=4.7 Hz), 2.85 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 167.3, 
163.5, 146.5, 145.3, 141.3, 137.8, 136.3, 134.3, 131.7, 127.14, 127.10, 126.1, 123.6, 119.9, 20.8. 
 
 
3-amino-N-(4-(1,3-dioxoisoindolin-2-yl)phenyl)picolinamide (4.84). This compound 
was synthesized using the general procedure to obtain library 4.13-4.65, but using 4.82 as starting 
material. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.27 (1H, s), 7.98 (3H, m), 7.91 (2H, d, J =9.0 
Hz), 7.82 (2H, m), 7.47 (2H, J =8.7 Hz), 7.25 (2H, J =8.4 Hz, J =4.4 Hz,), 7.25 (2H, J =8.4 Hz, J 
=1.3 Hz). 
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3-chloro-N-(4-(1,3-dioxoisoindolin-2-yl)phenyl)picolinamide (4.85). This compound 
was synthesized using the general procedure to obtain library 4.13-4.65, but using 4.82 as starting 
material. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.1 (1H, s), 8.57 (1H, d, J =3.9 Hz), 7.95 (5H, 
m), 7.82 (2H, m), 7.49 (3H, m).  
 
 
N-(4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-hydroxypicolinamide (4.86). This compound 
was synthesized using the general procedure to obtain library 4.13-4.65, but using 4.82 as starting 
material. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.07 (1H, s), 8.17 (1H, dd, J =4.2 Hz, J = 
1.4Hz), 7.99 (2H, m), 7.91 (2H, d, J=8.8 Hz), 7.83 (2H, m), 7.53 (2H, d, J=8.8 Hz), 7.48 (2H, d, 
J=8.8 Hz), 7.45 (1H, dd, J=8.4 Hz, J=4.2 Hz), 7.40 (1H, dd, J=8.4 Hz, J=1.4 Hz).  
 
 
 N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)amines (4.105-4.140). In a microwave 
vial, 4.12 (20 mg, 0.073 mmol, 1.0 equiv.), the corresponding aldehyde (1.2 equiv.) and polymer 
bound cyanoborohydride (1.5 equiv.) were added. The mixture was suspended in 600 µL of DCM 
and 50 µL of glacial acetic acid were added. The vial was sealed and heated in the microwave for 
seven minutes at 110 °C. The reactions were monitored by LC-MS to confirm the presence of 
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product. The matrix was filtered, and volatiles evaporated in vacuo. The crude product was 
dissolved in DMSO and purified by preparative HPLC. 
 
 2-(4-((benzo[d][1,3]dioxol-5-ylmethyl)amino)-2-chlorophenyl)isoindoline-1,3-dione 
(4.122). White solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 7.96 (2H, m), 7.81 (2H, m), 7.2 
(1H, d, J=8.3 Hz), 6.83 (4H, m), 6.68 (1H, d, J=7.9 Hz), 5.99 (2H, s), 4.28 (2H, s). 
 
General procedure for the esterification of ortho-methylbenzoic acids. In a flask, the 
carboxylic acid (11.72 mmol, 1.0 equiv.) was dissolved in 6 mL of methanol. Then, 0.5 mL of 
concentrated sulfuric acid were added dropwise. The reaction was heated at reflux and monitored 
by LC-MS until there was no starting material in the chromatogram. At this point, the reaction 
was stopped and cooled to room temperature. For the workup, water was added to the mixture 
and successive extractions with ethyl ether were performed. The organic phases were combined 
and washed with NaHCO3 5% and brine. The organic phase was dried with anhydrous MgSO4, 
filtered and concentrated in vacuo. The crude product was purified by silica gel flash 
chromatography (Teledyne ISCO) using a gradient of hexanes to 10% EtOAc in hexanes. 
 
Methyl 2-chloro-6-methylbenzoate (4.148). Clear oil. 
1
H-NMR (400.1 MHz, CDCl3) δ 
(ppm): 7.08 (2H, m), 6.96 (1H, m), 3.81 (3H, s),  2.19 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ 
(ppm): 167.7, 136.80, 133.61, 130.51, 130.10, 128.51, 126.86, 52.26, 19.33. 
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General procedure for the bromination of ortho-methylbenzoate esters. The ester 
(9.60 mmol, 1.0 equiv.) was dissolved in 60 mL of CCl4. Then, N-bromosuccinimide (10.56 
mmol, 1.2 equiv.) was added, followed by benzoyl peroxide (0.192 mmol, 0.02 equiv.). The 
reaction was heated at reflux and monitored by LC-MS until there was no starting material in the 
chromatogram. At this point, the reaction was stopped and cooled to room temperature. For the 
workup, the mixture was filtered and concentrated in vacuo. The crude product was purified by 
silica gel flash chromatography (Teledyne ISCO) using a gradient of hexanes to 5% EtOAc in 
hexanes. 
 
Methyl 2-(bromomethyl)-3-chlorobenzoate (4.144).  Clear light orange oil. 
1
H-NMR 
(400.1 MHz, CDCl3) δ (ppm): 7.75 (1H, dd, J=7.9 Hz, J=1.3 Hz), 7.47 (1H, dd, J=8.0 Hz, J=1.3 
Hz), 7.21 (1H, t, J=8.0 Hz), 5.01 (2H, s), 3.86 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 
166.4, 136.4, 136.3, 133.6, 131.4, 129.7, 129.1, 52.6, 26.7. 
 
General procedure for the synthesis of isoindolinones 4.145-4.146 and 4.150-4.151. 
In a microwave vial, the corresponding methyl bromomethylbenzoate (0.085 mmol, 1.2 equiv.) 
and aniline (0.0709, 1.0 equiv.) were added and dissolved in 1 mL of DMF. Then, K2CO3 (0.141 
mmol, 2.0 equiv.) was added and the vial was sealed. The reaction was heated in the microwave 
at 150 °C for 15 minutes. The reaction was monitored by LC-MS and a second round of heating 
was applied if there was presence of starting material or the acyclic ester intermediate. The 
reaction was worked up by addition of water and successive extractions with DCM. The organic 
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phases were filtered through a phase separator, combined and volatiles were evaporated in vacuo. 
Crude products were dissolved in DMSO and purified by preparative HPLC. 
 
 N-(3-chloro-4-(4-chloro-1-oxoisoindolin-2-yl)phenyl)-3-methylpicolinamide (4.145). 
Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.13 (1H, s), 8.54 (1H, dd, J= 4.5 Hz, 
J= 1.3 Hz), 8.15 (1H, d, J= 2.4 Hz), 7.92 (1H, dd, J= 8.2 Hz, J= 1.3 Hz), 7.87 (1H, d, J=7.4 Hz), 
7.71 (1H, dd, J= 8.6 Hz, J= 2.4 Hz), 7.59 (1H, d, J= 7.9 Hz), 7.49 (2H, m), 7.42 (1H, d, J= 8.6 
Hz), 4.80 (2H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 167.3, 160.7, 145.8, 144.6, 141.1, 
139.8, 138.6, 133.9, 133.1, 132.9, 131.9, 130.9, 130.2, 129.9, 129.2, 127.1, 122.8, 121.1, 118.7, 
51.4 
  
 3-chloro-N-(3-chloro-4-(4-chloro-1-oxoisoindolin-2-yl)phenyl)picolinamide (4.146). 
Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 10.13 (1H, s), 8.54 (1H, dd, J= 4.5 Hz, 
J= 1.3 Hz), 8.15 (1H, d, J= 2.4 Hz), 7.92 (1H, dd, J= 8.2 Hz, J= 1.3 Hz), 7.87 (1H, d, J=7.4 Hz), 
7.71 (1H, dd, J= 8.6 Hz, J= 2.4 Hz), 7.59 (1H, d, J= 7.9 Hz), 7.49 (2H, m), 7.42 (1H, d, J= 8.6 
Hz), 4.80 (2H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 167.3, 160.7, 145.8, 144.6, 141.1, 
139.8, 138.6, 133.9, 133.1, 132.9, 131.9, 130.9, 130.2, 129.9, 129.2, 127.1, 122.8, 121.1, 118.7, 
51.4. 
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N-(3-chloro-4-(7-chloro-1-oxoisoindolin-2-yl)phenyl)-3- (4.150). Cream powder. 
1
H-
NMR (400.1 MHz, CDCl3) δ (ppm): 10.56 (1H, s), 8.40 (1H, d, J= 4.2 Hz), 8.12 (1H, J= 2.3 Hz), 
7.70 (2H, m), 7.46 (5H, m), 4.76 (2H, s), 2.80 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 
165.9, 163.0, 145.9, 144.6, 144.0, 142.0, 138.8, 136.5, 133.0, 132.7, 132.2, 130.8, 130.3, 129.9, 
127.9, 126.5, 121.3, 121.1, 118.8, 51.1, 20.5. 
 
Molecular pharmacology 
Tetracycline-tested fetal bovine serum (FBS) was purchased from Atlanta Biologicals 
(Lawrenceville, GA), and all other cell culture reagents and Fluo-4-acetoxymethylester (Fluo-4-
AM) were purchased from Life Technologies (Carlsbad, CA). Tetracycline hydrochloride 
(Sigma), L-glutamic acid (Tocris, Minneapolis, MN). 
Cell Culture and mutagenesis. Tetracycline-inducible rat and human mGlu1 WT-T-
REx
TM
-293 cells
112
 were cultured at 37 ºC in Dulbecco’s Modified Eagle Medium (DMEM) 
growth medium containing 10% Tet-tested FBS, 2 mM L-glutamine, 20 mM HEPES, 0.1 mM 
non-essential amino acids, 1 mM sodium pyruvate, antibiotic/antimycotic, 100 μg/mL 
hygromycin and 5  μg/mL blasticidin in the presence of 5% CO2. To generate a collection of 
stable cell lines carrying tetracycline-inducible hmGlu1 schizophrenic mutants,
241,242 
site-directed 
mutagenesis of  human mGlu1 WT in pcDNA5/TO was performed using Quikchange II XL kit 
(Agilent Technologies, Santa Clara, CA), and all point-mutations were confirmed by sequencing. 
The mutant stable cell lines were generated in the same manner as the WT as previously 
described and cultured in the growth medium described above.  
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Human mGlu4 CHO cells stably transfected expressing the chimeric G protein Gqi5 in 
pIRESneo3 (Invitrogen, Carlsbad, CA) were cultured in 90% Dulbecco’s Modified Eagle Media 
(DMEM), 10% dialyzed fetal bovine serum (FBS), 100 units/ml penicillin/streptomycin, 20 mM 
HEPES (pH 7.3), 1 mM sodium pyruvate, 2 mM glutamine, 400 μg/ml G418 sulfate (Mediatech, 
Inc., Herndon, VA) and 5 nM methotrexate (Calbiochem, EMD Chemicals, Gibbstown, NJ). 
Biotinylation of cell surface expression of mGlu1 receptor. To determine the receptor 
expression level on the cell surface among the mGlu1 WT and schizophrenia (Sz) mutant cell 
lines, cells were plated in a 10 cm dish at 8x10
6
 cells/8mL density in the assay medium 
containing either 20 ng/mL (WT) or 1µg/mL (mutants) TET to induce the receptor expression. 
The next morning, dishes were placed on ice and gently washed with ice cold PBS. Immediately, 
cells were scraped in cold PBS into a 1.5 mL tube, and spun down at 500xg for 4 min at 4 ºC. All 
steps were carried at 4 ºC unless otherwise noted. Cells were gently resuspended in 1 mL of cold 
PBS containing 2 mg of EZ-Link Sulfo-NHS-SS-Biotin and gently rocked for 30 min. 
Biotinylation was quenched by adding 500 µL of 150 mM Tris (pH 8.0) and cells were spun 
down and resuspended in 1 mL of 50 mM Tris (pH 8.0) to completely quench the reaction. Cells 
were spun down and resuspended in 1 mL of lysis buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 
1% NP-40, 0.5% sodium deoxycholate containing protease inhibitors) and incubated for 30 min. 
The lysates were spun at 16,000xg for 15 min, and the resulting supernatants were gently 
transferred to a new 1.5 mL tube to incubate with 60 µL of 50% slurry of NeutrAvidin beads by 
nutating at room temperature for 1 h. The beads were washed three times with lysis buffer and the 
biotinylated proteins bound to the beads were extracted by heating the beads at 65 °C for 5 min in 
SDS sample buffer containing 150 mM DTT. The proteins were resolved by 8% SDS-PAGE and 
the mGlu1 expression level was determined by Western blotting using the mGlu1–specific 
antibody (Clone 20, BD Transduction Lab). The density of the mGlu1 protein bands was 
measured using Quantity One software (Bio-Rad, Hercules, CA). 
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Poly-D-lysine plate coating. See Molecular Pharmacology in the experimental methods 
in chapter 3.    
Calcium Mobilization Assay. Single point screening and determination of potency for 
human and rat mGlu1 PAM activity was performed following the experimental procedure stated 
in chapter 3. 
To examine the functional activity of all hmGlu1-mutants compared to the WT, calcium 
flux was measured using the Functional Drug Screening System (FDSS7000, Hamamatsu, Japan) 
as previously described.
39 
 Briefly, the day before the assay,  the mGlu1-T-REx
TM
-293 cells were 
plated in black-walled, clear-bottomed, poly-D-lysine coated 384-well plates (BD Biosciences, 
San Jose, CA) at 20,000 cells/ well in 20 μL of assay medium  (DMEM supplemented with 10% 
dialyzed FBS, 20 mM HEPES, and 1 mM sodium pyruvate) that contains tetracycline (TET) to 
induce mGlu1 expression; 20 ng/mL TET was used for WT and 1 µg/mL TET for all mutants. 
The next day, cells were washed with assay buffer (Hank’s balanced salt solution, 20 mM 
HEPES, and 2.5 mM probenecid) using ELx microplate washer (BioTek Instruments, Winooski, 
VT), and immediately incubated with 20 µL of 1.15 µM Fluo-4 AM dye solution prepared in 
assay buffer for 45 min at 37 °C.  The dye was removed and washed with assay buffer before 
measuring the florescent calcium traces in FDSS. Agonists, glutamate or DHPG, were 1:5 serially 
diluted into 11 point concentrations, added to the cells, and incubated for 2 min. The agonist-
mediated calcium response was calculated by substracting the basal fluorescent peak before 
agonist addition from the maximal peak elicited by agonist. When testing the effect of the mGlu1 
PAMs, cells were first incubated with the PAMs (10 µM final concentration) or DMSO vehicle 
diluted in assay buffer for 2.2 min and then stimulated with glutamate or DHPG. Concentration 
response curves were generated using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, 
CA).  
To determine the PAM potency of the compounds on human mGlu4 PAMs in calcium 
assays, Ca flux was measured as previously described.
285
 Human mGlu4/Gqi5/CHO cells (30,000 
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cells/20 µl/well) were plated in blackwalled, clear-bottomed, TC treated, 384 well plates (Greiner 
Bio-One, Monroe, North Carolina) in DMEM containing 10% dialyzed FBS, 20 mM HEPES, 
100 units/ml penicillin/streptomycin, and 1 mM sodium pyruvate (Plating Medium). The cells 
were grown overnight at 37 °C in the presence of 5% CO2. During the day of assay, the medium 
was replaced with 20 μL of 1 μM Fluo-4 AM (Invitrogen, Carlsbad, CA) prepared as a 2.3 mM 
stock in DMSO and mixed in a 1:1 ratio with 10% (w/v) pluronic acid F-127 and diluted in Assay 
Buffer (Hank’s balanced salt solution, 20 mM HEPES and 2.5 mM Probenecid (Sigma-Aldrich, 
St. Louis, MO)) for 45 minutes at 37 °C. The dye was removed and replaced with 20 μL of Assay 
Buffer. Test compounds were transferred to daughter plates using an Echo acoustic plate 
reformatter (Labcyte, Sunnyvale, CA) and then diluted into Assay Buffer. Ca
2+
 flux was 
measured using the Functional Drug Screening System 7000 (FDSS7000, Hamamatsu, Japan). 
Baseline readings were taken (10 images at 1 Hz, excitation, 470 ± 20 nm, emission, 540 ± 30 
nm) and then 20 µl/well test compounds at 2X their final concentration were added using the 
FDSS’s integrated pipettor. Cells were incubated with compounds for approximately 2.5 minutes 
and then an EC20 concentration of glutamate was applied; 2 min. later an EC80 concentration of 
glutamate was added. Data was collected at ½ Hz until 10 seconds prior to agonist addition, when 
the rate was increased to 1 Hz for the remainder of the assay. For concentration-response curve 
experiments, compounds were serially diluted 1:3 into 10 point concentration response curves 
and were transferred to daughter plates using the Echo. Test compounds were again applied and 
followed by EC20 and EC80 concentrations of glutamate. Curves were fitted using a four point 
logistical equation using Microsoft XLfit (IDBS, Bridgewater, NJ). Subsequent confirmations of 
concentration response parameters were performed using independent serial dilutions of source 
compounds and data from multiple days experiments were integrated and fitted using a four point 
logistical equation in GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).  
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Pharmacokinetic characterization 
The in vitro DMPK assays, including those assessing hepatic microsomal intrinsic 
clearance (Clint), cytochrome P450 inhibition, plasma protein binding (PPB) and brain 
homogenate binding (BHB) were performed as described previously.
285
 The experimental 
procedures for the pharmacokinetic characterization of the compounds are described in chapter 3.  
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CHAPTER V 
 
DISCOVERY OF VU0486321, A POTENT, PREFERENTIAL AND BRAIN PENETRANT 
MGLU1 PAM 
 
Finding a more potent eastern piece as a replacement of the VU0405622’s picolinamide  
 
Bioisostere replacements for the picolinamide 
After finding that the removal of one of the carbonyls in the scaffold of VU0483605 
4.77b renders the molecule plasma stable but accompanied with a decrease in mGlu1 activity of 3 
to 5-fold, we thought that this could be a reasonable modification if applied to a more potent 
parent compound. In order to assess this, we embarked in finding a compound with a higher 
potency. 
We chose to continue exploring the picolinamide region of the VU0405622 scaffold, as 
our previous iterations have shown that the structure-activity in this part of the molecule 
presented more texture, while the chemical modification on the central phenyl ring and the linker 
showed steep changes in mGlu1 activity. As multiple heteroaromatic six-membered rings were 
already explored as a replacement for the pyridine, we chose to analyze the effect of five-
membered heterocyclic rings. These analogs were prepared in one step, performing an amide 
coupling with the different heterocyclic carboxylic acids and the previously synthesized aniline 
4.12  (Scheme 5.1); only 5.4 required an additional deprotection step as the protected tert-
(butoxycarbonyl)proline was employed for the formation of the amide. 
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Scheme 5.1. Synthesis of pyridine bioisostere analogs 5.1-5.17. 
 
The compounds were evaluated in a TR-Ex
TM
 293 human mGlu1 expressing cell line to 
determine its capacity of enhancing the glutamate response of the receptor. The test at 10 µM 
concentration showed that only three compounds potentiate mGlu1 PAM activity above 50% 
GluMax (Fig. 5.1 and Table 5.1). Here, the pyrrole 5.1, thiophene 5.3 an pyrrolidine 5.4 were 
inactive, while the furan analog 5.2 the mGlu1 response to 64% GluMax, an example of how subtle 
changes in the structure can have a strong effect in mGlu1 PAM activity.  
Similar observations were made in the case of the azole compounds. In the nitrogen-only 
azoles, it was observed that pyrazole 5.5 and triazole 5.7 were not active in mGlu1 but the close 
relative imidazole 5.6 potentiated the receptor’s response (55% GluMax). Nitrogenated fused-rings 
also proved to generate inactive analogs (5.15-5.17). The different oxazole and isoxazole 
compounds 5.8-5.11 did not show any activity as mGlu1 PAMs, while in the thiazoles, only 5.13 
display enhancement of mGlu1 signal. The other members in this family demonstrated that 
rearrangement of the nitrogen and sulfur atoms 5.12 or introduction of an additional nitrogen 5.14 
decrease mGlu1 PAM activity. 5.13 showed the highest response from this set of bioisosteres 
(105% GluMax); this thiazole can be described as the “thiophene” version of the picolinamide in 
VU0405622 and has the same disposition of heteroatoms as the active imidazole 5.6.  
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Figure 5.1. Comparison of the single point screen result for PAM activity in human mGlu1 at 10 
µM for the pyridine bioisostere library, analogs 5.1-5.17. Calcium mobilization was used to 
obtain %GluMax values for each compound in the presence of a submaximal concentration of 
glutamate (EC20) in cell lines expressing human mGlu1. Data represent the mean ± S.E.M. of at 
least three experiments with similar results. 
 
Table 5.1. Structures of the pyridine bioisostere library, analogs 5.1-5.17 and associated PAM 
activity from the single point screening at 10 µM in human mGlu1. Calcium mobilization 
responses for each compound are reported as a percentage of the maximum glutamate response. 
VU number denotes the compound identifier assigned by Vanderbilt University. Data represent 
the mean ± S.E.M. of at least three replicate experiments with similar results. 
Structure Cpd # VU # hmGlu1 %GluMax 
 
5.1 VU0474672 32.2±5.9 
 
5.2 VU0487495 64.1±9.8 
 
5.3 VU0474635 20.3±10.2 
0.0 
20.0 
40.0 
60.0 
80.0 
100.0 
120.0 
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5.4 VU6003715 25.6±2.8 
 
5.5 VU0475789 9.1±1.0 
 
5.6 VU6002231 54.7±5.2 
 
5.7 VU0475662 12.7±0.3 
 
5.8 VU6002201 32.7±2.6 
 
5.9 VU6002196 29.2±2.5 
 
5.10 VU6002195 14.8±2.0 
 
5.11 VU0474545 14.0±6.4 
 
5.12 VU6002167 29.8±3.4 
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5.13 VU0474567 105.4±11.5 
 
5.14 VU6002168 38.5±2.3 
 
5.15 VU0475754 19.3±0.8 
 
5.16 VU0475762 10.3±0.4 
 
5.17 VU0475776 10.3±1.3 
 
We decided to further analyze analogs 5.2 (VU0487495), 5.6 (VU6002231) and 5.13 
(VU0474567) and to determine their mGlu1 EC50. The results from this experiment identified 
marked differences between these PAMs (Fig. 5.2). The imidazole 5.6 was a very weak mGlu1 
PAM with potency above 10 µM. The thiazole 5.13 despite presenting great efficacy levels at 10 
µM, showed a borderline activity with an EC50 of 4.5 µM. The most active compound from this 
panel was the furan 5.2, the compound presented partial PAM activity with maximum response of 
74% GluMax and a submicromolar potency of 484 nM. 
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Figure 5.2. Comparison of the concentration-response of curve for PAM activity of 5.2 
(VU0487495) and 5.13 (VU0474567) in human mGlu1. Calcium mobilization was used to obtain 
%GluMax values for each compound at different concentrations in the presence of a submaximal 
concentration of glutamate (EC20) in cell lines expressing human mGlu1. Data represent the mean 
± S.E.M. of at least three experiments with similar results. 
 
Exploration of the SAR around the furan 
 Due to its high potency, we decided to take analog 5.2 and explore the effect of different 
substitutions on the furan ring for mGlu1 PAM activity. In this case, compounds were synthesized 
in a similar manner as shown in Scheme 5.1 and were screened in a 10 µM single point assay 
(Fig. 5.3 and Table 5.2).  
The substitution on the furan ring demonstrated a very steep SAR, as most modifications 
were detrimental for activity. All substituents in position 5 caused a loss in mGlu1 potentiation 
with respect to the parent compound, and only the smallest substituents, like the methyl 5.18 
(59% GluMax), chlorine 5.21 (48% GluMax), bromine 5.22 (42% GluMax) and trifluoromethyl 5.23 
(37% GluMax) maintain some activity. Substitutions in position 3 of the furan showed a similar 
pattern where the phenyl analog 5.28 was inactive, while a gain in activity was observed with the 
small methyl substituent 5.27, that allowed potentiation of the receptor response to 110% GluMax. 
Doubly substituted 3,5-dimethyl 5.29, the reduced tetrahydrofuran 5.32 and benzofuran variants 
5.30 and 5.31, did not display enhancement of mGlu1 activity. 
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Figure 5.3. Comparison of the single point screening results for PAM activity in human mGlu1 at 
10 µM for the pyridine bioisostere library, analogs 5.18-5.32. Calcium mobilization was used to 
obtain %GluMax values for each compound in the presence of a submaximal concentration of 
glutamate (EC20) in cell lines expressing human mGlu1. Data represent the mean ± S.E.M. of at 
least three experiments with similar results. 
 
Table 5.2. Structures of the pyridine bioisostere library, analogs 5.18-5.32 and associated PAM 
activity from the single point screening at 10 µM in human mGlu1. Calcium mobilization 
responses for each compound are reported as a percentage of the maximum glutamate response. 
VU number denotes the compound identifier assigned by Vanderbilt University. Data represent 
the mean ± S.E.M. of at least three replicate experiments with similar results. 
Structure Cpd # VU # hmGlu1 %GluMax 
 
5.18 VU0475715 58.9±8.6 
 
5.19 VU0474663 32.2±9.0 
 
5.20 VU0474437 8.9±1.2 
0.0 
20.0 
40.0 
60.0 
80.0 
100.0 
120.0 
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5.21 VU0474399 47.5±1.3 
 
5.22 VU0474622 42.3±15.0 
 
5.23 VU0474398 37.3±2.2 
 
5.24 VU0474475 18.6±1.7 
 
5.25 VU0474460 27.9±2.4 
 
5.26 VU0474469 26.5±1.7 
 
5.27 VU0474633 109.7±22.8 
 
5.28 VU0474409 19.6±0.5 
 
5.29 VU0474613 25.8±9.4 
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5.30 VU0475758 14.9±1.7 
 
5.31 VU0475716 19.4±3.6 
 
5.32 VU0475675 22.3±1.3 
 
The potencies of compounds 5.18 (5-methyl) and 5.27 (3-methyl) were analyzed in a 
concentration-response assay. It was determined that 5.18 was a weak potentiator with an EC50 
above 10 µM. Meanwhile, 5.27 (VU0474633) showed good potency (hu mGlu1 EC50 = 96 nM) 
and high efficacy (119% GluMax) for mGlu1, being the most potent PAM with an unsubstituted 
phthalimide at the time. It was decided to evaluate this PAM in the rat mGlu1 receptor, where the 
compound demonstrated to be potent (rat mGlu1 EC50 = 238 nM) and highly efficacious (126% 
GluMax). 5.27 was also evaluated for its mGlu4 potency where it showed 12-fold preference for 
mGlu1 (hu mGlu4 EC50 = 1.2 µM, 117% PHCCCMax). 
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Figure 5.4. Concentration-response of curve for PAM activity of VU0474633 5.27 in human and 
rat mGlu1. Calcium mobilization was used to obtain %GluMax values for each compound at 
different concentrations in the presence of a submaximal concentration of glutamate (EC20) in cell 
lines expressing human mGlu1. Data represent the mean ± S.E.M. of at least three experiments 
with similar results. 
 
Discovery and characterization of VU0486321 
 
Phthalimide modifications of VU0474633 5.27 
 The potency and selectivity characteristics of 5.27 prompted us to evaluate the impact of 
the different substituents of the phthalimide on mGlu1 potency. For this effort, analogs with the 
substituents used in previous scaffolds (VU0477930 4.51 and VU0474640 4.28) were 
synthesized, allowing a more direct comparison between these analogs and those reported in 
chapter 4. We envisioned accessing these compounds through a similar 3-step approach as in 
scheme 4.2; however, after using EDCI, HATU and PyClU at room temperature and with 
microwave heating, only little amounts of product were obtained. Using the acyl chloride 5.32 
with the aniline 4.66 at room temperature was not a viable approach, but the reaction was 
considerably more productive when heating in the microwave at 120 °C for 20 minutes, allowing 
5.33 to be obtained in excellent yields. Then, this nitro aromatic intermediate 5.33 was reduced 
almost quantitatively with tin(II) chloride to obtain aniline 5.34, which in turn was condensed 
with the phthalic anhydrides in refluxing acetic acid to yield analogs 5.35a-g (Scheme 5.2).  
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Scheme 5.2. Synthesis of analogs 5.35a-g derived from VU0474633 5.27 with modifications on 
the phthalimide.  
 
These analogs were tested in human mGlu1 and mGlu4 to assess their potency and 
selectivity (Table 5.3). It was observed that the 3-substituted phthalimide analogs 5.35a-5.35c 
decrease the EC50 for mGlu1 by 3 to 4-fold compared to VU0474633 5.27. The 4-substituted 
5.35d-5.35f also increased their potency with respect to the parent compound, but this effect was 
more variable and more important for the 4-fluoro analog 5.35f. While the introduction of a 
nitrogen in the phthalimide (5.35g) maintained the original activity of VU0474633 5.27. These 
results showed a substantial improvement in potency compared with the compounds derived from 
VU0474640 4.28 and VU0477930 4.51, as an example, in both these cases the direct comparators 
of 4.77g and 4.76g were weak PAMs with over 10 µM potencies. 
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Table 5.3. Potencies in human mGlu1 and mGlu4 of VU0474633 analogs 5.35a-5.35g. Calcium 
mobilization responses for each compound are reported as a percentage of the maximum 
glutamate response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean ± S.E.M. of at least three independent experiments with 
similar results. ---, no potentiation. ND, not determined. 
Structure Cpd # VU # 
hmGlu1 hmGlu4 
EC50 
(nM) 
%Glu
Max 
EC50 
(µM) 
%Glu
Max 
 
5.35a VU0486286 24.3 86 0.62 153 
 
5.35b VU0486388 33.0 91 1.14 163 
 
5.35c VU0486321 31.8 98 1.11 122 
 
5.35d VU0486322 54.4 86 0.32 69 
 
5.35e VU0486320 80.9 94 2.25 89 
 
5.35f VU0486323 24.1 88 0.71 97 
 
5.35g VU0486287 98.8 94 >10 18 
 
 In terms of selectivity, these new set of compounds proved to activate the human mGlu4 
receptor (Table 5.3). The higher efficacies were observed in the 3-substituted phthalimides 5.35a-
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5.35c, while the lower EC50s were observed with analogs 5.35b, 5.35e and 5.35g. Balancing these 
two factors, we chose analogs 5.35c, 5.35e and 5.35g for further analysis. Compounds 5.35c and 
5.35e are 35-fold and 28-fold selective for mGlu1 with respect to mGlu4, and 5.35g display full 
selectivity for mGlu1, being inactive at mGlu4 (EC50>10 µM, >101 fold selective). 
 
Pharmacodynamic characterization of VU0474633 analogs 
Analogs VU0486321 5.35c,VU0486320 5.35e and VU0486287 5.35g were advanced for 
further characterization. First, the cross species activity of the compounds was confirmed by 
determining their EC50 in the rat mGlu1. 5.35e (rat mGlu1 EC50 = 160 nM, 107%) and 5.35g (rat 
mGlu1 EC50 = 177 nM, 107%) are slightly less potent in the rat than in the human receptor, but 
this difference is associated to higher efficacy for the rat receptor as the concentration response 
curve are fairly similar. In the case of 5.35c, the EC50 and efficacy similar in both receptors (rat 
mGlu1 EC50 = 37 nM, 102%). 
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Figure 5.5. Concentration-response of curve for PAM activity of VU0486321 5.35c,VU0486320 
5.35e and VU0486287 5.35g in human and rat mGlu1. Calcium mobilization was used to obtain 
%GluMax values for each compound at different concentrations in the presence of a submaximal 
concentration of glutamate (EC20) in cell lines expressing human or rat mGlu1. Data represent the 
mean ± S.E.M. of at least three experiments with similar results. 
 
The selectivity of these analogs in other mGlu receptors was evaluated in fold-shift 
experiments (Fig. 5.6). None of the compounds potentiated the mGlu2 and mGlu3 receptors. In the 
mGlu5 receptor, the compounds presented weak fold-shift, with VU0486321 5.35c presenting the 
largest shift at 2.7. When selectivity against mGlu6 and mGlu7 was assessed a decrease in the 
EC50 of glutamate was observed for VU0486321 5.35c (6.7 and 7.0 fold-shift, respectively), but 
no potentiation was observed with VU0486320 5.35e and VU0486287 5.35g. Finally, the analogs 
did not potentiate mGlu8, with the exception of VU0486321 5.35c that presented a small fold-
shift of 2.3.  
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Figure 5.6. Selectivity of VU0486321 5.35c,VU0486320 5.35e and VU0486287 5.35g against 
the mGlu receptors determined in fold-shift mode. Calcium mobilization assays with rmGlu5 
were used to obtain CRCs in the presence of a fixed concentration of 10 µM of the PAMs. The 
analysis of rmGlu2,3,4,7,8 and rmGlu6 selectivity was performed with thallium flux assays. Data 
represent the mean ± S.E.M. of at least three independent experiments with similar results. 
 
 Continuing the pharmacological characterization of these mGlu1 PAMs, fold-shift 
experiments were performed with different concentrations of the compounds to evaluate their 
effect in the concentration-response curve of glutamate (Fig. 5.7). It was observed that these 
analogs behave as PAMs with different degrees of agonism at 10 µM. VU0486321 5.35c presents 
the higher agonism with 34% GluMax, followed by VU0486320 5.35e with 15% GluMax and 
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VU0486287 5.35g with 12% GluMax; in the three compounds, this agonist response is completely 
lost when using concentration of  1 µM or lower.  
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Figure 5.7. Effect of VU0486287 5.35g, VU0486320 5.35e and VU0486321 5.35c on the 
concentration-response curve of glutamate in hmGlu1. Calcium mobilization fold-shift assays 
with hmGlu1 were used to obtain glutamate CRCs in the absence and presence of 10 µM 
concentration of the PAMs. Data represent the mean ± S.E.M. of at least three independent 
experiments with similar results. 
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After the analysis of the fold-shift data using the compounds at 10 µM, we found that 
these PAMs provoked the largest fold-shift in the human mGlu1 (Table 5.4), being even higher 
than the one recorded for Ro 07-11401 (Table 4.6). VU0486321 5.35c increased the sensitivity of 
the receptor for glutamate almost 13-fold. Also, analogs 5.35c, 5.35e and 5.35g increased the 
efficacy of the receptor to 109%, a change of almost 15% with respect to the fitted value for the 
top of the concentration-response curve of glutamate alone. 
 
Table 5.4. Effect of VU0486287 5.35g, VU0486320 5.35e and VU0486321 5.35c on the 
parameters of concentration-response curve of glutamate in hmGlu1. Calcium mobilization fold-
shift assays with hmGlu1 were used to obtain glutamate CRCs in the absence and presence of 10 
µM concentration of the PAMs. Data represent the mean ± S.E.M. of at least three independent 
experiments with similar results. 
Cpd EC50 (nM) Fold-Shift Efficacy (%) 
Glutamate 535 1.0 94.7 
VU0486287 5.35g 49.9 10.7 109 
VU0486320 5.35e 65.0 8.2 109 
VU0486321 5.35c 41.4 12.9 109 
 
 We next evaluated the effect of these PAMs in representative schizophrenia related 
mutant constructs of mGlu1 (Fig. 5.8). The mutations Y632H, A683, P729T, and P1014S were 
selected for this analysis as these represent the most functionally affected receptors from the 
previously tested constructs. In this assay, VU0486320 5.35e and VU0486287 5.35g potentiated 
the mutant receptors, and at a concentration of 10 µM they show larger fold-shifts than Ro 07-
11401. VU0486321 5.35c showed more of a mixed profile, performing better than the Roche 
compound in Y632H, similar in P729T, and causing a smaller shift in the EC50 in A683E and 
P1014S; these intriguing discrepancies can be rationalized as an artifact caused by the agonistic 
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effect of VU0486321 5.35c, as raising the efficacy in the left part of the curve cause a right-shift 
in the inflexion point of concentration response curve.  
The efficacies of the compounds are also affected by the agonistic effect. The efficacies 
in Table 5.5 show how only VU0486320 5.35e manages to increase the efficacy of the mutant 
receptor in 15 to 25% of its original response. However, if the curves at lower concentration are 
analyzed it is possible to find that the 1 µM concentration gives consistently the highest efficacies 
for VU0486321 5.35c and VU0486287 5.35g, which are comparable to the values obtained for 
VU0486320 5.35e. The importance of this in vitro effect in the EC50 and efficacy of the glutamate 
response of mutant receptor can only be determined in in vivo studies.   
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Figure 5.8. Effect of the application of mGlu1 PAMs VU0486287 5.35g (panel A, D, G, J), 
VU0486320 5.35e (panel B, E, H, K) and VU0486321 5.35c (panel C, F, I, L) on the 
concentration response curve of glutamate in hmGlu1 mutant constructs. Calcium mobilization 
fold-shift assays with different mGlu1 constructs were used to obtain glutamate CRCs in the 
absence and presence of 10 µM concentration of the PAMs. Data represent the mean ± S.E.M. of 
at least three independent experiments with similar results different mGlu1 constructs 
 
 
 
 
A B C 
D E F 
G H I 
J K L 
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Table 5.5. Effect of VU0486287 5.35g, VU0486320 5.35e and VU0486321 5.35c on the 
parameters of concentration-response curve of glutamate in hmGlu1 mutant constructs. Calcium 
mobilization fold-shift assays with different mGlu1 constructs were used to obtain glutamate 
CRCs in the absence and presence of 10 µM concentration of the PAMs. Data represent the mean 
± S.E.M. of at least three independent experiments with similar results. 
Cpd 
 Mutant 
 Y632H A683E P729T P1014S 
Vehicle 
EC50 (nM) 389 417 404 390 
Efficacy (%) 53.0 49.9 45.5 56.0 
VU0486287 
EC50 (nM) 60.9 70.5 32.1 40.8 
Fold-shift 6.39 5.91 12.6 9.56 
Efficacy (%) 54.2 53.6 50.9 55.2 
VU0486320 
EC50 (nM) 58.2 81.1 60.5 38.5 
Fold-shift 6.68 5.14 6.68 10.12 
Efficacy (%) 61.0 62.5 47.3 64.0 
VU0486321 
EC50 (nM) 58.0 178 70.1 66.4 
Fold-shift 6.71 2.34 5.76 5.87 
Efficacy (%) 56.8 52.2 52.0 56.3 
 
Pharmacokinetic characterization of VU0474633 analogs 
The in vitro pharmacokinetic properties of the three pharmacologically characterized 
analogs were studied (Table 5.6). In this set VU0486287 5.35g showed high intrinsic clearance in 
human and rat liver microsomes, with the predicted hepatic clearance approximating 85% of the 
hepatic blood flow in both species. VU0486320 5.35e and VU0486321 5.35c displayed low 
intrinsic clearance in human liver microsomes, but they behaved differently in the rat microsomal 
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preparation, where VU0486320 5.35e showed low clearance and an improvement from 
VU0483605 4.77b, while VU0486321 5.35c displayed a hepatic clearance of close to 75% of rat 
hepatic blood flow.  
 
Table 5.6. In vitro pharmacokinetic properties of analogs VU0486287 5.35g, VU0486320 5.35e 
and VU0486321 5.35c. 
Parameter RO 07-11401 VU0483605 VU0486320 VU0486321 VU0486287 
Hu Clint (mL/min/kg) 262 17.2 2.90 3.10 167 
Hu Clhep (mL/min/kg) 19.4 9.46 2.54 2.70 18.6 
Rat Clint (mL/min/kg) 661 39.9 22.8 207 405 
Rat Clhep (mL/min/kg) 63.3 25.4 17.2 52.3 59.7 
P450 IC50 (µM) 
1A2 
2C9 
2D6 
3A4 
 
13 
0.6 
>30 
>30 
 
>30 
>30 
>30 
>30 
 
>30 
>30 
>30 
>30 
 
25.2 
6.45 
>30 
>30 
 
>30 
>30 
>30 
>30 
Hu fu plasma 0.014 unstable unstable 0.051 unstable 
Rat fu plasma 0.003 unstable unstable 0.030 0.030 
Rat fu brain 0.001 ND 0.001 0.005 0.346 
 
The compounds also displayed a different inhibition profile of P450 enzymes (Table 5.6). 
Similarly to picolinamide VU0483605 4.77b, VU0486287 5.35g and VU0486320 5.35e did not 
show inhibition of the evaluated cytochromes at a concentration of 30 µM. However, the 
introduction of the furan ring in the context of the 4-fluoropthalimide caused VU0486321 5.35c 
to gain inhibition for 1A2 and 2C9. While the 1A2 inhibition is weak, the effect on 2C9 inhibition 
is considerable and we would like to decrease it; the replacement of the furan ring would 
probably ameliorate this parameter.  
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The fraction unbound in plasma was evaluated for these analogs using rat and human 
plasma (Table 5.6). As it was observed previously with VU0483605 analogs, we found that 
VU0486320 5.35e was unstable in the plasma preparations, while VU0486287 5.35g was labile in 
human plasma but it allowed the determination of fraction unbound in rat plasma (fu = 0.03). 
Interestingly, VU0486321 5.35c was stable enough in both human and rat plasma, and had a 
fraction unbound of 0.05 and 0.03, respectively. These values are encouraging for a chemical 
probe designed to access the central nervous system; though, it was found that VU0486321 5.35c 
was still highly unstable after 4 hours incubations in plasma. Biotransformation analysis 
confirmed analogous metabolism to the analyzed picolinamide VU0405623 4.141, with 
hydrolysis of the phthalimide to generate the phthalamic acid regioisomers (Fig. 5.9). 
 
 
Figure 5.9. Biotransformation analysis of VU04863215.35c in rat and human plasma. Analysis of 
samples incubated for 4 hours in plasma was made by LC-MS
n
. 
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Exploration of the in vivo pharmacokinetic properties was performed in rats 
administering the compounds intravenously at a dose of 0.2 mg/kg (Table 5.7).  The highest 
clearance was observed with VU0486287 5.35g which had a half-life of five minutes. 
VU0486320 5.35e was the analog with the longest half-life (~1.5 hours), however its calculated 
plasma clearance is similar to Ro 07-11401.  VU0486321 5.35c has a 54 minute half-life, but its 
clearance is considerably slower with respect to VU0486320 5.35e and Ro 07-11401. Also, when 
the concentrations are analyzed, it was observed that VU0486321 5.35c reach plasma 
concentrations more than two times higher than VU0486320 5.35e, and more than four times 
higher than VU0486287 5.35g. 
 
Table 5.6. In vivo rat pharmacokinetic properties of analogs VU0486287 5.35g, VU0486320 
5.35e and VU0486321 5.35c. 
Parameter RO 07-11401 VU0486320 VU0486321 VU0486287 
Rat IV PK (0.2 mg/kg) 
t1/2 (min) 
MRT (min) 
Clp (mL/min/kg) 
Vss (L/kg) 
 
54 
50 
35 
1.34 
 
91.1 
53.5 
33.0 
1.76 
 
53.6 
64.1 
13.3 
0.85 
 
5.38 
7.85 
382 
3.00 
Rat IV PBL (0.25 h, 0.2 mg/kg) 
Cn plasma (ng/mL) 
Cn brain (ng/mL) 
Kp 
Kp,uu 
 
276 
81 
0.29 
0.10 
 
173 
108 
0.63 
ND 
 
200 
204 
1.02 
0.17 
 
12.5 
35.2 
2.81 
ND 
 
Concerning brain penetrance, VU0486321 5.35c  demonstrated to be the best PAM in 
this set, reaching a brain to plasma coefficient of approximately 1, with concentrations in brain 
and in plasma of 200 ng/mL (~500 nM), more than 15-fold its mGlu1 EC50. Compound 
VU0486287 5.35g achieved a high Kp but with very low concentrations of the PAM. Finally, 
VU0486320 5.35e reached lower concentrations in the brain than VU0486321 5.35c, but higher 
than Ro 07-11401 with a Kp close to 0.6. When the unbound partition coefficient is calculated, 
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compound VU0486321 still represents the best from this batch, although there is considerable 
room for improvement for this parameter. 
 
Adverse event propensity of VU0474633 analogs 
The orthosteric, amino acid agonists of group I mGlu1 allowed early efforts directed to 
understand the physiological role of these receptors; though their excitotoxicity and seizure 
liability has limited their utility.
292–297
 For example, DHPG, the dual mGlu1/5 agonist, induces 
severe epileptiform activity, and this liability was important in early mGlu5 PAM programs, as it 
was not clear if this was due to mGlu1, mGlu5 or both. Moreover, it was not clear if a pure mGlu5 
modulator would avoid this behavior.  Over the years, multiple mGlu5 PAMs, across diverse 
chemotypes, that possessed even modest ago-PAM, or pure PAMs that in vivo generated ago-
PAM metabolites, have induced epileptiform activity in slice electrophysiology as well as Racine 
scale (4+) seizures in rodents.
298–300
  This severe adverse effect has hindered the development of 
positive allosteric modulators for mGlu5.   
 Thus, with analogs 5.35c, 5.35e and 5.35g, we were poised to assess the adverse effect 
liability of mGlu1 PAM with various levels of agonism and that can penetrated the blood brain 
barrier reaching the CNS.  We decided to explore VU0486321 5.35c as we believed that if there 
was a propensity to induce an adverse event, it would be more discernible after the administration 
of the compound with higher agonism. 
In vitro extracellular electrophysiology recordings of epileptiform activity in the CA3 
region of the hippocampus were performed with either vehicle control, 10 µM VU0486321 5.35c 
or the group I agonist DHPG.   In this experiment, DHPG induced significant epileptiform 
activity in the CA3 region in the hippocampus, as it has been observed in the literature. In 
contrast, VU0486321 5.35c does not cause this form of activity in slices, despite possessing 
~35% agonism at this concentration (Fig. 5.10).  
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Figure 5.10. mGlu1 ago-PAM VU0486321 5.35c did not induce epileptiform activity in CA3 
region of the hippocampus. A. Traces of extracellular recordings from CA3 pyramidal cell body 
layer in hippocampal slices treated with 10 µM 5.35c (A1) and 50 µM DHPG (A2).  B. Average 
time courses of frequency of spontaneous activity during application of 5.35c (n = 6) and DHPG 
(n = 6), respectively.  Gray bar indicates the time point at which the data were taken to make 
statistical comparison to the control. C. Bar graphs summarizing the effects of 10 µM 17e (left) 
and 50 µM DHPG (right) on the frequency of spontaneous activity in hippocampal CA3 region. 
n.s. p = 0.36;  ** p = 0.0084; paired t-test.  
 
To corroborate this effect in vivo, the tendency of producing seizures by VU0486321 
5.35c was evaluated in C57bl/6 mice (Fig. 5.11). After administering the compound 
intraperitoneally at 100 mg/kg, the animals presented no seizures. Using satellite animals the total 
concentration in the brain was quantified, observing an exposure of 9.2 µM, a value over 280-fold 
larger than the mGlu1 PAM EC50, and over 8-fold when taking into account fraction unbound (fu 
= 0.03). VU0486320 5.35e and VU0486287 5.35g were also administered at 100 mg/kg i.p. in 
C57bl/6 mice, and no seizures were observed; although, total brain levels of 1.4 µM and 2.52 µM 
were achieved.  
250 
 
 
Figure 5.11. mGlu1 PAMs do not induce behavioral convulsions in mice. Animals were dose 
intraperitoneally mGlu5 ago-PAM VU0424465 (1 and 3 mg/kg), VU0486287 5.35g, VU0486320 
5.35e or VU0486321 5.35c at 100 mg/kg. Data represent the mean ± SEM, n = 3. 
 
As a comparison, the mGlu5 ago-PAM VU0424465 and a pure mGlu5 PAM were 
administered to mice. Historically, drug levels within 2-fold of the mGlu5 EC50 of the ago-PAM 
induced seizures in this test.
301
  For the first time, these data suggest that the epileptiform activity 
induced by the group I dual mGlu1/5 agonist is mediated by agonism at mGlu5.  This data set 
provided the basis to speculate that mGlu1 ago-PAMs will have a larger therapeutic window than 
mGlu5 ago-PAMs, and could avoid excitotoxicity and seizures.  
VU0486287 
VU0486320 
VU0486321 
VU0424465 
VU0424465 
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Summary and future directions 
 In order to find a mGlu1 PAM with better potency and pharmacokinetic properties than 
compound VU0483605 4.77b, further SAR exploration on this scaffold was made (Figure 5.12). 
First, different analogs carrying bioisosteres of the picolinamide were synthesized. From this 
library, the 5-thiazolecarboxamide 5.13 and the 2-furancarboxamide 5.2 analogs show good 
efficacy for potentiating the effect of glutamate in mGlu1, the latter the most potent of the pair 
with an EC50 of 484 nM. After the development of analogs of 5.18-5.32 with different 
substituents in the furan, it was shown that small changes in this region had a big impact in 
activity and steep SAR. This iteration led to only one active compound, the 3-methylfuran 
carboxamide 5.27 which showed a 5-fold improved potency in mGlu1, but only 12-fold 
selectivity against mGlu4. Subsequent modifications of the phthalimide proved beneficial for 
mGlu1 potency and allowed the discovery of analogs 5.35c, 5.35e, and 5.35g which have 
decreased activity for mGlu4 in comparison to VU0474633 5.27 (Fig. 5.12). 
  
 
Figure 5.12. SAR summary for the obtention of analogs 5.35c, 5.35e and 5.35g. 
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Further pharmacological characterization of PAMs VU0486321 5.35c, VU0486320 
5.35e, and VU0486287 5.35g let us to confirme that the compounds had similar EC50 in the rat 
mGlu1, stablishing cross-species activity. These compounds were screened against the other 
members of the mGlu family where they show good selectivity, with only VU0486321 5.35c 
showing some potentiation in mGlu6 and mGlu7. 
These analogs displayed a larger fold-shift in the glutamate concentration response curve 
for mGlu1, compared to Ro 0711401; probably due to their higher potency. The compounds also 
showed different degrees of agonism, with VU0486321 5.35c giving the strongest agonistic 
response (35% at 10 µM). In mutants, 5.35e and 5.35g enhanced more the glutamate response 
than Ro 07-11401, but this was not the case for 5.35c, which was probably due to its agonistic 
effect. Also the compounds induced an increase in the maximum efficacy achieved by the 
mutants, being more robust with 5.35e at 10 µM which enhances the original mutant response 15 
to 25%. 
In terms of pharmacokinetic properties, in vitro intrinsic clearance was high for 
VU0486287 5.35g, while it was moderate for VU0486321 5.35c and low for VU0486320 5.35e. 
Only VU0486321 5.35c showed moderate inhibition of CYP2C9, while the others showed no 
effect in the main P450 drug enzymes. These compounds suffered also from plasma instability as 
VU0483605 4.77b, but in the case of VU0486321 5.35c, we were able to measured plasma 
fraction unbound which was between 3 to 5%. Despite this, a disconnect was observed when 
clearance was evaluated in vivo after intravenous administration as VU0486320 5.35e and 
VU0486321 5.35c were more stable than expected, with half-lives of close to one hour. In terms 
of brain penetrance, VU0486321 5.35c performed better, achieving good brain exposure and 
brain to plasma concentration coefficient close to 1 (Fig. 5.13).   
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Figure 5.13. Summary of VU0486287 5.35g, VU0486320 5.35e and VU0486321 5.35c 
properties. 
 
The propensity to cause seizures and epileptiform activity in the CA3 region of mice 
brain was evaluated for these compounds, as non-selective group I agonists and mGlu5 ago-PAMs 
have been shown to cause this adverse events and excitotoxicity. Our mGlu1 ago-PAMs did not 
exhibited these features, arguing for a possible advantage in safety for the enhancement of mGlu1 
compared to mGlu5 activation. 
Characterization of these compounds showed that the scaffold can generate potent and 
brain penetrant compounds but there is still room for improvement in their selectivity and 
pharmacokinetic properties, especially in their plasma stability and in vivo half-life. Further SAR 
exploration in an attempt to improve these compounds and produce a better in vivo chemical 
probe is outlined in the next chapter.   
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EXPERIMENTAL METHODS 
 
General chemical synthesis and characterization  
All reactions were carried out employing standard chemical techniques under inert 
atmosphere. All reagents and solvents were commercial grade and purified prior to use when 
necessary. Solvents used for extraction, washing, and chromatography were HPLC grade. 
Analytical thin layer chromatography was performed on 250 μm silica gel glass backed plates 
from Sorbent Technologies. Visualization was accomplished with UV light, and/or the use of 
iodine or ninhydrin solution followed by heating. Analytical HPLC was performed on an Agilent 
1200 LCMS with UV detection at 215 and 254 nm along with ELSD detection and electrospray 
ionization, with all final compounds showing >95% purity and a parent mass ion consistent with 
the desired structure. Low resolution mass spectra were obtained on an Agilent 6130 mass 
spectrometer with electrospray ionization source.  MS parameters were as follows:  fragmentor:  
100, capillary voltage:  3000 V, nebulizer pressure:  40 psig, drying gas flow:  11 L/min, drying 
gas temperature:  350° C.  Samples were introduced via an Agilent 1200 HPLC comprised of a 
degasser, G1312A binary pump, G1367B HP-ALS, G1316A TCC, G1315D DAD, and a Varian 
380 ELSD.  UV absorption was generally observed at 215 nm and 254 nm with a 4 nm 
bandwidth.  Column:  Thermo Accucore C18, 2.1 x 30 mm, 2.6 µm. Gradient conditions:  7% to 
95% CH3CN in H2O (0.1% TFA) over 1.6 min, hold at 95% CH3CN for 0.35 min, 1.5 mL/min, 
45° C. Flash column chromatography was performed on a Teledyne ISCO Combiflash Rf system. 
Preparative purification of library compounds was performed on a Gilson 215 preparative LC 
system. Column: Thermo Accucore C18, 2.1 x 30 mm, 2.6 µm.  Gradients condition: variable, 
CH3CN in H2O (0.1% TFA) over 4 minutes, hold at 95% CH3CN for 0.35 min, 50 mL/min. 
Purity for all final compounds was >95%, and each showed a parent mass ion consistent with the 
desired structure in low resolution LC-MS. 
1
H and 
13
C NMR spectra were recorded on Bruker 
DRX-400 (400 MHz) instrument. Chemical shifts are reported in ppm relative to residual solvent 
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peaks as an internal standard at the following chemical shifts (
1
H and 
13
C respectively): 7.26 and 
77.0 ppm for CDCl3; 2.50 and 39.52 ppm for DMSO-d6, 3.31 and 49.2 ppm for CD3OD. Data are 
reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q 
= quartet, dd = doublet of doublets, br = broad, m = multiplet), coupling constant (Hz).  
 
General synthesis of N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)amides (5.1-
5.32). In a vial, 0.088 mmol (1.2 equiv.) of the carboxylic acid were added and dissolved in 0.5 
mL mixture of DCM:DIEA (9:1), then 41 mg (0.110 mmol, 1.5 equiv.) of HATU were added. 
The mixture was stirred for 10 minutes, and 20 mg (0.073 mmol, 1.0 equiv.) of 4.12 dissolved in 
0.5 mL of DCM:DIEA (9:1) were added, followed by 3 drops of DMF. The reaction was stirred 
for 24 hours at room temperature. After this time, the reaction was quenched with the addition of 
water, and was worked up by extraction with DCM (2 mL, thrice). The organic phase was filtered 
through a phase separator, volatiles were evaporated, the crude product was dissolved in DMSO 
and purified by preparative HPLC.  
 
N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide 
(5.27). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.14 (1H, s), 8.06 (1H, d, J=2.4 
Hz), 7.97 (2H, m), 7.81 (2H, m), 7.64 (1H, dd, J=8.6 Hz, J=2.4 Hz), 7.40 (1H, d, J=1.5 Hz), 7.32 
(1H, d, J=8.6 Hz), 6.43 (1H, d, J=1.5 Hz), 2.47 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 
166.7, 157.1, 142.8, 141.4, 139.6, 134.4, 133.7, 131.8, 130.8, 129.9, 124.8, 123.9, 120.8, 118.3, 
116.0, 11.2. HRMS (TOF, ES+) C20H14ClN2O4 [M+H]+ calc. mass 381.0642, found 381.0644. 
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N-(2-Chloro-4-nitrophenyl)-3-methylfuran-2-carboxamide (5.33). In a microwave 
vial, 912 mg (5.28 mmol, 1.2 equiv.) 2-chloro-4-nitroaniline were added and dissolved in 20 mL 
of DCE:DIEA (9:1), followed by addition of 500 µL (4.40 mmol, 1.0 equiv.) of the 3-
methylfurancarbonyl chloride. The reaction was heated in the microwave at 120 °C for 30 
minutes. The reaction was cooled to room temperature and water was added, causing the 
precipitation of the product. The crude was filtered in vacuo and titrated with methanol to give a 
cream colored solid (1195 mg, 97% yield). 
1
H-NMR (400.1 MHz, DMSO-d
6) δ (ppm): 10.71 
(1H, s), 8.27 (1H, d, J=2.2 Hz), 8.14 (1H, d, J=9.1 Hz), 7.99 (1H, dd, J=9.1 Hz, J=2.2 Hz), 7.88 
(1H, d, J=1.5 Hz), 6.66 (1H, d, J=1.5 Hz), 2.37 (3H, s). 
13
CNMR (100.6 MHz, DMSO-d
6) δ 
(ppm): 158.1, 144.9, 144.3, 141.9, 141.4, 130.3, 127.7, 126.9, 121.7, 119.0, 116.4, 11.5. HRMS 
(TOF, ES+) C12H9ClN2O4 [M+] calc. mass 280.0251, found 280.0254. 
 
 
N-(4-Amino-2-chlorophenyl)-3-methylfuran-2-carboxamide (5.34). In a flask, 480 mg 
(1.71 mmol, 1.0 equiv.) of 5.33 were suspended in dioxane. The suspension was cold in an ice 
bath and purged with argon. A previously prepared solution of tin(II) chloride (1.45 g, 7.70 
mmol, 4.5 equiv.) in concentrated hydrochloric acid (5M concentration of SnCl2) was added 
dropwise to the suspension. After 2 hour of stirring at room temperature, the reaction was 
neutralized carefully with aqueous potassium carbonate 20%, filtered and extracted with diethyl 
ether. The organic phase was dried with magnesium sulfate, filtered and the volatiles eliminated 
in vacuo to yield a cream solid (410 mg, 96% yield). 
1
H-NMR (400.1 MHz, DMSO-d
6) δ (ppm): 
9.87 (1H, s), 7.76 (1H, d, J=1.6 Hz), 7.74 (1H, d, J=2.3 Hz), 7.41 (1H, dd, J=8.7 Hz, J=2.3 Hz), 
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6.82 (1H, d, J=8.7 Hz), 6.58 (1H, d, J=1.6 Hz), 5.51 (2H, br), 2.32 (3H, s). 
13
CNMR (100.6 MHz, 
DMSO-d
6) δ (ppm): 157.5, 143.8, 142.3, 139.8, 129.9, 127.7, 121.8, 121.2, 117.8, 116.4, 116.0, 
11.4. HRMS (TOF, ES+) C12H11ClN2O2 [M+] calc. mass 250.0509, found 250.0513. 
 
General synthesis of substituted N-acyl N-(4-aminophenyl)-3-methylfuran-2-
carboxamides (5.35a-g). In a vial, (30 mg, 0.12 mmol, 1.0 equiv.) of the aniline 5.34 and (0.18 
mmol, 1.5 equiv,) of the phthalic anhydride were added and dissolved in 1 mL of acetic acid. The 
mixture was heated at 110 °C while stirring for 4 hours. After this time, volatiles were 
evaporated, the crude product was dissolved in DMSO and resolved by preparative HPLC.  
 
 
N-(3-Chloro-4-(4-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-
carboxamide (5.35a). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.15 (1H, s), 8.05 
(1H, d, J=2.4 Hz), 7.79 (1H, d, J=7.4 Hz), 7.65 (2H,m), 7.55 (1H, d, J=7.7 Hz), 7.39 (1H, d, 
J=1.5 Hz), 7.29 (1H, d, J=8.6 Hz), 6.43 (1H, d, J=1.6 Hz), 2.47 (3H, s), 2.46 (3H, s). 
13
CNMR 
(100.6 MHz, CDCl3) δ (ppm): 167.5, 166.8, 157.1, 142.8, 141.4, 139.5, 138.6, 136.7, 133.9, 
133.8, 132.3, 130.8, 129.9, 128.6, 125.0, 121.5, 120.8, 118.2, 116.0, 17.7, 11.2. HRMS (TOF, 
ES+) C21H16ClN2O4 [M+H]+ calc. mass 395.0799, found 395.0798. 
 
 
N-(3-Chloro-4-(4-chloro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-
carboxamide (5.35b). Cream powder 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.16 (1H, s), 8.06 
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(1H, d, J=2.3 Hz), 7.88 (1H, m) 7.74 (2H, m), 7.63 (1H, dd, J=8.6 Hz, J=2.3 Hz), 7.39 (1H, d, 
J=1.2 Hz), 7.29 (1H, d, J=8.6 Hz), 6.42 (1H, d, J=1.2 Hz), 2.46 (3H, s). 
13
CNMR (100.6 MHz, 
CDCl3) δ (ppm): 165.2, 164.3, 157.2, 142.9, 141.4, 139.8, 136.1, 135.2, 133.9, 133.7, 132.0, 
130.7, 130.0, 127.6, 124.4, 122.3, 120.8, 118.3, 116.1, 11.2. HRMS (TOF, ES+) C20H13Cl2N2O4 
[M+H]+ calc. mass 415.0252, found 415.0254. 
 
 
N-(3-Chloro-4-(4-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-
carboxamide (5.35c). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.16 (1H, s), 8.06 
(1H, d, J=2.3 Hz), 7.80 (2H, m), 7.65 (1H, dd, J=8.6 Hz, J=2.4 Hz), 7.49 (1H, m), 7.39 (1H, d, 
J=1.4 Hz), 7.30 (1H, d, J=8.6 Hz), 6.42 (1H, d, J=1.4 Hz), 2.46 (3H, s). 
13
CNMR (100.6 MHz, 
CDCl3) δ (ppm): 165.5, 163.3, 157.9 (
1
JCF, d, J=266 Hz), 157.2, 142.9, 142.7, 141.4, 139.8, 137.0 
(
3
JCF, d, J=7.6 Hz), 133.8 ((
2
JCF, d, J=22.6 Hz), 130.8, 130.0, 124.3, 122.7 (
2
JCF, d, J=19.6 Hz), 
120.8, 120.1 (
4
JCF, d, J=3.2 Hz), 118.7, 118.3,116.1, 11.2. HRMS (TOF, ES+) C20H13ClFN2O4 
[M+H]+ calc. mass 399.0548, found 399.0547. 
 
 
N-(3-Chloro-4-(5-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-
carboxamide (5.35d). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.15 (1H, s), 8.05 
(1H, d, J=2.3 Hz), 7.84 (1H, d, J=7.7 Hz), 7.77 (1H, d, J=7.4 Hz), 7.62 (1H, dd, J=8.6 Hz, J=2.4 
Hz), 7.59 (1H, d, J=7.7 Hz), 7.38 (1H, d, J=1.5 Hz), 7.30 (1H, d, J=8.6 Hz), 6.42 (1H, d, J=1.5 
Hz), 2.56 (3H, s), 2.46 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 166.9, 166.8, 157.1, 
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145.8, 142.8, 141.4, 139.6, 135.0, 133.8, 132.2, 130.8, 129.9, 129.2, 124.9, 124.4, 123.8, 120.8, 
118.3, 116.0, 22.0, 11.2. HRMS (TOF, ES+) C21H16ClN2O4 [M+H]+ calc. mass 395.0799, found 
395.0798.  
 
 
N-(3-Chloro-4-(5-chloro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-
carboxamide (5.35e). Cream powder. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.16 (1H, s), 8.06 
(1H, d, J=2.3 Hz), 7.94 (1H, d, J=1.7 Hz), 7.90 (1H, d, J=8.0 Hz), 7.77 (1H, dd, J=8.0 Hz, J=1.7 
Hz), 7.63 (1H, dd, J=8.6 Hz, J=2.3 Hz), 7.40 (1H, d, J=1.4 Hz), 7.30 (1H, d, J=8.6 Hz), 6.43 (1H, 
d, J=1.4 Hz), 2.46 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 165.8, 165.4, 157.1, 142.9, 
141.4, 141.2, 139.8, 134.5, 133.6, 133.5, 130.7, 130.0, 129.8, 125.1, 124.4, 124.3, 120.8, 118.3, 
116.1, 11.2. HRMS (TOF, ES+) C20H13Cl2N2O4 [M+H]+ calc. mass 415.0252, found 415.0251. 
 
 
N-(3-Chloro-4-(5-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-
carboxamide (5.35f). Cream powder.
 1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.16 (1H, s), 8.06 
(1H, d, J=2.3 Hz), 7.97 (1H, dd, J=8.2 Hz, J=4.5 Hz), 7.64 (2H, m), 7.47 (1H, td, J=8.5 Hz, J=2.2 
Hz), 7.40 (1H, d, J=1.5 Hz), 7.30 (1H, d, J=8.6 Hz), 6.43 (1H, d, J=1.5 Hz), 2.47 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 165.6, 165.3, 157.1, 142.9, 141.4, 139.8, 134.6 (
3
JCF, d, 
J=9.7 Hz), 133.7, 130.7, 130.0, 127.6 (
4
JCF, d, J=2.9 Hz), 126.3 (
3
JCF, d, J=9.1 Hz), 124.5, 121.5 
(
2
JCF, d, J=22.9 Hz), 120.8, 118.3, 116.1, 111.6 (
2
JCF, d, J=25.0 Hz), 11.2. HRMS (TOF, ES+) 
C20H13ClFN2O4 [M+H]+ calc. mass 399.0548, found 399.0546. 
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N-(3-chloro-4-(1,3-dioxo-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin2-yl)phenyl)-3-
methylfuran-2-carboxamide (5.35 g). Cream powder. 
1
H-NMR (400.1 MHz, DMSO-d
6) δ 
(ppm): 10.47 (1H, s), 9.31 (1H, s), 9.21 (1H, d, J=4.8 Hz), 8.21 (1H, d, J=2.2 Hz), 8.06 (1H, d, 
J=4.8 Hz), 7.92 (1H, dd, J=8.7 Hz, J=2.2 Hz), 7.86 (1H, d, J=1.4 Hz), 7.56 (1H, d, J=8.7 Hz),  
6.65 (1H, d, J=1.4 Hz), 2.37 (1H, s). 
13
CNMR (100.6 MHz, DMSO-d
6) δ (ppm): 166.2, 165.9, 
158.0, 156.8, 145.1, 144.5, 141.7, 141.4, 139.3, 132.3, 131.5, 129.4, 125.9, 124.1, 121.1, 120.0, 
117.8, 116.3, 11.5. HRMS (TOF, ES+) C19H12ClN3O4 [M]+ calc. mass 381.0516, found 
381.0519. 
 
Molecular pharmacology 
Molecular pharmacology experiments to characterize the mGlu1 PAMs were performed 
following the procedures described in chapter 3 and 4. 
 
Pharmacokinetic characterization 
The in vitro DMPK assays, including those assessing hepatic microsomal intrinsic 
clearance (Clint), cytochrome P450 inhibition, plasma protein binding (PPB) and brain 
homogenate binding (BHB) were performed as described previously.
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 The experimental 
procedures for the pharmacokinetic characterization of the compounds are described in chapter 3.  
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Evaluation for propensity for seizures 
Extracellular recordings of epileptiform activity from CA3 region of the 
hippocampus in vitro. Male C57BL/6 mice (69–75 days old, JAX) were deeply anaesthetized 
with isoflurane and decapitated. The brains were quickly removed from the skull and submerged 
in oxygenated (95% O2/5% CO2), ice-cold cutting solution composed of (in mM): 220 glucose, 
2.5 KCl, 8 MgSO4, 0.5 CaCl2, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose. Coronal brain 
slices (400 µm) containing the hippocampus were cut using a Leica VT1200S  microtome (Leica 
Microsystems Inc.), incubated in artificial cerebrospinal fluid (ACSF) at 32°C for 30 minutes, 
and then maintained at room temperature for at least 30 minutes until transferred to a recording 
chamber.   The chamber was continuously perfused with oxygenated ACSF at 32°C. The ACSF 
contained (in mM): 126 NaCl, 2.5 KCl, 2.0 CaCl2, 1.3 MgSO4, 1.25 NaH2PO4, 26 NaHCO3, and 
10 D-glucose. Spontaneous field epileptiform activity was recorded from hippocampal CA3 
regions using a grass patch pipette filled with ACSF and placed in the CA3 pyramidal cell body 
layer.  The electrophysiological signal was acquired using a MultiClamp 700B amplifier coupled 
with pClamp10 software (Molecular Devices). Data were analyzed offline using MiniAnalysis 
(Synaptosoft Inc.). Compound stock solutions were made using DMSO and diluted to the 
appropriate concentration in ACSF with the final DMSO concentration of 0.1%.  All compounds 
were bath applied.  
Behavioral manifestations of seizure activity. Mice received a single intraperitoneal 
(i.p.) administration of either mGlu5 ago-PAM VU0424465 (1 or 3 mg/kg) or mGlu1 ago-PAMs 
5.35c, 5.35e, or 5.35g (100 mg/kg) at a volume of 10 ml/kg. Compounds were formulated in 10% 
Tween 80 (pH 7.0). Animals were monitored continuously and scored for behavioral 
manifestations of seizure activity at 5, 10, 15, 30, 60, 120 and 180 minutes. Behavioral 
manifestations of seizures were scored using a modified Racine scoring system.
301,302
 Briefly, a 
score of 0 represents no behavior alterations; score 1, immobility, mouth and facial movements, 
or facial clonus; score 2, head nodding, tail extension; score 3, forelimb clonus, repetitive 
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movements; score 4, rearing, and tonic clonic seizures; and score 5, continuous rearing and 
falling, climbing, running, severe generalized tonic clonic seizure. Mice were then euthanized and 
brains removed and processed to measure compound exposure levels. 
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CHAPTER VI 
 
LEAD OPTIMIZATION OF VU0486321 SERIES: DISCOVERY OF VU0487351 AND 
VU6004909, MGLU1 PAMS WITH AN IMPROVED PHARMACOKINETIC PROFILE 
 
Upon the discovery and characterization of VU0486321 5.35c, it was found that the 
compound fulfills our requisites of potency for a chemical probe and displays enhanced plasma 
stability compared to VU0483605 4.77b, with a half-life in rat close to one hour; however, this 
mGlu1 PAM still showed activity in human mGlu4 and can be improved in terms of selectivity 
and in vivo plasmatic clearance. Therefore, in order to improve these properties, we decided to 
further explore the SAR around this scaffold making chemical modifications in the following 
three regions of the molecule: the phthalimide, the central phenyl ring and the furan ring.  
 
SAR exploration for the replacement of the furan ring 
 
Screening of different methyl substituted rings as replacements of the furan  
 We started by exploring replacements of the furan, this time employing rings with a 
methyl substitution analogous to the one in VU0486321 5.35c. We wanted to explore different 
pyrrole and thiophene regioisomers, as well as members of the azole family. Synthetically, these 
compounds were accessed by amide coupling of intermediate 4.12 and different methyl 
substituted heteroaromatic carboxylic acids (Scheme 6.1) 
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Scheme 6.1. Synthesis of analogs 6.1-6.14. 
  
 The compounds were evaluated in our human mGlu1 expressing cell line in a 
concentration-response study to obtain their EC50 for PAM activity. From this batch, we observed 
that the different pyrroles 6.2-6.4 had weak activity as PAMs. The most active pyrrole 6.2 was the 
direct comparator to VU0474633 5.27, with potency around 3.4 µM and good efficacy of 86% 
GluMax; while the N-methylpyrrole 6.4 EC50 was 5.2 µM and 6.3 showed over 10 µM potency. 
Alkyl derivatives, N-methyl proline analogs 6.5 and 6.6 were not active. In the case of the 
thiophenes, the regioisomers tested showed similar potency for mGlu1 potentiation, with the 3-
thiophenecarboxamide 6.8 being more active than the 2-thiophene analog 6.7, displaying the 
inverse tendency from the pyrrole data.  
In the azole family, the nitrogenated rings 6.9-6.10 maintained mGlu1 PAM activity. The 
N-methylimidazole 6.9 was potent (EC50 = 297 nM) but it showed only partial PAM efficacy, 
while the pyrazole 6.10 was completely efficacious but with a potency of 1.2 µM. In the case of 
the oxazoles 6.11-6.12 and thiazoles 6.13-6.14, an important difference in activity was observed 
for the assessed regioisomers. In both groups the most active compounds were the constitutional 
isomers 6.12 and 6.14 with the amide in position 4, while 5-carboxamide analogs 6.11 and 6.13 
were inactive. The oxazole 6.12 was a full PAM with EC50 of 1.30 µM, while the thiazole 6.14 
was found to be the most active replacement, with better potency than the original furan 
compound VU0474633 5.27. 
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Table 6.1. Structures of the amide library analogs 6.1-6.14 and associated PAM activity from the 
single point screening at 10 µM in human mGlu1. Calcium mobilization responses for each 
compound are reported as a percentage of the maximum glutamate response. VU number denotes 
the compound identifier assigned by Vanderbilt University. Data represent the mean ± S.E.M. of 
at least three replicate experiments with similar results. 
Structure Cpd # VU # 
hmGlu1 
EC50 (µM) %GluMax 
 
6.1 VU6003723 3.64 71 
 
6.2 VU6002198 3.42 86 
 
6.3 VU0487504 >10 59 
 
6.4 VU0487386 5.26 95 
 
6.5 VU517519 >10 31 
 
6.6 VU0487622 >10 26 
 
6.7 VU6002203 2.71 96 
 
6.8 VU6002202 1.51 105 
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6.9 VU0487384 0.30 63 
 
6.10 VU6002197 1.24 107 
 
6.11 VU0487564 >10 44 
 
6.12 VU0517529 1.30 99 
 
6.13 VU0487388 >10 40 
 
6.14 VU0487563 0.063 97 
 
Modification of the phthalimide in the context of methyl-substituted furan replacements in 6.9, 
6.10, 6.12 and 6.14 
From this group of compounds, the rings in 6.9, 6.10, 6.12 and 6.14 were selected for 
further study, as they have shown to have potencies below 1.5 µM and they would likely 
engender molecules with less propensity for P450 inhibition with respect to the furan. Thus, a 
matrix library with two points of diversity was planned, to explore the effect of phthalimide 
substitutions in the context of these heteroaromatic rings. These compounds were prepared using 
a three-step process similarly to the synthesis of VU0483605 4.77b (Scheme 6.2). Starting with 
the nitroaniline 4.66, an amide coupling reaction with the selected acids was carried under 
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microwave heating and using HATU. Anilines 6.19-6.22 were obtained through reduction of 
6.15-6.18 with tin(II) chloride, and then condensed with different phthalic anhydrides to prepare 
the final analogs 6.23a-6.26g. 
 
Scheme 6.2. Synthesis of matrix library analogs 6.23a-6.26g to assess alternatives to the 3-
methylfuran carboxamide in VU0486321 5.35c. 
 
 The compounds were evaluated for mGlu1 and mGlu4 PAM activity in calcium 
mobilization assays. Phthalimide substitution in the N-methylimidazole analogs 6.23a-6.23g 
showed a beneficial effect when it occurred at the 3 position, 6.23a-6.23c, maintaining good 
potency and increasing significantly the efficacy of the glutamate response in the case of the 3-
methyl (6.23a) and 3-chloro (6.23b) substitution. The 3-fluoro compound (6.23c) showed better 
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efficacy, but a 2-fold decrease in potency. In sharp contrast, the 4-substituted 6.23d-6.23f and the 
4-aza 6.23g phthalimides render very weak PAMs. Despite the increase in efficacy and relative 
good standing potency of compounds around this scaffold, the imidazole moiety did not 
demonstrate improved selectivity over mGlu4, as these compounds were less selective than 
VU0486321 5.35c with fold-selectivities between 1.6 and 5.8. 
 
Table 6.2. Potencies in human mGlu1 and mGlu4 of compounds derived from the matrix library 
6.23a-6.26g. Calcium mobilization responses for each compound are reported as a percentage of 
the maximum glutamate response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean ± S.E.M. of at least three independent 
experiments with similar results. ---, no potentiation. ND, not determined. 
Structure Cpd # VU # 
hmGlu1 hmGlu4 
EC50 
(µM) 
%Glu
Max 
EC50 
(µM) 
%Glu
Max 
 
6.23a VU6002211 0.25 108 0.60 124 
 
6.23b VU6002212 0.27 103 1.57 145 
 
6.23c VU6002213 0.67 87 1.07 63 
 
6.23d VU6002214 >10 30 0.51 32 
 
6.23e VU6002215 >10 30 >10 30 
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6.23f VU6002216 >10 43 1.09 42 
 
6.23g VU6002217 >10 44 >10 - 
 
6.24a VU6002218 0.56 106 2.75 133 
 
6.24b VU6002219 0.86 113 3.38 117 
 
6.24c VU6002220 0.63 106 6.20 59 
 
6.24d VU6002221 4.94 110 >10 - 
 
6.24e VU6002222 >10 94 >10 - 
 
6.24f VU6002223 0.60 106 >10 - 
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6.24g VU6002232 >10 37 >10 27 
 
6.25a VU6001777 0.041 98 0.198 75 
 
6.25b VU6001778 0.054 104 0.41 67 
 
6.25c VU6001779 0.14 93 0.64 36 
 
6.25d VU6001780 0.47 91 0.519 39 
 
6.25e VU6001781 1.29 112 0.983 24 
 
6.25f VU6001782 0.24 98 0.397 39 
 
6.25g VU6001783 1.70 91 2.53 45 
 
6.26a VU517592 0.022 86 1.12 161 
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6.26b VU517526 0.051 91 1.98 169 
 
6.26c VU517527 0.063 98 0.31 52 
 
6.26d VU517621 0.23 104 1.41 75 
 
6.26e VU517472 1.37 121 >10 59 
 
6.26f VU517463 0.19 111 0.47 52 
 
6.26g VU517622 0.19 98 >10 - 
 
In the context of the pyrazole, a similar effect to the imidazole library was observed, 
where 3-substituted phthalimides 6.24a-6.24c managed to increase the potency and maintain 
efficacy for the target, with the 3-methyl substituent (6.24a) engendering the most active 
molecule in the family (EC50 = 560 nM). A decrease in activity was observed for the 4-subsituted 
analogs 6.24d-6.24g, except for 6.24f, where the 4-fuoro phthalimide was actually beneficial 
(EC50 = 600 nM) and increased mGlu1 activity with respect to the parent compound. When 
compounds were evaluated against mGlu4, they demonstrated to be preferential for mGlu1; 
however, their selectivity was not as high as desired. In the 3-substituted phthalimide group 
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6.24a-6.24c,  it was found that the analogs were between 4.9 and 9.8 times more potent in mGlu1 
than mGlu4, and in the case of the 4-fluoro 6.24f selectivity was over 16-fold. So, despite the 
pyrazole ring demonstrated to impart more selectivity than the imidazole towards mGlu1, it still 
does not represent a good replacement for the furan. 
The oxazole analogs 6.25a-6.25g showed a similar tendency to the one observed in the 
pyrazole and the imidazole, were 3-substitutions (6.25a-6.25c) increased mGlu1 activity. But in 
this case, the improvement in potency was dramatic, achieving EC50 values even 30-fold smaller 
with respect to the parent compound in the case of 3-methyl 6.25a (EC50 = 41 nM vs. 6.12 EC50 = 
1.3 µM), 24-fold for 3-chloro 6.25b and 9-fold for 3-fluoro 6.25c.  In contrast to the other rings, 
the 4-methyl 6.25d and 4-fluoro 6.25f also showed an improvement in potency (2.8 and 5.4-folds, 
respectively) but it was less than what was observed in the 3-substituted phthalimides; the other 
4-substituted analogs, 6.25e and 6.25g maintained potency values close to the parent compound 
EC50. Despite the improvement in mGlu1 activity, none of these compounds showed a significant 
improvement in terms of selectivity. Most analogs showed preferential activity for mGlu1 with 
fold-selectivities between 4.6 and 7.4, where the more potent 3-substituted analogs 6.25a-6.25c 
had the lower relative activity in mGlu4. 
The thiazole ring generated the most potent compound in the previous iteration and, as in 
the SAR described above, the 3-substitutions (6.26a-6.26c) in the phthalimide were beneficial for 
mGlu1 activity. Similar to the other five-member rings, the 3-methyl 6.26a was the more potent 
analog in this family, being slightly more potent than VU0486321 5.35c. 4-substituted analogs 
6.26d-6.26f showed a variable decrease in mGlu1 PAM activity. While the 4-chloro 6.26e showed 
a substantial loss in potency (22 fold) with respect to the parent compound 6.14, the other analogs 
maintained considerable potency with EC50s values around 200 nM. All compounds in the family 
showed preferential activity for mGlu1. The 4-substituted analogs 6.26d-6.26f showed little 
selectivity being only 2.5-6.1 times preferent for mGlu1. The 3-substituted phthalimides 6.26a-
6.26c showed different degrees of mGlu4 activity, 3-fluoro 6.26c was the less selective with only 
273 
 
a 5-fold preference for mGlu1. Analogs 6.26a and 6.26b demonstrated 51 and 39-fold selectivity 
for mGlu1, a difference driven by their high potency in mGlu1 as these analogs also activated the 
mGlu4 receptor with EC50s between 1 and 2 µM. These compounds represented an improvement 
in selectivity in terms of potency with respect to VU0486321 5.35c that is 35-fold selective for 
mGlu1; however, 6.26a and 6.26b displayed very high efficacy for mGlu4 activation, being close 
to 170% of the maximal glutamate response, a factor that halted further study of this compounds. 
Analog 4-aza 6.26g showed good selectivity; but, despite a relatively good potency of 190 nM, 
this analog is almost 6-fold less potent than VU0486321 5.35c. 
 
Exploration of different heteroaromatic rings in the context of a methylene linker 
 To evaluate the importance of the carbonyl linker in the furan carboxamide, a small 
library of compounds with a methylene linker was synthesized. These analogs were accessed by 
using aniline intermediate 4.12 and different aldehydes in a reductive amination reaction with 
polymer supported cyanoborohydride (Scheme 6.3). 
  
 
Scheme 6.3. Synthesis of analogs 6.27-6.33 to assess the effect of the removal of the carbonyl 
group in the furancarboxamide side of VU0486321 scaffold. 
 
 Different five member ring aldehydes were used to obtain this library, including direct 
comparators of active compounds, such as 6.27 which is the reduced version of VU0474633 5.27. 
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Evaluation of this library at a single concentration of 10 µM showed that the amide is essential 
for activity as none of the synthesized compounds could enhance the glutamate’s mGlu1 response. 
 
SAR exploration in the central phenyl ring 
 
Study of substituents in the central phenyl ring. 
 As most of the previous work exploring VU0483605 4.77b and VU0486321 5.35c 
scaffolds focused in the eastern amide and modifications of the phthalimide, it was decided to 
explore the structure-activity relationships in the central phenyl ring (Fig. 6.1). We proposed to 
study the effect of different substituents on the phenyl ring, as well as replacing it with 
naphthalene, pyridine and pyrimidine moieties.  
 
 
Figure 6.1. SAR exploration around the central phenyl ring of the VU0486321 scaffold. 
  
The obtention of the necessary compounds to assess the effect of the modifications of the 
phenyl ring was performed in a three-step synthetic route. Similarly to the previously described in 
scheme 5.3, the route involves the amide coupling of nitroanilines 6.34a-6.34l with acyl chloride 
5.32, reduction of the nitro group 6.35a-6.35l and condensation with phthalic anhydrides in 
refluxing acetic acid (Scheme 6.4A). For this matrix library, only the unsubstituted and 3-
substituted phthalimides were prepared, as these are the patterns that usually presented better 
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mGlu1 activity. It was possible to synthesize most of the examples this way, with the exception of 
the methoxy analogs 6.37m1-6.37m4, pyridines 6.37n1-6.37n4 and pyrimidines 6.37o1-6.37o4 
where a different approach deemed necessary. For these latter analogs, the process started with 
the DMAP catalyzed Boc protection of the corresponding 4-nitroaniline 6.38m-6.38o and then 
the reduction of nitro 6.39m-6.39o group with hydrogen and palladium on carbon to produce 
intermediates 6.40m-6.40o (Scheme 6.4B). The bis Boc protected 4-aminoanilines 6.40m-6.40o 
had the advantage that the unprotected amino group now became more nucleophilic than its 
counterpart in the 4-nitroanilines; this change in reactivity allowed the amide coupling with the 
acyl chloride 5.32 to obtain intermediates 6.41m-6.41o without heating in the microwave. Then, 
furancarboxamides 6.41m-6.41o were Boc deprotected with TFA at room temperature, and the 
obtained anilines were condensed with phthalic anhydrides in acetic acid at reflux. 
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Scheme 6.4. Synthesis of  analogs 6.37a-6.37o to assess the effect of modifications on the central 
phenyl ring of VU0486321 scaffold. For each example of modification on the central phenyl ring 
phthalic anhydride, 3-methylphthalic anhydride, 3-chlorophthalic anhydride and 3-fluorophthalic 
anhydride were used. 
 
The activity of the compounds was evaluated in the human mGlu1 and human mGlu4 
receptors to assess the effect of the modifications in potency on target and selectivity (Table 6.3). 
The removal of the chlorines (6.37a1-6.37a4) from the central ring was beneficial or maintained 
A 
B 
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mGlu1 PAM activity. The naked phthalimide 6.37a1 displayed excellent selectivity with no 
observable activity in mGlu4; however, further exploration of the product was halted due to its 
low solubility in water and in our common solvent systems. The other analogs 6.37a2-6.37a4 
showed moderate selectivity, being 8.6 to 21.7 times more active in mGlu1 than mGlu4, where 
they presented low efficacy values (34%-62% PHCCCMax). 
 
Table 6.3. Potencies in human mGlu1 and mGlu4 of compounds derived from the matrix library 
with modifications in the central phenyl ring, 6.37a, 6.37b, 6.37c, 6.37d and 6.37m. Calcium 
mobilization responses for each compound are reported as a percentage of the maximum 
glutamate response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean ± S.E.M. of at least three independent experiments with 
similar results. ---, no potentiation. ND, not determined. 
Structure Cpd # VU # 
hmGlu1 hmGlu4 
EC50 
(µM) 
%Glu
Max 
EC50 
(µM) 
%Glu
Max 
 
6.37a1 VU0484010 0.0430 81 >10.0 --- 
 
6.37a2 VU0487230 0.0161 108 0.349 62 
 
6.37a3 VU0487372 0.0300 101 0.483 35 
 
6.37a4 VU0487251 0.0442 96 0.382 34 
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6.37b1 VU6001769 0.0888 105 0.885 75 
 
6.37b2 VU6001770 0.0213 100 0.422 122 
 
6.37b3 VU6001771 0.0493 117 1.01 127 
 
6.37b4 VU6001772 0.0490 95 1.10 86 
 
6.37c1 VU6001773 0.0223 101 0.265 65 
 
6.37c2 VU6001774 0.0261 107 0.287 102 
 
6.37c3 VU6001775 0.0277 100 0.264 93 
 
6.37c4 VU601776 0.0350 104 0.674 78 
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6.37d1 VU0604490 0.130 108 6.66 86 
 
6.37d2 VU0604389 0.533 117 5.76 109 
 
6.37d3 VU0604390 0.106 105 2.47 120 
 
6.37d4 VU0604641 0.155 110 2.87 80 
 
6.37m1 VU6002224 0.0461 96 1.18 50 
 
6.37m2 VU6002225 0.0490 94 0.882 107 
 
6.37m3 VU6002226 0.0179 93 0.647 103 
 
6.37m4 VU6002224 0.144 103 1.93 73 
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 The exchange of the chlorine for a methyl or a fluorine in the 2-position of the central 
ring proved to be beneficial, as analogs 6.37b1-6.37c4 maintained excellent potencies in mGlu1 
with efficacies around 100% of GluMax. In terms of selectivity, both replacements generated 
preferential compounds for mGlu1; however, these were more efficacious than the deschloro 
analogs 6.37a1-6.37a4. Reduced selectivity was obtained with the fluoro analogs 6.37c1-6.37c4 
as most of them had only 10-fold selectivity versus mGlu4, with 6.37c4 displaying 19 times better 
potency in mGlu1 with respect to mGlu4. The methyl group 6.37b engendered more selective 
compounds with fold-selectivities around 20, except for the naked phthalimide 6.37b1 where 
difference was only 10-fold.  
 The use of the trifluoromethyl substituent (6.37d1-6.37d4) led to a decrease in mGlu1 
activity. In contrast to what has been observed in our previous SAR, the 3-methyl substituent in 
6.37d2 caused a substantial decrease in potency (around 20-fold) with respect to the direct 
comparator derived from the VU0486321 scaffold (5.35a), in the other cases the decrease in 
potency was of only 2-3 times and in the naked phthalimide 6.37d1 the EC50 value was 
comparable to the parent compounds. These PAMs are also preferential for the mGlu1 receptor 
and they present different degrees of modulation of the glutamate response in mGlu4. Here, the 
most selective compound was the naked phthalimide 6.37d1 which is 54 times more potent in 
mGlu1 than in mGlu4.  
 The bulkier methoxy substituent was tolerated and still provided potent mGlu1 PAMs 
(6.37m1-6.37m4). The only case where it showed a decrease in activity was in the 3-fluoro 
analog 6.37m4, causing a 4-fold decrease in potency with respect to VU0486321 5.35c. The other 
substituted phthalimides analogs 6.37m1-6.37m3 displayed EC50s between 18 and 49 nM. 
However, none of these analogs (6.37m1-6.37m4) presented an improvement in selectivity with 
respect to VU0486321 5.35c, as they are only 13 to 36 times preferent for mGlu1 versus mGlu4. 
 The replacement of the phenyl ring with pyridine, pyrimidine and naphthalene was also 
evaluated (Table 6.4).  The introduction of a pyridine (6.37n1-6.37n4), having the nitrogen in the 
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position where the chlorine is in VU0486321 5.35c, led to a variable effect in mGlu1 PAM 
potency depending on the substituents on the phthalimide. While the 3-chloro phthalimide 6.37n3 
retain the original mGlu1 potency, all the other analogs (6.37n1, 6.37n2 and 6.37n4) suffered 
from a decrease in PAM activity from 3 to 6 times. The decrease in mGlu1 activity was 
accompanied also by a decrease in mGlu4 potentiation, and the compounds showed preference for 
mGlu1. The 3-chloro 6.37n3 was the most selective from this batch (53-fold selective versus 
mGlu4), which was driven by its good potency in mGlu1; while the other compounds (6.37n1, 
6.37n2 and 6.37n4) had micromolar potencies in mGlu4 and fold-selectivities between 18 and 32. 
 
Table 6.4. Potencies in human mGlu1 and mGlu4 of compounds derived from the matrix library 
with modifications in the central phenyl ring, 6.37n, 6.37o and 6.37l. Calcium mobilization 
responses for each compound are reported as a percentage of the maximum glutamate response. 
VU number denotes the compound identifier assigned by Vanderbilt University. Data represent 
the mean ± S.E.M. of at least three independent experiments with similar results. ---, no 
potentiation. ND, not determined. 
Structure Cpd # VU # 
hmGlu1 hmGlu4 
EC50 
(µM) 
%Glu
Max 
EC50 
(µM) 
%Glu
Max 
 
6.37n1 VU6002166 0.387 80 >10.0 --- 
 
6.37n2 VU6002228 0.0947 105 5.00 100 
 
6.37n3 VU6002229 0.0348 91 1.11 44 
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6.37n4 VU6002230 0.198 93 3.55 19 
 
6.37o1 VU6003724 4.61 89 4.67 23 
 
6.37o2 VU6003725 0.751 111 4.47 104 
 
6.37o3 VU6003726 0.208 84 2.53 45 
 
6.37o4 VU6003727 5.33 99 >10.0 24 
 
6.37l1 VU6003750 0.0203 99 0.353 54 
 
6.37l2 VU6003751 0.0157 88 0.429 103 
 
6.37l3 VU6003752 0.0225 92 0.513 102 
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6.37l4 VU6003753 0.0197 90 0.809 83 
 
 The introduction of one additional nitrogen (6.37o1-6.37o4) to obtain a pyrimidine in the 
central ring caused a significant decrease in activity with respect to VU0486321 5.35c and to the 
pyridine analogs 6.37n1-6.37n4, showing that increasing the polar surface area in the central ring 
beyond the addition of one nitrogen is detrimental for activity. The most potent compound in this 
set was the 3-chloro 6.37o3, similarly to what occurred with pyridine 6.37n3, but with an 8-fold 
loss in potency with respect to the 3-chloro version of VU0486321 5.35b. With the other 
substituents, the decrease in potency was more marked, being 30-fold for 3-methyl 6.37o2 and up 
to 160 times for the 3-fluoro 6.37o4. These compounds showed micromolar potencies in the 
mGlu4 receptor; however, due to their lower potencies in mGlu1 they do not differentiate well 
between the two receptors. 
 The larger naphthalene group showed that the binding site of this PAMs can tolerate 
more bulk around the central phenyl ring, as analogs 6.37l1-6.37l4 exhibited excellent potency 
between 15 and 20 nM in all cases for mGlu1 potentiation. Yet, these analogs are active and have 
submicromolar activities in human mGlu4, which caused these compounds to be moderately 
selective with 17 to 41 higher potencies for mGlu1. 
 Overall,  the replacement of the chlorine in VU0486321 5.35c, with the different 
substituents shown in Table 6.3 and Table 6.4, did not provide a considerable increase in 
selectivity against mGlu4.The next attempt to improve the selectivity was to switch the position of 
the substituents in the central ring, from adjacent to the phthalimide to next to the furan 
carboxamide. The same group of substituents was prepared in the context of the naked 
phthalimide (Scheme 6.4) and the potency in mGlu1 and mGlu4 was evaluated in our fluorescence 
284 
 
calcium mobilization assay (Table 6.5). It was found that analogs 6.37e, 6.37f and 6.37g achieved 
excellent potency in human mGlu1, improving around 5-fold the potency with respect to its direct 
comparator VU0474633 5.27. Meanwhile, the introduction of a methoxy group (6.37i) led to a 
three-fold decrease in mGlu1 and to the complete loss of activity in the case of trifluoromethyl 
6.37h; showing that smaller substituents such as fluoro, methyl and chloro are desirable in this 
position. Also, the replacement of the phenyl group by the pyridine (6.37j) and the pyrimidine 
(6.37k) abolished entirely the mGlu1 PAM activity of the compounds. While the 6.37e methyl 
and the 6.37i methoxy analogs achieved a moderate preference for mGlu1 (40 and 30-fold 
respectively),  6.37f and 6.37g stood out from this collection for its excellent selectivity against 
mGlu4, being over 793 and 384 times more potent for mGlu1. 
 
Table 6.5. Potencies in human mGlu1 and mGlu4 of compounds derived from modifications in 
the central phenyl ring, 6.37e-k. Calcium mobilization responses for each compound are reported 
as a percentage of the maximum glutamate response. VU number denotes the compound 
identifier assigned by Vanderbilt University. Data represent the mean ± S.E.M. of at least three 
independent experiments with similar results. ---, no potentiation. ND, not determined. 
Structure Cpd # VU # 
hmGlu1 hmGlu4 
EC50 
(µM) 
%Glu
Max 
EC50 
(µM) 
%Glu
Max 
 
6.37e VU6002193 0.015 90+2 0.609 52 
 
6.37f VU6002194 0.013 84+2 >10.0 --- 
 
6.37g VU0487104 0.029 68+5 >10.0 --- 
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6.37h VU6003728 >10.0 - >10.0 --- 
 
6.37i VU6003729 330 80+6 >10.0 --- 
 
6.37j VU6003730 >10.0 - >10.0 --- 
 
6.37k VU6003768 >10.0 - >10.0 --- 
 
 Considering the selectivity of analogs 6.37f (VU6002194) and 6.37g (VU0487104), these 
were also explored in the mGlu5 receptor, where they demonstrated selectivity with potencies of 
over 10 µM. The in vitro pharmacokinetic properties of these compounds were also studied (Fig. 
6.2). Incubations with preparations of liver microsomes showed that the two compounds had a 
similar predicted hepatic clearance, being moderate in human (44% of hepatic blood flow) and 
high in rat (70% hepatic blood flow). Interestingly, the compounds were stable enough in plasma 
to determine their fraction unbound in plasma; although, the observed free fraction was very 
small in rat and human plasma. A similar behavior was observed when the fraction unbound in rat 
brain homogenate binding was evaluated, as free fractions under 1% were obtained. Therefore, 
these analogs displayed comparable in vitro pharmacokinetic characteristics.  
 The main differentiator for these PAMs was noticed when CNS penetration was assessed. 
Intravenous administration of a dosage of 0.2 mg/kg of the compounds proved that the fluoro 
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analog VU6002194 6.37f is substantially more brain penetrant than its chloro counterpart 
VU0487104 6.37g, having a Kp of 1.57 compared to 0.12. This behavior is hard to explain as both 
analogs have the same value of calculated topological polar surface area (81.3 Å
2
) and the same 
number of rotatable bonds. Furthermore, the calculated logP of the chloro analog 6.37g is higher 
(4.14) compared to the fluoro analog 6.37f (clogP = 3.63), a relationship that is in disagreement 
with the Kps observed. To explain this effect, it could be hypothesized that the fluoro decreased 
the magnitude of the dipolar moment of the molecule or that there may be a considerable change 
in the conformational equilibrium that makes fluoro 6.37f more rigid and less flexible than the 
chloro 6.37g, such as the consequence for an electrostatic interaction between the C-F δ- in the 
aryl and N-H δ+ in the furancarboxamide.303 
 
 
Figure 6.2. Comparison of the pharmacodynamic and pharmacokinetic properties of analogs 
VU6002194 6.37f and VU0487104 6.37g. 
 
 As the fluorine substitution in VU6002194 6.37f represented a great improvement in 
selectivity for the scaffold while maintaining brain penetrance, we proceeded to develop a library 
with different substituents in the phthalimide. The compounds were prepared similar to the 
analogs with the modified central phenyl ring and starting with the Boc protection of 3-fluoro-4-
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nitroaniline 6.37c, followed by the reduction of the nitro group 6.42, the amide coupling between 
aniline 6.43 and acyl chloride 5.32, deprotection of the bis Boc protected aniline 6.44 and finally 
condensation of the unmasked aniline with the phthalic anhydrides to afford the desired analogs 
6.45-6.51 (Scheme 6.5). 
 
 
Scheme 6.5. Synthesis of analogs of VU6002194 6.37f with modifications in the phthalimide, 
6.45-6.51. 
 
 The analogs of VU6002194, 6.45-6.51, were evaluated in calcium mobilization assays to 
obtain their potencies in human mGlu1 and mGlu4 (Table 6.6). All analogs except for the 4-chloro 
6.49 and 4-aza phthalimide 6.51 displayed excellent potencies between 5 and 26 nM and behaved 
as partial mGlu1 PAMs with efficacies between 60 and 81%. When analyzed in the mGlu4 
receptor, all analogs were inactive or weak potentiators with EC50s above 10 µM, which gives 
several hundred fold-selectivity for the mGlu1 receptor. The compounds were also tested in the 
mGlu5 receptor where they also displayed potencies above 10 µM. 
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Table 6.6. Potencies in human mGlu1 and mGlu4 of compounds derived from modifications of 
the phthalimide in VU6002194, 6.45-6.51. Calcium mobilization responses for each compound 
are reported as a percentage of the maximum glutamate response. VU number denotes the 
compound identifier assigned by Vanderbilt University. Data represent the mean ± S.E.M. of at 
least three independent experiments with similar results. ---, no potentiation. ND, not determined. 
Structure 
 
Cpd # VU # 
hmGlu1 hmGlu4 
EC50 
(µM) 
%Glu
Max 
EC50 
(µM) 
%Glu
Max 
 
6.45 VU6004907 0.011 81 >10.0 37 
 
6.46 VU6004910 0.0053 60 >10.0 28 
 
6..47 VU6004911 0.019 81 >10.0 49 
 
6.48 VU6004909 0.026 70 >10.0 34 
 
6.49 VU6005703 >10.0 60 ND ND 
 
6.50 VU6004912 0.022 67 >10.0 31 
 
6.51 VU6005704 2.04 104 ND ND 
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 The pharmacokinetic properties of these compounds were analyzed in vitro, and it was 
observed that in general they are less metabolically labile in comparison to VU6002194 6.37f.  
The predicted hepatic clearance with human liver microsomes was lower with all compounds 
except for the 3-chloro analog 6.46, while in the case of the rat microsomes this improvement was 
observed in three analogs from the set:  3-methyl 6.45 (50% hepatic blood flow), 4-methyl 6.48 
(41% hepatic blood flow) and 4-fluoro 6.50 (51% hepatic blood flow). The P450 inhibition of 
drug metabolizing enzymes was also ameliorated with respect to VU0486321 5.35c, as now the 
compounds did not inhibit CYP2C9 and only slight inhibition of CYP1A2 is observed with 6.45 
and 6.46. 
 
Table 6.7. In vitro pharmacokinetic properties of analogs 6.45-6.48 and 6.50. 
Parameter 6.45 6.46 6.47 6.48 6.50 
Hum CLhep (ml/min/kg) 4.40 11.9 6.72 6.64 4.48 
Rat CLhep (ml/min/kg) 35.0 46.7 52.0 28.9 35.8 
P450 IC50 (µM) 
1A2     2C9 
2D6     3A4 
 
10   >30 
>30 >30 
 
6.3  >30 
>30 >30 
 
>30 >30 
>30 >30 
 
>30  >30 
>30  >30 
 
>30   >30 
>30  >30 
Hum Fu plasma 0.002 <0.001 0.030 0.009 0.027 
Rat Fu plasma
 
0.009 0.001 0.011 0.038 0.011 
Rat Fu brain 0.193 0.272 0.170 0.298 0.034 
 
We were pleased to find that these compounds were stable enough in plasma to estimate 
their unbound fraction. In the plasma protein binding assays, the best free fractions in rat plasma 
were observed with 4-methyl 6.48 with 3.8% free drug, while in the case of human plasma the 3-
fluoro 6.47 provided the higher fraction unbound with 3.0% free drug; while the lowest free 
fractions in both preparations were observed with 3-chloro 6.46. Additionally, this set of 
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compounds (6.45-6.48 and 6.50) showed high free fraction in brain homogenate with the majority 
of them presenting between 17% and 30% of fraction unbound. 
Then, the brain penetrance and in vivo clearance of these PAMs was determined in rats 
(Table 6.8). It was found that 3-methyl 6.45 had the lowest brain to plasma partition coefficient, 
while the highest Kps were observed with 4-methyl 6.48 and 3fluoro 6.47, being in both cases 
close to 1. In terms of th unbound partition coefficient, all these analogs displayed values superior 
to the unity. In terms of clearance, the analogs ranked similarly as in the in vitro microsomal 
experiment; however, clearance differed considerably in magnitude. While clearance was 
underestimated for the highly metabolized 3-chloro 6.46 and 3-fluoro 6.47, it was overestimated 
for the other three analogs. The 4-fluoro 6.50 had a half-life of 77 minutes, but the most 
impressive improvement was observed with the methyl-substituted analogs 6.45 and 6.48, which 
displayed half-lives close to five hours. All data combined points to the superiority of 
VU6004909 (6.48), an analog that achieved excellent potency and selectivity, and combines good 
fraction unbound and brain penetrance with an adequate half-life for in vivo target validation 
studies.  
 
Table 6.8. In vivo pharmacokinetic properties of analogs 6.45-6.48 and 6.50. 
Parameter 6.45 6.46 6.47 6.48 6.50 
Rat IV PBL (0.25 mg/kg) 
Cn plasma (ng/mL) 
Cn brain (ng/g) 
Kp (at 0.25 h) 
Kp,uu 
 
699 
177 
0.25 
5.36 
 
217 
120 
0.55 
150 
 
151 
147 
0.97 
15.0 
 
191 
182 
0.95 
7.45 
 
151 
97.2 
0.64 
1.98 
Rat IV PK (0.25 mg/kg) 
t1/2 (min) 
MRT (min) 
Clp (mL/min/kg) 
Vss (L/kg) 
 
296 
330 
4.61 
1.52 
 
51.5 
45.4 
65.5 
2.97 
 
38.9 
30.7 
62.6 
1.92 
 
285 
186 
6.94 
1.29 
 
76.6 
80.4 
16.7 
1.34 
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Due to the interesting possibilities that offer the use of the fluorine in the central phenyl 
ring along with the substituted phthalimides, the implementation of these functionalities was 
assessed in the context of the oxazole and thiazole amides. These compounds, in theory, would 
have the advantage of possessing selectivity but eliminating the potentially undesirable furan. The 
analogs were synthesized using a similar strategy as for the fluoro PAMs 6.45-6.51, using as key 
intermediate the bis Boc protected 4-aminoanilines 6.43.  
 
Scheme 6.6. Synthesis of analogs of VU6002194 6.37f with modifications in the furan, 6.53-
6.67. 
 
The compounds were screened using a 10 µM concentration in our calcium mobilization 
assay to assess mGlu1 activation, and it was found that none of them exert an important 
enhancement of the glutamate response in the receptor (Table 6.9). While the oxazoles 6.53-6.60 
did not potentiate glutamate’s EC20, only a few from the thiazole examples (6.61-6.67) managed 
to increase the observed signal, and to small values around 45% GluMax in the best cases. This 
demonstrated how the effect of substitutions in the central ring is context dependent and varied 
with the substituent in the amide, an example that illustrates the intricacies of allosteric 
modulation SAR. 
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Table 6.9. Comparison of the single point screen result for PAM activity in human mGlu1 at 10 
µM for compounds derived from modifications in the furan region of VU6002194, analogs 6.53-
6.67. Calcium mobilization was used to obtain %GluMax values for each compound in the 
presence of a submaximal concentration of glutamate (EC20) in cell lines expressing human 
mGlu1. Data represent the mean ± S.E.M. of at least three experiments with similar results. 
Structure Cpd # VU # hmGlu1 %GluMax 
 
6.53 VU6005712 18 
 
6.54 VU6005717 14 
 
6.55 VU6005713 25 
 
6.56 VU6005715 16 
 
6.57 VU6005718 20 
 
6.58 VU6005714 27 
 
6.59 VU6005716 36 
 
6.60 VU6005719 9 
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6.61 VU6005705 49 
 
6.62 VU6005709 36 
 
6.63 VU6005707 22 
 
6.64 VU6005710 17 
 
6.65 VU6005706 40 
 
6.66 VU6005708 45 
 
6.67 
 
VU6005711 
42 
 
Homologation of the anilines in the central phenyl ring 
 In an effort to explore the appropriate distance between the phthalimide and the 
furancarboxamide of the central phenyl ring of the scaffold of VU0486321 5.35c, we prepared 
compounds where methylene groups were introduced in between the ring and the nitrogen. For 
these analogs, we eliminated the chlorine in the central phenyl ring as it had shown to have little 
impact in the activity of compounds in the VU0486321 scaffold. This also allowed a simpler 
synthetic route to quickly access the desired analogs. The synthesis of these compounds 
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proceeded with a sequence of three steps (Scheme 6.7). Analogs 6.71-6.74 were synthesized 
starting with 4-nitrobenzylamine 6.68 and performing the amide coupling with acyl chloride 5.32 
to obtain intermediate 6.69 in 68% yield. This nitroaromatic compound was reduced with tin(II) 
chloride to the aniline 6.70 in good yield (92%) and then the aniline was condensed with the 
selected phthalic anhydrides to provide the desired final compounds 6.71-6.74. Analogs 6.77-6.80 
were prepared using 4-(Boc-aminomethyl)aniline 6.75 as the starting material to perforn the 
amide coupling with acyl chloride 5.32 and obtain intermediate 6.76 in excellent yields. Then, 
this intermediate was Boc deprotected with TFA, and the amine was condensed with the selected 
phthalic anhydrides. A similar procedure was performed to obtain analogs 6.83-6.86, with 
methylenes on both sides of the phenyl ring, but this time employing the Boc-protected amine 
6.81 as starting material.  
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Scheme 6.7. Synthesis of homologues of VU0486321 5.35c, analogs 6.71-6.74, 6.77-6.80 and 
6.83-6.86. 
 
 
A 
B 
C 
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 The preparation of these compounds was followed by the evaluation of their mGlu1 
PAM activity at a single concentration of 10 µM in a calcium mobilization assay. The addition of 
one extra carbon on either side of the phenyl ring (distance between nitrogens: 6.2 Å), or addition 
of a methylene in both ends (distance between nitrogens: 7.3 Å) led to complete loss of activity in 
the prepared analogs, demonstrating that the separation between the nitrogens is important for 
mGlu1 PAM activity and that the phenyl ring spacer gives an optimal distance (around 5.3 Å). 
 
Cycloalkanes replacement for the central phenyl ring 
 As only aromatic versions had been tested in the central phenyl ring, compounds with a 
saturated hydrocarbon core were synthesized as replacements of the phenyl ring. For this purpose, 
the cyclohexyl and the cyclobutyl were selected in order to not vary considerably the distance and 
orientation of substituents in the ring. In these cases, the trans isomers of the cyclohexyl and 
cyclobutyl diamines was our main focus of interest, but the cis were also prepared to explore their 
biological activity. The analogs were synthesized using the mono Boc protected diamines 6.87A-
6.87D to perform the amide couplings with acyl chloride 5.32. Then, the intermediates 6.88A-
6.88D were Boc deprotected to generate the amines, which in turn were condensed using phthalic 
anhydride to obtain the final compounds 6.89A-6.89D (Scheme 6.8).  After evaluation for mGlu1 
PAM activity in a single point concentration calcium mobilization assay, it was discovered that 
none of the produced analogs exert potentiation in the glutamate’s receptor response, highlighting 
the importance of the aromaticity and planarity of the central ring of VU0486321 scaffold. 
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Scheme 6.8. Synthesis of analogs of VU0486321 5.35c with a cycloalkyl central ring, analogs 
6.89A-6.89D. 
 
Substitution pattern in the central phenyl ring 
 All analogs synthesized showed a 1,4-diamino phenyl ring in the central portion of the 
molecule, or a close relative with the same para distribution. In an effort to assess the importance 
of this substitution pattern, meta-substituted analogs were synthesized (Scheme 6.9). Chlorinated 
and non-chlorinated nitroanilines were employed to also assess the effect of the presence of 
halogen in these compounds. Similar to the 1,4-substituted analogs, the synthesis began with 3-
nitroanilines 6.90-6.92 and an amide coupling with acyl chloride 5.32 in the microwave, followed 
by reduction of a nitro group 6.93-6.95 and condensation with phthalic anhydride. The 
synthesized compounds 6.99-6.101 did not enhance the mGlu1 response towards glutamate in our 
calcium mobilization assay, indicating the importance of the 1,4-substitution pattern in the central 
phenyl ring, which likely provides a more rod-like overall structure than the 1,3 arrangement 
which produced a more ramified shape.  
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Scheme 6.9. Synthesis of analogs of VU0486321 5.35c with meta distribution in the central 
phenyl ring, analogs 6.99-6.101. 
 
SAR exploration for the replacement of the phthalimide 
 
Fused rings as substitutes of the phthalimide ring 
 As the phthalimide in VU0486321 5.35c causes the molecule to be plasma unstable, we 
surveyed different approaches to remove this moiety. One of the first attempts consisted of the 
introduction of different fused rings carboxamides instead of the phthalimide. Here, the analogs 
were prepared through a HATU mediated amide coupling using intermediate 5.34 along with the 
desired carboxylic acids to afford final compounds (Scheme 6.10). In this case, no potentiation of 
glutamate’s mGlu1 response was observed at a concentration of 10 µM of test article. Therefore, 
the evaluated fused ring systems were not suitable alternatives to the phthalimide for mGlu1 PAM 
activity. 
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Scheme 6.10. Synthesis of analogs of VU0486321 5.35c to replace the phthalimide with fused 
ring amides, analogs 6.102-6.112. 
 
Reverse amides as replacements of the phthalimide 
Another strategy to find an appropriate substitute to the phthalimide moiety was the 
introduction of reverse amides. To assess this idea, a library was created with different amines in 
which the location of the carbonyl was switched with respect to the phthalimide in VU0486321 
5.35c. These compounds were synthesized in three steps, starting with the amide coupling 
between 4-aminobenzoate ester 6.113 and acyl chloride 5.32 at room temperature, followed by 
the basic hydrolysis of the ethyl ester 6.114 (Scheme 6.11). The library step consisted of a HATU 
mediated amide coupling with the different amines to generate analogs 6.116-6.140. 
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Scheme 6.11. Synthesis of analogs of VU0486321 5.35c to replace the phthalimide with reverse 
amides, analogs 6.116-6.140. 
  
 After evaluation of analogs 6.116-6.140 for their capacity to potentiate glutamate’s 
mGlu1 response, it was observed that only a few examples presented observable PAM activity 
(Fig. 6.3 and Table 6.10).  From the aniline examples, only the o-anisidine analog 6.117, showed 
potentiation of the receptor activity, but further studies showed that it was a weak potentiator with 
an EC50 over 10 µM. Examples of benzylamines, cyclohexylamines, aminoindanes and 
substituted pyrrolidines did not engender mGlu1 PAM activity. The compounds showing the 
highest efficacies were isoindoline 6.122 (90%), indoline 6.123 (90%) and tetrahydroisoquinoline 
6.124 (78%). When the analogs were tested to obtain their concentration-response curves for 
PAM activity, a similar tendency was observed in the ranking for their potencies. 6.124 proved to 
be the least potent of the set with an EC50 of 3.60 µM (86% GluMax), while 6.122 and 6.123 were 
the most active (EC50 = 0.90 µM, 110% GluMax and EC50 = 1.23 µM, 105% GluMax, respectively). 
So, this strategy was not pursued further as it was observed that in the best scenario these 
modifications caused around a nine-fold loss in potency versus their direct comparator 
VU0474633 5.27.  
301 
 
 
Figure 6.3. Comparison of the single point screen result for PAM activity in human mGlu1 at 10 
µM for reverse amide analogs 6.116-6.140. Calcium mobilization was used to obtain %GluMax 
values for each compound in the presence of a submaximal concentration of glutamate (EC20) in 
cell lines expressing human mGlu1. Data represent the mean ± S.E.M. of at least three 
experiments with similar results. 
 
Table 6.10. Structures of the reverse amide analogs 6.116-6.140 and associated PAM activity 
from the single point screening at 10 µM in human mGlu1. Calcium mobilization responses for 
each compound are reported as a percentage of the maximum glutamate response. VU number 
denotes the compound identifier assigned by Vanderbilt University. Data represent the mean ± 
S.E.M. of at least three replicate experiments with similar results. 
Structure Cpd # VU # hmGlu1 %GluMax 
 
6.116 VU6002173 29.2±6.4 
 
6.117 VU6002175 72.3±4.7 
 
6.118 VU6002176 20.8±1.7 
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6.119 VU6002177 20.1±5.6 
 
6.120 VU6002179 31.0±1.9 
 
6.121 VU6002178 17.4±2.4 
 
6.122 VU6002171 90.7±2.0 
 
6.123 VU6002172 90.0±6.8 
 
6.124 VU6002174 78.8±7.5 
 
6.125 VU6003781 22.0±1.6 
 
6.126 VU6003787 32.0±3.3 
 
6.127 VU6003792 19.6±3.6 
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6.128 VU6003793 18.1±1.7 
 
6.129 VU6003796 14.6±3.9 
 
6.130 VU6003788 19.4±3.5 
 
6.131 VU6003782 38.2±5.9 
 
6.132 VU6003794 19.9±2.7 
 
6.133 VU6003790 17.4±1.9 
 
6.134 VU6003795 22.3±4.5 
 
6.135 VU6003789 21.1±5.8 
 
6.136 VU6003783 40.3±0.3 
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6.137 VU6003784 24.7±0.8 
 
6.138 VU6003791 33.0±1.6 
 
6.139 VU6003785 26.1±2.8 
 
6.140 VU6003786 36.00±0.04 
 
Ring opening of the phthalimide 
 We also explored the effect of analogs that mimicked the ring opening or fragmentation 
of the phthalimide. In this case, different ortho-benzoic acids were used to generate analogs 
6.141-6.148 following similar procedures to those described in scheme 6.10 (Scheme 6.12A). 
Analogs representing fragmented versions of the phthalimide rings 6.158-6.160 were synthesized 
in four-steps (Scheme 6.12B), starting with the alkylation of nitroaniline 6.34g with alkyl iodides 
to produce intermediates 6.149-6.151, followed by acylation and reduction to obtain anilines 
6.155-6.157. Then, the final step involved the amide coupling between 6.155-6.157 and 5.32. 
Additionally, phthalamic acid related compounds 6.161-6.163 were synthesized by the opening of 
cyclic anhydride with aniline 5.34 in THF at room temperature (Scheme 6.12C); these analogs 
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represent the structures generated during the incubations in plasma which allowed the testing of 
these metabolites for mGlu1 PAM activity. 
 
 
Scheme 6.12. Synthesis of analogs of VU0486321 5.35c to replace the phthalimide with open 
ring variants, analogs 6.141-6.148 and 6.158-6.163. 
 
Evaluation of the compounds at 10 µM demonstrated the importance of the phthalimide 
in the VU0486321 scaffold for mGlu1 PAM activity, as most compounds displayed significantly 
reduced or completely absent mGlu1 potentiation (Fig. 6.4 and Table 6.11). Between the 
synthesized benzamides 6.141-6.148, only the naked benzamide 6.141, the o-methyl 6.142, the o-
A 
B 
C 
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ethyl 6.143, the 2,3-dimethyl 6.146 and the o-ethoxy 6.145 showed some weak PAM activity, 
with the latter been the most efficacious achieving 68% GluMax. The fragmented versions of the 
phthalimide 6.158-6.160 with the alkylated amide did not show an enhanced glutamate response. 
The best results were observed with phthalamic acid 6.161 that achieved the highest calcium 
mobilization signal in our assay, with a potency in human mGlu1 of 0.93 µM (108% %GluMax). 
This shows that the metabolites generated in plasma, despite maintaining mGlu1 PAM activity, 
are likely to be less potent. For example, 6.161 is 9-fold less active than its direct phthalimide 
comparator VU0474633 5.27; while the cyclohexyl analogs 6.162 and 6.163 were completely 
inactive. 
 
Figure 6.4. Comparison of the single point screen result for PAM activity in human mGlu1 at 10 
µM for open ring analogs 6.141-6.148 and 6.158-6.163. Calcium mobilization was used to obtain 
%GluMax values for each compound in the presence of a submaximal concentration of glutamate 
(EC20) in cell lines expressing human mGlu1. Data represent the mean ± S.E.M. of at least three 
experiments with similar results. 
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Table 6.11. Structures of the open ring analogs 6.141-6.148 and 6.158-6.163, and associated 
PAM activity from the single point screening at 10 µM in human mGlu1. Calcium mobilization 
responses for each compound are reported as a percentage of the maximum glutamate response. 
VU number denotes the compound identifier assigned by Vanderbilt University. Data represent 
the mean ± S.E.M. of at least three replicate experiments with similar results. 
Structure Cpd # VU # hmGlu1 %GluMax 
 
6.141 VU0517591 49.2±10.7 
 
6.142 VU0517517 59.9±11.3 
 
6.143 VU0517520 58.8±13.9 
 
6.143 VU0517549 23.4±1.3 
 
6.145 VU0517525 67.7±8.4 
 
6.146 VU0517532 43.8±3.5 
 
6.147 VU0517566 22.5±3.8 
 
6.148 VU0517588 22.6±4.8 
 
6.158 VU6005365 35.7±2.2 
 
6.159 VU6005366 36.2±2.7 
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6.160 VU6005364 31.4±3.2 
 
6.161 VU0517466 95.0±5.8 
 
6.162 VU6000697 33.5±4.5 
 
6.163 VU6000698 18.8±4.6 
 
Tied-back rings as replacements of the phthalimide 
 Another effort to attempt to remove the phthalimide group from the scaffold was the 
development of different tied back rings. In these examples, one of the carbonyl groups from the 
phthalimide will still remain in the molecule forming a more plasma stable amide, while the other 
one will be removed and the nitrogen would be connected to the ring through a linker to form a 
bicyclic fused ring. Analogs to evaluate this idea were synthesized starting with different nitro 
substituted bicyclic heterocycles 6.164A-6.164G, which were acylated using benzoyl chloride to 
form intermediates 6.165A-6.165G. Then, the nitro group was reduced with tin(II) chloride and 
the generated anilines 6.166A-6.166G were used in an amide coupling with acyl chloride 5.32 to 
provide the final compounds 6.167A-6.167G (Scheme 6.13).  
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Scheme 6.13. Synthesis of analogs of VU0486321 5.35c to replace the phthalimide with a tied 
back ring strategy, analogs 6.167A-6.167G. 
 
These analogs where tested in our calcium mobilization assay, and only 6.167A displayed 
enhancement of mGlu1 activity at 10 µM. The mGlu1 PAM potency for this compound was 2.64 
µM (74% GluMax). As the best compound in this set represented nearly a 26-fold decrease in 
potency with respect to the parent compound, this effort was abandoned.  
 
Other replacements of the phthalimide 
 To replace the phthalimide moiety, analogs maintaining the imide functional group but in 
an aliphatic scaffold or with a methylene linker were prepared; these compounds would virtually 
have a more stable imide compared to the aromatic imide. Analogs 6.168-6.171 were prepared by 
condensation of cyclic anhydrides with intermediate 5.34 in refluxing acetic acid (Scheme 
6.14A). Moreover, analogs where the phthalimide was replaced with other fused rings, 
maintaining the nitrogen directly connected to the central phenyl ring, were synthesized. In this 
case, a three-step procedure was employed starting with a nucleophilic aromatic substitution 
using fluoronitrobenzene 6.172 and different cyclic amines. Then, intermediates 6.173-6.179 
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where reduced with tin(II) chloride, and a HATU-mediated amide coupling with the anilines 
6.180-6.186 and acyl chloride 5.32 was performed to produce final compounds 6.187-6.193 
(Scheme 6.14B). 
 
 
Scheme 6.14. Synthesis of analogs of VU0486321 5.35c with different phthalimide replacements, 
analogs 6.168-6.171 and 6.187-6.193. 
 
Analogs 6.168-6.171 and 6.187-6.193 were screened at a 10 µM concentration to assess 
their effect in mGlu1 response. It was encouraging that very different structures provided 
potentiation of the EC20, as active compounds were found in the imide and the non-imide 
replacement analogs with %GluMax between 68 and 86%, with only quinazoline 6.179 giving low 
levels of potentiation. 
A 
B 
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Figure 6.5. Comparison of the single point screen result for PAM activity in human mGlu1 at 10 
µM for different phthalimide replacements, analogs 6.168-6.171 and 6.187-6.193. Calcium 
mobilization was used to obtain %GluMax values for each compound in the presence of a 
submaximal concentration of glutamate (EC20) in cell lines expressing human mGlu1. Data 
represent the mean ± S.E.M. of at least three experiments with similar results. 
 
Table 6.12. Structures of the phthalimide replacement analogs 6.168-6.171 and 6.187-6.193, and 
associated PAM activity from the single point screening at 10 µM in human mGlu1. Calcium 
mobilization responses for each compound are reported as a percentage of the maximum 
glutamate response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean ± S.E.M. of at least three replicate experiments with similar 
results. 
Structure Cpd # VU # hmGlu1 %GluMax 
 
6.168 VU6000699 80.5±14.3 
 
6.169 VU6000700 83.5±14.0 
 
6.170 VU6000713 85.9±8.2 
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6.171 VU6005368 70.6±0.9 
 
6.187 VU6000709 74.6±12.4 
 
6.188 VU6000710 75.6±18.9 
 
6.189 VU6000711 75.0±11.2 
 
6.190 VU6000836 69.1±5.8 
 
6.191 VU6000715 36.3±11.7 
 
6.192 VU6000714 68.3±6.4 
 
6.193 VU6000712 82.3±10.2 
 
 These compounds were further screened at different concentrations to obtain their EC50 
for mGlu1 PAM activity. The set of imides revealed different potencies, where the cyclohexyl 
congeners 6.168 and 6.169 were the weakest PAMs in the group with over 10 µM EC50s, 
followed by the seven-ring member 6.171 with 3.6 µM potency (95% GluMax); the most potent 
was the homophthalimide analog 6.170 (human mGlu1 EC50 = 0.22 µM, 104% GluMax). As 6.170 
represented only a two-fold loss in potency from its comparator phthalimide 5.27, the PAM was 
analyzed further. The compound was found to be equally potent in the rat mGlu1 (EC50 = 0.24 
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µM, 105% GluMax); however, its pharmacokinetic characteristics were not stellar. In vitro 
evaluation of intrinsic clearance showed moderate clearance in human liver microsomes (Clhep = 
13.5 mL/min/kg) and high clearance in rat liver microsomes (Clhep = 54.0 mL/min/kg), along with 
moderate inhibition of CYP2C9 (IC50 = 5.18 µM). These properties along with their instability, 
made it impossible to measure fraction unbound in plasma and made us not explore further this 
series of compounds. 
 
Table 6.13. Potencies in human mGlu1 of VU0486321phthalimide replacements analogs 6.168-
6.171 and 6.187-6.193. Calcium mobilization responses for each compound are reported as a 
percentage of the maximum glutamate response. VU number denotes the compound identifier 
assigned by Vanderbilt University. Data represent the mean ± S.E.M. of at least three independent 
experiments with similar results. ---, no potentiation. ND, not determined. 
Structure Cpd # VU # 
hmGlu1 
EC50 (µM) %GluMax 
 
6.168 VU6000699 >10 80.5 
 
6.169 VU6000700 >10 83.5 
 
6.170 VU6000713 0.22 104.3 
 
6.171 VU6005368 3.57 94.9 
 
6.187 VU6000709 1.77 95.3 
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6.188 VU6000710 5.71 82.6 
 
6.189 VU6000711 9.55 78.7 
 
6.190 VU6000836 2.47 93.8 
 
6.192 VU6000714 3.62 100.0 
 
6.193 VU6000712 2.61 93.4 
 
In the non-imide replacement assays, the isoindoline 6.187 was the most potent of the set 
with an EC50 of 1.8 µM. Switching the nitrogen location to the indoline 6.188 or introduction of 
an additional  nitrogens in position 4 (6.189) led to a decrease in activity of up to 5-fold. 
Homologation of the isoindoline to the tetrahydroisoquinoline (6.190) showed a less harmful 
effect, increasing the potency only to 2.47 µM. However, when an attempt was performed to 
measure the intrinsic clearance and plasma fraction unbound of isoindoline 6.187, it was observed 
that the DMSO stock solution of this compound decompose rapidly after exposure to air, making 
hard to accurately measure its concentration. LC-MS
n
 analysis narrowed down the decomposition 
process to the electron rich isoindolines, where oxidation of one of the methylenes of the rings 
was found to generate a lactam (+14 m/z). Meanwhile, the benzoxazines analog 6.192 and 6.193 
displayed modest activity with an opposite trend as the isoindolines, as the azabenzoxazine is the 
most potent of the pair. So, from these analogs, despite achieving good glutamate responses at 10 
µM, it was not possible to find a suitable replacement for the phthalimide that engendered good 
potency for mGlu1 PAM activity. 
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Isoindolinones as replacements of the phthalimide 
 At the end of chapter 4, the generation of isoindolinone analogs (4.145-4.146) was 
presented. These compounds while having decrease potency represented an improvement in 
plasma stability, as they are not metabolized significantly in plasma preparations for four hours. 
These results led us to hypothesize that if a phthalimide with enough potency was generated, it 
would be possible to accomodate for the decrease in potency after the removal of a carbonyl and 
generate a potent and plasma stable isoindolinone. 
Several analogues that achieved two-digit nanomolar potencies have been presented. 
From this, it was believed that the VU0486321 5.35c had enough potency to start developing 
isoindolinone analogs and test our hypothesis. These compounds were synthesized following a 
similar procedure to the one presented in chapter 4, where aniline 5.34 was reacted with different 
bromomethylbenzoates in a tandem nucleophilic substitution-cyclization reaction to produce 
analogs 6.194-6.206. To produce these analogs, most bromomethylbenzoates were produced by 
radical bromination of o-methylbenzoate esters while others were commercially available. In 
addition to substituted isoindolinones, other analogs that represented changes in the isoindolinone 
core such as the homologues 6.207-6.212 were prepared. In this case, the route depicted in 
Scheme 6.14B was used, starting with nucleophilic aromatic substitution in a fluoronitroaniline 
6.172 and the corresponding amides instead of the aromatic amines. 
 
 
Scheme 6.15. Synthesis of analogs of VU0486321 5.35c to replace the phthalimide with an 
isoindolinone, analogs 6.194-6.206. 
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These isoindolinone analogs were tested in calcium mobilization assays to determine 
their EC50 for mGlu1 PAM activity. The unsubstituted isoindolinone 6.194 showed weak activity, 
and it caused a decrease of more than 37-fold with respect to its direct phthalimide comparator 
5.27. Walking a chlorine around the phenyl ring showed that positions 4 (6.197) and 7 (6.195), 
gave active compounds while the 5-chloro 6.196 exert only weak PAM activity with 59% GluMax. 
The most active isoindolinone from this effort was the 4-chloro 6.197, having an EC50 of 220 nM 
(88% GluMax) and maintaining the same SAR tendency observed with the isoindolinones in the 
context of the picolinamides 4.145 and 4.146. 
 
Table 6.14. Potencies in human mGlu1 of isoindolinone related analogs 6.194-6.212. Calcium 
mobilization responses for each compound are reported as a percentage of the maximum 
glutamate response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean ± S.E.M. of at least three independent experiments with 
similar results. ---, no potentiation. ND, not determined.      
   
Structure Cpd # VU # 
hmGlu1 
EC50 (µM) %GluMax 
 
6.194 VU6003731 3.72 91 
 
6.195 VU04867266 0.48 109 
 
6.196 VU6005374 >10 59 
 
6.197 VU0487351 0.22 88 
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6.198 VU6005370 0.88 83 
 
6.199 VU6000821 0.39 100 
 
6.200 VU6005417 1.08 90 
 
6.201 VU6005367 1.13 105 
 
6.202 VU6005373 2.10 108 
 
6.203 VU0517648 >10 56 
 
6.204 VU6000704 >10 11 
 
6.205 VU6001123 >10 55 
 
6.206 VU6000705 >10 39 
 
6.207 VU6005371 1.76 76 
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6.208 VU0517521 6.93 89 
 
6.209 VU6005415 3.38 105 
 
6.210 VU6005416 0.78 94 
 
6.211 VU6000823 >10 41 
 
6.212 VU6000822 1.29 108 
 
 As the 4-chloro analog 6.197 (VU0487351) showed good potency for mGlu1, several 
analogs with different substitutions were prepared and screened. From this set it was observed the 
halogen substituted analogs 6.198 and 6.199 gave the better potencies. The bromo compound 
6.199 was found to be the most active of the pair and 2-fold less potent compared to 6.197. It was 
observed that as the size of the substituent in the 4 position increased, the PAM potency subtly 
decreases. The 4-methyl 6.200 and 4-trifluoromethyl 6.201 have decreased activity with respect 
to 6.197 but comparable activity between each other (human mGlu1 EC50 = 1.08 µM and 1.13 
µM, respectively). There was an extra drop in activity with the more extended cyano group 
(6.202, human mGlu1 EC50 = 2.10 µM) and the bulkier methoxy group (6.203) generated a very 
weak PAM with over 10 µM potency and 56% GluMax. The benzoindolone analog 6.207 
represented a tied back ring strategy between the position 4 and the methylene linker, and despite 
retaining activity, the modification was not beneficial in comparison to 6.197. Additionally, the 
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introduction of nitrogens in the 4 and 7 positions were explored with analogs 6.204-6.206 as a 
way to introduced polar surface area in this ring: however, these compounds showed weak mGlu1 
PAM activity.  
The attempted modifications in the isoindolinone scaffold demonstrated that there is 
room for change in the structure, especially when these compounds are compared with the naked 
isoindolinone 6.194. The isoindolinone homologues 6.209 and 6.210 maintained mGlu1 PAM 
activity, being the 3,4-dihydroisoquinolinone 6.210 the most active of these examples with a 
submicromolar EC50 of 780 nM. The oxyindole 6.211 showed low PAM activity while its 
homologue dihydroquinolinone 6.212 was highly efficacious and had an mGlu1 PAM potency 
close to 1 µM. These isoindolinone-related ring systems are interesting, and they could be starting 
points for more SAR directed to find if their substituted analogs can increase potency on target. 
From this group, it was decided to explore further the 4-chloro analog 6.197 VU0487351, 
as it represented the most potent isoindolinone example. The activity of 6.197 VU0487351in rat 
mGlu1 was evaluated to determine its PAM activity cross-species, and it was found that the 
compound presented a 2-fold decrease in activity with respect to the human receptor, achieving a 
potency of 513 nM (93% GluMax). The compound was also analyzed for mGlu selectivity against 
mGlu4 and mGlu5 where it demonstrated to be highly selective, showing over 10 µM potencies 
and efficacies below 40% in both cases. 
The in vitro pharmacokinetic properties of 6.197 VU0487351were analyzed to evaluate 
its intrinsic clearance and plasma fraction unbound (Table 6.15). VU0487351 displayed moderate 
clearance in human liver microsomes (40% of the hepatic blood flow) and high clearance in the 
rat microsomal preparation (77% of the hepatic blood flow) with a clean P450 inhibition profile 
(1A2, 2D6, 2C9, 3A4). The compound was remarkably stable in plasma, maintaining high 
concentrations of test article after incubations in this media for 4 hours. However, the main caveat 
of 6.197 is its small free fraction in plasma and brain homogenate, as it was found to be around 
0.1%. 
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Table 6.15. In vitro pharmacokinetic properties of isoindolinone 6.197 VU0487351. 
PK parameter VU0487351 
Human Clint (mL/min/kg) 14.4 
Human Clhep (mL/min/kg) 8.53 
Rat Clint (mL/min/kg) 239 
Rat Clhep (mL/min/kg) 54.1 
P450 IC50 (µM) 
1A2, 2C9, 2D6, 3A4 
>30 
Human Plasma Stability (4h) 91% 
Rat Plasma Stability (4h) 78% 
Human Fu plasma <0.001 
Rat Fu plasma 0.001 
Rat Fu Brain 0.001 
 
 In vivo pharmacokinetic analysis of 6.197 VU0487351 demonstrated that the compound 
is brain penetrant after IV administration, with a Kp higher than 1 (Table 6.16). VU0487351 6.197 
displayed a disconnect from its in vivo metabolism, as after IV administration it was observed that 
the compound had low clearance and a half-life close to 90 minutes. The pharmacodynamic and 
pharmacokinetic properties of VU0487351 6.197 make this compound the most attractive PAM 
after VU6004909 6.48. 
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Table 6.16. In vivo pharmacokinetic properties of isoindolinone 6.197 VU0487351. 
PK parameter VU0487351 
Kp  (0.2 mg/kg IV, 0.25 h) 1.39 
Kp,uu 1.39 
Rat IV PK (0.2 mg/kg IV) 
t1/2 (min) 
Clp (mL/min/kg) 
Vss (L/Kg) 
 
93 
11.1 
3.36 
 
Finally, changes in the central phenyl ring were assessed in the context of the 
isoindolinones. For this purpose, the naked phenyl ring and the fluoro substituted one were 
selected as they demonstrated to maintain good potency in the context of the phthalimide. In 
addition, a dichlorophenyl central ring was employed to assess the effect of hindered rotation on 
the isoindolinone side, as well as the replacement of the furan of the VU0486321 5.35c for the 
thiazole moiety. The synthesis of analogs to explore different phenyl rings was made as described 
in scheme 6.15, but using different anilines 6.36a, 6.44 and 6.213 (Scheme 6.16A). While for the 
thiazole analogs intermediate 6.18 was employed and reacted with the bromomethylbenzoates to 
produce isoindolinones 6.223-6.225 (Scheme 6.16B). 
 
Scheme 6.16. Synthesis of isoindolinone analogs of VU0486321 5.35c with additional 
modifications in the central phenyl ring, analogs 6.223-6.225. 
A 
B 
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 When the analogs were tested in our calcium mobilization assay to obtain their mGlu1 
potencies, it was observed that unsubstituted phenyl ring analogs 6.214-6.216 had similar 
potencies compared to the chloro substituted phenyl analogs like VU0487351 6.197. The 
fluorophenyl isoindolinones 6.217-6.219 demonstrated that the changes in activity observed in 
the modified central phenyl ring analogs of the phthalimide cannot be directly extrapolated to the 
isoindolinone scaffold; as this fluoro substitution was beneficial in the phthalimide scaffold 
generating compounds with potencies under 25 nM, while in the case of the isoindolinones it 
induced an important decrease of mGlu1 PAM activity. The introduction of two chlorines in the 
ring (6.220-6.222) was also detrimental for activity, identifying that hindering rotation around in 
the isoindolinone side of the scaffold is not a good feature for PAM activity on the receptor. 
 
Table 6.17. Potencies in human mGlu1 of isoindolinone related analogs 6.214-6.225. Calcium 
mobilization responses for each compound are reported as a percentage of the maximum 
glutamate response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean ± S.E.M. of at least three independent experiments with 
similar results. ---, no potentiation. ND, not determined.      
   
Structure Cpd # VU # 
hmGlu1 
EC50 (µM) %GluMax 
 
6.214 VU6005732 1.60 94 
 
6.215 VU0487916 0.35 101 
 
6.216 VU0487915 0.25 100 
 
6.217 VU6005728 >10 6 
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6.218 VU6005686 1.26 86 
 
6.219 VU6005685 >10 9 
 
6.220 VU0517623 >10 28 
 
6.221 VU0517516 6.53 82 
 
6.222 VU0517528 >10 49 
 
6.223 VU6003733 >10 33 
 
6224 VU6005687 2.67 71 
 
6.225 VU0517646 0.95 66 
 
Another example of the non-additive behavior of the SAR allosteric modulators was 
observed with the introduction of the thiazole group (6.223-6.225). This ring that engendered 
potent compounds in the context of the phthalimide, decreased considerably the activity with 
respect to the furan in the isoindolinone analogs; but, it maintained a similar order in the 
potencies (EC50 unsubstituted 6.223 > 7-chloro 6.224 > 4-chloro 6.225). 
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Summary and future directions 
 
In an effort to improve the pharmacodynamic and pharmacokinetic properties around the 
scaffold VU0486321 5.35c, its SAR was explored in the furancarboxamide, the central phenyl 
ring and the phthalimide region. Attempts to replace the 3-methylfuran with other methyl 
substituted five-member rings produced more tractable SAR compared to the unsubstituted 
versions tested in chapter 5. From this group, the pyrazole, imidazole, oxazole and thiazole 
delivered good potencies, and phthalimides focused libraries where synthesized containing these 
four pieces. Better mGlu1 PAMs were obtained with the thiazole moiety in terms of potency and 
selectivity; however, they did not represent an important improvement with respect to 
VU0486321 5.35c. The removal of the carbonyl was also attempted on this side of the molecule, 
but it caused a complete loss in mGlu1 PAM. 
 
 
Figure 6.6. Structure activity relationship around VU0486321 5.35c. 
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 In the central phenyl ring, the insertion of methylenes between the nitrogen and the 
aromatic ring in either side of the molecule was detrimental for mGlu1 activity, as well as using 
saturated hydrocarbon rings such as the cyclohexyl and the cyclobutyl. Additionally, it was found 
that the ring could tolerate a vast array of small substituents to replace the chlorine, as well as 
swapping the ring for a pyridine or a naphthalene. In the adjacent position, SAR demonstrated to 
be tighter, only allowing fluoro, chlorine and methyl substituents; but increasing considerably the 
selectivity in the case of the fluoro and the chloro analogs. The fluoro 6.37f was found to be the 
best of the pair due to its good brain penetrance. Additional analogs of 6.37f with different 
substitutions in the phthalimide also showed good potency and selectivity. From this group, 
VU6004909 (6.48) stood out due its low clearance and longer half-life of close to five hours. 
Because of its optimized pharmacodynamic and pharmacokinetic characteristics, VU6004909 
6.48 is the best mGlu1 PAM that has been reported to date (Fig. 6.7). 
 
  
Figure 6.7. Pharmacodynamic and pharmacokinetic profile of VU6004909 6.48 and VU0487351 
6.197. 
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Different strategies to replace the phthalimide were also tested in this chapter to develop 
compounds with no plasma instability. From these efforts, it was observed that ring opening, tied-
back ring analogs and reverse amides were not suitable alternatives to the phthalimide group due 
to a great decrease in potency against the mGlu1 receptor. The production of isoindolinones was 
also assayed, as in chapter 4 with analogs of VU0483605 4.77b. In the context of the furan, a 
similar tendency was observed after walking the chlorine around the ring, with the 4-
chloroisoindolinone 6.197 (VU0487351) being the most potent analog of this class. Different 
substituents, the introduction of nitrogens in the ring as well as the homologation of the 
isoindolinone, were attempted; however, none of these modifications generated a compound with 
better activity than 6.197. Interestingly, when the selectivity and pharmacokinetic properties of 
VU0487351 6.197 were evaluated, the compound demonstrated to not potentiate the mGlu4 
receptor and to possess relatively good pharmacokinetic properties with an in vivo half-life close 
to 90 minutes, good plasma stability and relatively small plasma fraction unbound (Fig. 6.7).  
VU0487351 6.197 and VU6004909 6.48 were found to be the best compounds obtained 
from our efforts in the development of novel mGlu1 PAMS. In the future, we plan to analyze the 
pharmacokinetic properties of these compounds using different routes of administration besides 
intravenous, and to determine the best way to deliver the PAMs into animals. Once this is 
clarified, the effect of these modulators will be evaluated in in vivo behavioral assays such 
amphetamine or MK-801 induced hyperlocomotion and prepulse inhibition, typical models that 
try to imitate relevant features of the schizophrenic phenotype. Additionally, an effort to 
characterize the consequences of in vitro mGlu1 activation in neurons has recently been initiated 
in the laboratory of P. Jeffrey Conn. Preliminary electrophysiological studies have shown that the 
application of VU6004909 potentiates the decrease in dopamine release in the striatum, a 
desirable feature for antipsychotic activity. 
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EXPERIMENTAL METHODS 
 
General chemical synthesis and characterization  
All reactions were carried out employing standard chemical techniques under inert 
atmosphere. All reagents and solvents were commercial grade and purified prior to use when 
necessary. Solvents used for extraction, washing, and chromatography were HPLC grade. 
Analytical thin layer chromatography was performed on 250 μm silica gel glass backed plates 
from Sorbent Technologies. Visualization was accomplished with UV light, and/or the use of 
iodine or ninhydrin solution followed by heating. Analytical HPLC was performed on an Agilent 
1200 LCMS with UV detection at 215 and 254 nm along with ELSD detection and electrospray 
ionization, with all final compounds showing >95% purity and a parent mass ion consistent with 
the desired structure. Low resolution mass spectra were obtained on an Agilent 6130 mass 
spectrometer with electrospray ionization source.  MS parameters were as follows:  fragmentor:  
100, capillary voltage:  3000 V, nebulizer pressure:  40 psig, drying gas flow:  11 L/min, drying 
gas temperature:  350° C.  Samples were introduced via an Agilent 1200 HPLC comprised of a 
degasser, G1312A binary pump, G1367B HP-ALS, G1316A TCC, G1315D DAD, and a Varian 
380 ELSD.  UV absorption was generally observed at 215 nm and 254 nm with a 4 nm 
bandwidth.  Column:  Thermo Accucore C18, 2.1 x 30 mm, 2.6 µm. Gradient conditions:  7% to 
95% CH3CN in H2O (0.1% TFA) over 1.6 min, hold at 95% CH3CN for 0.35 min, 1.5 mL/min, 
45° C. Flash column chromatography was performed on a Teledyne ISCO Combiflash Rf system. 
Preparative purification of library compounds was performed on a Gilson 215 preparative LC 
system. Column: Thermo Accucore C18, 2.1 x 30 mm, 2.6 µm.  Gradients condition: variable, 
CH3CN in H2O (0.1% TFA) over 4 minutes, hold at 95% CH3CN for 0.35 min, 50 mL/min. 
Purity for all final compounds was >95%, and each showed a parent mass ion consistent with the 
desired structure in low resolution LC-MS. 
1
H and 
13
C NMR spectra were recorded on Bruker 
DRX-400 (400 MHz) instrument. Chemical shifts are reported in ppm relative to residual solvent 
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peaks as an internal standard at the following chemical shifts (
1
H and 
13
C respectively): 7.26 and 
77.0 ppm for CDCl3; 2.50 and 39.52 ppm for DMSO-d6, 3.31 and 49.2 ppm for CD3OD. Data are 
reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q 
= quartet, dd = doublet of doublets, br = broad, m = multiplet), coupling constant (Hz).  
 
General synthesis N-(nitroaryl)-3-methylfuran-2-carboxamide (6.35a-6.35l). In a 
microwave vial, the aromatic amine (1.2 equiv.) was added and dissolved in a mixture 
DCE:DIEA (9:1) (concentration of the amine 0.15 M), followed by addition of 3-
methylfurancarbonyl chloride. The reaction was heated in the microwave at 120 °C for 30 
minutes. The reaction was cooled to room temperature and water was added, causing the 
precipitation of the product. The crude product was filtrated in vacuo and titrated with cold 
methanol to give product. 
 
3-methyl-N-(4-nitrophenyl)furan-2-carboxamide (6.35a). Cream solid. 
1
H-NMR 
(400.1 MHz, DMSO-d
6) δ (ppm): 8.35 (1H, s), 8.26 (2H, d, J=9.2 Hz), 7.85 (2H, d, J=9.1 Hz), 
7.43 (1H, d, J=1.3 Hz), 6.46 (1H, d, J=1.3 Hz), 2.48 (3H, s). 
13
CNMR (100.6 MHz, DMSO-d
6) δ 
(ppm): 157.1, 143.5, 143.4, 143.1, 141.2, 130.6, 125.1, 118.9, 116.2, 11.3 
 
General synthesis N-(aminoaryl)-3-methylfuran-2-carboxamide (6.36a-6.36l). In a 
flask, the corresponding nitroaryl 6.35 (1.0 equiv.) was suspended in dioxane (0.1 M 
concentration of 6.35). The suspension was cold in an ice bath and purged with argon. A 
previously prepared solution of tin(II) chloride (4.5 equiv.) in concentrated hydrochloric acid (5M 
concentration of SnCl2) was added dropwise to the suspension. After 2 hour of stirring at room 
temperature, the reaction was neutralized carefully with aqueous potassium carbonate 20%, 
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filtered and extracted with diethyl ether. The organic phase was dried with magnesium sulfate, 
filtered and the volatiles eliminated in vacuo to yield product. 
  
N-(4-aminophenyl)-3-methylfuran-2-carboxamide (6.36a). Yellow solid. 
1
H-NMR 
(400.1 MHz, CDCl3) δ (ppm): 7.97 (1H, s), 7.39 (2H, d, J=8.4 Hz), 7.31 (1H, s), 6.65 (2H, d, 
J=8.4 Hz), 6.36 (1H, s), 3.59 (2H, s), 2.43 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 157.3, 
143.3, 142.2, 142.1, 128.8, 128.1, 121.8, 115.6, 115.4, 11.2. 
 
General synthesis N-(4-(1,3-dioxoisoindolin-2-yl)aryl)-3-methylfuran-2-carboxamide 
(6.37a-6.37l). In a vial, the corresponding aniline 6.36 (1.0 equiv.) and the corresponding phthalic 
anhydride (1.5 equiv.) were added and dissolved in acetic acid (0.12 M concentration of the 
aniline). The mixture was heated at 110 °C while stirring for 4 hours. After this time, volatiles 
were evaporated, the crude product was dissolved in DMSO and purified by preparative HPLC. 
 
N-(4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide (6.37a1). 
Cream solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.13 (1H, s), 7.95 (2H, m), 7.80 (4H, m), 
7.44 (2H, m), 7.39 (1H, d, J=1.5 Hz), 6.41 (1H, d, J=1.5 Hz), 2.47 (3H, s). 
13
CNMR (100.6 MHz, 
CDCl3) δ (ppm): 167.3, 157.2, 142.6, 141.7, 137.4, 134.3, 131.7, 129.3, 127.3, 127.2, 123.7, 
120.0, 115.9, 11.2. 
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3-methyl-N-(4-(4-methyl-1,3-dioxoisoindolin-2-yl)phenyl)furan-2-carboxamide 
(6.37a2). Cream solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.14 (1H, s), 7.79 (3H, m), 7.64 
(1H, t, J= 7.5 Hz), 7.53 (1H, d, J= 7.8 Hz), 7.43 (2H, d, J= 8.8 Hz), 7.38 (1H, d, J= 1.5 Hz), 6.41 
(1H, d, J= 1.5 Hz), 2.75 (3H, s), 2.47 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 167.8, 
167.3, 157.2, 142.5, 141.7, 138.4, 137.3, 136.7, 133.8, 132.1, 129.2, 128.3, 127.4, 127.2, 121.3, 
119.9, 115.9, 17.7, 11.2. 
 
N-(4-(4-chloro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide 
(6.37a3). Cream solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.14 (1H, s), 7.88 (1H, t, J= 4.1 
Hz), 7.80 (2H, d, J= 8.8 Hz), 7.71 (2H, m), 7.44 (2H, d, J= 8.8 Hz), 7.38 (1H, d, J= 1.4 Hz), 6.41 
(1H, d, J= 1.4 Hz), 2.46 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 165.8, 164.8, 157.3, 
142.6, 141.7, 137.6, 136.1, 135.2, 133.8, 131.8, 129.4, 127.3, 127.2, 126.9, 122.2, 120.0, 115.9, 
11.2. 
  
N-(4-(4-fluoro-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide 
(6.37a4). Cream solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.14 (1H, s), 7.80 (4H, m), 7.45 
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(3H, m), 7.39 (1H, d, J= 1.5 Hz), 6.42 (1H, d, J= 1.5 Hz), 2.46 (3H, s). 
13
CNMR (100.6 MHz, 
DMSO-d6) δ (ppm): 166.5, 164.4, 157.9, 157.3 (
1
JCF=261.0 Hz), 144.1, 142.1, 138.9, 138.0 
(
3
JCF=7.8 Hz), 134.3, 128.5, 128.1, 127.1, 123.0 (
2
JCF=19.8 Hz), 121.0, 120.3 (
4
JCF=3.0 Hz), 
117.9 (
2
JCF=12.4 Hz), 116.1, 11.5. 
General synthesis of bis Boc-protected nitroanilines (638m-6.38o and 6.42). In a 
flask, the corresponding nitroaniline (1.0 equiv.) was added and dissolved in THF (0.2 M 
concentration of the aniline). Then, ditert-butyl dicarbonate (2.2 equiv.) was added, followed by 
DMAP (0.2 equiv.). The mixture was stirred at room temperature and monitored by LC-MS. The 
reaction was stopped when full conversion to the bis Boc-protected nitroaniline was observed 
with no sign of the mono-Boc product. The reaction was worked up by the addition of water and 
performing successive extractions with DCM. The organic phases were combined, dried with 
anhydrous MgSO4, filtered and concentrated in vacuo. 
 
Bis(tert-butyl)(3-fluoro-4-nitrophenyl)carbamate (6.42). White solid. 
1
H-NMR (400.1 
MHz, CDCl3) δ (ppm): 8.08 (1H, t, J=8.6 Hz), 7.15 (1H, dd, J=11.4, J=2.1), 7.11 (1H, m), 1.46 
(18H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 155.3 (
1
JCF=266 Hz), 150.4, 145.5 (
2
JCF=10.0 
Hz), 135.7 (
3
JCF=7.2 Hz), 126.1 (
4
JCF=1.5 Hz), 123.8 (
3
JCF=3.9 Hz), 117.7 (
2
JCF=22.5 Hz), 84.2, 
27.7. 
 
General synthesis of bis Boc-protected aminoanilines (639m-6.39o and 6.43). In a 
flask, the corresponding Boc-protected nitroaniline (1.0 equiv.) was added and dissolved in 
ethanol (0.1 M concentration of the aniline). Then 10% Pd/C was added (50 mg/mmol of 
nitroaniline). The flask was filled with argon and evacuated three times. This procedure was 
repeated with hydrogen, maintaining the system under hydrogen after last purge. The mixture was 
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stirred at room temperature and monitored by LC-MS. The reaction was stopped when full 
conversion to the bis Boc-protected aminoaniline was observed with no sign of starting material. 
The product was obtained by filtration of the reaction matrix through a celite pad, washing with 
DCM and evaporating the volatiles from the filtrate in vacuo. 
 
Bis(tert-butyl)(4-amino-3-fluorophenyl)carbamate (6.43). Yellow oil. 
1
H-NMR (400.1 
MHz, CDCl3) δ (ppm): 6.76 (1H, d, J=11.6 Hz), 6.69 (2H, m), 3.77 (2H, br s), 1.40 (18H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 152.0, 150.6 (
1
JCF=239 Hz), 134.0 (
2
JCF=12.68 Hz), 
129.5 (
3
JCF=9.0 Hz), 124.0 (
4
JCF=3.0 Hz), 116.0 (
3
JCF=4.3 Hz), 115.1 (
2
JCF=20.0 Hz), 84.5, 27.8. 
 
General synthesis of bis Boc N-(aminoaryl)-3-methylfuran-2-carboxamides (6.40m-
6.40o and 6.44). In a flask, the corresponding bis Boc-protected aminoaniline (1.2 equiv.) was 
added and dissolved in a mixture DCE:DIEA (9:1) (concentration of the amine 0.15 M), followed 
by addition of 3-methylfurancarbonyl chloride. The reaction was stirred at room temperature and 
monitored by LC-MS. The reaction was stopped when full conversion to the furancarboxamide 
was observed with no sign of starting material. The reaction was worked up by the addition of 
water and successive extractions with DCM. The organic phases were combined, dried with 
MgSO4, filtered and the volatiles concentrated in vacuo. The crude product was purified by silica 
gel flash chromatography, using a gradient of hexanes:EtOAc. 
 
Bis(tert-butyl)(3-fluoro-4-(3-methylfuran-2-carboxamido)phenyl)carbamate (6.44). 
White solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.41 (1H, dd, J=9.0 Hz, J=8.6 Hz), 8.24 
(J=2.8 Hz), 7.32 (J=1.6 Hz), 6.90 (1H, m), 6.87 (1H, m), 6.33 (J=1.6 Hz), 2.38 (3H, s), 1.35 
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(18H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 157.1, 151.5 (
1
JCF=244.5 Hz), 151.4, 142.9, 
141.6, 134.7 (
3
JCF=9.7 Hz), 129.5, 125.6 (
3
JCF=9.7 Hz), 124.2 (
4
JCF=3.1 Hz), 120.5, 115.9, 114.8 
(
2
JCF=20.7 Hz), 82.9, 27.8, 11.2. 
 
General synthesis N-(4-(1,3-dioxoisoindolin-2-yl)aryl)-3-methylfuran-2-
carboxamides (6.37m-6.37o and 6.45-6.51). In a vial, the corresponding bis Boc-protected 
aniline (1.0 equiv.) was added and dissolved in DCM (0.1 M concentration of the bis Boc-
protected aniline). TFA was added drop wise to a final concentration of 10% v/v. The reaction 
was stirred at room temperature for and monitored by LC-MS. The reaction was stopped when 
full deprotection of the starting material was observed. The reaction was worked up by 
evaporating the volatiles in vacuo and the product was use crude for the subsequent step. In a 
vial, the crude deprotected aniline (1.0 equiv.) and the corresponding phthalic anhydride (1.5 
equiv.) were added and dissolved in acetic acid (0.12 M concentration of the aniline). The 
mixture was heated at 110 °C while stirring for 4 hours. After this time, volatiles were 
evaporated, the crude product was dissolved in DMSO and purified by preparative HPLC. 
 
N-(2-fluoro-4-(4-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-
carboxamide (6.45). Pale yellow solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.64 (1H, dd, 
J=9.1 Hz, J=8.6 Hz), 8.39 (1H, br s), 7.80 (1H, d, J=7.3 Hz), 7.66 (1H, t, J=7.3 Hz), 7.56 (1H, d, 
J=7.7 Hz), 7.43 (J=1.4 Hz), 7.30-7.36 (m, 2H), 6.44 (1H, d, J=1.4 Hz), 2.77 (3H, s), 2.49 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 167.6, 166.9, 157.1, 151.8 (
1
JCF=244.2 Hz), 143.0, 141.6, 
138.6, 136.8, 134.0, 131.9, 129.7, 128.1, 127.1 (
3
JCF=10.0 Hz), 126.0 (
3
JCF=10.0 Hz), 122.6 
(
4
JCF=3.3 Hz), 121.4, 121.0, 115.9, 113.4 (
2
JCF=22.3 Hz), 17.7, 11.2. 
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N-(2-fluoro-4-(5-methyl-1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-
carboxamide (6.48). Pale yellow solid. 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.62 (1H, dd, 
J=9.2 Hz, J=8.5 Hz), 8.35 (1H, d, J=2.2 Hz), 7.83 (1H, d, J=7.7 Hz), 7.75 (1H, s), 7.58 (1H, d, 
J=7.6 Hz), 7.41 (1H, d, J=1.6 Hz), 7.34-7.28 (2H, m), 6.41 (1H, d, J=1.5 Hz), 2.55 (3H, s), 2.46 
(3H, s).
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 167.1, 166.9, 157.1, 151.7 (
1
JCF=245.0 Hz), 
145.9, 142.9, 141.6, 135.1, 131.9, 129.7, 128.9, 127.2 (
3
JCF=10.0 Hz), 126.9 (
3
JCF=9.9 Hz), 124.3, 
123.7, 122.5 (
4
JCF=3.5 Hz), 121.0, 115.9, 113.3 (
2
JCF=22.3 Hz), 22.0, 11.2. 
 
General procedure for the synthesis of N-(3-chloro-4-(1-oxoisoindolin-2-yl)phenyl)-
3-methylfuran-2-carboxamide (6.194-6.206). In a microwave vial, the corresponding methyl 
bromomethylbenzoate (0.085 mmol, 1.2 equiv.) and aniline (0.0709, 1.0 equiv.) were added and 
dissolved in 1 mL of DMF. Then, K2CO3 (0.141 mmol, 2.0 equiv.) was added and the vial was 
sealed. The reaction was heated in the microwave at 150 °C for 15 minutes. The reaction was 
monitored by LC-MS and a second round of heating was applied if there was presence of starting 
material or the acyclic ester intermediate. The reaction was worked up by addition of water and 
successive extractions with DCM. The organic phases were filtered through a phase separator, 
combined and volatiles were evaporated in vacuo. Crude products were dissolved in DMSO and 
purified by preparative HPLC. 
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N-(3-chloro-4-(7-chloro-1-oxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide 
(6.195). 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.22 (1H, s), 8.00 (1H, d, J= 2.4 Hz), 7.56 (1H, 
J= 8.5 Hz, J= 2.4 Hz), 7.52 (1H, d, J= 7.5 Hz), 7.47 (1H, d, J= 7.5 Hz), 7.41 (1H, d, J= 7.4 Hz), 
7.36 (2H, m), 6.41 (1H, d, J= 1.5 Hz), 4.75 (2H, s), 2.46 (3H, s). 
13
CNMR (100.6 MHz, CDCl3) δ 
(ppm): 165.9, 157.3, 144.0, 142.8, 141.5, 138.5, 132.9, 132.7, 132.2, 130.8, 130.2, 129.9, 129.7, 
127.9, 121.3, 121.2, 118.7, 116.0, 51.1, 11.2. 
 
N-(3-chloro-4-(4-chloro-1-oxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide 
(6.197). 
1
H-NMR (400.1 MHz, CDCl3) δ (ppm): 8.16 (1H, s), 8.02 (1H, d, J= 2.3 Hz), 7.87 (1H, 
J= 7.4 Hz), 7.59 (2H, m), 7.51 (1H, t, J= 7.7 Hz), 7.38 (2H, m), 6.42 (1H), 4.78 (2H, s), 2.47 (3H, 
s). 
13
CNMR (100.6 MHz, CDCl3) δ (ppm): 167.3, 157.2, 142.8, 141.4, 139.8, 138.6, 133.9, 133.1, 
131.9, 130.7, 130.1, 129.9, 129.8, 129.2, 129.8, 129.2, 122.8, 121.1, 118.7, 116.0, 51.4, 11.2. 
 
Molecular pharmacology 
Molecular pharmacology experiments to characterize the mGlu1 PAMs were performed 
following the procedures in chapter 3 and 4. 
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Pharmacokinetic characterization 
The in vitro DMPK assays, including those assessing hepatic microsomal intrinsic 
clearance (Clint), cytochrome P450 inhibition, plasma protein binding (PPB) and brain 
homogenate binding (BHB) were performed as described previously.
285
 The experimental 
procedures for the pharmacokinetic characterization of the compounds are described in chapter 3.  
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Appendix A 
 
Relevant spectra for chapter I 
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Current Data Parameters
NAME          pmg-9-192
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20160517
Time               9.28
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                76.59
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300098 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME       PMG-9-74_Pub
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20160512
Time              17.58
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                 7.07
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300095 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          pmg-9-193
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20160517
Time              19.27
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   64
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                27.16
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300090 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          pmg-9-123
EXPNO                 4
PROCNO                1
F2 - Acquisition Parameters
Date_          20160517
Time              17.35
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                15.57
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300689 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME           pmg-9-73
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160505
Time               6.45
INSTRUM           spect
PROBHD   5 mm CPTCI 1H-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            7836.991 Hz
FIDRES         0.239166 Hz
AQ            2.0906484 sec
RG                 7.12
DW               63.800 usec
DE                12.36 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1330006 MHz
NUC1                 1H
P1                 9.25 usec
PLW1         6.35610008 W
F2 - Processing parameters
SI                32768
SF          600.1300846 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          pmg-9-142
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160505
Time               0.13
INSTRUM           spect
PROBHD   5 mm CPTCI 1H-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            7836.991 Hz
FIDRES         0.239166 Hz
AQ            2.0906484 sec
RG                    8
DW               63.800 usec
DE                12.36 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1330006 MHz
NUC1                 1H
P1                 9.25 usec
PLW1         6.35610008 W
F2 - Processing parameters
SI                32768
SF          600.1300235 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          PMG-9-172
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160318
Time              13.19
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                34.15
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300039 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME          pmg-4-112
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160504
Time              22.04
INSTRUM           spect
PROBHD   5 mm CPTCI 1H-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            7836.991 Hz
FIDRES         0.239166 Hz
AQ            2.0906484 sec
RG                 7.12
DW               63.800 usec
DE                12.36 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1330006 MHz
NUC1                 1H
P1                 9.25 usec
PLW1         6.35610008 W
F2 - Processing parameters
SI                32768
SF          600.1300151 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          pmg-9-144
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160505
Time               2.24
INSTRUM           spect
PROBHD   5 mm CPTCI 1H-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            7836.991 Hz
FIDRES         0.239166 Hz
AQ            2.0906484 sec
RG                 7.12
DW               63.800 usec
DE                12.36 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1330006 MHz
NUC1                 1H
P1                 9.25 usec
PLW1         6.35610008 W
F2 - Processing parameters
SI                32768
SF          600.1300148 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          pmg-9-171
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160505
Time               4.35
INSTRUM           spect
PROBHD   5 mm CPTCI 1H-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            7836.991 Hz
FIDRES         0.239166 Hz
AQ            2.0906484 sec
RG                 7.12
DW               63.800 usec
DE                12.36 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1330006 MHz
NUC1                 1H
P1                 9.25 usec
PLW1         6.35610008 W
F2 - Processing parameters
SI                32768
SF          600.1300151 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          pmg-9-173
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160505
Time               8.55
INSTRUM           spect
PROBHD   5 mm CPTCI 1H-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            7836.991 Hz
FIDRES         0.239166 Hz
AQ            2.0906484 sec
RG                 7.12
DW               63.800 usec
DE                12.36 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1330006 MHz
NUC1                 1H
P1                 9.25 usec
PLW1         6.35610008 W
F2 - Processing parameters
SI                32768
SF          600.1300159 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          pmg-9-189
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160517
Time              21.03
INSTRUM           spect
PROBHD   5 mm CPTCI 1H-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            7836.991 Hz
FIDRES         0.239166 Hz
AQ            2.0906484 sec
RG                 7.12
DW               63.800 usec
DE                12.36 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1330006 MHz
NUC1                 1H
P1                 9.25 usec
PLW1         6.35610008 W
F2 - Processing parameters
SI                32768
SF          600.1300154 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          PMG-9-191
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160503
Time              14.55
INSTRUM           spect
PROBHD   5 mm CPTCI 1H-
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                    4
DS                    0
SWH            7836.991 Hz
FIDRES         0.239166 Hz
AQ            2.0906484 sec
RG                   32
DW               63.800 usec
DE                12.36 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1330006 MHz
NUC1                 1H
P1                 9.25 usec
PLW1         6.35610008 W
F2 - Processing parameters
SI                32768
SF          600.1300084 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Appendix B 
 
Relevant spectra for chapter II
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Appendix C 
 
Relevant spectra for chapter III 
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Current Data Parameters
NAME           pmg-1-72
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160906
Time              13.56
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               121.51
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME        pmg-5-88-19
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20160906
Time              13.46
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                95.05
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME        pmg-5-88-28
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20160906
Time              13.24
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               108.86
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Relevant spectra for chapter IV
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Current Data Parameters
NAME          pmg-1-149
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140227
Time              16.30
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                86.04
DW               96.000 usec
DE                15.87 usec
TE                297.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300381 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME         pmg-1-151b
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140227
Time              16.34
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                76.59
DW               96.000 usec
DE                15.87 usec
TE                296.9 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME        PMG-1-21_1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130516
Time              16.29
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                287.4
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-21_1
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20130520
Time              19.11
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-21_2H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130516
Time              16.34
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  362
DW               96.000 usec
DE                 6.00 usec
TE                297.9 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-21_2
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20130521
Time               2.41
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME           pmg-5-87
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140610
Time              11.17
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               172.42
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME         PMG-1-21_3
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20130521
Time               5.01
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-21_4H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130516
Time              16.44
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                287.4
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-21_4
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20130521
Time               7.22
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME         pmg-1-28-1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140227
Time              16.38
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               137.48
DW               96.000 usec
DE                15.87 usec
TE                296.9 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME         pmg-1-28-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140227
Time              16.41
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               108.86
DW               96.000 usec
DE                15.87 usec
TE                296.9 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME         pmg-1-32-1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140227
Time              17.43
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                95.05
DW               96.000 usec
DE                15.87 usec
TE                296.9 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME         pmg-1-32-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140227
Time              17.47
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               108.86
DW               96.000 usec
DE                15.87 usec
TE                296.9 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME      PMG-1-35-4_3H
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20130910
Time              17.41
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  362
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-35-4
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20130627
Time               8.45
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 1834
DS                    0
SWH           31446.541 Hz
FIDRES         0.959672 Hz
AQ            0.5210612 sec
RG                16384
DW               15.900 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                10.00 usec
PL1      0 dB
SFO1        125.7715720 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2            100.00 usec
PL2              120.00 dB
PL12              19.42 dB
PL13              19.00 dB
SFO2        500.1325010 MHz
F2 - Processing parameters
SI                32768
SF          125.7577917 MHz
WDW                  EM
SSB      0
LB                 1.50 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-101-2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20130924
Time              19.55
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                322.5
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME        PMG-1-101-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130927
Time               0.05
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
  
 
4
1
4
 
 
Current Data Parameters
NAME       PMG-1-35-1_H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130627
Time               8.23
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                574.7
DW               96.000 usec
DE                25.61 usec
TE                298.0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                11.38 usec
PL1               -2.50 dB
PL1W        18.35869598 W
SFO1        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          400.1300065 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME        PMG-1-101-4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time              16.53
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  362
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
11 10 9 8 7 6 5 4 3 2 1 0 ppm
2
.
8
4
6
7
.
2
8
4
7
.
3
3
8
7
.
3
5
9
7
.
4
3
1
7
.
4
4
3
7
.
4
5
1
7
.
4
6
3
7
.
7
0
9
7
.
7
2
8
7
.
7
6
5
7
.
7
7
1
7
.
7
8
8
7
.
7
9
2
7
.
8
0
4
7
.
8
0
8
7
.
9
2
3
7
.
9
4
3
7
.
9
6
5
7
.
9
6
9
8
.
2
0
1
8
.
2
0
7
8
.
4
7
2
8
.
4
8
2
1
0
.
5
6
0
3
.
1
8
1
1
.
0
0
6
1
.
0
1
0
1
.
0
2
9
2
.
0
2
3
1
.
0
1
6
0
.
9
2
1
1
.
0
0
3
1
.
0
1
4
1
.
0
0
0
  
 
4
1
7
 
 
 
220 200 180 160 140 120 100 80 60 40 20 ppm
2
0
.
5
3
8
7
6
.
6
2
0
7
6
.
9
3
7
7
7
.
2
5
5
1
1
8
.
5
0
6
1
2
0
.
8
2
9
1
2
4
.
2
9
5
1
2
4
.
3
7
1
1
2
5
.
1
1
9
1
2
6
.
4
6
8
1
2
9
.
8
7
5
1
3
0
.
6
7
5
1
3
3
.
4
8
6
1
3
3
.
5
9
2
1
3
4
.
4
7
4
1
3
6
.
6
6
5
1
4
0
.
1
2
2
1
4
1
.
1
7
4
1
4
2
.
0
4
0
1
4
4
.
5
9
1
1
4
5
.
7
7
2
1
6
3
.
0
4
0
1
6
5
.
4
8
8
1
6
5
.
8
0
5
Current Data Parameters
NAME        PMG-1-101-4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130927
Time               2.27
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME       PMG-1-35-2_H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130627
Time               8.29
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                574.7
DW               96.000 usec
DE                25.61 usec
TE                298.0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                11.38 usec
PL1               -2.50 dB
PL1W        18.35869598 W
SFO1        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          400.1300065 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME        PMG-1-101-6
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time              17.21
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                456.1
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME        PMG-1-101-6
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130928
Time               2.37
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-101-8
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time              17.35
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  512
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
11 10 9 8 7 6 5 4 3 2 1 0 ppm
1
.
8
1
2
2
.
8
5
1
7
.
2
8
4
7
.
3
4
5
7
.
3
6
7
7
.
4
4
4
7
.
4
5
5
7
.
4
6
3
7
.
4
7
5
7
.
9
0
7
7
.
9
1
9
8
.
2
2
6
8
.
2
3
1
8
.
4
8
5
8
.
4
9
5
9
.
1
8
3
9
.
1
9
5
9
.
3
1
1
1
0
.
5
8
6
3
.
2
0
8
0
.
9
7
5
1
.
0
4
5
1
.
0
4
2
0
.
9
9
9
0
.
9
7
6
0
.
9
8
5
1
.
0
3
5
0
.
9
8
0
0
.
8
9
8
1
.
0
0
0
  
 
4
2
3
 
 220 200 180 160 140 120 100 80 60 40 20 ppm
2
0
.
6
7
9
7
6
.
6
1
7
7
6
.
9
3
4
7
7
.
2
5
1
1
1
7
.
3
0
5
1
1
8
.
4
6
4
1
2
0
.
7
8
8
1
2
3
.
8
2
5
1
2
5
.
6
9
8
1
2
6
.
4
7
2
1
3
0
.
5
5
9
1
3
3
.
5
1
6
1
3
6
.
6
8
1
1
3
9
.
2
1
6
1
4
0
.
3
8
0
1
4
1
.
7
2
4
1
4
5
.
0
5
5
1
4
5
.
3
1
7
1
4
5
.
7
5
6
1
5
5
.
8
1
0
1
6
3
.
3
4
7
1
6
5
.
1
8
9
Current Data Parameters
NAME        PMG-1-101-8
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130928
Time               4.57
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME         PMG-1-36-4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130627
Time               8.31
INSTRUM           spect
PROBHD   5 mm CPTCI 1H-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                    1
DS                    0
SWH            8417.509 Hz
FIDRES         0.256882 Hz
AQ            1.9464692 sec
RG                    4
DW               59.400 usec
DE                33.66 usec
TE                300.0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 9.25 usec
PL1                3.80 dB
PL1W         6.35607052 W
SFO1        600.1330006 MHz
F2 - Processing parameters
SI                32768
SF          600.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME         PMG-1-36-4
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20130627
Time               8.36
INSTRUM           spect
PROBHD   5 mm CPTCI 1H-
PULPROG            zgpg
TD                32632
SOLVENT           CDCl3
NS                 1387
DS                    8
SWH           36231.883 Hz
FIDRES         1.110318 Hz
AQ            0.4503716 sec
RG                 1820
DW               13.800 usec
DE                 6.00 usec
TE                300.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 5.00 usec
PL1               -3.00 dB
PL1W       178.92384338 W
SFO1        150.9194080 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             90.00 usec
PL2                3.80 dB
PL12              24.30 dB
PL13              24.40 dB
PL2W         6.35607052 W
PL12W        0.05664854 W
PL13W        0.05535906 W
SFO2        600.1330010 MHz
F2 - Processing parameters
SI                32768
SF          150.9028165 MHz
WDW                  EM
SSB      0
LB                 1.50 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-102-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130924
Time              20.15
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  362
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
11 10 9 8 7 6 5 4 3 2 1 0 ppm
2
.
5
8
3
7
.
2
8
4
7
.
3
5
1
7
.
3
7
3
7
.
4
7
8
7
.
4
8
9
7
.
4
9
8
7
.
5
1
0
7
.
6
1
0
7
.
6
2
9
7
.
7
5
7
7
.
7
6
3
7
.
7
7
8
7
.
7
8
4
7
.
7
9
5
7
.
8
6
2
7
.
8
8
1
7
.
9
2
2
7
.
9
2
6
7
.
9
4
3
7
.
9
4
6
8
.
1
9
5
8
.
2
0
1
8
.
5
6
2
8
.
5
6
5
8
.
5
7
3
8
.
5
7
6
1
0
.
1
8
6
3
.
0
5
9
0
.
9
8
8
1
.
0
1
7
0
.
9
9
6
1
.
0
5
5
0
.
9
0
8
0
.
9
7
6
0
.
9
7
0
0
.
9
8
5
1
.
0
3
8
1
.
0
0
0
  
 
4
2
7
 
 220 200 180 160 140 120 100 80 60 40 20 ppm
2
2
.
0
1
7
7
6
.
6
2
1
7
6
.
9
3
9
7
7
.
2
5
7
1
1
8
.
3
3
9
1
2
0
.
8
1
5
1
2
3
.
7
9
3
1
2
4
.
3
7
3
1
2
5
.
1
9
1
1
2
7
.
1
4
8
1
2
9
.
2
4
4
1
3
0
.
8
6
1
1
3
2
.
2
1
8
1
3
2
.
9
1
8
1
3
3
.
8
2
5
1
3
4
.
9
6
0
1
3
9
.
4
6
2
1
4
1
.
1
3
1
1
4
4
.
5
7
5
1
4
5
.
7
8
1
1
4
5
.
8
3
3
1
6
0
.
7
0
7
1
6
6
.
8
1
4
1
6
6
.
9
3
3
Current Data Parameters
NAME        PMG-1-102-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130928
Time               7.18
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME       PMG-1-36-1_H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130626
Time              18.11
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                645.1
DW               96.000 usec
DE                25.61 usec
TE                298.0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                11.38 usec
PL1               -2.50 dB
PL1W        18.35869598 W
SFO1        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          400.1300065 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME       PMG-1-36-1_C
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20130626
Time              20.05
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 2500
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-102-4
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time              18.11
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                574.7
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME        pmg-1-102-4
EXPNO                 5
PROCNO                1
F2 - Acquisition Parameters
Date_          20140228
Time              20.36
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 2048
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME      PMG-1-36-2_3H
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20130910
Time              17.51
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                456.1
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
11 10 9 8 7 6 5 4 3 2 1 0 ppm
1
.
6
0
3
7
.
2
8
4
7
.
6
8
0
7
.
6
8
6
7
.
7
0
8
7
.
7
6
5
7
.
7
7
1
7
.
7
8
7
7
.
7
9
3
7
.
8
0
9
7
.
8
2
0
7
.
8
2
7
7
.
8
3
5
7
.
8
4
5
7
.
8
5
4
7
.
8
6
4
7
.
9
1
5
7
.
9
1
8
7
.
9
2
6
7
.
9
2
9
7
.
9
3
5
7
.
9
3
9
7
.
9
4
6
7
.
9
4
9
8
.
2
0
7
8
.
2
1
3
8
.
3
1
5
8
.
3
2
1
8
.
3
8
9
8
.
5
4
3
8
.
5
6
6
8
.
5
7
6
8
.
5
7
9
1
0
.
0
6
0
1
0
.
2
0
2
0
.
8
3
7
2
.
1
1
0
2
.
8
6
9
0
.
9
5
0
0
.
9
6
7
1
.
1
5
9
1
.
0
0
0
  
 
4
3
3
 
 220 200 180 160 140 120 100 80 60 40 20 ppm
1
1
7
.
7
8
3
1
1
8
.
3
9
1
1
1
8
.
7
5
8
1
2
0
.
0
7
1
1
2
0
.
8
4
1
1
2
1
.
6
9
6
1
2
2
.
6
6
0
1
2
2
.
8
5
5
1
2
4
.
5
5
8
1
2
7
.
1
8
3
1
3
0
.
7
9
4
1
3
2
.
9
4
2
1
3
3
.
7
6
8
1
3
3
.
9
4
6
1
3
4
.
5
2
3
1
3
6
.
9
1
4
1
3
6
.
9
9
0
1
3
9
.
7
0
6
1
4
1
.
1
4
4
1
4
4
.
5
1
7
1
4
5
.
8
3
9
1
5
6
.
5
2
9
1
5
9
.
2
5
9
1
6
0
.
7
3
3
1
6
3
.
2
3
1
Current Data Parameters
NAME       PMG-1-36-2_C
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20130627
Time               7.53
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 2500
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-102-6
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time              18.24
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                456.1
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME        PMG-1-102-8
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130924
Time              20.28
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  512
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME        PMG-1-102-8
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20130928
Time              20.12
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME           pmg-1-44
EXPNO                 5
PROCNO                1
F2 - Acquisition Parameters
Date_          20160908
Time               9.13
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               137.48
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME           pmg-1-52
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160906
Time              22.20
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               121.51
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300018 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME         PMG-1-58-4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160906
Time              20.43
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               162.56
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME         PMG-1-58-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160906
Time              20.52
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               162.56
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME         PMG-1-58-3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160906
Time              20.32
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               172.42
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME         PMG-1-58-1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160906
Time              19.42
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               121.51
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME        KAB-1-110-5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140815
Time              15.42
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               137.48
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME          pmg-10-35
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160908
Time              19.12
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                15.57
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300443 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME          PMG-1-118
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160906
Time              20.22
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                54.09
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300467 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME        PMG-1-122-1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130924
Time              20.55
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  362
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME        PMG-1-122-1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time              20.01
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME          PMG-1-120
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130924
Time              20.41
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  362
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME          PMG-1-120
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20130930
Time               2.04
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-124-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time               0.21
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  362
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME        PMG-1-124-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130926
Time               2.27
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
 458 
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Current Data Parameters
NAME        PMG-1-21_5H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130516
Time              16.49
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                322.5
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-21_5
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20130521
Time               9.43
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
  
 
4
6
1
 
 
Current Data Parameters
NAME           pmg-1-42
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150312
Time              19.51
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               137.48
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME            PMG-7-1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150326
Time              16.33
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               108.86
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME         PMG-1-98-1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130917
Time              17.13
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                456.1
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-98-1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20130918
Time              16.51
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME         PMG-1-98-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130924
Time              19.28
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                322.5
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-98-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130929
Time              21.13
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME         PMG-1-98-3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130917
Time              17.26
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                456.1
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-98-3
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20130918
Time              21.20
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME         PMG-1-98-4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time              16.34
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                406.4
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
11 10 9 8 7 6 5 4 3 2 1 0 ppm
2
.
4
8
5
6
.
4
5
0
6
.
4
5
4
7
.
2
8
4
7
.
3
1
1
7
.
3
3
2
7
.
4
1
7
7
.
4
2
0
7
.
6
4
3
7
.
6
4
9
7
.
6
6
5
7
.
6
7
1
7
.
7
8
3
7
.
7
8
7
7
.
8
0
3
7
.
8
0
7
7
.
9
1
8
7
.
9
3
8
7
.
9
6
0
7
.
9
6
4
8
.
0
8
3
8
.
0
8
9
8
.
1
7
9
3
.
1
5
9
1
.
0
0
0
1
.
0
4
1
0
.
9
7
5
1
.
0
5
3
1
.
0
5
1
1
.
0
7
5
0
.
9
7
2
1
.
0
0
2
0
.
9
5
9
  
 
4
7
2
 
 
 
220 200 180 160 140 120 100 80 60 40 20 ppm
1
1
.
2
4
3
7
6
.
6
2
1
7
6
.
9
3
8
7
7
.
2
5
6
1
1
6
.
0
6
9
1
1
8
.
3
0
7
1
2
0
.
7
9
7
1
2
4
.
3
0
2
1
2
4
.
4
3
4
1
2
5
.
1
2
8
1
2
9
.
8
4
5
1
3
0
.
0
1
7
1
3
0
.
6
9
3
1
3
3
.
4
5
6
1
3
3
.
6
4
3
1
3
4
.
4
8
8
1
3
9
.
7
9
3
1
4
1
.
1
9
1
1
4
1
.
3
7
2
1
4
2
.
8
6
8
1
5
7
.
1
4
2
1
6
5
.
4
4
0
1
6
5
.
7
5
8
Current Data Parameters
NAME         PMG-1-98-4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130930
Time              22.10
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME         PMG-1-98-5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130917
Time              17.40
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  362
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-98-5
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20130918
Time              23.40
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME         PMG-1-98-6
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130924
Time              19.41
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  512
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-98-6
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130929
Time              23.43
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        pmg-5-138-7
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150318
Time              18.11
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   64
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               108.86
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Appendix F 
 
Relevant spectra for chapter VI
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Current Data Parameters
NAME          pmg-10-36
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20160908
Time              18.04
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                95.05
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          pmg-10-38
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20160912
Time              13.27
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                27.16
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME         PMG-1-58-5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130924
Time              19.14
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                456.1
DW               96.000 usec
DE                 6.00 usec
TE                297.9 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME         PMG-1-58-5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130928
Time              22.32
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-125-1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time               0.34
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  256
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME        PMG-1-125-1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130929
Time               1.00
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-125-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time               0.48
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                574.7
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME        PMG-1-125-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130929
Time               3.20
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-125-3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time               1.02
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  512
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
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Current Data Parameters
NAME          pmg-10-37
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160909
Time              16.36
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                15.57
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          pmg-10-39
EXPNO                 4
PROCNO                1
F2 - Acquisition Parameters
Date_          20160912
Time              15.19
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                 9.77
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          pmg-10-40
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160912
Time              18.46
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                34.15
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300332 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          PMG-10-34
EXPNO                 5
PROCNO                1
F2 - Acquisition Parameters
Date_          20160912
Time              19.21
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               108.86
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME          PMG-10-33
EXPNO                 5
PROCNO                1
F2 - Acquisition Parameters
Date_          20160912
Time              19.17
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG               108.86
DW               96.000 usec
DE                15.87 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320007 MHz
NUC1                 1H
P1                10.00 usec
PLW1        16.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300104 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
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Current Data Parameters
NAME        PMG-1-122-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130924
Time              21.08
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  512
DW               96.000 usec
DE                 6.00 usec
TE                298.0 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME        PMG-1-122-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130926
Time               0.07
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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Current Data Parameters
NAME        PMG-1-124-1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time               0.08
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                  128
DS                    0
SWH            5208.333 Hz
FIDRES         0.158946 Hz
AQ            3.1457779 sec
RG                  362
DW               96.000 usec
DE                 6.00 usec
TE                297.8 K
D1           1.50000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.60 usec
PL1               -3.50 dB
SFO1        400.1320007 MHz
F1 - Acquisition parameters
TD                  512
SFO1            400.132 MHz
FIDRES        10.172506 Hz
SW               13.017 ppm
FnMODE    Echo-Antiecho
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
F1 - Processing parameters
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW
SSB                   2
LB                 0.30 Hz
GB                  0.1
11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME        PMG-1-124-1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130926
Time              21.34
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 3000
DS                    8
SWH           26178.010 Hz
FIDRES         0.798889 Hz
AQ            0.6259188 sec
RG                16384
DW               19.100 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                12.00 usec
PL1               -1.00 dB
PL1W        37.63110352 W
SFO1        100.6238364 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2               -2.50 dB
PL12              14.44 dB
PL13              14.44 dB
PL2W        18.35869598 W
PL12W        0.37139997 W
PL13W        0.37139997 W
SFO2        400.1320007 MHz
F2 - Processing parameters
SI                32768
SF          100.6127772 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40
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